|
- [{"head": {"id": "0", "type": "", "word": "CKD", "begin": "208", "end": "211", "new_begin": "247", "new_end": "250", "replace_begin": "247", "replace_end": "252"}, "tail": {"id": "1", "type": "", "word": "atorvastatin", "begin": "258", "end": "270", "new_begin": "308", "new_end": "320", "replace_begin": "310", "replace_end": "315"}, "sentence": "Statins have similar , if not greater , efficacy in altering the lipid profile in patients with dialysis - dependent CKD ( HD and PD ) compared to those with normal renal function , and are well tolerated in CKD patients at moderate doses ( < or=20 mg @ day atorvastatin or simvastatin ) .", "new_sentence": "Statins@@have@@similar@@,@@if@@not@@greater@@,@@efficacy@@in@@altering@@the@@lipid@@profile@@in@@patients@@with@@dialysis@@-@@dependent@@CKD@@(@@HD@@and@@PD@@)@@compared@@to@@those@@with@@normal@@renal@@function@@,@@and@@are@@well@@tolerated@@in@@CKD@@patients@@at@@moderate@@doses@@(@@<@@or=20@@mg@@@@@day@@atorvastatin@@or@@simvastatin@@)@@.@@", "replace_sentence": "Statins@@have@@similar@@,@@if@@not@@greater@@,@@efficacy@@in@@altering@@the@@lipid@@profile@@in@@patients@@with@@dialysis@@-@@dependent@@CKD@@(@@HD@@and@@PD@@)@@compared@@to@@those@@with@@normal@@renal@@function@@,@@and@@are@@well@@tolerated@@in@@drug1@@patients@@at@@moderate@@doses@@(@@<@@or=20@@mg@@@@@day@@drug2@@or@@simvastatin@@)@@.@@", "new_pair": "CKD@@patients@@at@@moderate@@doses@@(@@<@@or=20@@mg@@@@@day@@atorvastatin", "replace_pair": "drug1@@patients@@at@@moderate@@doses@@(@@<@@or=20@@mg@@@@@day@@drug2", "relation": "NA"}, {"head": {"id": "2", "type": "", "word": "N-acetylcysteine", "begin": "0", "end": "16", "new_begin": "0", "new_end": "16", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "3", "type": "", "word": "renalUfailure", "begin": "48", "end": "61", "new_begin": "54", "new_end": "67", "replace_begin": "43", "replace_end": "48"}, "sentence": "N-acetylcysteine attenuates NSAID - induced rat renalUfailure by restoring intrarenal prostaglandin synthesis .", "new_sentence": "N-acetylcysteine@@attenuates@@NSAID@@-@@induced@@rat@@renalUfailure@@by@@restoring@@intrarenal@@prostaglandin@@synthesis@@.@@", "replace_sentence": "drug1@@attenuates@@NSAID@@-@@induced@@rat@@drug2@@by@@restoring@@intrarenal@@prostaglandin@@synthesis@@.@@", "new_pair": "N-acetylcysteine@@attenuates@@NSAID@@-@@induced@@rat@@renalUfailure", "replace_pair": "drug1@@attenuates@@NSAID@@-@@induced@@rat@@drug2", "relation": "may_prevent"}, {"head": {"id": "4", "type": "", "word": "ganciclovir", "begin": "42", "end": "53", "new_begin": "48", "new_end": "59", "replace_begin": "48", "replace_end": "53"}, "tail": {"id": "5", "type": "", "word": "cytomegalovirusUinfection", "begin": "132", "end": "157", "new_begin": "153", "new_end": "178", "replace_begin": "147", "replace_end": "152"}, "sentence": "A randomized , controlled trial comparing ganciclovir to ganciclovir plus foscarnet ( each at half dose ) for preemptive therapy of cytomegalovirusUinfection in transplant recipients .", "new_sentence": "A@@randomized@@,@@controlled@@trial@@comparing@@ganciclovir@@to@@ganciclovir@@plus@@foscarnet@@(@@each@@at@@half@@dose@@)@@for@@preemptive@@therapy@@of@@cytomegalovirusUinfection@@in@@transplant@@recipients@@.@@", "replace_sentence": "A@@randomized@@,@@controlled@@trial@@comparing@@drug1@@to@@ganciclovir@@plus@@foscarnet@@(@@each@@at@@half@@dose@@)@@for@@preemptive@@therapy@@of@@drug2@@in@@transplant@@recipients@@.@@", "new_pair": "ganciclovir@@to@@ganciclovir@@plus@@foscarnet@@(@@each@@at@@half@@dose@@)@@for@@preemptive@@therapy@@of@@cytomegalovirusUinfection", "replace_pair": "drug1@@to@@ganciclovir@@plus@@foscarnet@@(@@each@@at@@half@@dose@@)@@for@@preemptive@@therapy@@of@@drug2", "relation": "NA"}, {"head": {"id": "6", "type": "", "word": "fluvastatin", "begin": "22", "end": "33", "new_begin": "25", "new_end": "36", "replace_begin": "25", "replace_end": "30"}, "tail": {"id": "7", "type": "", "word": "heartUdisease", "begin": "110", "end": "123", "new_begin": "126", "new_end": "139", "replace_begin": "120", "replace_end": "125"}, "sentence": "Effectiveness data on fluvastatin was derived directly from LIPS and utility weights from previous studies on heartUdisease .", "new_sentence": "Effectiveness@@data@@on@@fluvastatin@@was@@derived@@directly@@from@@LIPS@@and@@utility@@weights@@from@@previous@@studies@@on@@heartUdisease@@.@@", "replace_sentence": "Effectiveness@@data@@on@@drug1@@was@@derived@@directly@@from@@LIPS@@and@@utility@@weights@@from@@previous@@studies@@on@@drug2@@.@@", "new_pair": "fluvastatin@@was@@derived@@directly@@from@@LIPS@@and@@utility@@weights@@from@@previous@@studies@@on@@heartUdisease", "replace_pair": "drug1@@was@@derived@@directly@@from@@LIPS@@and@@utility@@weights@@from@@previous@@studies@@on@@drug2", "relation": "NA"}, {"head": {"id": "8", "type": "", "word": "asthma", "begin": "63", "end": "69", "new_begin": "75", "new_end": "81", "replace_begin": "75", "replace_end": "80"}, "tail": {"id": "9", "type": "", "word": "dexamethasone", "begin": "113", "end": "126", "new_begin": "138", "new_end": "151", "replace_begin": "137", "replace_end": "142"}, "sentence": "Excepting those in the GA , all rats were established into the asthma model and rats in GC-GH were intervened by dexamethasone , with the dosage reduced by 0 . 1 mg @ kg per week starting from the 3rd week and withdrawn completely till the 7th week .", "new_sentence": "Excepting@@those@@in@@the@@GA@@,@@all@@rats@@were@@established@@into@@the@@asthma@@model@@and@@rats@@in@@GC@@-@@GH@@were@@intervened@@by@@dexamethasone@@,@@with@@the@@dosage@@reduced@@by@@0@@.@@1@@mg@@@@@kg@@per@@week@@starting@@from@@the@@3rd@@week@@and@@withdrawn@@completely@@till@@the@@7th@@week@@.@@", "replace_sentence": "Excepting@@those@@in@@the@@GA@@,@@all@@rats@@were@@established@@into@@the@@drug1@@model@@and@@rats@@in@@GC@@-@@GH@@were@@intervened@@by@@drug2@@,@@with@@the@@dosage@@reduced@@by@@0@@.@@1@@mg@@@@@kg@@per@@week@@starting@@from@@the@@3rd@@week@@and@@withdrawn@@completely@@till@@the@@7th@@week@@.@@", "new_pair": "asthma@@model@@and@@rats@@in@@GC@@-@@GH@@were@@intervened@@by@@dexamethasone", "replace_pair": "drug1@@model@@and@@rats@@in@@GC@@-@@GH@@were@@intervened@@by@@drug2", "relation": "NA"}, {"head": {"id": "10", "type": "", "word": "fluoride", "begin": "9", "end": "17", "new_begin": "10", "new_end": "18", "replace_begin": "10", "replace_end": "15"}, "tail": {"id": "11", "type": "", "word": "caries", "begin": "47", "end": "53", "new_begin": "54", "new_end": "60", "replace_begin": "51", "replace_end": "56"}, "sentence": "Although fluoride is an important resource for caries control , its use must be adequate to the needs of each specific population .", "new_sentence": "Although@@fluoride@@is@@an@@important@@resource@@for@@caries@@control@@,@@its@@use@@must@@be@@adequate@@to@@the@@needs@@of@@each@@specific@@population@@.@@", "replace_sentence": "Although@@drug1@@is@@an@@important@@resource@@for@@drug2@@control@@,@@its@@use@@must@@be@@adequate@@to@@the@@needs@@of@@each@@specific@@population@@.@@", "new_pair": "fluoride@@is@@an@@important@@resource@@for@@caries", "replace_pair": "drug1@@is@@an@@important@@resource@@for@@drug2", "relation": "may_prevent"}, {"head": {"id": "12", "type": "", "word": "mumps", "begin": "60", "end": "65", "new_begin": "71", "new_end": "76", "replace_begin": "71", "replace_end": "76"}, "tail": {"id": "13", "type": "", "word": "rubellaUvaccine", "begin": "70", "end": "85", "new_begin": "83", "new_end": "98", "replace_begin": "83", "replace_end": "88"}, "sentence": "MAIN OUTCOME MEASURES : Number of doses of single measles , mumps and rubellaUvaccine , by age of child ( in months ) , year given and area of residence , and number of children who have received all three single vaccinations .", "new_sentence": "MAIN@@OUTCOME@@MEASURES@@:@@Number@@of@@doses@@of@@single@@measles@@,@@mumps@@and@@rubellaUvaccine@@,@@by@@age@@of@@child@@(@@in@@months@@)@@,@@year@@given@@and@@area@@of@@residence@@,@@and@@number@@of@@children@@who@@have@@received@@all@@three@@single@@vaccinations@@.@@", "replace_sentence": "MAIN@@OUTCOME@@MEASURES@@:@@Number@@of@@doses@@of@@single@@measles@@,@@drug1@@and@@drug2@@,@@by@@age@@of@@child@@(@@in@@months@@)@@,@@year@@given@@and@@area@@of@@residence@@,@@and@@number@@of@@children@@who@@have@@received@@all@@three@@single@@vaccinations@@.@@", "new_pair": "mumps@@and@@rubellaUvaccine", "replace_pair": "drug1@@and@@drug2", "relation": "NA"}, {"head": {"id": "14", "type": "", "word": "isoniazid", "begin": "12", "end": "21", "new_begin": "14", "new_end": "23", "replace_begin": "14", "replace_end": "19"}, "tail": {"id": "15", "type": "", "word": "humanUimmunodeficiencyUvirusUinfection", "begin": "91", "end": "129", "new_begin": "107", "new_end": "145", "replace_begin": "103", "replace_end": "108"}, "sentence": "Efficacy of isoniazid ( INH ) chemoprophylaxis has been seen in other situations , such as humanUimmunodeficiencyUvirusUinfection .", "new_sentence": "Efficacy@@of@@isoniazid@@(@@INH@@)@@chemoprophylaxis@@has@@been@@seen@@in@@other@@situations@@,@@such@@as@@humanUimmunodeficiencyUvirusUinfection@@.@@", "replace_sentence": "Efficacy@@of@@drug1@@(@@INH@@)@@chemoprophylaxis@@has@@been@@seen@@in@@other@@situations@@,@@such@@as@@drug2@@.@@", "new_pair": "isoniazid@@(@@INH@@)@@chemoprophylaxis@@has@@been@@seen@@in@@other@@situations@@,@@such@@as@@humanUimmunodeficiencyUvirusUinfection", "replace_pair": "drug1@@(@@INH@@)@@chemoprophylaxis@@has@@been@@seen@@in@@other@@situations@@,@@such@@as@@drug2", "relation": "may_prevent"}, {"head": {"id": "16", "type": "", "word": "cerebralUischemia", "begin": "52", "end": "69", "new_begin": "61", "new_end": "78", "replace_begin": "61", "replace_end": "66"}, "tail": {"id": "17", "type": "", "word": "oxygen", "begin": "92", "end": "98", "new_begin": "107", "new_end": "113", "replace_begin": "95", "replace_end": "100"}, "sentence": "It is not rare that pathological conditions such as cerebralUischemia , head trauma and low oxygen result in marked impairment of cerebral function , even if the patient s life is saved .", "new_sentence": "It@@is@@not@@rare@@that@@pathological@@conditions@@such@@as@@cerebralUischemia@@,@@head@@trauma@@and@@low@@oxygen@@result@@in@@marked@@impairment@@of@@cerebral@@function@@,@@even@@if@@the@@patient@@s@@life@@is@@saved@@.@@", "replace_sentence": "It@@is@@not@@rare@@that@@pathological@@conditions@@such@@as@@drug1@@,@@head@@trauma@@and@@low@@drug2@@result@@in@@marked@@impairment@@of@@cerebral@@function@@,@@even@@if@@the@@patient@@s@@life@@is@@saved@@.@@", "new_pair": "cerebralUischemia@@,@@head@@trauma@@and@@low@@oxygen", "replace_pair": "drug1@@,@@head@@trauma@@and@@low@@drug2", "relation": "NA"}, {"head": {"id": "18", "type": "", "word": "Pravastatin", "begin": "130", "end": "141", "new_begin": "162", "new_end": "173", "replace_begin": "162", "replace_end": "167"}, "tail": {"id": "19", "type": "", "word": "MyocardialUInfarction", "begin": "207", "end": "228", "new_begin": "251", "new_end": "272", "replace_begin": "245", "replace_end": "250"}, "sentence": "However , the 2 trials of high-dose versus standard- dose statin therapy in patients with ACS , Aggrastat to Zocor ( A to Z ) and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In MyocardialUInfarction 22 ( PROVE -IT-TIMI 22 ) , were not individually powered to evaluate the impact on mortality alone .", "new_sentence": "However@@,@@the@@2@@trials@@of@@high@@-@@dose@@versus@@standard@@-@@dose@@statin@@therapy@@in@@patients@@with@@ACS@@,@@Aggrastat@@to@@Zocor@@(@@A@@to@@Z@@)@@and@@Pravastatin@@or@@Atorvastatin@@Evaluation@@and@@Infection@@Therapy@@-@@Thrombolysis@@In@@MyocardialUInfarction@@22@@(@@PROVE@@-@@IT@@-@@TIMI@@22@@)@@,@@were@@not@@individually@@powered@@to@@evaluate@@the@@impact@@on@@mortality@@alone@@.@@", "replace_sentence": "However@@,@@the@@2@@trials@@of@@high@@-@@dose@@versus@@standard@@-@@dose@@statin@@therapy@@in@@patients@@with@@ACS@@,@@Aggrastat@@to@@Zocor@@(@@A@@to@@Z@@)@@and@@drug1@@or@@Atorvastatin@@Evaluation@@and@@Infection@@Therapy@@-@@Thrombolysis@@In@@drug2@@22@@(@@PROVE@@-@@IT@@-@@TIMI@@22@@)@@,@@were@@not@@individually@@powered@@to@@evaluate@@the@@impact@@on@@mortality@@alone@@.@@", "new_pair": "Pravastatin@@or@@Atorvastatin@@Evaluation@@and@@Infection@@Therapy@@-@@Thrombolysis@@In@@MyocardialUInfarction", "replace_pair": "drug1@@or@@Atorvastatin@@Evaluation@@and@@Infection@@Therapy@@-@@Thrombolysis@@In@@drug2", "relation": "NA"}, {"head": {"id": "20", "type": "", "word": "FP", "begin": "83", "end": "85", "new_begin": "98", "new_end": "100", "replace_begin": "98", "replace_end": "103"}, "tail": {"id": "21", "type": "", "word": "asthmatics", "begin": "89", "end": "99", "new_begin": "106", "new_end": "116", "replace_begin": "109", "replace_end": "114"}, "sentence": "This study shows that the clinical improvement achieved by the use of low doses of FP in asthmatics is related , at least in part , to the resolution of eosinophilic inflammation and the downregulation of remodelling markers .", "new_sentence": "This@@study@@shows@@that@@the@@clinical@@improvement@@achieved@@by@@the@@use@@of@@low@@doses@@of@@FP@@in@@asthmatics@@is@@related@@,@@at@@least@@in@@part@@,@@to@@the@@resolution@@of@@eosinophilic@@inflammation@@and@@the@@downregulation@@of@@remodelling@@markers@@.@@", "replace_sentence": "This@@study@@shows@@that@@the@@clinical@@improvement@@achieved@@by@@the@@use@@of@@low@@doses@@of@@drug1@@in@@drug2@@is@@related@@,@@at@@least@@in@@part@@,@@to@@the@@resolution@@of@@eosinophilic@@inflammation@@and@@the@@downregulation@@of@@remodelling@@markers@@.@@", "new_pair": "FP@@in@@asthmatics", "replace_pair": "drug1@@in@@drug2", "relation": "may_prevent"}, {"head": {"id": "22", "type": "", "word": "aspirin", "begin": "48", "end": "55", "new_begin": "56", "new_end": "63", "replace_begin": "56", "replace_end": "61"}, "tail": {"id": "23", "type": "", "word": "cerebrovascularUaccidents", "begin": "67", "end": "92", "new_begin": "78", "new_end": "103", "replace_begin": "76", "replace_end": "81"}, "sentence": "Clinical studies have shown that the ability of aspirin to prevent cerebrovascularUaccidents is weaker in patients with diabetes .", "new_sentence": "Clinical@@studies@@have@@shown@@that@@the@@ability@@of@@aspirin@@to@@prevent@@cerebrovascularUaccidents@@is@@weaker@@in@@patients@@with@@diabetes@@.@@", "replace_sentence": "Clinical@@studies@@have@@shown@@that@@the@@ability@@of@@drug1@@to@@prevent@@drug2@@is@@weaker@@in@@patients@@with@@diabetes@@.@@", "new_pair": "aspirin@@to@@prevent@@cerebrovascularUaccidents", "replace_pair": "drug1@@to@@prevent@@drug2", "relation": "may_prevent"}, {"head": {"id": "24", "type": "", "word": "estrogen", "begin": "11", "end": "19", "new_begin": "13", "new_end": "21", "replace_begin": "13", "replace_end": "18"}, "tail": {"id": "25", "type": "", "word": "myocardialUnecrosis", "begin": "150", "end": "169", "new_begin": "195", "new_end": "214", "replace_begin": "192", "replace_end": "197"}, "sentence": "Moreover , estrogen improved functional recovery ( 55 . 0 + @ -5 . 0 % vs . 22 . 0 + @ -7 . 0 % , P < 0 . 05 ) , decreased LV apoptosis , and reduced myocardialUnecrosis .", "new_sentence": "Moreover@@,@@estrogen@@improved@@functional@@recovery@@(@@55@@.@@0@@+@@@@@-@@5@@.@@0@@%@@vs@@.@@22@@.@@0@@+@@@@@-@@7@@.@@0@@%@@,@@P@@<@@0@@.@@05@@)@@,@@decreased@@LV@@apoptosis@@,@@and@@reduced@@myocardialUnecrosis@@.@@", "replace_sentence": "Moreover@@,@@drug1@@improved@@functional@@recovery@@(@@55@@.@@0@@+@@@@@-@@5@@.@@0@@%@@vs@@.@@22@@.@@0@@+@@@@@-@@7@@.@@0@@%@@,@@P@@<@@0@@.@@05@@)@@,@@decreased@@LV@@apoptosis@@,@@and@@reduced@@drug2@@.@@", "new_pair": "estrogen@@improved@@functional@@recovery@@(@@55@@.@@0@@+@@@@@-@@5@@.@@0@@%@@vs@@.@@22@@.@@0@@+@@@@@-@@7@@.@@0@@%@@,@@P@@<@@0@@.@@05@@)@@,@@decreased@@LV@@apoptosis@@,@@and@@reduced@@myocardialUnecrosis", "replace_pair": "drug1@@improved@@functional@@recovery@@(@@55@@.@@0@@+@@@@@-@@5@@.@@0@@%@@vs@@.@@22@@.@@0@@+@@@@@-@@7@@.@@0@@%@@,@@P@@<@@0@@.@@05@@)@@,@@decreased@@LV@@apoptosis@@,@@and@@reduced@@drug2", "relation": "may_prevent"}, {"head": {"id": "26", "type": "", "word": "fluoride", "begin": "239", "end": "247", "new_begin": "309", "new_end": "317", "replace_begin": "309", "replace_end": "314"}, "tail": {"id": "27", "type": "", "word": "caries", "begin": "327", "end": "333", "new_begin": "414", "new_end": "420", "replace_begin": "411", "replace_end": "416"}, "sentence": "In phase 1 , the fluoride released from samples ( n = 5 ) of the adhesives A ( Optibond Solo ) , B ( One -up Bond F ) , C ( Prime @ Bond NT ) , D ( Tenure Quick ) , and also of the controls ( + ) ( glass-ionomer cement ) and ( - ) ( non - fluoride releasing adhesive ) , was quantified on a daily basis during a pH - cycling , caries - simulating phenomenon .", "new_sentence": "In@@phase@@1@@,@@the@@fluoride@@released@@from@@samples@@(@@n@@=@@5@@)@@of@@the@@adhesives@@A@@(@@Optibond@@Solo@@)@@,@@B@@(@@One@@-@@up@@Bond@@F@@)@@,@@C@@(@@Prime@@@@@Bond@@NT@@)@@,@@D@@(@@Tenure@@Quick@@)@@,@@and@@also@@of@@the@@controls@@(@@+@@)@@(@@glass@@-@@ionomer@@cement@@)@@and@@(@@-@@)@@(@@non@@-@@fluoride@@releasing@@adhesive@@)@@,@@was@@quantified@@on@@a@@daily@@basis@@during@@a@@pH@@-@@cycling@@,@@caries@@-@@simulating@@phenomenon@@.@@", "replace_sentence": "In@@phase@@1@@,@@the@@fluoride@@released@@from@@samples@@(@@n@@=@@5@@)@@of@@the@@adhesives@@A@@(@@Optibond@@Solo@@)@@,@@B@@(@@One@@-@@up@@Bond@@F@@)@@,@@C@@(@@Prime@@@@@Bond@@NT@@)@@,@@D@@(@@Tenure@@Quick@@)@@,@@and@@also@@of@@the@@controls@@(@@+@@)@@(@@glass@@-@@ionomer@@cement@@)@@and@@(@@-@@)@@(@@non@@-@@drug1@@releasing@@adhesive@@)@@,@@was@@quantified@@on@@a@@daily@@basis@@during@@a@@pH@@-@@cycling@@,@@drug2@@-@@simulating@@phenomenon@@.@@", "new_pair": "fluoride@@releasing@@adhesive@@)@@,@@was@@quantified@@on@@a@@daily@@basis@@during@@a@@pH@@-@@cycling@@,@@caries", "replace_pair": "drug1@@releasing@@adhesive@@)@@,@@was@@quantified@@on@@a@@daily@@basis@@during@@a@@pH@@-@@cycling@@,@@drug2", "relation": "NA"}, {"head": {"id": "28", "type": "", "word": "malaria", "begin": "109", "end": "116", "new_begin": "127", "new_end": "134", "replace_begin": "127", "replace_end": "132"}, "tail": {"id": "29", "type": "", "word": "mefloquine", "begin": "119", "end": "129", "new_begin": "139", "new_end": "149", "replace_begin": "137", "replace_end": "142"}, "sentence": "Susceptibility of Plasmodium falciparum to the drugs used to treat severe malaria ( quinine ) and to prevent malaria ( mefloquine , cycloguanil ) in Comoros Union and Madagascar .", "new_sentence": "Susceptibility@@of@@Plasmodium@@falciparum@@to@@the@@drugs@@used@@to@@treat@@severe@@malaria@@(@@quinine@@)@@and@@to@@prevent@@malaria@@(@@mefloquine@@,@@cycloguanil@@)@@in@@Comoros@@Union@@and@@Madagascar@@.@@", "replace_sentence": "Susceptibility@@of@@Plasmodium@@falciparum@@to@@the@@drugs@@used@@to@@treat@@severe@@malaria@@(@@quinine@@)@@and@@to@@prevent@@drug1@@(@@drug2@@,@@cycloguanil@@)@@in@@Comoros@@Union@@and@@Madagascar@@.@@", "new_pair": "malaria@@(@@mefloquine", "replace_pair": "drug1@@(@@drug2", "relation": "may_prevent"}, {"head": {"id": "30", "type": "", "word": "MI", "begin": "71", "end": "73", "new_begin": "83", "new_end": "85", "replace_begin": "83", "replace_end": "88"}, "tail": {"id": "31", "type": "", "word": "aspirin", "begin": "149", "end": "156", "new_begin": "173", "new_end": "180", "replace_begin": "176", "replace_end": "181"}, "sentence": "METHODS : Medicare beneficiaries > or = 65 years old hospitalized with MI were evaluated to determine whether there was an association between prior aspirin use and mortality ( n = 118 , 992 ) , all- cause readmission , and condition - specific readmission ( n = 78 , 975 ) at one month and six months .", "new_sentence": "METHODS@@:@@Medicare@@beneficiaries@@>@@or@@=@@65@@years@@old@@hospitalized@@with@@MI@@were@@evaluated@@to@@determine@@whether@@there@@was@@an@@association@@between@@prior@@aspirin@@use@@and@@mortality@@(@@n@@=@@118@@,@@992@@)@@,@@all@@-@@cause@@readmission@@,@@and@@condition@@-@@specific@@readmission@@(@@n@@=@@78@@,@@975@@)@@at@@one@@month@@and@@six@@months@@.@@", "replace_sentence": "METHODS@@:@@Medicare@@beneficiaries@@>@@or@@=@@65@@years@@old@@hospitalized@@with@@drug1@@were@@evaluated@@to@@determine@@whether@@there@@was@@an@@association@@between@@prior@@drug2@@use@@and@@mortality@@(@@n@@=@@118@@,@@992@@)@@,@@all@@-@@cause@@readmission@@,@@and@@condition@@-@@specific@@readmission@@(@@n@@=@@78@@,@@975@@)@@at@@one@@month@@and@@six@@months@@.@@", "new_pair": "MI@@were@@evaluated@@to@@determine@@whether@@there@@was@@an@@association@@between@@prior@@aspirin", "replace_pair": "drug1@@were@@evaluated@@to@@determine@@whether@@there@@was@@an@@association@@between@@prior@@drug2", "relation": "NA"}, {"head": {"id": "32", "type": "", "word": "dentalUcaries", "begin": "4", "end": "17", "new_begin": "5", "new_end": "18", "replace_begin": "5", "replace_end": "10"}, "tail": {"id": "33", "type": "", "word": "fluoride", "begin": "39", "end": "47", "new_begin": "45", "new_end": "53", "replace_begin": "37", "replace_end": "42"}, "sentence": "All dentalUcaries were restored with a fluoride - releasing adhesive material .", "new_sentence": "All@@dentalUcaries@@were@@restored@@with@@a@@fluoride@@-@@releasing@@adhesive@@material@@.@@", "replace_sentence": "All@@drug1@@were@@restored@@with@@a@@drug2@@-@@releasing@@adhesive@@material@@.@@", "new_pair": "dentalUcaries@@were@@restored@@with@@a@@fluoride", "replace_pair": "drug1@@were@@restored@@with@@a@@drug2", "relation": "NA"}, {"head": {"id": "34", "type": "", "word": "mannitol", "begin": "54", "end": "62", "new_begin": "62", "new_end": "70", "replace_begin": "62", "replace_end": "67"}, "tail": {"id": "35", "type": "", "word": "renalUfailure", "begin": "113", "end": "126", "new_begin": "130", "new_end": "143", "replace_begin": "127", "replace_end": "132"}, "sentence": "The data emphasize that proper combination therapy of mannitol with katlex is an effective measure in preventing renalUfailure .", "new_sentence": "The@@data@@emphasize@@that@@proper@@combination@@therapy@@of@@mannitol@@with@@katlex@@is@@an@@effective@@measure@@in@@preventing@@renalUfailure@@.@@", "replace_sentence": "The@@data@@emphasize@@that@@proper@@combination@@therapy@@of@@drug1@@with@@katlex@@is@@an@@effective@@measure@@in@@preventing@@drug2@@.@@", "new_pair": "mannitol@@with@@katlex@@is@@an@@effective@@measure@@in@@preventing@@renalUfailure", "replace_pair": "drug1@@with@@katlex@@is@@an@@effective@@measure@@in@@preventing@@drug2", "relation": "may_prevent"}, {"head": {"id": "36", "type": "", "word": "asthma", "begin": "92", "end": "98", "new_begin": "109", "new_end": "115", "replace_begin": "109", "replace_end": "114"}, "tail": {"id": "37", "type": "", "word": "fluticasoneUpropionate", "begin": "304", "end": "326", "new_begin": "359", "new_end": "381", "replace_begin": "358", "replace_end": "363"}, "sentence": "METHODS : The study involved a 24- month retrospective analysis of patients with claims for asthma treatment ( primary diagnosis International Classification of Disease , Ninth Revision code of 493 . xx ) between January 1 , 1997 , and June 30 , 2000 , and at least I outpatient pharmaceutical claim for fluticasoneUpropionate ( 44 microg ) or montelukast ( 5 or 10 mg ) .", "new_sentence": "METHODS@@:@@The@@study@@involved@@a@@24@@-@@month@@retrospective@@analysis@@of@@patients@@with@@claims@@for@@asthma@@treatment@@(@@primary@@diagnosis@@International@@Classification@@of@@Disease@@,@@Ninth@@Revision@@code@@of@@493@@.@@xx@@)@@between@@January@@1@@,@@1997@@,@@and@@June@@30@@,@@2000@@,@@and@@at@@least@@I@@outpatient@@pharmaceutical@@claim@@for@@fluticasoneUpropionate@@(@@44@@microg@@)@@or@@montelukast@@(@@5@@or@@10@@mg@@)@@.@@", "replace_sentence": "METHODS@@:@@The@@study@@involved@@a@@24@@-@@month@@retrospective@@analysis@@of@@patients@@with@@claims@@for@@drug1@@treatment@@(@@primary@@diagnosis@@International@@Classification@@of@@Disease@@,@@Ninth@@Revision@@code@@of@@493@@.@@xx@@)@@between@@January@@1@@,@@1997@@,@@and@@June@@30@@,@@2000@@,@@and@@at@@least@@I@@outpatient@@pharmaceutical@@claim@@for@@drug2@@(@@44@@microg@@)@@or@@montelukast@@(@@5@@or@@10@@mg@@)@@.@@", "new_pair": "asthma@@treatment@@(@@primary@@diagnosis@@International@@Classification@@of@@Disease@@,@@Ninth@@Revision@@code@@of@@493@@.@@xx@@)@@between@@January@@1@@,@@1997@@,@@and@@June@@30@@,@@2000@@,@@and@@at@@least@@I@@outpatient@@pharmaceutical@@claim@@for@@fluticasoneUpropionate", "replace_pair": "drug1@@treatment@@(@@primary@@diagnosis@@International@@Classification@@of@@Disease@@,@@Ninth@@Revision@@code@@of@@493@@.@@xx@@)@@between@@January@@1@@,@@1997@@,@@and@@June@@30@@,@@2000@@,@@and@@at@@least@@I@@outpatient@@pharmaceutical@@claim@@for@@drug2", "relation": "NA"}, {"head": {"id": "38", "type": "", "word": "IU @ UR", "begin": "0", "end": "7", "new_begin": "0", "new_end": "7", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "39", "type": "", "word": "L-arginine", "begin": "12", "end": "22", "new_begin": "14", "new_end": "24", "replace_begin": "12", "replace_end": "17"}, "sentence": "IU @ UR and L-arginine pretreatment ;", "new_sentence": "IU @ UR@@and@@L-arginine@@pretreatment@@;@@", "replace_sentence": "drug1@@and@@drug2@@pretreatment@@;@@", "new_pair": "IU @ UR@@and@@L-arginine", "replace_pair": "drug1@@and@@drug2", "relation": "NA"}, {"head": {"id": "40", "type": "", "word": "aspirin", "begin": "13", "end": "20", "new_begin": "16", "new_end": "23", "replace_begin": "16", "replace_end": "21"}, "tail": {"id": "41", "type": "", "word": "stroke", "begin": "71", "end": "77", "new_begin": "84", "new_end": "90", "replace_begin": "82", "replace_end": "87"}, "sentence": "In general , aspirin is the first line of treatment to prevent further stroke .", "new_sentence": "In@@general@@,@@aspirin@@is@@the@@first@@line@@of@@treatment@@to@@prevent@@further@@stroke@@.@@", "replace_sentence": "In@@general@@,@@drug1@@is@@the@@first@@line@@of@@treatment@@to@@prevent@@further@@drug2@@.@@", "new_pair": "aspirin@@is@@the@@first@@line@@of@@treatment@@to@@prevent@@further@@stroke", "replace_pair": "drug1@@is@@the@@first@@line@@of@@treatment@@to@@prevent@@further@@drug2", "relation": "may_prevent"}, {"head": {"id": "42", "type": "", "word": "nAPCsr", "begin": "20", "end": "26", "new_begin": "24", "new_end": "30", "replace_begin": "24", "replace_end": "29"}, "tail": {"id": "43", "type": "", "word": "raloxifene", "begin": "66", "end": "76", "new_begin": "80", "new_end": "90", "replace_begin": "79", "replace_end": "84"}, "sentence": "A small increase in nAPCsr with both rAPC and rTM was seen in the raloxifene - group , but the increase was less than in the low-dose HT group .", "new_sentence": "A@@small@@increase@@in@@nAPCsr@@with@@both@@rAPC@@and@@rTM@@was@@seen@@in@@the@@raloxifene@@-@@group@@,@@but@@the@@increase@@was@@less@@than@@in@@the@@low@@-@@dose@@HT@@group@@.@@", "replace_sentence": "A@@small@@increase@@in@@drug1@@with@@both@@rAPC@@and@@rTM@@was@@seen@@in@@the@@drug2@@-@@group@@,@@but@@the@@increase@@was@@less@@than@@in@@the@@low@@-@@dose@@HT@@group@@.@@", "new_pair": "nAPCsr@@with@@both@@rAPC@@and@@rTM@@was@@seen@@in@@the@@raloxifene", "replace_pair": "drug1@@with@@both@@rAPC@@and@@rTM@@was@@seen@@in@@the@@drug2", "relation": "NA"}, {"head": {"id": "44", "type": "", "word": "malaria", "begin": "91", "end": "98", "new_begin": "105", "new_end": "112", "replace_begin": "105", "replace_end": "110"}, "tail": {"id": "45", "type": "", "word": "chloroquine", "begin": "104", "end": "115", "new_begin": "120", "new_end": "131", "replace_begin": "118", "replace_end": "123"}, "sentence": "We followed parasite genotypes of 75 patients for 42 days after treatment of uncomplicated malaria with chloroquine + sulfadoxine-pyrimethamine in Kampala , Uganda .", "new_sentence": "We@@followed@@parasite@@genotypes@@of@@75@@patients@@for@@42@@days@@after@@treatment@@of@@uncomplicated@@malaria@@with@@chloroquine@@+@@sulfadoxine@@-@@pyrimethamine@@in@@Kampala@@,@@Uganda@@.@@", "replace_sentence": "We@@followed@@parasite@@genotypes@@of@@75@@patients@@for@@42@@days@@after@@treatment@@of@@uncomplicated@@drug1@@with@@drug2@@+@@sulfadoxine@@-@@pyrimethamine@@in@@Kampala@@,@@Uganda@@.@@", "new_pair": "malaria@@with@@chloroquine", "replace_pair": "drug1@@with@@drug2", "relation": "NA"}, {"head": {"id": "46", "type": "", "word": "asthma", "begin": "74", "end": "80", "new_begin": "87", "new_end": "93", "replace_begin": "87", "replace_end": "92"}, "tail": {"id": "47", "type": "", "word": "FP", "begin": "228", "end": "230", "new_begin": "263", "new_end": "265", "replace_begin": "262", "replace_end": "267"}, "sentence": "CONCLUSION : In this analysis , patients receiving FSC had lower rates of asthma - related symptoms and exacerbations as measured by SABA refills and hospitalization , respectively , when compared with patients receiving either FP or FP + SAL .", "new_sentence": "CONCLUSION@@:@@In@@this@@analysis@@,@@patients@@receiving@@FSC@@had@@lower@@rates@@of@@asthma@@-@@related@@symptoms@@and@@exacerbations@@as@@measured@@by@@SABA@@refills@@and@@hospitalization@@,@@respectively@@,@@when@@compared@@with@@patients@@receiving@@either@@FP@@or@@FP@@+@@SAL@@.@@", "replace_sentence": "CONCLUSION@@:@@In@@this@@analysis@@,@@patients@@receiving@@FSC@@had@@lower@@rates@@of@@drug1@@-@@related@@symptoms@@and@@exacerbations@@as@@measured@@by@@SABA@@refills@@and@@hospitalization@@,@@respectively@@,@@when@@compared@@with@@patients@@receiving@@either@@drug2@@or@@FP@@+@@SAL@@.@@", "new_pair": "asthma@@-@@related@@symptoms@@and@@exacerbations@@as@@measured@@by@@SABA@@refills@@and@@hospitalization@@,@@respectively@@,@@when@@compared@@with@@patients@@receiving@@either@@FP", "replace_pair": "drug1@@-@@related@@symptoms@@and@@exacerbations@@as@@measured@@by@@SABA@@refills@@and@@hospitalization@@,@@respectively@@,@@when@@compared@@with@@patients@@receiving@@either@@drug2", "relation": "NA"}, {"head": {"id": "48", "type": "", "word": "f", "begin": "153", "end": "154", "new_begin": "183", "new_end": "184", "replace_begin": "183", "replace_end": "188"}, "tail": {"id": "49", "type": "", "word": "plaque", "begin": "253", "end": "259", "new_begin": "306", "new_end": "312", "replace_begin": "310", "replace_end": "315"}, "sentence": "Understanding and anticipating all- cis open - chain structures not only make use of the classical Ramachandran maps at each C alpha i , relating to E = f ( phi i , psi i ) , but also require the profile of a new kind of conformational dependence , the plaque maps , relating to E = f ( phi i , psi i-1 ) .", "new_sentence": "Understanding@@and@@anticipating@@all@@-@@cis@@open@@-@@chain@@structures@@not@@only@@make@@use@@of@@the@@classical@@Ramachandran@@maps@@at@@each@@C@@alpha@@i@@,@@relating@@to@@E@@=@@f@@(@@phi@@i@@,@@psi@@i@@)@@,@@but@@also@@require@@the@@profile@@of@@a@@new@@kind@@of@@conformational@@dependence@@,@@the@@plaque@@maps@@,@@relating@@to@@E@@=@@f@@(@@phi@@i@@,@@psi@@i@@-@@1@@)@@.@@", "replace_sentence": "Understanding@@and@@anticipating@@all@@-@@cis@@open@@-@@chain@@structures@@not@@only@@make@@use@@of@@the@@classical@@Ramachandran@@maps@@at@@each@@C@@alpha@@i@@,@@relating@@to@@E@@=@@drug1@@(@@phi@@i@@,@@psi@@i@@)@@,@@but@@also@@require@@the@@profile@@of@@a@@new@@kind@@of@@conformational@@dependence@@,@@the@@drug2@@maps@@,@@relating@@to@@E@@=@@f@@(@@phi@@i@@,@@psi@@i@@-@@1@@)@@.@@", "new_pair": "f@@(@@phi@@i@@,@@psi@@i@@)@@,@@but@@also@@require@@the@@profile@@of@@a@@new@@kind@@of@@conformational@@dependence@@,@@the@@plaque", "replace_pair": "drug1@@(@@phi@@i@@,@@psi@@i@@)@@,@@but@@also@@require@@the@@profile@@of@@a@@new@@kind@@of@@conformational@@dependence@@,@@the@@drug2", "relation": "NA"}, {"head": {"id": "50", "type": "", "word": "myocardialUinfarction", "begin": "23", "end": "44", "new_begin": "28", "new_end": "49", "replace_begin": "28", "replace_end": "33"}, "tail": {"id": "51", "type": "", "word": "aspirin", "begin": "98", "end": "105", "new_begin": "120", "new_end": "127", "replace_begin": "104", "replace_end": "109"}, "sentence": "118 patients had had a myocardialUinfarction , 69 . 5 % were on a statin and 60 . 2 % were taking aspirin .", "new_sentence": "118@@patients@@had@@had@@a@@myocardialUinfarction@@,@@69@@.@@5@@%@@were@@on@@a@@statin@@and@@60@@.@@2@@%@@were@@taking@@aspirin@@.@@", "replace_sentence": "118@@patients@@had@@had@@a@@drug1@@,@@69@@.@@5@@%@@were@@on@@a@@statin@@and@@60@@.@@2@@%@@were@@taking@@drug2@@.@@", "new_pair": "myocardialUinfarction@@,@@69@@.@@5@@%@@were@@on@@a@@statin@@and@@60@@.@@2@@%@@were@@taking@@aspirin", "replace_pair": "drug1@@,@@69@@.@@5@@%@@were@@on@@a@@statin@@and@@60@@.@@2@@%@@were@@taking@@drug2", "relation": "NA"}, {"head": {"id": "52", "type": "", "word": "IR", "begin": "0", "end": "2", "new_begin": "0", "new_end": "2", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "53", "type": "", "word": "oxygen", "begin": "44", "end": "50", "new_begin": "54", "new_end": "60", "replace_begin": "57", "replace_end": "62"}, "sentence": "IR was achieved by placing animals in a 5 % oxygen environment and preventing venular flow , after which blood flow was allowed to resume .", "new_sentence": "IR@@was@@achieved@@by@@placing@@animals@@in@@a@@5@@%@@oxygen@@environment@@and@@preventing@@venular@@flow@@,@@after@@which@@blood@@flow@@was@@allowed@@to@@resume@@.@@", "replace_sentence": "drug1@@was@@achieved@@by@@placing@@animals@@in@@a@@5@@%@@drug2@@environment@@and@@preventing@@venular@@flow@@,@@after@@which@@blood@@flow@@was@@allowed@@to@@resume@@.@@", "new_pair": "IR@@was@@achieved@@by@@placing@@animals@@in@@a@@5@@%@@oxygen", "replace_pair": "drug1@@was@@achieved@@by@@placing@@animals@@in@@a@@5@@%@@drug2", "relation": "NA"}, {"head": {"id": "54", "type": "", "word": "Graft-versus-hostUdisease", "begin": "0", "end": "25", "new_begin": "0", "new_end": "25", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "55", "type": "", "word": "cyclosporine", "begin": "60", "end": "72", "new_begin": "69", "new_end": "81", "replace_begin": "49", "replace_end": "54"}, "sentence": "Graft-versus-hostUdisease prophylaxis consisted of low-dose cyclosporine alone .", "new_sentence": "Graft-versus-hostUdisease@@prophylaxis@@consisted@@of@@low@@-@@dose@@cyclosporine@@alone@@.@@", "replace_sentence": "drug1@@prophylaxis@@consisted@@of@@low@@-@@dose@@drug2@@alone@@.@@", "new_pair": "Graft-versus-hostUdisease@@prophylaxis@@consisted@@of@@low@@-@@dose@@cyclosporine", "replace_pair": "drug1@@prophylaxis@@consisted@@of@@low@@-@@dose@@drug2", "relation": "NA"}, {"head": {"id": "56", "type": "", "word": "vitaminUB12", "begin": "92", "end": "103", "new_begin": "106", "new_end": "117", "replace_begin": "106", "replace_end": "111"}, "tail": {"id": "57", "type": "", "word": "folateUdeficiency", "begin": "108", "end": "125", "new_begin": "124", "new_end": "141", "replace_begin": "118", "replace_end": "123"}, "sentence": "She was found to have bilateral central retinal vein occlusion with significant anaemia and vitaminUB12 and folateUdeficiency .", "new_sentence": "She@@was@@found@@to@@have@@bilateral@@central@@retinal@@vein@@occlusion@@with@@significant@@anaemia@@and@@vitaminUB12@@and@@folateUdeficiency@@.@@", "replace_sentence": "She@@was@@found@@to@@have@@bilateral@@central@@retinal@@vein@@occlusion@@with@@significant@@anaemia@@and@@drug1@@and@@drug2@@.@@", "new_pair": "vitaminUB12@@and@@folateUdeficiency", "replace_pair": "drug1@@and@@drug2", "relation": "NA"}, {"head": {"id": "58", "type": "", "word": "itraconazole", "begin": "99", "end": "111", "new_begin": "112", "new_end": "124", "replace_begin": "112", "replace_end": "117"}, "tail": {"id": "59", "type": "", "word": "fungalUinfections", "begin": "294", "end": "311", "new_begin": "332", "new_end": "349", "replace_begin": "325", "replace_end": "330"}, "sentence": "CONCLUSIONS : In specific groups of neutropenic patients treated for haematological malignancies , itraconazole prophylaxis could potentially reduce overall healthcare expenditure , without harming effectiveness , in settings where fluconazole is common practice in the prophylaxis of invasive fungalUinfections .", "new_sentence": "CONCLUSIONS@@:@@In@@specific@@groups@@of@@neutropenic@@patients@@treated@@for@@haematological@@malignancies@@,@@itraconazole@@prophylaxis@@could@@potentially@@reduce@@overall@@healthcare@@expenditure@@,@@without@@harming@@effectiveness@@,@@in@@settings@@where@@fluconazole@@is@@common@@practice@@in@@the@@prophylaxis@@of@@invasive@@fungalUinfections@@.@@", "replace_sentence": "CONCLUSIONS@@:@@In@@specific@@groups@@of@@neutropenic@@patients@@treated@@for@@haematological@@malignancies@@,@@drug1@@prophylaxis@@could@@potentially@@reduce@@overall@@healthcare@@expenditure@@,@@without@@harming@@effectiveness@@,@@in@@settings@@where@@fluconazole@@is@@common@@practice@@in@@the@@prophylaxis@@of@@invasive@@drug2@@.@@", "new_pair": "itraconazole@@prophylaxis@@could@@potentially@@reduce@@overall@@healthcare@@expenditure@@,@@without@@harming@@effectiveness@@,@@in@@settings@@where@@fluconazole@@is@@common@@practice@@in@@the@@prophylaxis@@of@@invasive@@fungalUinfections", "replace_pair": "drug1@@prophylaxis@@could@@potentially@@reduce@@overall@@healthcare@@expenditure@@,@@without@@harming@@effectiveness@@,@@in@@settings@@where@@fluconazole@@is@@common@@practice@@in@@the@@prophylaxis@@of@@invasive@@drug2", "relation": "NA"}, {"head": {"id": "60", "type": "", "word": "IR", "begin": "50", "end": "52", "new_begin": "64", "new_end": "66", "replace_begin": "64", "replace_end": "69"}, "tail": {"id": "61", "type": "", "word": "NAC", "begin": "55", "end": "58", "new_begin": "71", "new_end": "74", "replace_begin": "74", "replace_end": "79"}, "sentence": "Treatment groups were : ( 1 ) IR - Saline , ( 2 ) IR - NAC , ( 3 ) Sham - Saline and ( 4 ) Sham - NAC .", "new_sentence": "Treatment@@groups@@were@@:@@(@@1@@)@@IR@@-@@Saline@@,@@(@@2@@)@@IR@@-@@NAC@@,@@(@@3@@)@@Sham@@-@@Saline@@and@@(@@4@@)@@Sham@@-@@NAC@@.@@", "replace_sentence": "Treatment@@groups@@were@@:@@(@@1@@)@@IR@@-@@Saline@@,@@(@@2@@)@@drug1@@-@@drug2@@,@@(@@3@@)@@Sham@@-@@Saline@@and@@(@@4@@)@@Sham@@-@@NAC@@.@@", "new_pair": "IR@@-@@NAC", "replace_pair": "drug1@@-@@drug2", "relation": "NA"}, {"head": {"id": "62", "type": "", "word": "Aspirin", "begin": "0", "end": "7", "new_begin": "0", "new_end": "7", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "63", "type": "", "word": "heartUattacks", "begin": "57", "end": "70", "new_begin": "65", "new_end": "78", "replace_begin": "63", "replace_end": "68"}, "sentence": "Aspirin therapy does less than anticipated in preventing heartUattacks in women --but more than we knew in warding off strokes .", "new_sentence": "Aspirin@@therapy@@does@@less@@than@@anticipated@@in@@preventing@@heartUattacks@@in@@women@@-@@-@@but@@more@@than@@we@@knew@@in@@warding@@off@@strokes@@.@@", "replace_sentence": "drug1@@therapy@@does@@less@@than@@anticipated@@in@@preventing@@drug2@@in@@women@@-@@-@@but@@more@@than@@we@@knew@@in@@warding@@off@@strokes@@.@@", "new_pair": "Aspirin@@therapy@@does@@less@@than@@anticipated@@in@@preventing@@heartUattacks", "replace_pair": "drug1@@therapy@@does@@less@@than@@anticipated@@in@@preventing@@drug2", "relation": "may_prevent"}, {"head": {"id": "64", "type": "", "word": "GVHD", "begin": "0", "end": "4", "new_begin": "0", "new_end": "4", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "65", "type": "", "word": "cyclosporine", "begin": "26", "end": "38", "new_begin": "29", "new_end": "41", "replace_begin": "30", "replace_end": "35"}, "sentence": "GVHD prophylaxis included cyclosporine , methylprednisolone , and escalating doses of narrowband UV -B ( 311 nm ) according to skin tolerance , 3 days a week , from 10 days before to 28 days after transplantation .", "new_sentence": "GVHD@@prophylaxis@@included@@cyclosporine@@,@@methylprednisolone@@,@@and@@escalating@@doses@@of@@narrowband@@UV@@-@@B@@(@@311@@nm@@)@@according@@to@@skin@@tolerance@@,@@3@@days@@a@@week@@,@@from@@10@@days@@before@@to@@28@@days@@after@@transplantation@@.@@", "replace_sentence": "drug1@@prophylaxis@@included@@drug2@@,@@methylprednisolone@@,@@and@@escalating@@doses@@of@@narrowband@@UV@@-@@B@@(@@311@@nm@@)@@according@@to@@skin@@tolerance@@,@@3@@days@@a@@week@@,@@from@@10@@days@@before@@to@@28@@days@@after@@transplantation@@.@@", "new_pair": "GVHD@@prophylaxis@@included@@cyclosporine", "replace_pair": "drug1@@prophylaxis@@included@@drug2", "relation": "NA"}, {"head": {"id": "66", "type": "", "word": "graft-versus-host-disease", "begin": "303", "end": "328", "new_begin": "358", "new_end": "383", "replace_begin": "358", "replace_end": "363"}, "tail": {"id": "67", "type": "", "word": "cyclosporine", "begin": "365", "end": "377", "new_begin": "427", "new_end": "439", "replace_begin": "407", "replace_end": "412"}, "sentence": "We conducted an individual patient data meta-analysis using data from nine randomized trials comparing allogeneic peripheral blood stem cell ( PBSCT ) transplants to bone marrow ( BMT ) transplants , focusing on the administration of three vs four doses of methotrexate ( MTX ) as part of a regimen for graft-versus-host-disease ( GVHD ) prophylaxis which included cyclosporine .", "new_sentence": "We@@conducted@@an@@individual@@patient@@data@@meta@@-@@analysis@@using@@data@@from@@nine@@randomized@@trials@@comparing@@allogeneic@@peripheral@@blood@@stem@@cell@@(@@PBSCT@@)@@transplants@@to@@bone@@marrow@@(@@BMT@@)@@transplants@@,@@focusing@@on@@the@@administration@@of@@three@@vs@@four@@doses@@of@@methotrexate@@(@@MTX@@)@@as@@part@@of@@a@@regimen@@for@@graft-versus-host-disease@@(@@GVHD@@)@@prophylaxis@@which@@included@@cyclosporine@@.@@", "replace_sentence": "We@@conducted@@an@@individual@@patient@@data@@meta@@-@@analysis@@using@@data@@from@@nine@@randomized@@trials@@comparing@@allogeneic@@peripheral@@blood@@stem@@cell@@(@@PBSCT@@)@@transplants@@to@@bone@@marrow@@(@@BMT@@)@@transplants@@,@@focusing@@on@@the@@administration@@of@@three@@vs@@four@@doses@@of@@methotrexate@@(@@MTX@@)@@as@@part@@of@@a@@regimen@@for@@drug1@@(@@GVHD@@)@@prophylaxis@@which@@included@@drug2@@.@@", "new_pair": "graft-versus-host-disease@@(@@GVHD@@)@@prophylaxis@@which@@included@@cyclosporine", "replace_pair": "drug1@@(@@GVHD@@)@@prophylaxis@@which@@included@@drug2", "relation": "NA"}, {"head": {"id": "68", "type": "", "word": "Palivizumab", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "69", "type": "", "word": "respiratoryUsyncytialUvirusU ( URSVU ) Uinfections", "begin": "163", "end": "213", "new_begin": "191", "new_end": "241", "replace_begin": "185", "replace_end": "190"}, "sentence": "Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous ( RSV-IGIV ) are licensed by the Food and Drug Administration for use in preventing severe respiratoryUsyncytialUvirusU ( URSVU ) Uinfections in high-risk infants , children younger than 24 months with chronic lung disease ( formerly called bronchopulmonary dysplasia ) , and certain preterm infants .", "new_sentence": "Palivizumab@@and@@Respiratory@@Syncytial@@Virus@@Immune@@Globulin@@Intravenous@@(@@RSV@@-@@IGIV@@)@@are@@licensed@@by@@the@@Food@@and@@Drug@@Administration@@for@@use@@in@@preventing@@severe@@respiratoryUsyncytialUvirusU ( URSVU ) Uinfections@@in@@high@@-@@risk@@infants@@,@@children@@younger@@than@@24@@months@@with@@chronic@@lung@@disease@@(@@formerly@@called@@bronchopulmonary@@dysplasia@@)@@,@@and@@certain@@preterm@@infants@@.@@", "replace_sentence": "drug1@@and@@Respiratory@@Syncytial@@Virus@@Immune@@Globulin@@Intravenous@@(@@RSV@@-@@IGIV@@)@@are@@licensed@@by@@the@@Food@@and@@Drug@@Administration@@for@@use@@in@@preventing@@severe@@drug2@@in@@high@@-@@risk@@infants@@,@@children@@younger@@than@@24@@months@@with@@chronic@@lung@@disease@@(@@formerly@@called@@bronchopulmonary@@dysplasia@@)@@,@@and@@certain@@preterm@@infants@@.@@", "new_pair": "Palivizumab@@and@@Respiratory@@Syncytial@@Virus@@Immune@@Globulin@@Intravenous@@(@@RSV@@-@@IGIV@@)@@are@@licensed@@by@@the@@Food@@and@@Drug@@Administration@@for@@use@@in@@preventing@@severe@@respiratoryUsyncytialUvirusU ( URSVU ) Uinfections", "replace_pair": "drug1@@and@@Respiratory@@Syncytial@@Virus@@Immune@@Globulin@@Intravenous@@(@@RSV@@-@@IGIV@@)@@are@@licensed@@by@@the@@Food@@and@@Drug@@Administration@@for@@use@@in@@preventing@@severe@@drug2", "relation": "may_prevent"}, {"head": {"id": "70", "type": "", "word": "HBIG", "begin": "63", "end": "67", "new_begin": "72", "new_end": "76", "replace_begin": "72", "replace_end": "77"}, "tail": {"id": "71", "type": "", "word": "HepatitisUB", "begin": "97", "end": "108", "new_begin": "112", "new_end": "123", "replace_begin": "113", "replace_end": "118"}, "sentence": "Hepatitis B immunoglobulin with lamivudine prophylaxis ( LAM @ HBIG ) is effective in preventing HepatitisUB ( HBV ) recurrence posttransplant but is expensive and inconvenient .", "new_sentence": "Hepatitis@@B@@immunoglobulin@@with@@lamivudine@@prophylaxis@@(@@LAM@@@@@HBIG@@)@@is@@effective@@in@@preventing@@HepatitisUB@@(@@HBV@@)@@recurrence@@posttransplant@@but@@is@@expensive@@and@@inconvenient@@.@@", "replace_sentence": "Hepatitis@@B@@immunoglobulin@@with@@lamivudine@@prophylaxis@@(@@LAM@@@@@drug1@@)@@is@@effective@@in@@preventing@@drug2@@(@@HBV@@)@@recurrence@@posttransplant@@but@@is@@expensive@@and@@inconvenient@@.@@", "new_pair": "HBIG@@)@@is@@effective@@in@@preventing@@HepatitisUB", "replace_pair": "drug1@@)@@is@@effective@@in@@preventing@@drug2", "relation": "may_prevent"}, {"head": {"id": "72", "type": "", "word": "lipidemia", "begin": "83", "end": "92", "new_begin": "93", "new_end": "102", "replace_begin": "93", "replace_end": "98"}, "tail": {"id": "73", "type": "", "word": "calciumUcarbonate", "begin": "167", "end": "184", "new_begin": "189", "new_end": "206", "replace_begin": "185", "replace_end": "190"}, "sentence": "CONCLUSIONS : Increased calcium intakes from dairy products attenuate postprandial lipidemia , most probably because of reduced fat absorption , whereas supplementary calciumUcarbonate does not exert such an effect .", "new_sentence": "CONCLUSIONS@@:@@Increased@@calcium@@intakes@@from@@dairy@@products@@attenuate@@postprandial@@lipidemia@@,@@most@@probably@@because@@of@@reduced@@fat@@absorption@@,@@whereas@@supplementary@@calciumUcarbonate@@does@@not@@exert@@such@@an@@effect@@.@@", "replace_sentence": "CONCLUSIONS@@:@@Increased@@calcium@@intakes@@from@@dairy@@products@@attenuate@@postprandial@@drug1@@,@@most@@probably@@because@@of@@reduced@@fat@@absorption@@,@@whereas@@supplementary@@drug2@@does@@not@@exert@@such@@an@@effect@@.@@", "new_pair": "lipidemia@@,@@most@@probably@@because@@of@@reduced@@fat@@absorption@@,@@whereas@@supplementary@@calciumUcarbonate", "replace_pair": "drug1@@,@@most@@probably@@because@@of@@reduced@@fat@@absorption@@,@@whereas@@supplementary@@drug2", "relation": "NA"}, {"head": {"id": "74", "type": "", "word": "aspirin", "begin": "107", "end": "114", "new_begin": "123", "new_end": "130", "replace_begin": "123", "replace_end": "128"}, "tail": {"id": "75", "type": "", "word": "MI", "begin": "181", "end": "183", "new_begin": "207", "new_end": "209", "replace_begin": "205", "replace_end": "210"}, "sentence": "The ESTEEM study showed that the oral thrombin inhibitor ximelagatran plus aspirin was more effective than aspirin alone in the prophylaxis of major cardiovascular events following MI .", "new_sentence": "The@@ESTEEM@@study@@showed@@that@@the@@oral@@thrombin@@inhibitor@@ximelagatran@@plus@@aspirin@@was@@more@@effective@@than@@aspirin@@alone@@in@@the@@prophylaxis@@of@@major@@cardiovascular@@events@@following@@MI@@.@@", "replace_sentence": "The@@ESTEEM@@study@@showed@@that@@the@@oral@@thrombin@@inhibitor@@ximelagatran@@plus@@aspirin@@was@@more@@effective@@than@@drug1@@alone@@in@@the@@prophylaxis@@of@@major@@cardiovascular@@events@@following@@drug2@@.@@", "new_pair": "aspirin@@alone@@in@@the@@prophylaxis@@of@@major@@cardiovascular@@events@@following@@MI", "replace_pair": "drug1@@alone@@in@@the@@prophylaxis@@of@@major@@cardiovascular@@events@@following@@drug2", "relation": "NA"}, {"head": {"id": "76", "type": "", "word": "iron", "begin": "88", "end": "92", "new_begin": "101", "new_end": "105", "replace_begin": "101", "replace_end": "106"}, "tail": {"id": "77", "type": "", "word": "vitaminUB12Udeficiencies", "begin": "97", "end": "121", "new_begin": "112", "new_end": "136", "replace_begin": "113", "replace_end": "118"}, "sentence": "CONCLUSION : Our routine scheme of vitamin supplementation is not sufficient to prevent iron and vitaminUB12Udeficiencies in most patients .", "new_sentence": "CONCLUSION@@:@@Our@@routine@@scheme@@of@@vitamin@@supplementation@@is@@not@@sufficient@@to@@prevent@@iron@@and@@vitaminUB12Udeficiencies@@in@@most@@patients@@.@@", "replace_sentence": "CONCLUSION@@:@@Our@@routine@@scheme@@of@@vitamin@@supplementation@@is@@not@@sufficient@@to@@prevent@@drug1@@and@@drug2@@in@@most@@patients@@.@@", "new_pair": "iron@@and@@vitaminUB12Udeficiencies", "replace_pair": "drug1@@and@@drug2", "relation": "NA"}, {"head": {"id": "78", "type": "", "word": "Fluconazole", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "79", "type": "", "word": "fungalUinfections", "begin": "41", "end": "58", "new_begin": "45", "new_end": "62", "replace_begin": "39", "replace_end": "44"}, "sentence": "Fluconazole prophylaxis reduced invasive fungalUinfections by about 75 % ( RR 0 . 28 , 95 % CI : 0 . 13-0 . 57 ) .", "new_sentence": "Fluconazole@@prophylaxis@@reduced@@invasive@@fungalUinfections@@by@@about@@75@@%@@(@@RR@@0@@.@@28@@,@@95@@%@@CI@@:@@0@@.@@13@@-@@0@@.@@57@@)@@.@@", "replace_sentence": "drug1@@prophylaxis@@reduced@@invasive@@drug2@@by@@about@@75@@%@@(@@RR@@0@@.@@28@@,@@95@@%@@CI@@:@@0@@.@@13@@-@@0@@.@@57@@)@@.@@", "new_pair": "Fluconazole@@prophylaxis@@reduced@@invasive@@fungalUinfections", "replace_pair": "drug1@@prophylaxis@@reduced@@invasive@@drug2", "relation": "may_prevent"}, {"head": {"id": "80", "type": "", "word": "Aspirin", "begin": "0", "end": "7", "new_begin": "0", "new_end": "7", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "81", "type": "", "word": "myocardialUinfarction", "begin": "183", "end": "204", "new_begin": "212", "new_end": "233", "replace_begin": "210", "replace_end": "215"}, "sentence": "Aspirin has the largest and most persuasive body of randomized trial evidence to support its use in secondary prevention for cardiovascular disease ( CVD ) and primary prevention for myocardialUinfarction .", "new_sentence": "Aspirin@@has@@the@@largest@@and@@most@@persuasive@@body@@of@@randomized@@trial@@evidence@@to@@support@@its@@use@@in@@secondary@@prevention@@for@@cardiovascular@@disease@@(@@CVD@@)@@and@@primary@@prevention@@for@@myocardialUinfarction@@.@@", "replace_sentence": "drug1@@has@@the@@largest@@and@@most@@persuasive@@body@@of@@randomized@@trial@@evidence@@to@@support@@its@@use@@in@@secondary@@prevention@@for@@cardiovascular@@disease@@(@@CVD@@)@@and@@primary@@prevention@@for@@drug2@@.@@", "new_pair": "Aspirin@@has@@the@@largest@@and@@most@@persuasive@@body@@of@@randomized@@trial@@evidence@@to@@support@@its@@use@@in@@secondary@@prevention@@for@@cardiovascular@@disease@@(@@CVD@@)@@and@@primary@@prevention@@for@@myocardialUinfarction", "replace_pair": "drug1@@has@@the@@largest@@and@@most@@persuasive@@body@@of@@randomized@@trial@@evidence@@to@@support@@its@@use@@in@@secondary@@prevention@@for@@cardiovascular@@disease@@(@@CVD@@)@@and@@primary@@prevention@@for@@drug2", "relation": "may_prevent"}, {"head": {"id": "82", "type": "", "word": "cobalaminUdeficiency", "begin": "117", "end": "137", "new_begin": "135", "new_end": "155", "replace_begin": "135", "replace_end": "140"}, "tail": {"id": "83", "type": "", "word": "cobalamin", "begin": "155", "end": "164", "new_begin": "176", "new_end": "185", "replace_begin": "161", "replace_end": "166"}, "sentence": "Moreover , cobalamin resistance may occur in diabetes , renal insufficiency and advanced age , leading to functional cobalaminUdeficiency despite adequate cobalamin nutriture .", "new_sentence": "Moreover@@,@@cobalamin@@resistance@@may@@occur@@in@@diabetes@@,@@renal@@insufficiency@@and@@advanced@@age@@,@@leading@@to@@functional@@cobalaminUdeficiency@@despite@@adequate@@cobalamin@@nutriture@@.@@", "replace_sentence": "Moreover@@,@@cobalamin@@resistance@@may@@occur@@in@@diabetes@@,@@renal@@insufficiency@@and@@advanced@@age@@,@@leading@@to@@functional@@drug1@@despite@@adequate@@drug2@@nutriture@@.@@", "new_pair": "cobalaminUdeficiency@@despite@@adequate@@cobalamin", "replace_pair": "drug1@@despite@@adequate@@drug2", "relation": "NA"}, {"head": {"id": "84", "type": "", "word": "ganciclovir", "begin": "88", "end": "99", "new_begin": "100", "new_end": "111", "replace_begin": "100", "replace_end": "105"}, "tail": {"id": "85", "type": "", "word": "CMVUdisease", "begin": "130", "end": "141", "new_begin": "149", "new_end": "160", "replace_begin": "143", "replace_end": "148"}, "sentence": "Those with CMV reactivation ( positive antigenemia ) received preemptive treatment with ganciclovir and @ or foscarnet to prevent CMVUdisease .", "new_sentence": "Those@@with@@CMV@@reactivation@@(@@positive@@antigenemia@@)@@received@@preemptive@@treatment@@with@@ganciclovir@@and@@@@@or@@foscarnet@@to@@prevent@@CMVUdisease@@.@@", "replace_sentence": "Those@@with@@CMV@@reactivation@@(@@positive@@antigenemia@@)@@received@@preemptive@@treatment@@with@@drug1@@and@@@@@or@@foscarnet@@to@@prevent@@drug2@@.@@", "new_pair": "ganciclovir@@and@@@@@or@@foscarnet@@to@@prevent@@CMVUdisease", "replace_pair": "drug1@@and@@@@@or@@foscarnet@@to@@prevent@@drug2", "relation": "may_prevent"}, {"head": {"id": "86", "type": "", "word": "FluticasoneUpropionate", "begin": "0", "end": "22", "new_begin": "0", "new_end": "22", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "87", "type": "", "word": "asthma", "begin": "126", "end": "132", "new_begin": "144", "new_end": "150", "replace_begin": "127", "replace_end": "132"}, "sentence": "FluticasoneUpropionate ( FP ) and salmeterol ( S ) are clinically effective and act synergistically in controlling persistent asthma ;", "new_sentence": "FluticasoneUpropionate@@(@@FP@@)@@and@@salmeterol@@(@@S@@)@@are@@clinically@@effective@@and@@act@@synergistically@@in@@controlling@@persistent@@asthma@@;@@", "replace_sentence": "drug1@@(@@FP@@)@@and@@salmeterol@@(@@S@@)@@are@@clinically@@effective@@and@@act@@synergistically@@in@@controlling@@persistent@@drug2@@;@@", "new_pair": "FluticasoneUpropionate@@(@@FP@@)@@and@@salmeterol@@(@@S@@)@@are@@clinically@@effective@@and@@act@@synergistically@@in@@controlling@@persistent@@asthma", "replace_pair": "drug1@@(@@FP@@)@@and@@salmeterol@@(@@S@@)@@are@@clinically@@effective@@and@@act@@synergistically@@in@@controlling@@persistent@@drug2", "relation": "NA"}, {"head": {"id": "88", "type": "", "word": "TransientUIschaemicUAttack", "begin": "130", "end": "156", "new_begin": "157", "new_end": "183", "replace_begin": "157", "replace_end": "162"}, "tail": {"id": "89", "type": "", "word": "aspirin", "begin": "238", "end": "245", "new_begin": "286", "new_end": "293", "replace_begin": "265", "replace_end": "270"}, "sentence": "The results of the following studies are reviewed and compared : the Swedish Aspirin Low-Dose Trial ( SALT ) , the United Kingdom TransientUIschaemicUAttack ( UK-TIA ) Aspirin Trial , Dutch Transient Ischemic Attack ( Dutch TIA ) study ( aspirin ) , the Canadian American Ticlopidine Study ( CATS ) , the Ticlopidine Aspirin Stroke Study ( TASS ) , the African American Antiplatelet Stroke Prevention Study ( AAASPS ) ( ticlopidine ) , the Clopidogrel versus Aspirin in Patients at Risk of Recurrent Ischemic Events ( CAPRIE ) trial , the Management of Atherothrombosis With Clopidogrel in High-Risk Patients study ( MATCH ) ( clopidogrel ) , the second European Stroke Prevention Study ( ESPS2 ) ( aspirin plus ER-DP ) , and the Triflusal versus Aspirin in Cerebral Infarction Prevention ( TACIP ) study .", "new_sentence": "The@@results@@of@@the@@following@@studies@@are@@reviewed@@and@@compared@@:@@the@@Swedish@@Aspirin@@Low@@-@@Dose@@Trial@@(@@SALT@@)@@,@@the@@United@@Kingdom@@TransientUIschaemicUAttack@@(@@UK@@-@@TIA@@)@@Aspirin@@Trial@@,@@Dutch@@Transient@@Ischemic@@Attack@@(@@Dutch@@TIA@@)@@study@@(@@aspirin@@)@@,@@the@@Canadian@@American@@Ticlopidine@@Study@@(@@CATS@@)@@,@@the@@Ticlopidine@@Aspirin@@Stroke@@Study@@(@@TASS@@)@@,@@the@@African@@American@@Antiplatelet@@Stroke@@Prevention@@Study@@(@@AAASPS@@)@@(@@ticlopidine@@)@@,@@the@@Clopidogrel@@versus@@Aspirin@@in@@Patients@@at@@Risk@@of@@Recurrent@@Ischemic@@Events@@(@@CAPRIE@@)@@trial@@,@@the@@Management@@of@@Atherothrombosis@@With@@Clopidogrel@@in@@High@@-@@Risk@@Patients@@study@@(@@MATCH@@)@@(@@clopidogrel@@)@@,@@the@@second@@European@@Stroke@@Prevention@@Study@@(@@ESPS2@@)@@(@@aspirin@@plus@@ER@@-@@DP@@)@@,@@and@@the@@Triflusal@@versus@@Aspirin@@in@@Cerebral@@Infarction@@Prevention@@(@@TACIP@@)@@study@@.@@", "replace_sentence": "The@@results@@of@@the@@following@@studies@@are@@reviewed@@and@@compared@@:@@the@@Swedish@@Aspirin@@Low@@-@@Dose@@Trial@@(@@SALT@@)@@,@@the@@United@@Kingdom@@drug1@@(@@UK@@-@@TIA@@)@@Aspirin@@Trial@@,@@Dutch@@Transient@@Ischemic@@Attack@@(@@Dutch@@TIA@@)@@study@@(@@drug2@@)@@,@@the@@Canadian@@American@@Ticlopidine@@Study@@(@@CATS@@)@@,@@the@@Ticlopidine@@Aspirin@@Stroke@@Study@@(@@TASS@@)@@,@@the@@African@@American@@Antiplatelet@@Stroke@@Prevention@@Study@@(@@AAASPS@@)@@(@@ticlopidine@@)@@,@@the@@Clopidogrel@@versus@@Aspirin@@in@@Patients@@at@@Risk@@of@@Recurrent@@Ischemic@@Events@@(@@CAPRIE@@)@@trial@@,@@the@@Management@@of@@Atherothrombosis@@With@@Clopidogrel@@in@@High@@-@@Risk@@Patients@@study@@(@@MATCH@@)@@(@@clopidogrel@@)@@,@@the@@second@@European@@Stroke@@Prevention@@Study@@(@@ESPS2@@)@@(@@aspirin@@plus@@ER@@-@@DP@@)@@,@@and@@the@@Triflusal@@versus@@Aspirin@@in@@Cerebral@@Infarction@@Prevention@@(@@TACIP@@)@@study@@.@@", "new_pair": "TransientUIschaemicUAttack@@(@@UK@@-@@TIA@@)@@Aspirin@@Trial@@,@@Dutch@@Transient@@Ischemic@@Attack@@(@@Dutch@@TIA@@)@@study@@(@@aspirin", "replace_pair": "drug1@@(@@UK@@-@@TIA@@)@@Aspirin@@Trial@@,@@Dutch@@Transient@@Ischemic@@Attack@@(@@Dutch@@TIA@@)@@study@@(@@drug2", "relation": "NA"}, {"head": {"id": "90", "type": "", "word": "CLopidogrel", "begin": "397", "end": "408", "new_begin": "458", "new_end": "469", "replace_begin": "458", "replace_end": "463"}, "tail": {"id": "91", "type": "", "word": "MyocardialUInfarction", "begin": "540", "end": "561", "new_begin": "624", "new_end": "645", "replace_begin": "618", "replace_end": "623"}, "sentence": "Furthermore , the benefit of clopidogrel compared with placebo in patients with acute coronary syndromes , as well as those undergoing percutaneous coronary intervention receiving a standard therapy including aspirin , has been largely demonstrated by the Clopidogrel in Unstable angina to prevent Recurrent Events ( CURE ) , Clopidogrel for the Reduction of Events During Observation ( CREDO ) , CLopidogrel as Adjunctive ReperfusIon TherapY - Thrombolysis In Myocardial Infarction ( CLARITY -TIMI ) 28 , and Clopidogrel and Metoprolol in MyocardialUInfarction Trial @ Secon Chinese Cardiac Study ( COMMIT @ CCS -2 ) trials .", "new_sentence": "Furthermore@@,@@the@@benefit@@of@@clopidogrel@@compared@@with@@placebo@@in@@patients@@with@@acute@@coronary@@syndromes@@,@@as@@well@@as@@those@@undergoing@@percutaneous@@coronary@@intervention@@receiving@@a@@standard@@therapy@@including@@aspirin@@,@@has@@been@@largely@@demonstrated@@by@@the@@Clopidogrel@@in@@Unstable@@angina@@to@@prevent@@Recurrent@@Events@@(@@CURE@@)@@,@@Clopidogrel@@for@@the@@Reduction@@of@@Events@@During@@Observation@@(@@CREDO@@)@@,@@CLopidogrel@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@Myocardial@@Infarction@@(@@CLARITY@@-@@TIMI@@)@@28@@,@@and@@Clopidogrel@@and@@Metoprolol@@in@@MyocardialUInfarction@@Trial@@@@@Secon@@Chinese@@Cardiac@@Study@@(@@COMMIT@@@@@CCS@@-@@2@@)@@trials@@.@@", "replace_sentence": "Furthermore@@,@@the@@benefit@@of@@clopidogrel@@compared@@with@@placebo@@in@@patients@@with@@acute@@coronary@@syndromes@@,@@as@@well@@as@@those@@undergoing@@percutaneous@@coronary@@intervention@@receiving@@a@@standard@@therapy@@including@@aspirin@@,@@has@@been@@largely@@demonstrated@@by@@the@@Clopidogrel@@in@@Unstable@@angina@@to@@prevent@@Recurrent@@Events@@(@@CURE@@)@@,@@Clopidogrel@@for@@the@@Reduction@@of@@Events@@During@@Observation@@(@@CREDO@@)@@,@@drug1@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@Myocardial@@Infarction@@(@@CLARITY@@-@@TIMI@@)@@28@@,@@and@@Clopidogrel@@and@@Metoprolol@@in@@drug2@@Trial@@@@@Secon@@Chinese@@Cardiac@@Study@@(@@COMMIT@@@@@CCS@@-@@2@@)@@trials@@.@@", "new_pair": "CLopidogrel@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@Myocardial@@Infarction@@(@@CLARITY@@-@@TIMI@@)@@28@@,@@and@@Clopidogrel@@and@@Metoprolol@@in@@MyocardialUInfarction", "replace_pair": "drug1@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@Myocardial@@Infarction@@(@@CLARITY@@-@@TIMI@@)@@28@@,@@and@@Clopidogrel@@and@@Metoprolol@@in@@drug2", "relation": "NA"}, {"head": {"id": "92", "type": "", "word": "coronaryUthrombosis", "begin": "11", "end": "30", "new_begin": "13", "new_end": "32", "replace_begin": "13", "replace_end": "18"}, "tail": {"id": "93", "type": "", "word": "clopidogrel", "begin": "135", "end": "146", "new_begin": "164", "new_end": "175", "replace_begin": "150", "replace_end": "155"}, "sentence": "To prevent coronaryUthrombosis , long-term anti- thrombosis using anti-platelet drugs , such as aspirin , dipyridamole , ticlopidine , clopidogrel , and abciximab , with or without warfarin is recommended by official guidelines .", "new_sentence": "To@@prevent@@coronaryUthrombosis@@,@@long@@-@@term@@anti@@-@@thrombosis@@using@@anti@@-@@platelet@@drugs@@,@@such@@as@@aspirin@@,@@dipyridamole@@,@@ticlopidine@@,@@clopidogrel@@,@@and@@abciximab@@,@@with@@or@@without@@warfarin@@is@@recommended@@by@@official@@guidelines@@.@@", "replace_sentence": "To@@prevent@@drug1@@,@@long@@-@@term@@anti@@-@@thrombosis@@using@@anti@@-@@platelet@@drugs@@,@@such@@as@@aspirin@@,@@dipyridamole@@,@@ticlopidine@@,@@drug2@@,@@and@@abciximab@@,@@with@@or@@without@@warfarin@@is@@recommended@@by@@official@@guidelines@@.@@", "new_pair": "coronaryUthrombosis@@,@@long@@-@@term@@anti@@-@@thrombosis@@using@@anti@@-@@platelet@@drugs@@,@@such@@as@@aspirin@@,@@dipyridamole@@,@@ticlopidine@@,@@clopidogrel", "replace_pair": "drug1@@,@@long@@-@@term@@anti@@-@@thrombosis@@using@@anti@@-@@platelet@@drugs@@,@@such@@as@@aspirin@@,@@dipyridamole@@,@@ticlopidine@@,@@drug2", "relation": "may_prevent"}, {"head": {"id": "94", "type": "", "word": "asthma", "begin": "10", "end": "16", "new_begin": "11", "new_end": "17", "replace_begin": "11", "replace_end": "16"}, "tail": {"id": "95", "type": "", "word": "FP", "begin": "39", "end": "41", "new_begin": "44", "new_end": "46", "replace_begin": "43", "replace_end": "48"}, "sentence": "Effective asthma control achieved with FP therapy permits normal activity and development of asthmatic children which prevails over exceptionally noticed side effects .", "new_sentence": "Effective@@asthma@@control@@achieved@@with@@FP@@therapy@@permits@@normal@@activity@@and@@development@@of@@asthmatic@@children@@which@@prevails@@over@@exceptionally@@noticed@@side@@effects@@.@@", "replace_sentence": "Effective@@drug1@@control@@achieved@@with@@drug2@@therapy@@permits@@normal@@activity@@and@@development@@of@@asthmatic@@children@@which@@prevails@@over@@exceptionally@@noticed@@side@@effects@@.@@", "new_pair": "asthma@@control@@achieved@@with@@FP", "replace_pair": "drug1@@control@@achieved@@with@@drug2", "relation": "NA"}, {"head": {"id": "96", "type": "", "word": "BPD", "begin": "247", "end": "250", "new_begin": "284", "new_end": "287", "replace_begin": "284", "replace_end": "289"}, "tail": {"id": "97", "type": "", "word": "O2", "begin": "305", "end": "307", "new_begin": "356", "new_end": "358", "replace_begin": "358", "replace_end": "363"}, "sentence": "Selected follow-up outcomes ( use of pulmonary medications , rehospitalization for pulmonary causes , receipt of respiratory syncytial virus prophylaxis , and neurodevelopmental abnormalities ) were compared among infants who were identified with BPD defined as O2 for 28 days ( 28 days definition ) , as O2 at 36 weeks PMA ( 36 weeks definition ) , and with the consensus definition of BPD .", "new_sentence": "Selected@@follow@@-@@up@@outcomes@@(@@use@@of@@pulmonary@@medications@@,@@rehospitalization@@for@@pulmonary@@causes@@,@@receipt@@of@@respiratory@@syncytial@@virus@@prophylaxis@@,@@and@@neurodevelopmental@@abnormalities@@)@@were@@compared@@among@@infants@@who@@were@@identified@@with@@BPD@@defined@@as@@O2@@for@@28@@days@@(@@28@@days@@definition@@)@@,@@as@@O2@@at@@36@@weeks@@PMA@@(@@36@@weeks@@definition@@)@@,@@and@@with@@the@@consensus@@definition@@of@@BPD@@.@@", "replace_sentence": "Selected@@follow@@-@@up@@outcomes@@(@@use@@of@@pulmonary@@medications@@,@@rehospitalization@@for@@pulmonary@@causes@@,@@receipt@@of@@respiratory@@syncytial@@virus@@prophylaxis@@,@@and@@neurodevelopmental@@abnormalities@@)@@were@@compared@@among@@infants@@who@@were@@identified@@with@@drug1@@defined@@as@@O2@@for@@28@@days@@(@@28@@days@@definition@@)@@,@@as@@drug2@@at@@36@@weeks@@PMA@@(@@36@@weeks@@definition@@)@@,@@and@@with@@the@@consensus@@definition@@of@@BPD@@.@@", "new_pair": "BPD@@defined@@as@@O2@@for@@28@@days@@(@@28@@days@@definition@@)@@,@@as@@O2", "replace_pair": "drug1@@defined@@as@@O2@@for@@28@@days@@(@@28@@days@@definition@@)@@,@@as@@drug2", "relation": "NA"}, {"head": {"id": "98", "type": "", "word": "cyclosporinUA", "begin": "25", "end": "38", "new_begin": "28", "new_end": "41", "replace_begin": "28", "replace_end": "33"}, "tail": {"id": "99", "type": "", "word": "graft-versus-hostUdisease", "begin": "81", "end": "106", "new_begin": "95", "new_end": "120", "replace_begin": "87", "replace_end": "92"}, "sentence": "Mycophenolate mofetile , cyclosporinUA and short-term methotrexate were used for graft-versus-hostUdisease prophylaxis .", "new_sentence": "Mycophenolate@@mofetile@@,@@cyclosporinUA@@and@@short@@-@@term@@methotrexate@@were@@used@@for@@graft-versus-hostUdisease@@prophylaxis@@.@@", "replace_sentence": "Mycophenolate@@mofetile@@,@@drug1@@and@@short@@-@@term@@methotrexate@@were@@used@@for@@drug2@@prophylaxis@@.@@", "new_pair": "cyclosporinUA@@and@@short@@-@@term@@methotrexate@@were@@used@@for@@graft-versus-hostUdisease", "replace_pair": "drug1@@and@@short@@-@@term@@methotrexate@@were@@used@@for@@drug2", "relation": "may_prevent"}, {"head": {"id": "100", "type": "", "word": "ramipril", "begin": "108", "end": "116", "new_begin": "128", "new_end": "136", "replace_begin": "128", "replace_end": "133"}, "tail": {"id": "101", "type": "", "word": "stroke", "begin": "199", "end": "205", "new_begin": "231", "new_end": "237", "replace_begin": "228", "replace_end": "233"}, "sentence": "BACKGROUND : The results of the HOPE study , a randomized clinical trial , provide strong evidence that 1 ) ramipril prevents the composite outcome of cardiovascular death , myocardial infarction or stroke in patients who are at high risk of a cardiovascular event and 2 ) ramipril is cost - effective at a threshold willingness -to- pay of $ 10 , 000 to prevent an event of the composite outcome .", "new_sentence": "BACKGROUND@@:@@The@@results@@of@@the@@HOPE@@study@@,@@a@@randomized@@clinical@@trial@@,@@provide@@strong@@evidence@@that@@1@@)@@ramipril@@prevents@@the@@composite@@outcome@@of@@cardiovascular@@death@@,@@myocardial@@infarction@@or@@stroke@@in@@patients@@who@@are@@at@@high@@risk@@of@@a@@cardiovascular@@event@@and@@2@@)@@ramipril@@is@@cost@@-@@effective@@at@@a@@threshold@@willingness@@-@@to@@-@@pay@@of@@$@@10@@,@@000@@to@@prevent@@an@@event@@of@@the@@composite@@outcome@@.@@", "replace_sentence": "BACKGROUND@@:@@The@@results@@of@@the@@HOPE@@study@@,@@a@@randomized@@clinical@@trial@@,@@provide@@strong@@evidence@@that@@1@@)@@drug1@@prevents@@the@@composite@@outcome@@of@@cardiovascular@@death@@,@@myocardial@@infarction@@or@@drug2@@in@@patients@@who@@are@@at@@high@@risk@@of@@a@@cardiovascular@@event@@and@@2@@)@@ramipril@@is@@cost@@-@@effective@@at@@a@@threshold@@willingness@@-@@to@@-@@pay@@of@@$@@10@@,@@000@@to@@prevent@@an@@event@@of@@the@@composite@@outcome@@.@@", "new_pair": "ramipril@@prevents@@the@@composite@@outcome@@of@@cardiovascular@@death@@,@@myocardial@@infarction@@or@@stroke", "replace_pair": "drug1@@prevents@@the@@composite@@outcome@@of@@cardiovascular@@death@@,@@myocardial@@infarction@@or@@drug2", "relation": "may_prevent"}, {"head": {"id": "102", "type": "", "word": "F", "begin": "29", "end": "30", "new_begin": "35", "new_end": "36", "replace_begin": "35", "replace_end": "40"}, "tail": {"id": "103", "type": "", "word": "caries", "begin": "125", "end": "131", "new_begin": "153", "new_end": "159", "replace_begin": "157", "replace_end": "162"}, "sentence": "To conclude , school - based F varnish treatment every 6 months in 13- to 16- year - olds is excellent to prevent approximal caries in medium and high caries risk areas .", "new_sentence": "To@@conclude@@,@@school@@-@@based@@F@@varnish@@treatment@@every@@6@@months@@in@@13@@-@@to@@16@@-@@year@@-@@olds@@is@@excellent@@to@@prevent@@approximal@@caries@@in@@medium@@and@@high@@caries@@risk@@areas@@.@@", "replace_sentence": "To@@conclude@@,@@school@@-@@based@@drug1@@varnish@@treatment@@every@@6@@months@@in@@13@@-@@to@@16@@-@@year@@-@@olds@@is@@excellent@@to@@prevent@@approximal@@drug2@@in@@medium@@and@@high@@caries@@risk@@areas@@.@@", "new_pair": "F@@varnish@@treatment@@every@@6@@months@@in@@13@@-@@to@@16@@-@@year@@-@@olds@@is@@excellent@@to@@prevent@@approximal@@caries", "replace_pair": "drug1@@varnish@@treatment@@every@@6@@months@@in@@13@@-@@to@@16@@-@@year@@-@@olds@@is@@excellent@@to@@prevent@@approximal@@drug2", "relation": "may_prevent"}, {"head": {"id": "104", "type": "", "word": "ischemia", "begin": "25", "end": "33", "new_begin": "30", "new_end": "38", "replace_begin": "30", "replace_end": "35"}, "tail": {"id": "105", "type": "", "word": "choline", "begin": "179", "end": "186", "new_begin": "208", "new_end": "215", "replace_begin": "205", "replace_end": "210"}, "sentence": "METHODS : The effects of ischemia and reperfusion were tested in two different models of steatotic mice : ob @ ob as a model disclosing predominantly macrovesicular steatosis and choline deficient diet having mainly microvesicular steatosis .", "new_sentence": "METHODS@@:@@The@@effects@@of@@ischemia@@and@@reperfusion@@were@@tested@@in@@two@@different@@models@@of@@steatotic@@mice@@:@@ob@@@@@ob@@as@@a@@model@@disclosing@@predominantly@@macrovesicular@@steatosis@@and@@choline@@deficient@@diet@@having@@mainly@@microvesicular@@steatosis@@.@@", "replace_sentence": "METHODS@@:@@The@@effects@@of@@drug1@@and@@reperfusion@@were@@tested@@in@@two@@different@@models@@of@@steatotic@@mice@@:@@ob@@@@@ob@@as@@a@@model@@disclosing@@predominantly@@macrovesicular@@steatosis@@and@@drug2@@deficient@@diet@@having@@mainly@@microvesicular@@steatosis@@.@@", "new_pair": "ischemia@@and@@reperfusion@@were@@tested@@in@@two@@different@@models@@of@@steatotic@@mice@@:@@ob@@@@@ob@@as@@a@@model@@disclosing@@predominantly@@macrovesicular@@steatosis@@and@@choline", "replace_pair": "drug1@@and@@reperfusion@@were@@tested@@in@@two@@different@@models@@of@@steatotic@@mice@@:@@ob@@@@@ob@@as@@a@@model@@disclosing@@predominantly@@macrovesicular@@steatosis@@and@@drug2", "relation": "NA"}, {"head": {"id": "106", "type": "", "word": "chloroquine", "begin": "55", "end": "66", "new_begin": "65", "new_end": "76", "replace_begin": "65", "replace_end": "70"}, "tail": {"id": "107", "type": "", "word": "malarial", "begin": "365", "end": "373", "new_begin": "430", "new_end": "438", "replace_begin": "424", "replace_end": "429"}, "sentence": "In preparation for a clinical trial of the efficacy of chloroquine ( CQ ) and sulfadoxine-pyrimethamine ( SP ) containing prevention regimens during pregnancy , we conducted a one - year cross sectional study in Koro and Bandiagara , Mali using an assessment methodology developed by the Centers for Disease Control and Prevention ( CDC ) to generate basic data on malarial burden during pregnancy .", "new_sentence": "In@@preparation@@for@@a@@clinical@@trial@@of@@the@@efficacy@@of@@chloroquine@@(@@CQ@@)@@and@@sulfadoxine@@-@@pyrimethamine@@(@@SP@@)@@containing@@prevention@@regimens@@during@@pregnancy@@,@@we@@conducted@@a@@one@@-@@year@@cross@@sectional@@study@@in@@Koro@@and@@Bandiagara@@,@@Mali@@using@@an@@assessment@@methodology@@developed@@by@@the@@Centers@@for@@Disease@@Control@@and@@Prevention@@(@@CDC@@)@@to@@generate@@basic@@data@@on@@malarial@@burden@@during@@pregnancy@@.@@", "replace_sentence": "In@@preparation@@for@@a@@clinical@@trial@@of@@the@@efficacy@@of@@drug1@@(@@CQ@@)@@and@@sulfadoxine@@-@@pyrimethamine@@(@@SP@@)@@containing@@prevention@@regimens@@during@@pregnancy@@,@@we@@conducted@@a@@one@@-@@year@@cross@@sectional@@study@@in@@Koro@@and@@Bandiagara@@,@@Mali@@using@@an@@assessment@@methodology@@developed@@by@@the@@Centers@@for@@Disease@@Control@@and@@Prevention@@(@@CDC@@)@@to@@generate@@basic@@data@@on@@drug2@@burden@@during@@pregnancy@@.@@", "new_pair": "chloroquine@@(@@CQ@@)@@and@@sulfadoxine@@-@@pyrimethamine@@(@@SP@@)@@containing@@prevention@@regimens@@during@@pregnancy@@,@@we@@conducted@@a@@one@@-@@year@@cross@@sectional@@study@@in@@Koro@@and@@Bandiagara@@,@@Mali@@using@@an@@assessment@@methodology@@developed@@by@@the@@Centers@@for@@Disease@@Control@@and@@Prevention@@(@@CDC@@)@@to@@generate@@basic@@data@@on@@malarial", "replace_pair": "drug1@@(@@CQ@@)@@and@@sulfadoxine@@-@@pyrimethamine@@(@@SP@@)@@containing@@prevention@@regimens@@during@@pregnancy@@,@@we@@conducted@@a@@one@@-@@year@@cross@@sectional@@study@@in@@Koro@@and@@Bandiagara@@,@@Mali@@using@@an@@assessment@@methodology@@developed@@by@@the@@Centers@@for@@Disease@@Control@@and@@Prevention@@(@@CDC@@)@@to@@generate@@basic@@data@@on@@drug2", "relation": "NA"}, {"head": {"id": "108", "type": "", "word": "17beta-estradiol", "begin": "19", "end": "35", "new_begin": "22", "new_end": "38", "replace_begin": "22", "replace_end": "27"}, "tail": {"id": "109", "type": "", "word": "postmenopausalUboneUloss", "begin": "137", "end": "161", "new_begin": "155", "new_end": "179", "replace_begin": "144", "replace_end": "149"}, "sentence": "The combination of 17beta-estradiol with drospirenone offers a safe and effective medication for decreasing bone turnover and preventing postmenopausalUboneUloss in postmenopausal women .", "new_sentence": "The@@combination@@of@@17beta-estradiol@@with@@drospirenone@@offers@@a@@safe@@and@@effective@@medication@@for@@decreasing@@bone@@turnover@@and@@preventing@@postmenopausalUboneUloss@@in@@postmenopausal@@women@@.@@", "replace_sentence": "The@@combination@@of@@drug1@@with@@drospirenone@@offers@@a@@safe@@and@@effective@@medication@@for@@decreasing@@bone@@turnover@@and@@preventing@@drug2@@in@@postmenopausal@@women@@.@@", "new_pair": "17beta-estradiol@@with@@drospirenone@@offers@@a@@safe@@and@@effective@@medication@@for@@decreasing@@bone@@turnover@@and@@preventing@@postmenopausalUboneUloss", "replace_pair": "drug1@@with@@drospirenone@@offers@@a@@safe@@and@@effective@@medication@@for@@decreasing@@bone@@turnover@@and@@preventing@@drug2", "relation": "may_prevent"}, {"head": {"id": "110", "type": "", "word": "bacterialUinfections", "begin": "95", "end": "115", "new_begin": "109", "new_end": "129", "replace_begin": "109", "replace_end": "114"}, "tail": {"id": "111", "type": "", "word": "chloroquine", "begin": "121", "end": "132", "new_begin": "137", "new_end": "148", "replace_begin": "122", "replace_end": "127"}, "sentence": "All animals had been prophylactically treated for avian malaria , aspergillosis , and possible bacterialUinfections with chloroquine , itraconazole , and enrofloxacin .", "new_sentence": "All@@animals@@had@@been@@prophylactically@@treated@@for@@avian@@malaria@@,@@aspergillosis@@,@@and@@possible@@bacterialUinfections@@with@@chloroquine@@,@@itraconazole@@,@@and@@enrofloxacin@@.@@", "replace_sentence": "All@@animals@@had@@been@@prophylactically@@treated@@for@@avian@@malaria@@,@@aspergillosis@@,@@and@@possible@@drug1@@with@@drug2@@,@@itraconazole@@,@@and@@enrofloxacin@@.@@", "new_pair": "bacterialUinfections@@with@@chloroquine", "replace_pair": "drug1@@with@@drug2", "relation": "may_prevent"}, {"head": {"id": "112", "type": "", "word": "lovastatin", "begin": "15", "end": "25", "new_begin": "17", "new_end": "27", "replace_begin": "17", "replace_end": "22"}, "tail": {"id": "113", "type": "", "word": "boneUlossUinUpostmenopausal", "begin": "38", "end": "65", "new_begin": "43", "new_end": "70", "replace_begin": "38", "replace_end": "43"}, "sentence": "Treatment with lovastatin may prevent boneUlossUinUpostmenopausal women with type 2 DM .", "new_sentence": "Treatment@@with@@lovastatin@@may@@prevent@@boneUlossUinUpostmenopausal@@women@@with@@type@@2@@DM@@.@@", "replace_sentence": "Treatment@@with@@drug1@@may@@prevent@@drug2@@women@@with@@type@@2@@DM@@.@@", "new_pair": "lovastatin@@may@@prevent@@boneUlossUinUpostmenopausal", "replace_pair": "drug1@@may@@prevent@@drug2", "relation": "may_prevent"}, {"head": {"id": "114", "type": "", "word": "HBsAg", "begin": "55", "end": "60", "new_begin": "67", "new_end": "72", "replace_begin": "67", "replace_end": "72"}, "tail": {"id": "115", "type": "", "word": "HBV", "begin": "373", "end": "376", "new_begin": "442", "new_end": "445", "replace_begin": "442", "replace_end": "447"}, "sentence": "The school children vaccinated under EPI had a 0 . 4 % HBsAg carrier rate , which was significantly lower than school children vaccinated on a voluntary basis ( HBsAg carrier rate 1 . 3 % ) and non - vaccinated school children ( HBsAg carrier rate 2 . 7 % ) , suggesting that HBV vaccination of infants was the most effective measure in preventing vertical transmission of HBV in the hyperendemic region .", "new_sentence": "The@@school@@children@@vaccinated@@under@@EPI@@had@@a@@0@@.@@4@@%@@HBsAg@@carrier@@rate@@,@@which@@was@@significantly@@lower@@than@@school@@children@@vaccinated@@on@@a@@voluntary@@basis@@(@@HBsAg@@carrier@@rate@@1@@.@@3@@%@@)@@and@@non@@-@@vaccinated@@school@@children@@(@@HBsAg@@carrier@@rate@@2@@.@@7@@%@@)@@,@@suggesting@@that@@HBV@@vaccination@@of@@infants@@was@@the@@most@@effective@@measure@@in@@preventing@@vertical@@transmission@@of@@HBV@@in@@the@@hyperendemic@@region@@.@@", "replace_sentence": "The@@school@@children@@vaccinated@@under@@EPI@@had@@a@@0@@.@@4@@%@@drug1@@carrier@@rate@@,@@which@@was@@significantly@@lower@@than@@school@@children@@vaccinated@@on@@a@@voluntary@@basis@@(@@HBsAg@@carrier@@rate@@1@@.@@3@@%@@)@@and@@non@@-@@vaccinated@@school@@children@@(@@HBsAg@@carrier@@rate@@2@@.@@7@@%@@)@@,@@suggesting@@that@@HBV@@vaccination@@of@@infants@@was@@the@@most@@effective@@measure@@in@@preventing@@vertical@@transmission@@of@@drug2@@in@@the@@hyperendemic@@region@@.@@", "new_pair": "HBsAg@@carrier@@rate@@,@@which@@was@@significantly@@lower@@than@@school@@children@@vaccinated@@on@@a@@voluntary@@basis@@(@@HBsAg@@carrier@@rate@@1@@.@@3@@%@@)@@and@@non@@-@@vaccinated@@school@@children@@(@@HBsAg@@carrier@@rate@@2@@.@@7@@%@@)@@,@@suggesting@@that@@HBV@@vaccination@@of@@infants@@was@@the@@most@@effective@@measure@@in@@preventing@@vertical@@transmission@@of@@HBV", "replace_pair": "drug1@@carrier@@rate@@,@@which@@was@@significantly@@lower@@than@@school@@children@@vaccinated@@on@@a@@voluntary@@basis@@(@@HBsAg@@carrier@@rate@@1@@.@@3@@%@@)@@and@@non@@-@@vaccinated@@school@@children@@(@@HBsAg@@carrier@@rate@@2@@.@@7@@%@@)@@,@@suggesting@@that@@HBV@@vaccination@@of@@infants@@was@@the@@most@@effective@@measure@@in@@preventing@@vertical@@transmission@@of@@drug2", "relation": "NA"}, {"head": {"id": "116", "type": "", "word": "stroke", "begin": "61", "end": "67", "new_begin": "71", "new_end": "77", "replace_begin": "71", "replace_end": "76"}, "tail": {"id": "117", "type": "", "word": "aspirin", "begin": "110", "end": "117", "new_begin": "128", "new_end": "135", "replace_begin": "127", "replace_end": "132"}, "sentence": "Aspirin is a common first choice for prevention of recurrent stroke , but the combination of dipyridamole and aspirin should be considered for many patients because of its superior effectiveness in two clinical trials .", "new_sentence": "Aspirin@@is@@a@@common@@first@@choice@@for@@prevention@@of@@recurrent@@stroke@@,@@but@@the@@combination@@of@@dipyridamole@@and@@aspirin@@should@@be@@considered@@for@@many@@patients@@because@@of@@its@@superior@@effectiveness@@in@@two@@clinical@@trials@@.@@", "replace_sentence": "Aspirin@@is@@a@@common@@first@@choice@@for@@prevention@@of@@recurrent@@drug1@@,@@but@@the@@combination@@of@@dipyridamole@@and@@drug2@@should@@be@@considered@@for@@many@@patients@@because@@of@@its@@superior@@effectiveness@@in@@two@@clinical@@trials@@.@@", "new_pair": "stroke@@,@@but@@the@@combination@@of@@dipyridamole@@and@@aspirin", "replace_pair": "drug1@@,@@but@@the@@combination@@of@@dipyridamole@@and@@drug2", "relation": "NA"}, {"head": {"id": "118", "type": "", "word": "Clopidogrel", "begin": "256", "end": "267", "new_begin": "293", "new_end": "304", "replace_begin": "293", "replace_end": "298"}, "tail": {"id": "119", "type": "", "word": "MyocardialUInfarction", "begin": "540", "end": "561", "new_begin": "624", "new_end": "645", "replace_begin": "618", "replace_end": "623"}, "sentence": "Furthermore , the benefit of clopidogrel compared with placebo in patients with acute coronary syndromes , as well as those undergoing percutaneous coronary intervention receiving a standard therapy including aspirin , has been largely demonstrated by the Clopidogrel in Unstable angina to prevent Recurrent Events ( CURE ) , Clopidogrel for the Reduction of Events During Observation ( CREDO ) , CLopidogrel as Adjunctive ReperfusIon TherapY - Thrombolysis In Myocardial Infarction ( CLARITY -TIMI ) 28 , and Clopidogrel and Metoprolol in MyocardialUInfarction Trial @ Secon Chinese Cardiac Study ( COMMIT @ CCS -2 ) trials .", "new_sentence": "Furthermore@@,@@the@@benefit@@of@@clopidogrel@@compared@@with@@placebo@@in@@patients@@with@@acute@@coronary@@syndromes@@,@@as@@well@@as@@those@@undergoing@@percutaneous@@coronary@@intervention@@receiving@@a@@standard@@therapy@@including@@aspirin@@,@@has@@been@@largely@@demonstrated@@by@@the@@Clopidogrel@@in@@Unstable@@angina@@to@@prevent@@Recurrent@@Events@@(@@CURE@@)@@,@@Clopidogrel@@for@@the@@Reduction@@of@@Events@@During@@Observation@@(@@CREDO@@)@@,@@CLopidogrel@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@Myocardial@@Infarction@@(@@CLARITY@@-@@TIMI@@)@@28@@,@@and@@Clopidogrel@@and@@Metoprolol@@in@@MyocardialUInfarction@@Trial@@@@@Secon@@Chinese@@Cardiac@@Study@@(@@COMMIT@@@@@CCS@@-@@2@@)@@trials@@.@@", "replace_sentence": "Furthermore@@,@@the@@benefit@@of@@clopidogrel@@compared@@with@@placebo@@in@@patients@@with@@acute@@coronary@@syndromes@@,@@as@@well@@as@@those@@undergoing@@percutaneous@@coronary@@intervention@@receiving@@a@@standard@@therapy@@including@@aspirin@@,@@has@@been@@largely@@demonstrated@@by@@the@@drug1@@in@@Unstable@@angina@@to@@prevent@@Recurrent@@Events@@(@@CURE@@)@@,@@Clopidogrel@@for@@the@@Reduction@@of@@Events@@During@@Observation@@(@@CREDO@@)@@,@@CLopidogrel@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@Myocardial@@Infarction@@(@@CLARITY@@-@@TIMI@@)@@28@@,@@and@@Clopidogrel@@and@@Metoprolol@@in@@drug2@@Trial@@@@@Secon@@Chinese@@Cardiac@@Study@@(@@COMMIT@@@@@CCS@@-@@2@@)@@trials@@.@@", "new_pair": "Clopidogrel@@in@@Unstable@@angina@@to@@prevent@@Recurrent@@Events@@(@@CURE@@)@@,@@Clopidogrel@@for@@the@@Reduction@@of@@Events@@During@@Observation@@(@@CREDO@@)@@,@@CLopidogrel@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@Myocardial@@Infarction@@(@@CLARITY@@-@@TIMI@@)@@28@@,@@and@@Clopidogrel@@and@@Metoprolol@@in@@MyocardialUInfarction", "replace_pair": "drug1@@in@@Unstable@@angina@@to@@prevent@@Recurrent@@Events@@(@@CURE@@)@@,@@Clopidogrel@@for@@the@@Reduction@@of@@Events@@During@@Observation@@(@@CREDO@@)@@,@@CLopidogrel@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@Myocardial@@Infarction@@(@@CLARITY@@-@@TIMI@@)@@28@@,@@and@@Clopidogrel@@and@@Metoprolol@@in@@drug2", "relation": "NA"}, {"head": {"id": "120", "type": "", "word": "Misoprostol", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "121", "type": "", "word": "gastricUulcers", "begin": "90", "end": "104", "new_begin": "103", "new_end": "117", "replace_begin": "97", "replace_end": "102"}, "sentence": "Misoprostol 800 microg is as effective as PPIs for preventing symptomatic and complicated gastricUulcers , but less effective to prevent duodenal ulcer , with a high rate of adverse effects such as diarrhea .", "new_sentence": "Misoprostol@@800@@microg@@is@@as@@effective@@as@@PPIs@@for@@preventing@@symptomatic@@and@@complicated@@gastricUulcers@@,@@but@@less@@effective@@to@@prevent@@duodenal@@ulcer@@,@@with@@a@@high@@rate@@of@@adverse@@effects@@such@@as@@diarrhea@@.@@", "replace_sentence": "drug1@@800@@microg@@is@@as@@effective@@as@@PPIs@@for@@preventing@@symptomatic@@and@@complicated@@drug2@@,@@but@@less@@effective@@to@@prevent@@duodenal@@ulcer@@,@@with@@a@@high@@rate@@of@@adverse@@effects@@such@@as@@diarrhea@@.@@", "new_pair": "Misoprostol@@800@@microg@@is@@as@@effective@@as@@PPIs@@for@@preventing@@symptomatic@@and@@complicated@@gastricUulcers", "replace_pair": "drug1@@800@@microg@@is@@as@@effective@@as@@PPIs@@for@@preventing@@symptomatic@@and@@complicated@@drug2", "relation": "may_prevent"}, {"head": {"id": "122", "type": "", "word": "clopidogrel", "begin": "51", "end": "62", "new_begin": "61", "new_end": "72", "replace_begin": "61", "replace_end": "66"}, "tail": {"id": "123", "type": "", "word": "STEMI", "begin": "66", "end": "71", "new_begin": "78", "new_end": "83", "replace_begin": "72", "replace_end": "77"}, "sentence": "These data add further support to the early use of clopidogrel in STEMI and the strategy of routine clopidogrel pretreatment in patients undergoing PCI .", "new_sentence": "These@@data@@add@@further@@support@@to@@the@@early@@use@@of@@clopidogrel@@in@@STEMI@@and@@the@@strategy@@of@@routine@@clopidogrel@@pretreatment@@in@@patients@@undergoing@@PCI@@.@@", "replace_sentence": "These@@data@@add@@further@@support@@to@@the@@early@@use@@of@@drug1@@in@@drug2@@and@@the@@strategy@@of@@routine@@clopidogrel@@pretreatment@@in@@patients@@undergoing@@PCI@@.@@", "new_pair": "clopidogrel@@in@@STEMI", "replace_pair": "drug1@@in@@drug2", "relation": "may_prevent"}, {"head": {"id": "124", "type": "", "word": "mesna", "begin": "31", "end": "36", "new_begin": "35", "new_end": "40", "replace_begin": "35", "replace_end": "40"}, "tail": {"id": "125", "type": "", "word": "IU @ UR", "begin": "74", "end": "81", "new_begin": "84", "new_end": "91", "replace_begin": "84", "replace_end": "89"}, "sentence": "CONCLUSIONS : Prophylaxis with mesna prevents oxidative stress induced by IU @ UR in the intestine via inhibition of NF-kappaB activation .", "new_sentence": "CONCLUSIONS@@:@@Prophylaxis@@with@@mesna@@prevents@@oxidative@@stress@@induced@@by@@IU @ UR@@in@@the@@intestine@@via@@inhibition@@of@@NF@@-@@kappaB@@activation@@.@@", "replace_sentence": "CONCLUSIONS@@:@@Prophylaxis@@with@@drug1@@prevents@@oxidative@@stress@@induced@@by@@drug2@@in@@the@@intestine@@via@@inhibition@@of@@NF@@-@@kappaB@@activation@@.@@", "new_pair": "mesna@@prevents@@oxidative@@stress@@induced@@by@@IU @ UR", "replace_pair": "drug1@@prevents@@oxidative@@stress@@induced@@by@@drug2", "relation": "may_prevent"}, {"head": {"id": "126", "type": "", "word": "Atorvastatin", "begin": "0", "end": "12", "new_begin": "0", "new_end": "12", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "127", "type": "", "word": "stroke", "begin": "69", "end": "75", "new_begin": "79", "new_end": "85", "replace_begin": "72", "replace_end": "77"}, "sentence": "Atorvastatin reduced the adjusted relative risk of fatal or nonfatal stroke by 16 % ( p = 0 . 03 ) , and that of fatal stroke alone by 43 % ( p = 0 . 03 ) .", "new_sentence": "Atorvastatin@@reduced@@the@@adjusted@@relative@@risk@@of@@fatal@@or@@nonfatal@@stroke@@by@@16@@%@@(@@p@@=@@0@@.@@03@@)@@,@@and@@that@@of@@fatal@@stroke@@alone@@by@@43@@%@@(@@p@@=@@0@@.@@03@@)@@.@@", "replace_sentence": "drug1@@reduced@@the@@adjusted@@relative@@risk@@of@@fatal@@or@@nonfatal@@drug2@@by@@16@@%@@(@@p@@=@@0@@.@@03@@)@@,@@and@@that@@of@@fatal@@stroke@@alone@@by@@43@@%@@(@@p@@=@@0@@.@@03@@)@@.@@", "new_pair": "Atorvastatin@@reduced@@the@@adjusted@@relative@@risk@@of@@fatal@@or@@nonfatal@@stroke", "replace_pair": "drug1@@reduced@@the@@adjusted@@relative@@risk@@of@@fatal@@or@@nonfatal@@drug2", "relation": "may_prevent"}, {"head": {"id": "128", "type": "", "word": "F", "begin": "50", "end": "51", "new_begin": "66", "new_end": "67", "replace_begin": "66", "replace_end": "71"}, "tail": {"id": "129", "type": "", "word": "cavity", "begin": "225", "end": "231", "new_begin": "277", "new_end": "283", "replace_begin": "281", "replace_end": "286"}, "sentence": "As monitored by two-dimensional ( 19 ) F - ( 19 ) F nuclear Overhauser effect , the distance between two phenylalanine residues ( Phe ( 68 ) and Phe ( 93 ) ) located in the two different beta-sheets that enclose the internal cavity did not change up to 4 m urea .", "new_sentence": "As@@monitored@@by@@two@@-@@dimensional@@(@@19@@)@@F@@-@@(@@19@@)@@F@@nuclear@@Overhauser@@effect@@,@@the@@distance@@between@@two@@phenylalanine@@residues@@(@@Phe@@(@@68@@)@@and@@Phe@@(@@93@@)@@)@@located@@in@@the@@two@@different@@beta@@-@@sheets@@that@@enclose@@the@@internal@@cavity@@did@@not@@change@@up@@to@@4@@m@@urea@@.@@", "replace_sentence": "As@@monitored@@by@@two@@-@@dimensional@@(@@19@@)@@F@@-@@(@@19@@)@@drug1@@nuclear@@Overhauser@@effect@@,@@the@@distance@@between@@two@@phenylalanine@@residues@@(@@Phe@@(@@68@@)@@and@@Phe@@(@@93@@)@@)@@located@@in@@the@@two@@different@@beta@@-@@sheets@@that@@enclose@@the@@internal@@drug2@@did@@not@@change@@up@@to@@4@@m@@urea@@.@@", "new_pair": "F@@nuclear@@Overhauser@@effect@@,@@the@@distance@@between@@two@@phenylalanine@@residues@@(@@Phe@@(@@68@@)@@and@@Phe@@(@@93@@)@@)@@located@@in@@the@@two@@different@@beta@@-@@sheets@@that@@enclose@@the@@internal@@cavity", "replace_pair": "drug1@@nuclear@@Overhauser@@effect@@,@@the@@distance@@between@@two@@phenylalanine@@residues@@(@@Phe@@(@@68@@)@@and@@Phe@@(@@93@@)@@)@@located@@in@@the@@two@@different@@beta@@-@@sheets@@that@@enclose@@the@@internal@@drug2", "relation": "NA"}, {"head": {"id": "130", "type": "", "word": "VitaminUD", "begin": "0", "end": "9", "new_begin": "0", "new_end": "9", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "131", "type": "", "word": "post-menopausalUosteoporosis", "begin": "92", "end": "120", "new_begin": "104", "new_end": "132", "replace_begin": "100", "replace_end": "105"}, "sentence": "VitaminUD and vitamin D analogues for preventing fractures associated with involutional and post-menopausalUosteoporosis .", "new_sentence": "VitaminUD@@and@@vitamin@@D@@analogues@@for@@preventing@@fractures@@associated@@with@@involutional@@and@@post-menopausalUosteoporosis@@.@@", "replace_sentence": "drug1@@and@@vitamin@@D@@analogues@@for@@preventing@@fractures@@associated@@with@@involutional@@and@@drug2@@.@@", "new_pair": "VitaminUD@@and@@vitamin@@D@@analogues@@for@@preventing@@fractures@@associated@@with@@involutional@@and@@post-menopausalUosteoporosis", "replace_pair": "drug1@@and@@vitamin@@D@@analogues@@for@@preventing@@fractures@@associated@@with@@involutional@@and@@drug2", "relation": "may_prevent"}, {"head": {"id": "132", "type": "", "word": "aspirin", "begin": "196", "end": "203", "new_begin": "226", "new_end": "233", "replace_begin": "226", "replace_end": "231"}, "tail": {"id": "133", "type": "", "word": "stroke", "begin": "399", "end": "405", "new_begin": "465", "new_end": "471", "replace_begin": "463", "replace_end": "468"}, "sentence": "Medical strategies for secondary stroke prevention focus on four areas : control of hypertension , control of blood lipids , anticoagulant therapy , and treatment with antiplatelet agents such as aspirin , clopidogrel , and aspirin combined with extended-release dipyridamole , all of which the American College of Chest Physicians deems acceptable for first-line treatment for preventing secondary stroke .", "new_sentence": "Medical@@strategies@@for@@secondary@@stroke@@prevention@@focus@@on@@four@@areas@@:@@control@@of@@hypertension@@,@@control@@of@@blood@@lipids@@,@@anticoagulant@@therapy@@,@@and@@treatment@@with@@antiplatelet@@agents@@such@@as@@aspirin@@,@@clopidogrel@@,@@and@@aspirin@@combined@@with@@extended@@-@@release@@dipyridamole@@,@@all@@of@@which@@the@@American@@College@@of@@Chest@@Physicians@@deems@@acceptable@@for@@first@@-@@line@@treatment@@for@@preventing@@secondary@@stroke@@.@@", "replace_sentence": "Medical@@strategies@@for@@secondary@@stroke@@prevention@@focus@@on@@four@@areas@@:@@control@@of@@hypertension@@,@@control@@of@@blood@@lipids@@,@@anticoagulant@@therapy@@,@@and@@treatment@@with@@antiplatelet@@agents@@such@@as@@drug1@@,@@clopidogrel@@,@@and@@aspirin@@combined@@with@@extended@@-@@release@@dipyridamole@@,@@all@@of@@which@@the@@American@@College@@of@@Chest@@Physicians@@deems@@acceptable@@for@@first@@-@@line@@treatment@@for@@preventing@@secondary@@drug2@@.@@", "new_pair": "aspirin@@,@@clopidogrel@@,@@and@@aspirin@@combined@@with@@extended@@-@@release@@dipyridamole@@,@@all@@of@@which@@the@@American@@College@@of@@Chest@@Physicians@@deems@@acceptable@@for@@first@@-@@line@@treatment@@for@@preventing@@secondary@@stroke", "replace_pair": "drug1@@,@@clopidogrel@@,@@and@@aspirin@@combined@@with@@extended@@-@@release@@dipyridamole@@,@@all@@of@@which@@the@@American@@College@@of@@Chest@@Physicians@@deems@@acceptable@@for@@first@@-@@line@@treatment@@for@@preventing@@secondary@@drug2", "relation": "may_prevent"}, {"head": {"id": "134", "type": "", "word": "asthma", "begin": "20", "end": "26", "new_begin": "23", "new_end": "29", "replace_begin": "23", "replace_end": "28"}, "tail": {"id": "135", "type": "", "word": "mannitol", "begin": "77", "end": "85", "new_begin": "90", "new_end": "98", "replace_begin": "89", "replace_end": "94"}, "sentence": "INTERPRETATION : In asthma patients not being treated with steroids , AHR to mannitol and to methacholine indicated the presence of airway inflammation .", "new_sentence": "INTERPRETATION@@:@@In@@asthma@@patients@@not@@being@@treated@@with@@steroids@@,@@AHR@@to@@mannitol@@and@@to@@methacholine@@indicated@@the@@presence@@of@@airway@@inflammation@@.@@", "replace_sentence": "INTERPRETATION@@:@@In@@drug1@@patients@@not@@being@@treated@@with@@steroids@@,@@AHR@@to@@drug2@@and@@to@@methacholine@@indicated@@the@@presence@@of@@airway@@inflammation@@.@@", "new_pair": "asthma@@patients@@not@@being@@treated@@with@@steroids@@,@@AHR@@to@@mannitol", "replace_pair": "drug1@@patients@@not@@being@@treated@@with@@steroids@@,@@AHR@@to@@drug2", "relation": "NA"}, {"head": {"id": "136", "type": "", "word": "ASA", "begin": "77", "end": "80", "new_begin": "90", "new_end": "93", "replace_begin": "90", "replace_end": "95"}, "tail": {"id": "137", "type": "", "word": "stroke", "begin": "160", "end": "166", "new_begin": "188", "new_end": "194", "replace_begin": "190", "replace_end": "195"}, "sentence": "METHODS AND RESULTS : ACTIVE W is a noninferiority trial of clopidogrel plus ASA versus oral anticoagulation in patients with AF and at least 1 risk factor for stroke .", "new_sentence": "METHODS@@AND@@RESULTS@@:@@ACTIVE@@W@@is@@a@@noninferiority@@trial@@of@@clopidogrel@@plus@@ASA@@versus@@oral@@anticoagulation@@in@@patients@@with@@AF@@and@@at@@least@@1@@risk@@factor@@for@@stroke@@.@@", "replace_sentence": "METHODS@@AND@@RESULTS@@:@@ACTIVE@@W@@is@@a@@noninferiority@@trial@@of@@clopidogrel@@plus@@drug1@@versus@@oral@@anticoagulation@@in@@patients@@with@@AF@@and@@at@@least@@1@@risk@@factor@@for@@drug2@@.@@", "new_pair": "ASA@@versus@@oral@@anticoagulation@@in@@patients@@with@@AF@@and@@at@@least@@1@@risk@@factor@@for@@stroke", "replace_pair": "drug1@@versus@@oral@@anticoagulation@@in@@patients@@with@@AF@@and@@at@@least@@1@@risk@@factor@@for@@drug2", "relation": "NA"}, {"head": {"id": "138", "type": "", "word": "fluconazole", "begin": "51", "end": "62", "new_begin": "62", "new_end": "73", "replace_begin": "62", "replace_end": "67"}, "tail": {"id": "139", "type": "", "word": "fungalUinfection", "begin": "125", "end": "141", "new_begin": "150", "new_end": "166", "replace_begin": "144", "replace_end": "149"}, "sentence": "OBJECTIVES : To assess whether targeted short-term fluconazole prophylaxis reduces late - onset ( > 3 days of age ) invasive fungalUinfection ( IFI ) among very low birth weight infants and extremely low birth weight ( ELBW ) infants and to assess mortality rates , toxicity , and costs associated with this intervention .", "new_sentence": "OBJECTIVES@@:@@To@@assess@@whether@@targeted@@short@@-@@term@@fluconazole@@prophylaxis@@reduces@@late@@-@@onset@@(@@>@@3@@days@@of@@age@@)@@invasive@@fungalUinfection@@(@@IFI@@)@@among@@very@@low@@birth@@weight@@infants@@and@@extremely@@low@@birth@@weight@@(@@ELBW@@)@@infants@@and@@to@@assess@@mortality@@rates@@,@@toxicity@@,@@and@@costs@@associated@@with@@this@@intervention@@.@@", "replace_sentence": "OBJECTIVES@@:@@To@@assess@@whether@@targeted@@short@@-@@term@@drug1@@prophylaxis@@reduces@@late@@-@@onset@@(@@>@@3@@days@@of@@age@@)@@invasive@@drug2@@(@@IFI@@)@@among@@very@@low@@birth@@weight@@infants@@and@@extremely@@low@@birth@@weight@@(@@ELBW@@)@@infants@@and@@to@@assess@@mortality@@rates@@,@@toxicity@@,@@and@@costs@@associated@@with@@this@@intervention@@.@@", "new_pair": "fluconazole@@prophylaxis@@reduces@@late@@-@@onset@@(@@>@@3@@days@@of@@age@@)@@invasive@@fungalUinfection", "replace_pair": "drug1@@prophylaxis@@reduces@@late@@-@@onset@@(@@>@@3@@days@@of@@age@@)@@invasive@@drug2", "relation": "NA"}, {"head": {"id": "140", "type": "", "word": "vitaminUD", "begin": "141", "end": "150", "new_begin": "166", "new_end": "175", "replace_begin": "166", "replace_end": "171"}, "tail": {"id": "141", "type": "", "word": "osteoporosis", "begin": "204", "end": "216", "new_begin": "238", "new_end": "250", "replace_begin": "234", "replace_end": "239"}, "sentence": "Since the resistance factors for the effect of vitamin D increases by aging , ingestion of various nutrition factors , such as calcium , and vitaminUD is important for prevention and medical treatment of osteoporosis .", "new_sentence": "Since@@the@@resistance@@factors@@for@@the@@effect@@of@@vitamin@@D@@increases@@by@@aging@@,@@ingestion@@of@@various@@nutrition@@factors@@,@@such@@as@@calcium@@,@@and@@vitaminUD@@is@@important@@for@@prevention@@and@@medical@@treatment@@of@@osteoporosis@@.@@", "replace_sentence": "Since@@the@@resistance@@factors@@for@@the@@effect@@of@@vitamin@@D@@increases@@by@@aging@@,@@ingestion@@of@@various@@nutrition@@factors@@,@@such@@as@@calcium@@,@@and@@drug1@@is@@important@@for@@prevention@@and@@medical@@treatment@@of@@drug2@@.@@", "new_pair": "vitaminUD@@is@@important@@for@@prevention@@and@@medical@@treatment@@of@@osteoporosis", "replace_pair": "drug1@@is@@important@@for@@prevention@@and@@medical@@treatment@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "142", "type": "", "word": "F", "begin": "70", "end": "71", "new_begin": "80", "new_end": "81", "replace_begin": "80", "replace_end": "85"}, "tail": {"id": "143", "type": "", "word": "infestation", "begin": "83", "end": "94", "new_begin": "96", "new_end": "107", "replace_begin": "100", "replace_end": "105"}, "sentence": "Patients with eosinophilia and abdominal pain should be evaluated for F . hepatica infestation by parasitological , radiological and serological tests .", "new_sentence": "Patients@@with@@eosinophilia@@and@@abdominal@@pain@@should@@be@@evaluated@@for@@F@@.@@hepatica@@infestation@@by@@parasitological@@,@@radiological@@and@@serological@@tests@@.@@", "replace_sentence": "Patients@@with@@eosinophilia@@and@@abdominal@@pain@@should@@be@@evaluated@@for@@drug1@@.@@hepatica@@drug2@@by@@parasitological@@,@@radiological@@and@@serological@@tests@@.@@", "new_pair": "F@@.@@hepatica@@infestation", "replace_pair": "drug1@@.@@hepatica@@drug2", "relation": "NA"}, {"head": {"id": "144", "type": "", "word": "iron", "begin": "13", "end": "17", "new_begin": "14", "new_end": "18", "replace_begin": "14", "replace_end": "19"}, "tail": {"id": "145", "type": "", "word": "chronicUkidneyUdisease", "begin": "49", "end": "71", "new_begin": "56", "new_end": "78", "replace_begin": "57", "replace_end": "62"}, "sentence": "Replenishing iron stores in anemic patients with chronicUkidneyUdisease significantly increases hemoglobin levels and should be considered as an integral part of the therapy for treating anemia in the predialysis population .", "new_sentence": "Replenishing@@iron@@stores@@in@@anemic@@patients@@with@@chronicUkidneyUdisease@@significantly@@increases@@hemoglobin@@levels@@and@@should@@be@@considered@@as@@an@@integral@@part@@of@@the@@therapy@@for@@treating@@anemia@@in@@the@@predialysis@@population@@.@@", "replace_sentence": "Replenishing@@drug1@@stores@@in@@anemic@@patients@@with@@drug2@@significantly@@increases@@hemoglobin@@levels@@and@@should@@be@@considered@@as@@an@@integral@@part@@of@@the@@therapy@@for@@treating@@anemia@@in@@the@@predialysis@@population@@.@@", "new_pair": "iron@@stores@@in@@anemic@@patients@@with@@chronicUkidneyUdisease", "replace_pair": "drug1@@stores@@in@@anemic@@patients@@with@@drug2", "relation": "NA"}, {"head": {"id": "146", "type": "", "word": "ENOXaparin", "begin": "41", "end": "51", "new_begin": "47", "new_end": "57", "replace_begin": "47", "replace_end": "52"}, "tail": {"id": "147", "type": "", "word": "infectiousUdisease", "begin": "515", "end": "533", "new_begin": "599", "new_end": "617", "replace_begin": "594", "replace_end": "599"}, "sentence": "The prophylaxis in MEDical patients with ENOXaparin ( MEDENOX ) , Prospective Evaluation of Dalteparin Efficacy for PREVENTion of VTE in Immobilized Patients Trial ( PREVENT ) , and ARixta for ThromboEmbolism Prevention in a Medical Indications Study ( ARTEMIS ) studies have compared the low-molecular-weight heparins enoxaparin and dalteparin , and the specific factor Xa inhibitor fondaparinux , respectively , with placebo in acutely ill medical patients hospitalized with heart failure , respiratory failure , infectiousUdisease , or inflammatory disease .", "new_sentence": "The@@prophylaxis@@in@@MEDical@@patients@@with@@ENOXaparin@@(@@MEDENOX@@)@@,@@Prospective@@Evaluation@@of@@Dalteparin@@Efficacy@@for@@PREVENTion@@of@@VTE@@in@@Immobilized@@Patients@@Trial@@(@@PREVENT@@)@@,@@and@@ARixta@@for@@ThromboEmbolism@@Prevention@@in@@a@@Medical@@Indications@@Study@@(@@ARTEMIS@@)@@studies@@have@@compared@@the@@low@@-@@molecular@@-@@weight@@heparins@@enoxaparin@@and@@dalteparin@@,@@and@@the@@specific@@factor@@Xa@@inhibitor@@fondaparinux@@,@@respectively@@,@@with@@placebo@@in@@acutely@@ill@@medical@@patients@@hospitalized@@with@@heart@@failure@@,@@respiratory@@failure@@,@@infectiousUdisease@@,@@or@@inflammatory@@disease@@.@@", "replace_sentence": "The@@prophylaxis@@in@@MEDical@@patients@@with@@drug1@@(@@MEDENOX@@)@@,@@Prospective@@Evaluation@@of@@Dalteparin@@Efficacy@@for@@PREVENTion@@of@@VTE@@in@@Immobilized@@Patients@@Trial@@(@@PREVENT@@)@@,@@and@@ARixta@@for@@ThromboEmbolism@@Prevention@@in@@a@@Medical@@Indications@@Study@@(@@ARTEMIS@@)@@studies@@have@@compared@@the@@low@@-@@molecular@@-@@weight@@heparins@@enoxaparin@@and@@dalteparin@@,@@and@@the@@specific@@factor@@Xa@@inhibitor@@fondaparinux@@,@@respectively@@,@@with@@placebo@@in@@acutely@@ill@@medical@@patients@@hospitalized@@with@@heart@@failure@@,@@respiratory@@failure@@,@@drug2@@,@@or@@inflammatory@@disease@@.@@", "new_pair": "ENOXaparin@@(@@MEDENOX@@)@@,@@Prospective@@Evaluation@@of@@Dalteparin@@Efficacy@@for@@PREVENTion@@of@@VTE@@in@@Immobilized@@Patients@@Trial@@(@@PREVENT@@)@@,@@and@@ARixta@@for@@ThromboEmbolism@@Prevention@@in@@a@@Medical@@Indications@@Study@@(@@ARTEMIS@@)@@studies@@have@@compared@@the@@low@@-@@molecular@@-@@weight@@heparins@@enoxaparin@@and@@dalteparin@@,@@and@@the@@specific@@factor@@Xa@@inhibitor@@fondaparinux@@,@@respectively@@,@@with@@placebo@@in@@acutely@@ill@@medical@@patients@@hospitalized@@with@@heart@@failure@@,@@respiratory@@failure@@,@@infectiousUdisease", "replace_pair": "drug1@@(@@MEDENOX@@)@@,@@Prospective@@Evaluation@@of@@Dalteparin@@Efficacy@@for@@PREVENTion@@of@@VTE@@in@@Immobilized@@Patients@@Trial@@(@@PREVENT@@)@@,@@and@@ARixta@@for@@ThromboEmbolism@@Prevention@@in@@a@@Medical@@Indications@@Study@@(@@ARTEMIS@@)@@studies@@have@@compared@@the@@low@@-@@molecular@@-@@weight@@heparins@@enoxaparin@@and@@dalteparin@@,@@and@@the@@specific@@factor@@Xa@@inhibitor@@fondaparinux@@,@@respectively@@,@@with@@placebo@@in@@acutely@@ill@@medical@@patients@@hospitalized@@with@@heart@@failure@@,@@respiratory@@failure@@,@@drug2", "relation": "NA"}, {"head": {"id": "148", "type": "", "word": "atovaquone", "begin": "14", "end": "24", "new_begin": "16", "new_end": "26", "replace_begin": "16", "replace_end": "21"}, "tail": {"id": "149", "type": "", "word": "HIVUinfection", "begin": "145", "end": "158", "new_begin": "166", "new_end": "179", "replace_begin": "161", "replace_end": "166"}, "sentence": "Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIVUinfection .", "new_sentence": "Comparison@@of@@atovaquone@@and@@azithromycin@@with@@trimethoprim@@-@@sulfamethoxazole@@for@@the@@prevention@@of@@serious@@bacterial@@infections@@in@@children@@with@@HIVUinfection@@.@@", "replace_sentence": "Comparison@@of@@drug1@@and@@azithromycin@@with@@trimethoprim@@-@@sulfamethoxazole@@for@@the@@prevention@@of@@serious@@bacterial@@infections@@in@@children@@with@@drug2@@.@@", "new_pair": "atovaquone@@and@@azithromycin@@with@@trimethoprim@@-@@sulfamethoxazole@@for@@the@@prevention@@of@@serious@@bacterial@@infections@@in@@children@@with@@HIVUinfection", "replace_pair": "drug1@@and@@azithromycin@@with@@trimethoprim@@-@@sulfamethoxazole@@for@@the@@prevention@@of@@serious@@bacterial@@infections@@in@@children@@with@@drug2", "relation": "NA"}, {"head": {"id": "150", "type": "", "word": "17beta-estradiol", "begin": "22", "end": "38", "new_begin": "26", "new_end": "42", "replace_begin": "26", "replace_end": "31"}, "tail": {"id": "151", "type": "", "word": "ischemia", "begin": "52", "end": "60", "new_begin": "59", "new_end": "67", "replace_begin": "48", "replace_end": "53"}, "sentence": "The results show that 17beta-estradiol prevents the ischemia - induced release of cytochrome c from mitochondria , subsequent inhibition of mitochondrial respiration , and inhibits caspase activation and apoptosis .", "new_sentence": "The@@results@@show@@that@@17beta-estradiol@@prevents@@the@@ischemia@@-@@induced@@release@@of@@cytochrome@@c@@from@@mitochondria@@,@@subsequent@@inhibition@@of@@mitochondrial@@respiration@@,@@and@@inhibits@@caspase@@activation@@and@@apoptosis@@.@@", "replace_sentence": "The@@results@@show@@that@@drug1@@prevents@@the@@drug2@@-@@induced@@release@@of@@cytochrome@@c@@from@@mitochondria@@,@@subsequent@@inhibition@@of@@mitochondrial@@respiration@@,@@and@@inhibits@@caspase@@activation@@and@@apoptosis@@.@@", "new_pair": "17beta-estradiol@@prevents@@the@@ischemia", "replace_pair": "drug1@@prevents@@the@@drug2", "relation": "may_prevent"}, {"head": {"id": "152", "type": "", "word": "stroke", "begin": "18", "end": "24", "new_begin": "23", "new_end": "29", "replace_begin": "23", "replace_end": "28"}, "tail": {"id": "153", "type": "", "word": "aspirin", "begin": "127", "end": "134", "new_begin": "156", "new_end": "163", "replace_begin": "155", "replace_end": "160"}, "sentence": "In general , at a stroke rate of 1 % with aspirin , half of the participants would prefer warfarin , and at a rate of 2 % with aspirin , two thirds would prefer warfarin .", "new_sentence": "In@@general@@,@@at@@a@@stroke@@rate@@of@@1@@%@@with@@aspirin@@,@@half@@of@@the@@participants@@would@@prefer@@warfarin@@,@@and@@at@@a@@rate@@of@@2@@%@@with@@aspirin@@,@@two@@thirds@@would@@prefer@@warfarin@@.@@", "replace_sentence": "In@@general@@,@@at@@a@@drug1@@rate@@of@@1@@%@@with@@aspirin@@,@@half@@of@@the@@participants@@would@@prefer@@warfarin@@,@@and@@at@@a@@rate@@of@@2@@%@@with@@drug2@@,@@two@@thirds@@would@@prefer@@warfarin@@.@@", "new_pair": "stroke@@rate@@of@@1@@%@@with@@aspirin@@,@@half@@of@@the@@participants@@would@@prefer@@warfarin@@,@@and@@at@@a@@rate@@of@@2@@%@@with@@aspirin", "replace_pair": "drug1@@rate@@of@@1@@%@@with@@aspirin@@,@@half@@of@@the@@participants@@would@@prefer@@warfarin@@,@@and@@at@@a@@rate@@of@@2@@%@@with@@drug2", "relation": "NA"}, {"head": {"id": "154", "type": "", "word": "aspirin", "begin": "134", "end": "141", "new_begin": "161", "new_end": "168", "replace_begin": "161", "replace_end": "166"}, "tail": {"id": "155", "type": "", "word": "myocardialUinfarction", "begin": "175", "end": "196", "new_begin": "212", "new_end": "233", "replace_begin": "210", "replace_end": "215"}, "sentence": "We generated funnel plots ( with control limits at 3 sigma ) of Door to Needle and Call to Needle thrombolysis times , and the use of aspirin , beta-blockers and statins post myocardialUinfarction .", "new_sentence": "We@@generated@@funnel@@plots@@(@@with@@control@@limits@@at@@3@@sigma@@)@@of@@Door@@to@@Needle@@and@@Call@@to@@Needle@@thrombolysis@@times@@,@@and@@the@@use@@of@@aspirin@@,@@beta@@-@@blockers@@and@@statins@@post@@myocardialUinfarction@@.@@", "replace_sentence": "We@@generated@@funnel@@plots@@(@@with@@control@@limits@@at@@3@@sigma@@)@@of@@Door@@to@@Needle@@and@@Call@@to@@Needle@@thrombolysis@@times@@,@@and@@the@@use@@of@@drug1@@,@@beta@@-@@blockers@@and@@statins@@post@@drug2@@.@@", "new_pair": "aspirin@@,@@beta@@-@@blockers@@and@@statins@@post@@myocardialUinfarction", "replace_pair": "drug1@@,@@beta@@-@@blockers@@and@@statins@@post@@drug2", "relation": "NA"}, {"head": {"id": "156", "type": "", "word": "estrogens", "begin": "213", "end": "222", "new_begin": "250", "new_end": "259", "replace_begin": "250", "replace_end": "255"}, "tail": {"id": "157", "type": "", "word": "osteoporosis", "begin": "227", "end": "239", "new_begin": "266", "new_end": "278", "replace_begin": "262", "replace_end": "267"}, "sentence": "Thus , the extended knowledge of glucocorticoid - induced cellular signalling should allow the design and development of even more specifically acting drugs - as it has been obtained with other steroids , e . g . estrogens for osteoporosis prevention .", "new_sentence": "Thus@@,@@the@@extended@@knowledge@@of@@glucocorticoid@@-@@induced@@cellular@@signalling@@should@@allow@@the@@design@@and@@development@@of@@even@@more@@specifically@@acting@@drugs@@-@@as@@it@@has@@been@@obtained@@with@@other@@steroids@@,@@e@@.@@g@@.@@estrogens@@for@@osteoporosis@@prevention@@.@@", "replace_sentence": "Thus@@,@@the@@extended@@knowledge@@of@@glucocorticoid@@-@@induced@@cellular@@signalling@@should@@allow@@the@@design@@and@@development@@of@@even@@more@@specifically@@acting@@drugs@@-@@as@@it@@has@@been@@obtained@@with@@other@@steroids@@,@@e@@.@@g@@.@@drug1@@for@@drug2@@prevention@@.@@", "new_pair": "estrogens@@for@@osteoporosis", "replace_pair": "drug1@@for@@drug2", "relation": "may_prevent"}, {"head": {"id": "158", "type": "", "word": "dehydration", "begin": "150", "end": "161", "new_begin": "174", "new_end": "185", "replace_begin": "174", "replace_end": "179"}, "tail": {"id": "159", "type": "", "word": "Lys", "begin": "301", "end": "304", "new_begin": "355", "new_end": "358", "replace_begin": "349", "replace_end": "354"}, "sentence": "The epimerization of l-talarate to galactarate that competes with dehydration can be rationalized by partitioning of the enolate intermediate between dehydration ( departure of the 3- OH group catalyzed by the conjugate acid of His 328 ) and epimerization ( protonation on C2 by the conjugate acid of Lys 197 ) .", "new_sentence": "The@@epimerization@@of@@l@@-@@talarate@@to@@galactarate@@that@@competes@@with@@dehydration@@can@@be@@rationalized@@by@@partitioning@@of@@the@@enolate@@intermediate@@between@@dehydration@@(@@departure@@of@@the@@3@@-@@OH@@group@@catalyzed@@by@@the@@conjugate@@acid@@of@@His@@328@@)@@and@@epimerization@@(@@protonation@@on@@C2@@by@@the@@conjugate@@acid@@of@@Lys@@197@@)@@.@@", "replace_sentence": "The@@epimerization@@of@@l@@-@@talarate@@to@@galactarate@@that@@competes@@with@@dehydration@@can@@be@@rationalized@@by@@partitioning@@of@@the@@enolate@@intermediate@@between@@drug1@@(@@departure@@of@@the@@3@@-@@OH@@group@@catalyzed@@by@@the@@conjugate@@acid@@of@@His@@328@@)@@and@@epimerization@@(@@protonation@@on@@C2@@by@@the@@conjugate@@acid@@of@@drug2@@197@@)@@.@@", "new_pair": "dehydration@@(@@departure@@of@@the@@3@@-@@OH@@group@@catalyzed@@by@@the@@conjugate@@acid@@of@@His@@328@@)@@and@@epimerization@@(@@protonation@@on@@C2@@by@@the@@conjugate@@acid@@of@@Lys", "replace_pair": "drug1@@(@@departure@@of@@the@@3@@-@@OH@@group@@catalyzed@@by@@the@@conjugate@@acid@@of@@His@@328@@)@@and@@epimerization@@(@@protonation@@on@@C2@@by@@the@@conjugate@@acid@@of@@drug2", "relation": "NA"}, {"head": {"id": "160", "type": "", "word": "GVHD", "begin": "13", "end": "17", "new_begin": "15", "new_end": "19", "replace_begin": "15", "replace_end": "20"}, "tail": {"id": "161", "type": "", "word": "CsA", "begin": "35", "end": "38", "new_begin": "40", "new_end": "43", "replace_begin": "41", "replace_end": "46"}, "sentence": "All received GVHD prophylaxis with CsA ( 2 mg @ kg @ day ) and methotrexate ( on days 1 , 3 , and 6 ) .", "new_sentence": "All@@received@@GVHD@@prophylaxis@@with@@CsA@@(@@2@@mg@@@@@kg@@@@@day@@)@@and@@methotrexate@@(@@on@@days@@1@@,@@3@@,@@and@@6@@)@@.@@", "replace_sentence": "All@@received@@drug1@@prophylaxis@@with@@drug2@@(@@2@@mg@@@@@kg@@@@@day@@)@@and@@methotrexate@@(@@on@@days@@1@@,@@3@@,@@and@@6@@)@@.@@", "new_pair": "GVHD@@prophylaxis@@with@@CsA", "replace_pair": "drug1@@prophylaxis@@with@@drug2", "relation": "may_prevent"}, {"head": {"id": "162", "type": "", "word": "ganciclovir", "begin": "23", "end": "34", "new_begin": "26", "new_end": "37", "replace_begin": "26", "replace_end": "31"}, "tail": {"id": "163", "type": "", "word": "CMVUdisease", "begin": "114", "end": "125", "new_begin": "131", "new_end": "142", "replace_begin": "125", "replace_end": "130"}, "sentence": "Therefore , preemptive ganciclovir therapy based on early detection of CMV reactivation is widely used to prevent CMVUdisease .", "new_sentence": "Therefore@@,@@preemptive@@ganciclovir@@therapy@@based@@on@@early@@detection@@of@@CMV@@reactivation@@is@@widely@@used@@to@@prevent@@CMVUdisease@@.@@", "replace_sentence": "Therefore@@,@@preemptive@@drug1@@therapy@@based@@on@@early@@detection@@of@@CMV@@reactivation@@is@@widely@@used@@to@@prevent@@drug2@@.@@", "new_pair": "ganciclovir@@therapy@@based@@on@@early@@detection@@of@@CMV@@reactivation@@is@@widely@@used@@to@@prevent@@CMVUdisease", "replace_pair": "drug1@@therapy@@based@@on@@early@@detection@@of@@CMV@@reactivation@@is@@widely@@used@@to@@prevent@@drug2", "relation": "may_prevent"}, {"head": {"id": "164", "type": "", "word": "aspirin", "begin": "120", "end": "127", "new_begin": "139", "new_end": "146", "replace_begin": "139", "replace_end": "144"}, "tail": {"id": "165", "type": "", "word": "theUprimaryUpreventionUofUCHD", "begin": "281", "end": "310", "new_begin": "325", "new_end": "354", "replace_begin": "323", "replace_end": "328"}, "sentence": "This consensus statement will examine the evidence regarding HRT and non - estrogen therapies ( lipid lowering agents , aspirin , antihypertensives , antidiabetic medications , selective estrogen receptor modulators ( SERMs ) ) as well as diet , lifestyle and smoking cessation in theUprimaryUpreventionUofUCHD in women .", "new_sentence": "This@@consensus@@statement@@will@@examine@@the@@evidence@@regarding@@HRT@@and@@non@@-@@estrogen@@therapies@@(@@lipid@@lowering@@agents@@,@@aspirin@@,@@antihypertensives@@,@@antidiabetic@@medications@@,@@selective@@estrogen@@receptor@@modulators@@(@@SERMs@@)@@)@@as@@well@@as@@diet@@,@@lifestyle@@and@@smoking@@cessation@@in@@theUprimaryUpreventionUofUCHD@@in@@women@@.@@", "replace_sentence": "This@@consensus@@statement@@will@@examine@@the@@evidence@@regarding@@HRT@@and@@non@@-@@estrogen@@therapies@@(@@lipid@@lowering@@agents@@,@@drug1@@,@@antihypertensives@@,@@antidiabetic@@medications@@,@@selective@@estrogen@@receptor@@modulators@@(@@SERMs@@)@@)@@as@@well@@as@@diet@@,@@lifestyle@@and@@smoking@@cessation@@in@@drug2@@in@@women@@.@@", "new_pair": "aspirin@@,@@antihypertensives@@,@@antidiabetic@@medications@@,@@selective@@estrogen@@receptor@@modulators@@(@@SERMs@@)@@)@@as@@well@@as@@diet@@,@@lifestyle@@and@@smoking@@cessation@@in@@theUprimaryUpreventionUofUCHD", "replace_pair": "drug1@@,@@antihypertensives@@,@@antidiabetic@@medications@@,@@selective@@estrogen@@receptor@@modulators@@(@@SERMs@@)@@)@@as@@well@@as@@diet@@,@@lifestyle@@and@@smoking@@cessation@@in@@drug2", "relation": "NA"}, {"head": {"id": "166", "type": "", "word": "TransientUIschaemicUAttack", "begin": "130", "end": "156", "new_begin": "157", "new_end": "183", "replace_begin": "157", "replace_end": "162"}, "tail": {"id": "167", "type": "", "word": "Aspirin", "begin": "459", "end": "466", "new_begin": "545", "new_end": "552", "replace_begin": "524", "replace_end": "529"}, "sentence": "The results of the following studies are reviewed and compared : the Swedish Aspirin Low-Dose Trial ( SALT ) , the United Kingdom TransientUIschaemicUAttack ( UK-TIA ) Aspirin Trial , Dutch Transient Ischemic Attack ( Dutch TIA ) study ( aspirin ) , the Canadian American Ticlopidine Study ( CATS ) , the Ticlopidine Aspirin Stroke Study ( TASS ) , the African American Antiplatelet Stroke Prevention Study ( AAASPS ) ( ticlopidine ) , the Clopidogrel versus Aspirin in Patients at Risk of Recurrent Ischemic Events ( CAPRIE ) trial , the Management of Atherothrombosis With Clopidogrel in High-Risk Patients study ( MATCH ) ( clopidogrel ) , the second European Stroke Prevention Study ( ESPS2 ) ( aspirin plus ER-DP ) , and the Triflusal versus Aspirin in Cerebral Infarction Prevention ( TACIP ) study .", "new_sentence": "The@@results@@of@@the@@following@@studies@@are@@reviewed@@and@@compared@@:@@the@@Swedish@@Aspirin@@Low@@-@@Dose@@Trial@@(@@SALT@@)@@,@@the@@United@@Kingdom@@TransientUIschaemicUAttack@@(@@UK@@-@@TIA@@)@@Aspirin@@Trial@@,@@Dutch@@Transient@@Ischemic@@Attack@@(@@Dutch@@TIA@@)@@study@@(@@aspirin@@)@@,@@the@@Canadian@@American@@Ticlopidine@@Study@@(@@CATS@@)@@,@@the@@Ticlopidine@@Aspirin@@Stroke@@Study@@(@@TASS@@)@@,@@the@@African@@American@@Antiplatelet@@Stroke@@Prevention@@Study@@(@@AAASPS@@)@@(@@ticlopidine@@)@@,@@the@@Clopidogrel@@versus@@Aspirin@@in@@Patients@@at@@Risk@@of@@Recurrent@@Ischemic@@Events@@(@@CAPRIE@@)@@trial@@,@@the@@Management@@of@@Atherothrombosis@@With@@Clopidogrel@@in@@High@@-@@Risk@@Patients@@study@@(@@MATCH@@)@@(@@clopidogrel@@)@@,@@the@@second@@European@@Stroke@@Prevention@@Study@@(@@ESPS2@@)@@(@@aspirin@@plus@@ER@@-@@DP@@)@@,@@and@@the@@Triflusal@@versus@@Aspirin@@in@@Cerebral@@Infarction@@Prevention@@(@@TACIP@@)@@study@@.@@", "replace_sentence": "The@@results@@of@@the@@following@@studies@@are@@reviewed@@and@@compared@@:@@the@@Swedish@@Aspirin@@Low@@-@@Dose@@Trial@@(@@SALT@@)@@,@@the@@United@@Kingdom@@drug1@@(@@UK@@-@@TIA@@)@@Aspirin@@Trial@@,@@Dutch@@Transient@@Ischemic@@Attack@@(@@Dutch@@TIA@@)@@study@@(@@aspirin@@)@@,@@the@@Canadian@@American@@Ticlopidine@@Study@@(@@CATS@@)@@,@@the@@Ticlopidine@@Aspirin@@Stroke@@Study@@(@@TASS@@)@@,@@the@@African@@American@@Antiplatelet@@Stroke@@Prevention@@Study@@(@@AAASPS@@)@@(@@ticlopidine@@)@@,@@the@@Clopidogrel@@versus@@drug2@@in@@Patients@@at@@Risk@@of@@Recurrent@@Ischemic@@Events@@(@@CAPRIE@@)@@trial@@,@@the@@Management@@of@@Atherothrombosis@@With@@Clopidogrel@@in@@High@@-@@Risk@@Patients@@study@@(@@MATCH@@)@@(@@clopidogrel@@)@@,@@the@@second@@European@@Stroke@@Prevention@@Study@@(@@ESPS2@@)@@(@@aspirin@@plus@@ER@@-@@DP@@)@@,@@and@@the@@Triflusal@@versus@@Aspirin@@in@@Cerebral@@Infarction@@Prevention@@(@@TACIP@@)@@study@@.@@", "new_pair": "TransientUIschaemicUAttack@@(@@UK@@-@@TIA@@)@@Aspirin@@Trial@@,@@Dutch@@Transient@@Ischemic@@Attack@@(@@Dutch@@TIA@@)@@study@@(@@aspirin@@)@@,@@the@@Canadian@@American@@Ticlopidine@@Study@@(@@CATS@@)@@,@@the@@Ticlopidine@@Aspirin@@Stroke@@Study@@(@@TASS@@)@@,@@the@@African@@American@@Antiplatelet@@Stroke@@Prevention@@Study@@(@@AAASPS@@)@@(@@ticlopidine@@)@@,@@the@@Clopidogrel@@versus@@Aspirin", "replace_pair": "drug1@@(@@UK@@-@@TIA@@)@@Aspirin@@Trial@@,@@Dutch@@Transient@@Ischemic@@Attack@@(@@Dutch@@TIA@@)@@study@@(@@aspirin@@)@@,@@the@@Canadian@@American@@Ticlopidine@@Study@@(@@CATS@@)@@,@@the@@Ticlopidine@@Aspirin@@Stroke@@Study@@(@@TASS@@)@@,@@the@@African@@American@@Antiplatelet@@Stroke@@Prevention@@Study@@(@@AAASPS@@)@@(@@ticlopidine@@)@@,@@the@@Clopidogrel@@versus@@drug2", "relation": "NA"}, {"head": {"id": "168", "type": "", "word": "aspirin", "begin": "15", "end": "22", "new_begin": "18", "new_end": "25", "replace_begin": "18", "replace_end": "23"}, "tail": {"id": "169", "type": "", "word": "thromboembolism", "begin": "44", "end": "59", "new_begin": "50", "new_end": "65", "replace_begin": "48", "replace_end": "53"}, "sentence": "The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty .", "new_sentence": "The@@benefit@@of@@aspirin@@chemoprophylaxis@@for@@thromboembolism@@after@@total@@knee@@arthroplasty@@.@@", "replace_sentence": "The@@benefit@@of@@drug1@@chemoprophylaxis@@for@@drug2@@after@@total@@knee@@arthroplasty@@.@@", "new_pair": "aspirin@@chemoprophylaxis@@for@@thromboembolism", "replace_pair": "drug1@@chemoprophylaxis@@for@@drug2", "relation": "may_prevent"}, {"head": {"id": "170", "type": "", "word": "hepatitisUBUimmuneUglobulin", "begin": "34", "end": "61", "new_begin": "40", "new_end": "67", "replace_begin": "40", "replace_end": "45"}, "tail": {"id": "171", "type": "", "word": "hepatitisUB", "begin": "156", "end": "167", "new_begin": "180", "new_end": "191", "replace_begin": "158", "replace_end": "163"}, "sentence": "The introduction of high doses of hepatitisUBUimmuneUglobulin ( HBIG ) and lamivudine for liver transplantation ( OLT ) prophylaxis has reduced the risk of hepatitisUB recurrence and improved the survival of patients transplanted for hepatitis B virus ( HBV ) - related liver disease .", "new_sentence": "The@@introduction@@of@@high@@doses@@of@@hepatitisUBUimmuneUglobulin@@(@@HBIG@@)@@and@@lamivudine@@for@@liver@@transplantation@@(@@OLT@@)@@prophylaxis@@has@@reduced@@the@@risk@@of@@hepatitisUB@@recurrence@@and@@improved@@the@@survival@@of@@patients@@transplanted@@for@@hepatitis@@B@@virus@@(@@HBV@@)@@-@@related@@liver@@disease@@.@@", "replace_sentence": "The@@introduction@@of@@high@@doses@@of@@drug1@@(@@HBIG@@)@@and@@lamivudine@@for@@liver@@transplantation@@(@@OLT@@)@@prophylaxis@@has@@reduced@@the@@risk@@of@@drug2@@recurrence@@and@@improved@@the@@survival@@of@@patients@@transplanted@@for@@hepatitis@@B@@virus@@(@@HBV@@)@@-@@related@@liver@@disease@@.@@", "new_pair": "hepatitisUBUimmuneUglobulin@@(@@HBIG@@)@@and@@lamivudine@@for@@liver@@transplantation@@(@@OLT@@)@@prophylaxis@@has@@reduced@@the@@risk@@of@@hepatitisUB", "replace_pair": "drug1@@(@@HBIG@@)@@and@@lamivudine@@for@@liver@@transplantation@@(@@OLT@@)@@prophylaxis@@has@@reduced@@the@@risk@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "172", "type": "", "word": "NAC", "begin": "44", "end": "47", "new_begin": "49", "new_end": "52", "replace_begin": "49", "replace_end": "54"}, "tail": {"id": "173", "type": "", "word": "chronicUrenalUinsufficiency", "begin": "103", "end": "130", "new_begin": "119", "new_end": "146", "replace_begin": "121", "replace_end": "126"}, "sentence": "BACKGROUND : Prophylactic administration of NAC , along with hydration , prevents CAN in patients with chronicUrenalUinsufficiency who are undergoing contrast media administration .", "new_sentence": "BACKGROUND@@:@@Prophylactic@@administration@@of@@NAC@@,@@along@@with@@hydration@@,@@prevents@@CAN@@in@@patients@@with@@chronicUrenalUinsufficiency@@who@@are@@undergoing@@contrast@@media@@administration@@.@@", "replace_sentence": "BACKGROUND@@:@@Prophylactic@@administration@@of@@drug1@@,@@along@@with@@hydration@@,@@prevents@@CAN@@in@@patients@@with@@drug2@@who@@are@@undergoing@@contrast@@media@@administration@@.@@", "new_pair": "NAC@@,@@along@@with@@hydration@@,@@prevents@@CAN@@in@@patients@@with@@chronicUrenalUinsufficiency", "replace_pair": "drug1@@,@@along@@with@@hydration@@,@@prevents@@CAN@@in@@patients@@with@@drug2", "relation": "NA"}, {"head": {"id": "174", "type": "", "word": "Aspirin", "begin": "13", "end": "20", "new_begin": "15", "new_end": "22", "replace_begin": "15", "replace_end": "20"}, "tail": {"id": "175", "type": "", "word": "stroke", "begin": "117", "end": "123", "new_begin": "134", "new_end": "140", "replace_begin": "132", "replace_end": "137"}, "sentence": "BACKGROUND : Aspirin is a frequently prescribed drug for primary and secondary prevention of myocardial infarction , stroke and cardiovascular death .", "new_sentence": "BACKGROUND@@:@@Aspirin@@is@@a@@frequently@@prescribed@@drug@@for@@primary@@and@@secondary@@prevention@@of@@myocardial@@infarction@@,@@stroke@@and@@cardiovascular@@death@@.@@", "replace_sentence": "BACKGROUND@@:@@drug1@@is@@a@@frequently@@prescribed@@drug@@for@@primary@@and@@secondary@@prevention@@of@@myocardial@@infarction@@,@@drug2@@and@@cardiovascular@@death@@.@@", "new_pair": "Aspirin@@is@@a@@frequently@@prescribed@@drug@@for@@primary@@and@@secondary@@prevention@@of@@myocardial@@infarction@@,@@stroke", "replace_pair": "drug1@@is@@a@@frequently@@prescribed@@drug@@for@@primary@@and@@secondary@@prevention@@of@@myocardial@@infarction@@,@@drug2", "relation": "may_prevent"}, {"head": {"id": "176", "type": "", "word": "mefloquine", "begin": "58", "end": "68", "new_begin": "68", "new_end": "78", "replace_begin": "68", "replace_end": "73"}, "tail": {"id": "177", "type": "", "word": "malaria", "begin": "80", "end": "87", "new_begin": "93", "new_end": "100", "replace_begin": "88", "replace_end": "93"}, "sentence": "The risk of malarial infection and the proven efficacy of mefloquine to prevent malaria should be weighed against the risk of drug- associated adverse events .", "new_sentence": "The@@risk@@of@@malarial@@infection@@and@@the@@proven@@efficacy@@of@@mefloquine@@to@@prevent@@malaria@@should@@be@@weighed@@against@@the@@risk@@of@@drug@@-@@associated@@adverse@@events@@.@@", "replace_sentence": "The@@risk@@of@@malarial@@infection@@and@@the@@proven@@efficacy@@of@@drug1@@to@@prevent@@drug2@@should@@be@@weighed@@against@@the@@risk@@of@@drug@@-@@associated@@adverse@@events@@.@@", "new_pair": "mefloquine@@to@@prevent@@malaria", "replace_pair": "drug1@@to@@prevent@@drug2", "relation": "may_prevent"}, {"head": {"id": "178", "type": "", "word": "stroke", "begin": "56", "end": "62", "new_begin": "63", "new_end": "69", "replace_begin": "63", "replace_end": "68"}, "tail": {"id": "179", "type": "", "word": "aspirin", "begin": "230", "end": "237", "new_begin": "269", "new_end": "276", "replace_begin": "268", "replace_end": "273"}, "sentence": "Carotid endarterectomy is more effective for preventing stroke in symptomatic ( transient ischemic attack or stroke ) patients with = or > 50 % diameter stenosis and asymptomatic patients with = or > 60 % diameter stenosis , than aspirin therapy .", "new_sentence": "Carotid@@endarterectomy@@is@@more@@effective@@for@@preventing@@stroke@@in@@symptomatic@@(@@transient@@ischemic@@attack@@or@@stroke@@)@@patients@@with@@=@@or@@>@@50@@%@@diameter@@stenosis@@and@@asymptomatic@@patients@@with@@=@@or@@>@@60@@%@@diameter@@stenosis@@,@@than@@aspirin@@therapy@@.@@", "replace_sentence": "Carotid@@endarterectomy@@is@@more@@effective@@for@@preventing@@drug1@@in@@symptomatic@@(@@transient@@ischemic@@attack@@or@@stroke@@)@@patients@@with@@=@@or@@>@@50@@%@@diameter@@stenosis@@and@@asymptomatic@@patients@@with@@=@@or@@>@@60@@%@@diameter@@stenosis@@,@@than@@drug2@@therapy@@.@@", "new_pair": "stroke@@in@@symptomatic@@(@@transient@@ischemic@@attack@@or@@stroke@@)@@patients@@with@@=@@or@@>@@50@@%@@diameter@@stenosis@@and@@asymptomatic@@patients@@with@@=@@or@@>@@60@@%@@diameter@@stenosis@@,@@than@@aspirin", "replace_pair": "drug1@@in@@symptomatic@@(@@transient@@ischemic@@attack@@or@@stroke@@)@@patients@@with@@=@@or@@>@@50@@%@@diameter@@stenosis@@and@@asymptomatic@@patients@@with@@=@@or@@>@@60@@%@@diameter@@stenosis@@,@@than@@drug2", "relation": "may_prevent"}, {"head": {"id": "180", "type": "", "word": "allopurinol", "begin": "72", "end": "83", "new_begin": "86", "new_end": "97", "replace_begin": "86", "replace_end": "91"}, "tail": {"id": "181", "type": "", "word": "TLS", "begin": "108", "end": "111", "new_begin": "126", "new_end": "129", "replace_begin": "120", "replace_end": "125"}, "sentence": "CONCLUSIONS : A single dose of rasburicase ( based on IBW ) followed by allopurinol can effectively prevent TLS based on serum uric acid concentration .", "new_sentence": "CONCLUSIONS@@:@@A@@single@@dose@@of@@rasburicase@@(@@based@@on@@IBW@@)@@followed@@by@@allopurinol@@can@@effectively@@prevent@@TLS@@based@@on@@serum@@uric@@acid@@concentration@@.@@", "replace_sentence": "CONCLUSIONS@@:@@A@@single@@dose@@of@@rasburicase@@(@@based@@on@@IBW@@)@@followed@@by@@drug1@@can@@effectively@@prevent@@drug2@@based@@on@@serum@@uric@@acid@@concentration@@.@@", "new_pair": "allopurinol@@can@@effectively@@prevent@@TLS", "replace_pair": "drug1@@can@@effectively@@prevent@@drug2", "relation": "may_prevent"}, {"head": {"id": "182", "type": "", "word": "F", "begin": "232", "end": "233", "new_begin": "271", "new_end": "272", "replace_begin": "271", "replace_end": "276"}, "tail": {"id": "183", "type": "", "word": "infestation", "begin": "260", "end": "271", "new_begin": "306", "new_end": "317", "replace_begin": "310", "replace_end": "315"}, "sentence": "We determined that the number of insect fragments , quantified using the standard flotation method , in flour milled from wheat infested with larvae , pupae , or preemergent adults of the lesser grain borer , Rhyzopertha dominica ( F . ) , was proportional to infestation level .", "new_sentence": "We@@determined@@that@@the@@number@@of@@insect@@fragments@@,@@quantified@@using@@the@@standard@@flotation@@method@@,@@in@@flour@@milled@@from@@wheat@@infested@@with@@larvae@@,@@pupae@@,@@or@@preemergent@@adults@@of@@the@@lesser@@grain@@borer@@,@@Rhyzopertha@@dominica@@(@@F@@.@@)@@,@@was@@proportional@@to@@infestation@@level@@.@@", "replace_sentence": "We@@determined@@that@@the@@number@@of@@insect@@fragments@@,@@quantified@@using@@the@@standard@@flotation@@method@@,@@in@@flour@@milled@@from@@wheat@@infested@@with@@larvae@@,@@pupae@@,@@or@@preemergent@@adults@@of@@the@@lesser@@grain@@borer@@,@@Rhyzopertha@@dominica@@(@@drug1@@.@@)@@,@@was@@proportional@@to@@drug2@@level@@.@@", "new_pair": "F@@.@@)@@,@@was@@proportional@@to@@infestation", "replace_pair": "drug1@@.@@)@@,@@was@@proportional@@to@@drug2", "relation": "NA"}, {"head": {"id": "184", "type": "", "word": "graft-vsU . U-hostUdisease", "begin": "10", "end": "36", "new_begin": "11", "new_end": "37", "replace_begin": "11", "replace_end": "16"}, "tail": {"id": "185", "type": "", "word": "aUshortUcourseUofUtheUimmunosuppressiveUagentUcyclosporine", "begin": "162", "end": "220", "new_begin": "185", "new_end": "243", "replace_begin": "164", "replace_end": "169"}, "sentence": "Syngeneic graft-vsU . U-hostUdisease ( SGVHD ) develops in rodents following the treatment of lethally irradiated , bone marrow ( BM ) reconstituted animals with aUshortUcourseUofUtheUimmunosuppressiveUagentUcyclosporine A ( CsA ) .", "new_sentence": "Syngeneic@@graft-vsU . U-hostUdisease@@(@@SGVHD@@)@@develops@@in@@rodents@@following@@the@@treatment@@of@@lethally@@irradiated@@,@@bone@@marrow@@(@@BM@@)@@reconstituted@@animals@@with@@aUshortUcourseUofUtheUimmunosuppressiveUagentUcyclosporine@@A@@(@@CsA@@)@@.@@", "replace_sentence": "Syngeneic@@drug1@@(@@SGVHD@@)@@develops@@in@@rodents@@following@@the@@treatment@@of@@lethally@@irradiated@@,@@bone@@marrow@@(@@BM@@)@@reconstituted@@animals@@with@@drug2@@A@@(@@CsA@@)@@.@@", "new_pair": "graft-vsU . U-hostUdisease@@(@@SGVHD@@)@@develops@@in@@rodents@@following@@the@@treatment@@of@@lethally@@irradiated@@,@@bone@@marrow@@(@@BM@@)@@reconstituted@@animals@@with@@aUshortUcourseUofUtheUimmunosuppressiveUagentUcyclosporine", "replace_pair": "drug1@@(@@SGVHD@@)@@develops@@in@@rodents@@following@@the@@treatment@@of@@lethally@@irradiated@@,@@bone@@marrow@@(@@BM@@)@@reconstituted@@animals@@with@@drug2", "relation": "NA"}, {"head": {"id": "186", "type": "", "word": "lovastatin", "begin": "28", "end": "38", "new_begin": "32", "new_end": "42", "replace_begin": "32", "replace_end": "37"}, "tail": {"id": "187", "type": "", "word": "myocardialUinfarction", "begin": "241", "end": "262", "new_begin": "284", "new_end": "305", "replace_begin": "279", "replace_end": "284"}, "sentence": "These data demonstrate that lovastatin protects MSCs from Hypoxia @ SD- induced apoptosis via PI3K @ Akt and MEK @ ERK1 @ 2 pathways , suggesting that it may prove a useful therapeutic adjunct for transplanting MSCs into damaged heart after myocardialUinfarction .", "new_sentence": "These@@data@@demonstrate@@that@@lovastatin@@protects@@MSCs@@from@@Hypoxia@@@@@SD@@-@@induced@@apoptosis@@via@@PI3K@@@@@Akt@@and@@MEK@@@@@ERK1@@@@@2@@pathways@@,@@suggesting@@that@@it@@may@@prove@@a@@useful@@therapeutic@@adjunct@@for@@transplanting@@MSCs@@into@@damaged@@heart@@after@@myocardialUinfarction@@.@@", "replace_sentence": "These@@data@@demonstrate@@that@@drug1@@protects@@MSCs@@from@@Hypoxia@@@@@SD@@-@@induced@@apoptosis@@via@@PI3K@@@@@Akt@@and@@MEK@@@@@ERK1@@@@@2@@pathways@@,@@suggesting@@that@@it@@may@@prove@@a@@useful@@therapeutic@@adjunct@@for@@transplanting@@MSCs@@into@@damaged@@heart@@after@@drug2@@.@@", "new_pair": "lovastatin@@protects@@MSCs@@from@@Hypoxia@@@@@SD@@-@@induced@@apoptosis@@via@@PI3K@@@@@Akt@@and@@MEK@@@@@ERK1@@@@@2@@pathways@@,@@suggesting@@that@@it@@may@@prove@@a@@useful@@therapeutic@@adjunct@@for@@transplanting@@MSCs@@into@@damaged@@heart@@after@@myocardialUinfarction", "replace_pair": "drug1@@protects@@MSCs@@from@@Hypoxia@@@@@SD@@-@@induced@@apoptosis@@via@@PI3K@@@@@Akt@@and@@MEK@@@@@ERK1@@@@@2@@pathways@@,@@suggesting@@that@@it@@may@@prove@@a@@useful@@therapeutic@@adjunct@@for@@transplanting@@MSCs@@into@@damaged@@heart@@after@@drug2", "relation": "NA"}, {"head": {"id": "188", "type": "", "word": "ThromboEmbolism", "begin": "193", "end": "208", "new_begin": "224", "new_end": "239", "replace_begin": "224", "replace_end": "229"}, "tail": {"id": "189", "type": "", "word": "fondaparinux", "begin": "384", "end": "396", "new_begin": "449", "new_end": "461", "replace_begin": "439", "replace_end": "444"}, "sentence": "The prophylaxis in MEDical patients with ENOXaparin ( MEDENOX ) , Prospective Evaluation of Dalteparin Efficacy for PREVENTion of VTE in Immobilized Patients Trial ( PREVENT ) , and ARixta for ThromboEmbolism Prevention in a Medical Indications Study ( ARTEMIS ) studies have compared the low-molecular-weight heparins enoxaparin and dalteparin , and the specific factor Xa inhibitor fondaparinux , respectively , with placebo in acutely ill medical patients hospitalized with heart failure , respiratory failure , infectious disease , or inflammatory disease .", "new_sentence": "The@@prophylaxis@@in@@MEDical@@patients@@with@@ENOXaparin@@(@@MEDENOX@@)@@,@@Prospective@@Evaluation@@of@@Dalteparin@@Efficacy@@for@@PREVENTion@@of@@VTE@@in@@Immobilized@@Patients@@Trial@@(@@PREVENT@@)@@,@@and@@ARixta@@for@@ThromboEmbolism@@Prevention@@in@@a@@Medical@@Indications@@Study@@(@@ARTEMIS@@)@@studies@@have@@compared@@the@@low@@-@@molecular@@-@@weight@@heparins@@enoxaparin@@and@@dalteparin@@,@@and@@the@@specific@@factor@@Xa@@inhibitor@@fondaparinux@@,@@respectively@@,@@with@@placebo@@in@@acutely@@ill@@medical@@patients@@hospitalized@@with@@heart@@failure@@,@@respiratory@@failure@@,@@infectious@@disease@@,@@or@@inflammatory@@disease@@.@@", "replace_sentence": "The@@prophylaxis@@in@@MEDical@@patients@@with@@ENOXaparin@@(@@MEDENOX@@)@@,@@Prospective@@Evaluation@@of@@Dalteparin@@Efficacy@@for@@PREVENTion@@of@@VTE@@in@@Immobilized@@Patients@@Trial@@(@@PREVENT@@)@@,@@and@@ARixta@@for@@drug1@@Prevention@@in@@a@@Medical@@Indications@@Study@@(@@ARTEMIS@@)@@studies@@have@@compared@@the@@low@@-@@molecular@@-@@weight@@heparins@@enoxaparin@@and@@dalteparin@@,@@and@@the@@specific@@factor@@Xa@@inhibitor@@drug2@@,@@respectively@@,@@with@@placebo@@in@@acutely@@ill@@medical@@patients@@hospitalized@@with@@heart@@failure@@,@@respiratory@@failure@@,@@infectious@@disease@@,@@or@@inflammatory@@disease@@.@@", "new_pair": "ThromboEmbolism@@Prevention@@in@@a@@Medical@@Indications@@Study@@(@@ARTEMIS@@)@@studies@@have@@compared@@the@@low@@-@@molecular@@-@@weight@@heparins@@enoxaparin@@and@@dalteparin@@,@@and@@the@@specific@@factor@@Xa@@inhibitor@@fondaparinux", "replace_pair": "drug1@@Prevention@@in@@a@@Medical@@Indications@@Study@@(@@ARTEMIS@@)@@studies@@have@@compared@@the@@low@@-@@molecular@@-@@weight@@heparins@@enoxaparin@@and@@dalteparin@@,@@and@@the@@specific@@factor@@Xa@@inhibitor@@drug2", "relation": "NA"}, {"head": {"id": "190", "type": "", "word": "Aspirin", "begin": "0", "end": "7", "new_begin": "0", "new_end": "7", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "191", "type": "", "word": "myocardialUinfarction", "begin": "114", "end": "135", "new_begin": "132", "new_end": "153", "replace_begin": "130", "replace_end": "135"}, "sentence": "Aspirin or nonaspirin NSAIDs may be appropriate prevention therapy for patients at high risk of prostate cancer , myocardialUinfarction , Parkinson s disease , Alzheimer s disease , lung cancer , or colorectal cancer , but low risk for gastrointestinal complications or stroke .", "new_sentence": "Aspirin@@or@@nonaspirin@@NSAIDs@@may@@be@@appropriate@@prevention@@therapy@@for@@patients@@at@@high@@risk@@of@@prostate@@cancer@@,@@myocardialUinfarction@@,@@Parkinson@@s@@disease@@,@@Alzheimer@@s@@disease@@,@@lung@@cancer@@,@@or@@colorectal@@cancer@@,@@but@@low@@risk@@for@@gastrointestinal@@complications@@or@@stroke@@.@@", "replace_sentence": "drug1@@or@@nonaspirin@@NSAIDs@@may@@be@@appropriate@@prevention@@therapy@@for@@patients@@at@@high@@risk@@of@@prostate@@cancer@@,@@drug2@@,@@Parkinson@@s@@disease@@,@@Alzheimer@@s@@disease@@,@@lung@@cancer@@,@@or@@colorectal@@cancer@@,@@but@@low@@risk@@for@@gastrointestinal@@complications@@or@@stroke@@.@@", "new_pair": "Aspirin@@or@@nonaspirin@@NSAIDs@@may@@be@@appropriate@@prevention@@therapy@@for@@patients@@at@@high@@risk@@of@@prostate@@cancer@@,@@myocardialUinfarction", "replace_pair": "drug1@@or@@nonaspirin@@NSAIDs@@may@@be@@appropriate@@prevention@@therapy@@for@@patients@@at@@high@@risk@@of@@prostate@@cancer@@,@@drug2", "relation": "may_prevent"}, {"head": {"id": "192", "type": "", "word": "typhoidUfever", "begin": "96", "end": "109", "new_begin": "112", "new_end": "125", "replace_begin": "112", "replace_end": "117"}, "tail": {"id": "193", "type": "", "word": "mefloquine", "begin": "130", "end": "140", "new_begin": "152", "new_end": "162", "replace_begin": "144", "replace_end": "149"}, "sentence": "A 67 year old Caucasian lady received pre - travel immunizations against tetanus , diphtheria , typhoidUfever , hepatitis A , and mefloquine chemoprophylaxis .", "new_sentence": "A@@67@@year@@old@@Caucasian@@lady@@received@@pre@@-@@travel@@immunizations@@against@@tetanus@@,@@diphtheria@@,@@typhoidUfever@@,@@hepatitis@@A@@,@@and@@mefloquine@@chemoprophylaxis@@.@@", "replace_sentence": "A@@67@@year@@old@@Caucasian@@lady@@received@@pre@@-@@travel@@immunizations@@against@@tetanus@@,@@diphtheria@@,@@drug1@@,@@hepatitis@@A@@,@@and@@drug2@@chemoprophylaxis@@.@@", "new_pair": "typhoidUfever@@,@@hepatitis@@A@@,@@and@@mefloquine", "replace_pair": "drug1@@,@@hepatitis@@A@@,@@and@@drug2", "relation": "NA"}, {"head": {"id": "194", "type": "", "word": "Palivizumab", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "195", "type": "", "word": "bronchopulmonaryUdysplasia", "begin": "343", "end": "369", "new_begin": "403", "new_end": "429", "replace_begin": "397", "replace_end": "402"}, "sentence": "Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous ( RSV-IGIV ) are licensed by the Food and Drug Administration for use in preventing severe lower respiratory tract infections caused by respiratory syncytial virus ( RSV ) in high-risk infants , children younger than 24 months with chronic lung disease ( formerly called bronchopulmonaryUdysplasia ) , and certain preterm infants .", "new_sentence": "Palivizumab@@and@@Respiratory@@Syncytial@@Virus@@Immune@@Globulin@@Intravenous@@(@@RSV@@-@@IGIV@@)@@are@@licensed@@by@@the@@Food@@and@@Drug@@Administration@@for@@use@@in@@preventing@@severe@@lower@@respiratory@@tract@@infections@@caused@@by@@respiratory@@syncytial@@virus@@(@@RSV@@)@@in@@high@@-@@risk@@infants@@,@@children@@younger@@than@@24@@months@@with@@chronic@@lung@@disease@@(@@formerly@@called@@bronchopulmonaryUdysplasia@@)@@,@@and@@certain@@preterm@@infants@@.@@", "replace_sentence": "drug1@@and@@Respiratory@@Syncytial@@Virus@@Immune@@Globulin@@Intravenous@@(@@RSV@@-@@IGIV@@)@@are@@licensed@@by@@the@@Food@@and@@Drug@@Administration@@for@@use@@in@@preventing@@severe@@lower@@respiratory@@tract@@infections@@caused@@by@@respiratory@@syncytial@@virus@@(@@RSV@@)@@in@@high@@-@@risk@@infants@@,@@children@@younger@@than@@24@@months@@with@@chronic@@lung@@disease@@(@@formerly@@called@@drug2@@)@@,@@and@@certain@@preterm@@infants@@.@@", "new_pair": "Palivizumab@@and@@Respiratory@@Syncytial@@Virus@@Immune@@Globulin@@Intravenous@@(@@RSV@@-@@IGIV@@)@@are@@licensed@@by@@the@@Food@@and@@Drug@@Administration@@for@@use@@in@@preventing@@severe@@lower@@respiratory@@tract@@infections@@caused@@by@@respiratory@@syncytial@@virus@@(@@RSV@@)@@in@@high@@-@@risk@@infants@@,@@children@@younger@@than@@24@@months@@with@@chronic@@lung@@disease@@(@@formerly@@called@@bronchopulmonaryUdysplasia", "replace_pair": "drug1@@and@@Respiratory@@Syncytial@@Virus@@Immune@@Globulin@@Intravenous@@(@@RSV@@-@@IGIV@@)@@are@@licensed@@by@@the@@Food@@and@@Drug@@Administration@@for@@use@@in@@preventing@@severe@@lower@@respiratory@@tract@@infections@@caused@@by@@respiratory@@syncytial@@virus@@(@@RSV@@)@@in@@high@@-@@risk@@infants@@,@@children@@younger@@than@@24@@months@@with@@chronic@@lung@@disease@@(@@formerly@@called@@drug2", "relation": "NA"}, {"head": {"id": "196", "type": "", "word": "Caries", "begin": "0", "end": "6", "new_begin": "0", "new_end": "6", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "197", "type": "", "word": "fluoride", "begin": "53", "end": "61", "new_begin": "59", "new_end": "67", "replace_begin": "58", "replace_end": "63"}, "sentence": "Caries management for institutionalized elders using fluoride and chlorhexidine mouthrinses .", "new_sentence": "Caries@@management@@for@@institutionalized@@elders@@using@@fluoride@@and@@chlorhexidine@@mouthrinses@@.@@", "replace_sentence": "drug1@@management@@for@@institutionalized@@elders@@using@@drug2@@and@@chlorhexidine@@mouthrinses@@.@@", "new_pair": "Caries@@management@@for@@institutionalized@@elders@@using@@fluoride", "replace_pair": "drug1@@management@@for@@institutionalized@@elders@@using@@drug2", "relation": "may_prevent"}, {"head": {"id": "198", "type": "", "word": "graft-versus-hostUdisease", "begin": "10", "end": "35", "new_begin": "12", "new_end": "37", "replace_begin": "12", "replace_end": "17"}, "tail": {"id": "199", "type": "", "word": "cyclosporinUA", "begin": "148", "end": "161", "new_begin": "169", "new_end": "182", "replace_begin": "149", "replace_end": "154"}, "sentence": "Effect of graft-versus-hostUdisease on the outcome of bone marrow transplantation from an HLA - identical sibling donor using GVHD prophylaxis with cyclosporinUA and methotrexate .", "new_sentence": "Effect@@of@@graft-versus-hostUdisease@@on@@the@@outcome@@of@@bone@@marrow@@transplantation@@from@@an@@HLA@@-@@identical@@sibling@@donor@@using@@GVHD@@prophylaxis@@with@@cyclosporinUA@@and@@methotrexate@@.@@", "replace_sentence": "Effect@@of@@drug1@@on@@the@@outcome@@of@@bone@@marrow@@transplantation@@from@@an@@HLA@@-@@identical@@sibling@@donor@@using@@GVHD@@prophylaxis@@with@@drug2@@and@@methotrexate@@.@@", "new_pair": "graft-versus-hostUdisease@@on@@the@@outcome@@of@@bone@@marrow@@transplantation@@from@@an@@HLA@@-@@identical@@sibling@@donor@@using@@GVHD@@prophylaxis@@with@@cyclosporinUA", "replace_pair": "drug1@@on@@the@@outcome@@of@@bone@@marrow@@transplantation@@from@@an@@HLA@@-@@identical@@sibling@@donor@@using@@GVHD@@prophylaxis@@with@@drug2", "relation": "may_prevent"}, {"head": {"id": "200", "type": "", "word": "trandolapril", "begin": "50", "end": "62", "new_begin": "58", "new_end": "70", "replace_begin": "58", "replace_end": "63"}, "tail": {"id": "201", "type": "", "word": "myocardialUinfarctions", "begin": "125", "end": "147", "new_begin": "143", "new_end": "165", "replace_begin": "136", "replace_end": "141"}, "sentence": "In PROGRESS and PEACE trials ACEI perindopril and trandolapril as monotherapy turned out incapable to prevent development of myocardialUinfarctions and strokes in patients with cardiovascular diseases without left ventricular systolic dysfunction .", "new_sentence": "In@@PROGRESS@@and@@PEACE@@trials@@ACEI@@perindopril@@and@@trandolapril@@as@@monotherapy@@turned@@out@@incapable@@to@@prevent@@development@@of@@myocardialUinfarctions@@and@@strokes@@in@@patients@@with@@cardiovascular@@diseases@@without@@left@@ventricular@@systolic@@dysfunction@@.@@", "replace_sentence": "In@@PROGRESS@@and@@PEACE@@trials@@ACEI@@perindopril@@and@@drug1@@as@@monotherapy@@turned@@out@@incapable@@to@@prevent@@development@@of@@drug2@@and@@strokes@@in@@patients@@with@@cardiovascular@@diseases@@without@@left@@ventricular@@systolic@@dysfunction@@.@@", "new_pair": "trandolapril@@as@@monotherapy@@turned@@out@@incapable@@to@@prevent@@development@@of@@myocardialUinfarctions", "replace_pair": "drug1@@as@@monotherapy@@turned@@out@@incapable@@to@@prevent@@development@@of@@drug2", "relation": "NA"}, {"head": {"id": "202", "type": "", "word": "infections", "begin": "332", "end": "342", "new_begin": "388", "new_end": "398", "replace_begin": "388", "replace_end": "393"}, "tail": {"id": "203", "type": "", "word": "pegfilgrastim", "begin": "454", "end": "467", "new_begin": "529", "new_end": "542", "replace_begin": "524", "replace_end": "529"}, "sentence": "( 1 ) Neutropenia is a frequent complication of chemotherapy associated with life-threatening infections , hospitalisation , and chemotherapy dose reductions and delays . ( 2 ) Primary prophylaxis with granulocyte colony-stimulating factors has been shown to reduce the incidence and duration of neutropenia , febrile neutropenia , infections , hospitalisation and antibiotic use . ( 3 ) Recent randomised clinical trials of filgrastim , lenograstim and pegfilgrastim showed variable results across patient groups at different risks of febrile neutropenia . ( 4 ) Pegfilgrastim is at least as effective as filgrastim in the prophylaxis of chemotherapy - induced neutropenia and has improved pharmacokinetics requiring reduced administration .", "new_sentence": "(@@1@@)@@Neutropenia@@is@@a@@frequent@@complication@@of@@chemotherapy@@associated@@with@@life@@-@@threatening@@infections@@,@@hospitalisation@@,@@and@@chemotherapy@@dose@@reductions@@and@@delays@@.@@(@@2@@)@@Primary@@prophylaxis@@with@@granulocyte@@colony@@-@@stimulating@@factors@@has@@been@@shown@@to@@reduce@@the@@incidence@@and@@duration@@of@@neutropenia@@,@@febrile@@neutropenia@@,@@infections@@,@@hospitalisation@@and@@antibiotic@@use@@.@@(@@3@@)@@Recent@@randomised@@clinical@@trials@@of@@filgrastim@@,@@lenograstim@@and@@pegfilgrastim@@showed@@variable@@results@@across@@patient@@groups@@at@@different@@risks@@of@@febrile@@neutropenia@@.@@(@@4@@)@@Pegfilgrastim@@is@@at@@least@@as@@effective@@as@@filgrastim@@in@@the@@prophylaxis@@of@@chemotherapy@@-@@induced@@neutropenia@@and@@has@@improved@@pharmacokinetics@@requiring@@reduced@@administration@@.@@", "replace_sentence": "(@@1@@)@@Neutropenia@@is@@a@@frequent@@complication@@of@@chemotherapy@@associated@@with@@life@@-@@threatening@@infections@@,@@hospitalisation@@,@@and@@chemotherapy@@dose@@reductions@@and@@delays@@.@@(@@2@@)@@Primary@@prophylaxis@@with@@granulocyte@@colony@@-@@stimulating@@factors@@has@@been@@shown@@to@@reduce@@the@@incidence@@and@@duration@@of@@neutropenia@@,@@febrile@@neutropenia@@,@@drug1@@,@@hospitalisation@@and@@antibiotic@@use@@.@@(@@3@@)@@Recent@@randomised@@clinical@@trials@@of@@filgrastim@@,@@lenograstim@@and@@drug2@@showed@@variable@@results@@across@@patient@@groups@@at@@different@@risks@@of@@febrile@@neutropenia@@.@@(@@4@@)@@Pegfilgrastim@@is@@at@@least@@as@@effective@@as@@filgrastim@@in@@the@@prophylaxis@@of@@chemotherapy@@-@@induced@@neutropenia@@and@@has@@improved@@pharmacokinetics@@requiring@@reduced@@administration@@.@@", "new_pair": "infections@@,@@hospitalisation@@and@@antibiotic@@use@@.@@(@@3@@)@@Recent@@randomised@@clinical@@trials@@of@@filgrastim@@,@@lenograstim@@and@@pegfilgrastim", "replace_pair": "drug1@@,@@hospitalisation@@and@@antibiotic@@use@@.@@(@@3@@)@@Recent@@randomised@@clinical@@trials@@of@@filgrastim@@,@@lenograstim@@and@@drug2", "relation": "NA"}, {"head": {"id": "204", "type": "", "word": "pravastatin", "begin": "321", "end": "332", "new_begin": "374", "new_end": "385", "replace_begin": "374", "replace_end": "379"}, "tail": {"id": "205", "type": "", "word": "CongestiveUHeartUFailure", "begin": "796", "end": "820", "new_begin": "920", "new_end": "944", "replace_begin": "914", "replace_end": "919"}, "sentence": "Other trials that will be summarised in this report are the Na + @ H + Exchange Inhibition to Prevent Coronary Events in Acute Cardiac Conditions Trial ( EXPEDITION ; cariporide in coronary artery bypass graft surgery ) , the Reversal of Atherosclerosis with Aggressive Lipid Lowering Trial ( REVERSAL ; atorvastatin and pravastatin for atherosclerosis reversal ) , the Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation V ( SPORTIF V ; ximelagatran and warfarin for stroke prevention in atrial fibrillation ) , the Prophylactic Amiodarone for the Prevention of Arrhythmias that Begin Early After Revascularisation ( PAPABEAR ; amiodarone for the prevention of postoperative atrial fibrillation ) , the Acute and Chronic Therapeutic Impact of a Vasopressin 2 Antagonist in CongestiveUHeartUFailure ( ACTIV in CHF ; vasopressin 2 antagonist tolvaptan in congestive heart failure ) and Prevention of Renal and Vascular Endstage Disease Intervention Trial ( PREVEND IT ; fosinopril and pravastatin in microalbuminuric subjects without hypertension or hypercholesterolemia ) .", "new_sentence": "Other@@trials@@that@@will@@be@@summarised@@in@@this@@report@@are@@the@@Na@@+@@@@@H@@+@@Exchange@@Inhibition@@to@@Prevent@@Coronary@@Events@@in@@Acute@@Cardiac@@Conditions@@Trial@@(@@EXPEDITION@@;@@cariporide@@in@@coronary@@artery@@bypass@@graft@@surgery@@)@@,@@the@@Reversal@@of@@Atherosclerosis@@with@@Aggressive@@Lipid@@Lowering@@Trial@@(@@REVERSAL@@;@@atorvastatin@@and@@pravastatin@@for@@atherosclerosis@@reversal@@)@@,@@the@@Stroke@@Prevention@@Using@@an@@Oral@@Thrombin@@Inhibitor@@in@@Atrial@@Fibrillation@@V@@(@@SPORTIF@@V@@;@@ximelagatran@@and@@warfarin@@for@@stroke@@prevention@@in@@atrial@@fibrillation@@)@@,@@the@@Prophylactic@@Amiodarone@@for@@the@@Prevention@@of@@Arrhythmias@@that@@Begin@@Early@@After@@Revascularisation@@(@@PAPABEAR@@;@@amiodarone@@for@@the@@prevention@@of@@postoperative@@atrial@@fibrillation@@)@@,@@the@@Acute@@and@@Chronic@@Therapeutic@@Impact@@of@@a@@Vasopressin@@2@@Antagonist@@in@@CongestiveUHeartUFailure@@(@@ACTIV@@in@@CHF@@;@@vasopressin@@2@@antagonist@@tolvaptan@@in@@congestive@@heart@@failure@@)@@and@@Prevention@@of@@Renal@@and@@Vascular@@Endstage@@Disease@@Intervention@@Trial@@(@@PREVEND@@IT@@;@@fosinopril@@and@@pravastatin@@in@@microalbuminuric@@subjects@@without@@hypertension@@or@@hypercholesterolemia@@)@@.@@", "replace_sentence": "Other@@trials@@that@@will@@be@@summarised@@in@@this@@report@@are@@the@@Na@@+@@@@@H@@+@@Exchange@@Inhibition@@to@@Prevent@@Coronary@@Events@@in@@Acute@@Cardiac@@Conditions@@Trial@@(@@EXPEDITION@@;@@cariporide@@in@@coronary@@artery@@bypass@@graft@@surgery@@)@@,@@the@@Reversal@@of@@Atherosclerosis@@with@@Aggressive@@Lipid@@Lowering@@Trial@@(@@REVERSAL@@;@@atorvastatin@@and@@drug1@@for@@atherosclerosis@@reversal@@)@@,@@the@@Stroke@@Prevention@@Using@@an@@Oral@@Thrombin@@Inhibitor@@in@@Atrial@@Fibrillation@@V@@(@@SPORTIF@@V@@;@@ximelagatran@@and@@warfarin@@for@@stroke@@prevention@@in@@atrial@@fibrillation@@)@@,@@the@@Prophylactic@@Amiodarone@@for@@the@@Prevention@@of@@Arrhythmias@@that@@Begin@@Early@@After@@Revascularisation@@(@@PAPABEAR@@;@@amiodarone@@for@@the@@prevention@@of@@postoperative@@atrial@@fibrillation@@)@@,@@the@@Acute@@and@@Chronic@@Therapeutic@@Impact@@of@@a@@Vasopressin@@2@@Antagonist@@in@@drug2@@(@@ACTIV@@in@@CHF@@;@@vasopressin@@2@@antagonist@@tolvaptan@@in@@congestive@@heart@@failure@@)@@and@@Prevention@@of@@Renal@@and@@Vascular@@Endstage@@Disease@@Intervention@@Trial@@(@@PREVEND@@IT@@;@@fosinopril@@and@@pravastatin@@in@@microalbuminuric@@subjects@@without@@hypertension@@or@@hypercholesterolemia@@)@@.@@", "new_pair": "pravastatin@@for@@atherosclerosis@@reversal@@)@@,@@the@@Stroke@@Prevention@@Using@@an@@Oral@@Thrombin@@Inhibitor@@in@@Atrial@@Fibrillation@@V@@(@@SPORTIF@@V@@;@@ximelagatran@@and@@warfarin@@for@@stroke@@prevention@@in@@atrial@@fibrillation@@)@@,@@the@@Prophylactic@@Amiodarone@@for@@the@@Prevention@@of@@Arrhythmias@@that@@Begin@@Early@@After@@Revascularisation@@(@@PAPABEAR@@;@@amiodarone@@for@@the@@prevention@@of@@postoperative@@atrial@@fibrillation@@)@@,@@the@@Acute@@and@@Chronic@@Therapeutic@@Impact@@of@@a@@Vasopressin@@2@@Antagonist@@in@@CongestiveUHeartUFailure", "replace_pair": "drug1@@for@@atherosclerosis@@reversal@@)@@,@@the@@Stroke@@Prevention@@Using@@an@@Oral@@Thrombin@@Inhibitor@@in@@Atrial@@Fibrillation@@V@@(@@SPORTIF@@V@@;@@ximelagatran@@and@@warfarin@@for@@stroke@@prevention@@in@@atrial@@fibrillation@@)@@,@@the@@Prophylactic@@Amiodarone@@for@@the@@Prevention@@of@@Arrhythmias@@that@@Begin@@Early@@After@@Revascularisation@@(@@PAPABEAR@@;@@amiodarone@@for@@the@@prevention@@of@@postoperative@@atrial@@fibrillation@@)@@,@@the@@Acute@@and@@Chronic@@Therapeutic@@Impact@@of@@a@@Vasopressin@@2@@Antagonist@@in@@drug2", "relation": "NA"}, {"head": {"id": "206", "type": "", "word": "CyclosporinUA", "begin": "0", "end": "13", "new_begin": "0", "new_end": "13", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "207", "type": "", "word": "graftUversusUhostUdisease", "begin": "39", "end": "64", "new_begin": "45", "new_end": "70", "replace_begin": "37", "replace_end": "42"}, "sentence": "CyclosporinUA is an essential drug for graftUversusUhostUdisease ( GvHD ) prophylaxis in allogeneic hematopoietic stem cell transplantation .", "new_sentence": "CyclosporinUA@@is@@an@@essential@@drug@@for@@graftUversusUhostUdisease@@(@@GvHD@@)@@prophylaxis@@in@@allogeneic@@hematopoietic@@stem@@cell@@transplantation@@.@@", "replace_sentence": "drug1@@is@@an@@essential@@drug@@for@@drug2@@(@@GvHD@@)@@prophylaxis@@in@@allogeneic@@hematopoietic@@stem@@cell@@transplantation@@.@@", "new_pair": "CyclosporinUA@@is@@an@@essential@@drug@@for@@graftUversusUhostUdisease", "replace_pair": "drug1@@is@@an@@essential@@drug@@for@@drug2", "relation": "may_prevent"}, {"head": {"id": "208", "type": "", "word": "clopidogrel", "begin": "29", "end": "40", "new_begin": "34", "new_end": "45", "replace_begin": "34", "replace_end": "39"}, "tail": {"id": "209", "type": "", "word": "MyocardialUInfarction", "begin": "461", "end": "482", "new_begin": "530", "new_end": "551", "replace_begin": "524", "replace_end": "529"}, "sentence": "Furthermore , the benefit of clopidogrel compared with placebo in patients with acute coronary syndromes , as well as those undergoing percutaneous coronary intervention receiving a standard therapy including aspirin , has been largely demonstrated by the Clopidogrel in Unstable angina to prevent Recurrent Events ( CURE ) , Clopidogrel for the Reduction of Events During Observation ( CREDO ) , CLopidogrel as Adjunctive ReperfusIon TherapY - Thrombolysis In MyocardialUInfarction ( CLARITY -TIMI ) 28 , and Clopidogrel and Metoprolol in Myocardial Infarction Trial @ Secon Chinese Cardiac Study ( COMMIT @ CCS -2 ) trials .", "new_sentence": "Furthermore@@,@@the@@benefit@@of@@clopidogrel@@compared@@with@@placebo@@in@@patients@@with@@acute@@coronary@@syndromes@@,@@as@@well@@as@@those@@undergoing@@percutaneous@@coronary@@intervention@@receiving@@a@@standard@@therapy@@including@@aspirin@@,@@has@@been@@largely@@demonstrated@@by@@the@@Clopidogrel@@in@@Unstable@@angina@@to@@prevent@@Recurrent@@Events@@(@@CURE@@)@@,@@Clopidogrel@@for@@the@@Reduction@@of@@Events@@During@@Observation@@(@@CREDO@@)@@,@@CLopidogrel@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@MyocardialUInfarction@@(@@CLARITY@@-@@TIMI@@)@@28@@,@@and@@Clopidogrel@@and@@Metoprolol@@in@@Myocardial@@Infarction@@Trial@@@@@Secon@@Chinese@@Cardiac@@Study@@(@@COMMIT@@@@@CCS@@-@@2@@)@@trials@@.@@", "replace_sentence": "Furthermore@@,@@the@@benefit@@of@@drug1@@compared@@with@@placebo@@in@@patients@@with@@acute@@coronary@@syndromes@@,@@as@@well@@as@@those@@undergoing@@percutaneous@@coronary@@intervention@@receiving@@a@@standard@@therapy@@including@@aspirin@@,@@has@@been@@largely@@demonstrated@@by@@the@@Clopidogrel@@in@@Unstable@@angina@@to@@prevent@@Recurrent@@Events@@(@@CURE@@)@@,@@Clopidogrel@@for@@the@@Reduction@@of@@Events@@During@@Observation@@(@@CREDO@@)@@,@@CLopidogrel@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@drug2@@(@@CLARITY@@-@@TIMI@@)@@28@@,@@and@@Clopidogrel@@and@@Metoprolol@@in@@Myocardial@@Infarction@@Trial@@@@@Secon@@Chinese@@Cardiac@@Study@@(@@COMMIT@@@@@CCS@@-@@2@@)@@trials@@.@@", "new_pair": "clopidogrel@@compared@@with@@placebo@@in@@patients@@with@@acute@@coronary@@syndromes@@,@@as@@well@@as@@those@@undergoing@@percutaneous@@coronary@@intervention@@receiving@@a@@standard@@therapy@@including@@aspirin@@,@@has@@been@@largely@@demonstrated@@by@@the@@Clopidogrel@@in@@Unstable@@angina@@to@@prevent@@Recurrent@@Events@@(@@CURE@@)@@,@@Clopidogrel@@for@@the@@Reduction@@of@@Events@@During@@Observation@@(@@CREDO@@)@@,@@CLopidogrel@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@MyocardialUInfarction", "replace_pair": "drug1@@compared@@with@@placebo@@in@@patients@@with@@acute@@coronary@@syndromes@@,@@as@@well@@as@@those@@undergoing@@percutaneous@@coronary@@intervention@@receiving@@a@@standard@@therapy@@including@@aspirin@@,@@has@@been@@largely@@demonstrated@@by@@the@@Clopidogrel@@in@@Unstable@@angina@@to@@prevent@@Recurrent@@Events@@(@@CURE@@)@@,@@Clopidogrel@@for@@the@@Reduction@@of@@Events@@During@@Observation@@(@@CREDO@@)@@,@@CLopidogrel@@as@@Adjunctive@@ReperfusIon@@TherapY@@-@@Thrombolysis@@In@@drug2", "relation": "NA"}, {"head": {"id": "210", "type": "", "word": "Clopidogrel", "begin": "13", "end": "24", "new_begin": "15", "new_end": "26", "replace_begin": "15", "replace_end": "20"}, "tail": {"id": "211", "type": "", "word": "ischemicUheartUdiseases", "begin": "84", "end": "107", "new_begin": "95", "new_end": "118", "replace_begin": "89", "replace_end": "94"}, "sentence": "BACKGROUND : Clopidogrel and statins are frequently coadministered in patients with ischemicUheartUdiseases .", "new_sentence": "BACKGROUND@@:@@Clopidogrel@@and@@statins@@are@@frequently@@coadministered@@in@@patients@@with@@ischemicUheartUdiseases@@.@@", "replace_sentence": "BACKGROUND@@:@@drug1@@and@@statins@@are@@frequently@@coadministered@@in@@patients@@with@@drug2@@.@@", "new_pair": "Clopidogrel@@and@@statins@@are@@frequently@@coadministered@@in@@patients@@with@@ischemicUheartUdiseases", "replace_pair": "drug1@@and@@statins@@are@@frequently@@coadministered@@in@@patients@@with@@drug2", "relation": "NA"}, {"head": {"id": "212", "type": "", "word": "chronicUrenalUfailure", "begin": "17", "end": "38", "new_begin": "20", "new_end": "41", "replace_begin": "20", "replace_end": "25"}, "tail": {"id": "213", "type": "", "word": "vitaminUD", "begin": "260", "end": "269", "new_begin": "307", "new_end": "316", "replace_begin": "291", "replace_end": "296"}, "sentence": "As patients with chronicUrenalUfailure ( CRF ) often have renal osteodystrophy ( ROD ) , we investigated the role of osteoprotegerin ( OPG ) in ROD , and investigated whether there was any relationship between serum OPG , intact parathyroid ( PTH ) ( iPTH ) , vitaminUD , and trabecular bone .", "new_sentence": "As@@patients@@with@@chronicUrenalUfailure@@(@@CRF@@)@@often@@have@@renal@@osteodystrophy@@(@@ROD@@)@@,@@we@@investigated@@the@@role@@of@@osteoprotegerin@@(@@OPG@@)@@in@@ROD@@,@@and@@investigated@@whether@@there@@was@@any@@relationship@@between@@serum@@OPG@@,@@intact@@parathyroid@@(@@PTH@@)@@(@@iPTH@@)@@,@@vitaminUD@@,@@and@@trabecular@@bone@@.@@", "replace_sentence": "As@@patients@@with@@drug1@@(@@CRF@@)@@often@@have@@renal@@osteodystrophy@@(@@ROD@@)@@,@@we@@investigated@@the@@role@@of@@osteoprotegerin@@(@@OPG@@)@@in@@ROD@@,@@and@@investigated@@whether@@there@@was@@any@@relationship@@between@@serum@@OPG@@,@@intact@@parathyroid@@(@@PTH@@)@@(@@iPTH@@)@@,@@drug2@@,@@and@@trabecular@@bone@@.@@", "new_pair": "chronicUrenalUfailure@@(@@CRF@@)@@often@@have@@renal@@osteodystrophy@@(@@ROD@@)@@,@@we@@investigated@@the@@role@@of@@osteoprotegerin@@(@@OPG@@)@@in@@ROD@@,@@and@@investigated@@whether@@there@@was@@any@@relationship@@between@@serum@@OPG@@,@@intact@@parathyroid@@(@@PTH@@)@@(@@iPTH@@)@@,@@vitaminUD", "replace_pair": "drug1@@(@@CRF@@)@@often@@have@@renal@@osteodystrophy@@(@@ROD@@)@@,@@we@@investigated@@the@@role@@of@@osteoprotegerin@@(@@OPG@@)@@in@@ROD@@,@@and@@investigated@@whether@@there@@was@@any@@relationship@@between@@serum@@OPG@@,@@intact@@parathyroid@@(@@PTH@@)@@(@@iPTH@@)@@,@@drug2", "relation": "NA"}, {"head": {"id": "214", "type": "", "word": "CsA", "begin": "198", "end": "201", "new_begin": "227", "new_end": "230", "replace_begin": "227", "replace_end": "232"}, "tail": {"id": "215", "type": "", "word": "SGVHD", "begin": "212", "end": "217", "new_begin": "244", "new_end": "249", "replace_begin": "246", "replace_end": "251"}, "sentence": "The ability to reproducibly transfer SGVHD into secondary recipients will enhance our ability to study regulatory mechanisms that are altered during CsA therapy and permit the development of murine CsA - induced SGVHD .", "new_sentence": "The@@ability@@to@@reproducibly@@transfer@@SGVHD@@into@@secondary@@recipients@@will@@enhance@@our@@ability@@to@@study@@regulatory@@mechanisms@@that@@are@@altered@@during@@CsA@@therapy@@and@@permit@@the@@development@@of@@murine@@CsA@@-@@induced@@SGVHD@@.@@", "replace_sentence": "The@@ability@@to@@reproducibly@@transfer@@SGVHD@@into@@secondary@@recipients@@will@@enhance@@our@@ability@@to@@study@@regulatory@@mechanisms@@that@@are@@altered@@during@@CsA@@therapy@@and@@permit@@the@@development@@of@@murine@@drug1@@-@@induced@@drug2@@.@@", "new_pair": "CsA@@-@@induced@@SGVHD", "replace_pair": "drug1@@-@@induced@@drug2", "relation": "NA"}, {"head": {"id": "216", "type": "", "word": "fluconazole", "begin": "74", "end": "85", "new_begin": "86", "new_end": "97", "replace_begin": "86", "replace_end": "91"}, "tail": {"id": "217", "type": "", "word": "infections", "begin": "155", "end": "165", "new_begin": "179", "new_end": "189", "replace_begin": "173", "replace_end": "178"}, "sentence": "Unfortunately , this drug has substantial toxicities , and agents such as fluconazole were developed as an alternative to treat and prevent these invasive infections .", "new_sentence": "Unfortunately@@,@@this@@drug@@has@@substantial@@toxicities@@,@@and@@agents@@such@@as@@fluconazole@@were@@developed@@as@@an@@alternative@@to@@treat@@and@@prevent@@these@@invasive@@infections@@.@@", "replace_sentence": "Unfortunately@@,@@this@@drug@@has@@substantial@@toxicities@@,@@and@@agents@@such@@as@@drug1@@were@@developed@@as@@an@@alternative@@to@@treat@@and@@prevent@@these@@invasive@@drug2@@.@@", "new_pair": "fluconazole@@were@@developed@@as@@an@@alternative@@to@@treat@@and@@prevent@@these@@invasive@@infections", "replace_pair": "drug1@@were@@developed@@as@@an@@alternative@@to@@treat@@and@@prevent@@these@@invasive@@drug2", "relation": "may_prevent"}, {"head": {"id": "218", "type": "", "word": "17beta-estradiol", "begin": "18", "end": "34", "new_begin": "20", "new_end": "36", "replace_begin": "20", "replace_end": "25"}, "tail": {"id": "219", "type": "", "word": "ischemia", "begin": "75", "end": "83", "new_begin": "84", "new_end": "92", "replace_begin": "73", "replace_end": "78"}, "sentence": "Administration of 17beta-estradiol reduced neuronal damage caused by focal ischemia .", "new_sentence": "Administration@@of@@17beta-estradiol@@reduced@@neuronal@@damage@@caused@@by@@focal@@ischemia@@.@@", "replace_sentence": "Administration@@of@@drug1@@reduced@@neuronal@@damage@@caused@@by@@focal@@drug2@@.@@", "new_pair": "17beta-estradiol@@reduced@@neuronal@@damage@@caused@@by@@focal@@ischemia", "replace_pair": "drug1@@reduced@@neuronal@@damage@@caused@@by@@focal@@drug2", "relation": "may_prevent"}, {"head": {"id": "220", "type": "", "word": "oestradiol", "begin": "28", "end": "38", "new_begin": "32", "new_end": "42", "replace_begin": "32", "replace_end": "37"}, "tail": {"id": "221", "type": "", "word": "BPD", "begin": "92", "end": "95", "new_begin": "105", "new_end": "108", "replace_begin": "100", "replace_end": "105"}, "sentence": "CONCLUSION : Replacement of oestradiol and progesterone was not effective for prevention of BPD or death in extremely preterm born infants .", "new_sentence": "CONCLUSION@@:@@Replacement@@of@@oestradiol@@and@@progesterone@@was@@not@@effective@@for@@prevention@@of@@BPD@@or@@death@@in@@extremely@@preterm@@born@@infants@@.@@", "replace_sentence": "CONCLUSION@@:@@Replacement@@of@@drug1@@and@@progesterone@@was@@not@@effective@@for@@prevention@@of@@drug2@@or@@death@@in@@extremely@@preterm@@born@@infants@@.@@", "new_pair": "oestradiol@@and@@progesterone@@was@@not@@effective@@for@@prevention@@of@@BPD", "replace_pair": "drug1@@and@@progesterone@@was@@not@@effective@@for@@prevention@@of@@drug2", "relation": "NA"}, {"head": {"id": "222", "type": "", "word": "perindopril", "begin": "8", "end": "19", "new_begin": "10", "new_end": "21", "replace_begin": "10", "replace_end": "15"}, "tail": {"id": "223", "type": "", "word": "stroke", "begin": "41", "end": "47", "new_begin": "48", "new_end": "54", "replace_begin": "42", "replace_end": "47"}, "sentence": "Role of perindopril in the prevention of stroke .", "new_sentence": "Role@@of@@perindopril@@in@@the@@prevention@@of@@stroke@@.@@", "replace_sentence": "Role@@of@@drug1@@in@@the@@prevention@@of@@drug2@@.@@", "new_pair": "perindopril@@in@@the@@prevention@@of@@stroke", "replace_pair": "drug1@@in@@the@@prevention@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "224", "type": "", "word": "fungalUinfections", "begin": "50", "end": "67", "new_begin": "58", "new_end": "75", "replace_begin": "58", "replace_end": "63"}, "tail": {"id": "225", "type": "", "word": "ketoconazole", "begin": "107", "end": "119", "new_begin": "123", "new_end": "135", "replace_begin": "111", "replace_end": "116"}, "sentence": "For both outcomes of total mortality and invasive fungalUinfections , almost all trials of fluconazole and ketoconazole separately showed a non - significant risk reduction with prophylaxis .", "new_sentence": "For@@both@@outcomes@@of@@total@@mortality@@and@@invasive@@fungalUinfections@@,@@almost@@all@@trials@@of@@fluconazole@@and@@ketoconazole@@separately@@showed@@a@@non@@-@@significant@@risk@@reduction@@with@@prophylaxis@@.@@", "replace_sentence": "For@@both@@outcomes@@of@@total@@mortality@@and@@invasive@@drug1@@,@@almost@@all@@trials@@of@@fluconazole@@and@@drug2@@separately@@showed@@a@@non@@-@@significant@@risk@@reduction@@with@@prophylaxis@@.@@", "new_pair": "fungalUinfections@@,@@almost@@all@@trials@@of@@fluconazole@@and@@ketoconazole", "replace_pair": "drug1@@,@@almost@@all@@trials@@of@@fluconazole@@and@@drug2", "relation": "may_prevent"}, {"head": {"id": "226", "type": "", "word": "vitaminUDUdeficiency", "begin": "16", "end": "36", "new_begin": "19", "new_end": "39", "replace_begin": "19", "replace_end": "24"}, "tail": {"id": "227", "type": "", "word": "vitaminUD", "begin": "50", "end": "59", "new_begin": "57", "new_end": "66", "replace_begin": "42", "replace_end": "47"}, "sentence": "In mothers with vitaminUDUdeficiency , cord blood vitaminUD concentrations was lower than those from normal mothers ( P = . 001 ) .", "new_sentence": "In@@mothers@@with@@vitaminUDUdeficiency@@,@@cord@@blood@@vitaminUD@@concentrations@@was@@lower@@than@@those@@from@@normal@@mothers@@(@@P@@=@@.@@001@@)@@.@@", "replace_sentence": "In@@mothers@@with@@drug1@@,@@cord@@blood@@drug2@@concentrations@@was@@lower@@than@@those@@from@@normal@@mothers@@(@@P@@=@@.@@001@@)@@.@@", "new_pair": "vitaminUDUdeficiency@@,@@cord@@blood@@vitaminUD", "replace_pair": "drug1@@,@@cord@@blood@@drug2", "relation": "NA"}, {"head": {"id": "228", "type": "", "word": "Fluoride", "begin": "63", "end": "71", "new_begin": "74", "new_end": "82", "replace_begin": "74", "replace_end": "79"}, "tail": {"id": "229", "type": "", "word": "dentalUcaries", "begin": "129", "end": "142", "new_begin": "150", "new_end": "163", "replace_begin": "147", "replace_end": "152"}, "sentence": "CONCLUSION : Both chewing gum and tablets are valid methods of Fluoride administration and they can be considered useful aids in dentalUcaries prevention ( when used in addition to adequate oral hygiene ) .", "new_sentence": "CONCLUSION@@:@@Both@@chewing@@gum@@and@@tablets@@are@@valid@@methods@@of@@Fluoride@@administration@@and@@they@@can@@be@@considered@@useful@@aids@@in@@dentalUcaries@@prevention@@(@@when@@used@@in@@addition@@to@@adequate@@oral@@hygiene@@)@@.@@", "replace_sentence": "CONCLUSION@@:@@Both@@chewing@@gum@@and@@tablets@@are@@valid@@methods@@of@@drug1@@administration@@and@@they@@can@@be@@considered@@useful@@aids@@in@@drug2@@prevention@@(@@when@@used@@in@@addition@@to@@adequate@@oral@@hygiene@@)@@.@@", "new_pair": "Fluoride@@administration@@and@@they@@can@@be@@considered@@useful@@aids@@in@@dentalUcaries", "replace_pair": "drug1@@administration@@and@@they@@can@@be@@considered@@useful@@aids@@in@@drug2", "relation": "may_prevent"}, {"head": {"id": "230", "type": "", "word": "malaria", "begin": "37", "end": "44", "new_begin": "45", "new_end": "52", "replace_begin": "45", "replace_end": "50"}, "tail": {"id": "231", "type": "", "word": "chloroquine", "begin": "67", "end": "78", "new_begin": "80", "new_end": "91", "replace_begin": "78", "replace_end": "83"}, "sentence": "Less than 10 % of cases of childhood malaria had been treated with chloroquine at home , and 69 % of those giving home medication did not know the correct dosage for a child .", "new_sentence": "Less@@than@@10@@%@@of@@cases@@of@@childhood@@malaria@@had@@been@@treated@@with@@chloroquine@@at@@home@@,@@and@@69@@%@@of@@those@@giving@@home@@medication@@did@@not@@know@@the@@correct@@dosage@@for@@a@@child@@.@@", "replace_sentence": "Less@@than@@10@@%@@of@@cases@@of@@childhood@@drug1@@had@@been@@treated@@with@@drug2@@at@@home@@,@@and@@69@@%@@of@@those@@giving@@home@@medication@@did@@not@@know@@the@@correct@@dosage@@for@@a@@child@@.@@", "new_pair": "malaria@@had@@been@@treated@@with@@chloroquine", "replace_pair": "drug1@@had@@been@@treated@@with@@drug2", "relation": "NA"}, {"head": {"id": "232", "type": "", "word": "HeartUAttack", "begin": "54", "end": "66", "new_begin": "62", "new_end": "74", "replace_begin": "62", "replace_end": "67"}, "tail": {"id": "233", "type": "", "word": "lisinopril", "begin": "75", "end": "85", "new_begin": "86", "new_end": "96", "replace_begin": "79", "replace_end": "84"}, "sentence": "In the Antihypertensive and Lipid Lowering to Prevent HeartUAttack Trial , lisinopril - treated patients had a slightly lower incidence of myocardial infarction , despite much poorer control of blood pressure , perhaps because a second - line diuretic was prohibited by protocol .", "new_sentence": "In@@the@@Antihypertensive@@and@@Lipid@@Lowering@@to@@Prevent@@HeartUAttack@@Trial@@,@@lisinopril@@-@@treated@@patients@@had@@a@@slightly@@lower@@incidence@@of@@myocardial@@infarction@@,@@despite@@much@@poorer@@control@@of@@blood@@pressure@@,@@perhaps@@because@@a@@second@@-@@line@@diuretic@@was@@prohibited@@by@@protocol@@.@@", "replace_sentence": "In@@the@@Antihypertensive@@and@@Lipid@@Lowering@@to@@Prevent@@drug1@@Trial@@,@@drug2@@-@@treated@@patients@@had@@a@@slightly@@lower@@incidence@@of@@myocardial@@infarction@@,@@despite@@much@@poorer@@control@@of@@blood@@pressure@@,@@perhaps@@because@@a@@second@@-@@line@@diuretic@@was@@prohibited@@by@@protocol@@.@@", "new_pair": "HeartUAttack@@Trial@@,@@lisinopril", "replace_pair": "drug1@@Trial@@,@@drug2", "relation": "may_prevent"}, {"head": {"id": "234", "type": "", "word": "clopidogrel", "begin": "34", "end": "45", "new_begin": "39", "new_end": "50", "replace_begin": "39", "replace_end": "44"}, "tail": {"id": "235", "type": "", "word": "cerebralUischemia", "begin": "150", "end": "167", "new_begin": "173", "new_end": "190", "replace_begin": "167", "replace_end": "172"}, "sentence": "Based on cardiovascular studies , clopidogrel in combination with aspirin has not been proven superior to aspirin alone for the primary prevention of cerebralUischemia .", "new_sentence": "Based@@on@@cardiovascular@@studies@@,@@clopidogrel@@in@@combination@@with@@aspirin@@has@@not@@been@@proven@@superior@@to@@aspirin@@alone@@for@@the@@primary@@prevention@@of@@cerebralUischemia@@.@@", "replace_sentence": "Based@@on@@cardiovascular@@studies@@,@@drug1@@in@@combination@@with@@aspirin@@has@@not@@been@@proven@@superior@@to@@aspirin@@alone@@for@@the@@primary@@prevention@@of@@drug2@@.@@", "new_pair": "clopidogrel@@in@@combination@@with@@aspirin@@has@@not@@been@@proven@@superior@@to@@aspirin@@alone@@for@@the@@primary@@prevention@@of@@cerebralUischemia", "replace_pair": "drug1@@in@@combination@@with@@aspirin@@has@@not@@been@@proven@@superior@@to@@aspirin@@alone@@for@@the@@primary@@prevention@@of@@drug2", "relation": "NA"}, {"head": {"id": "236", "type": "", "word": "cyclosporine", "begin": "36", "end": "48", "new_begin": "41", "new_end": "53", "replace_begin": "41", "replace_end": "46"}, "tail": {"id": "237", "type": "", "word": "graft-versus-hostUdisease", "begin": "85", "end": "110", "new_begin": "99", "new_end": "124", "replace_begin": "92", "replace_end": "97"}, "sentence": "Cyclosporine plus methotrexate , or cyclosporine alone , or FK506 alone was used for graft-versus-hostUdisease ( GVHD ) prophylaxis .", "new_sentence": "Cyclosporine@@plus@@methotrexate@@,@@or@@cyclosporine@@alone@@,@@or@@FK506@@alone@@was@@used@@for@@graft-versus-hostUdisease@@(@@GVHD@@)@@prophylaxis@@.@@", "replace_sentence": "Cyclosporine@@plus@@methotrexate@@,@@or@@drug1@@alone@@,@@or@@FK506@@alone@@was@@used@@for@@drug2@@(@@GVHD@@)@@prophylaxis@@.@@", "new_pair": "cyclosporine@@alone@@,@@or@@FK506@@alone@@was@@used@@for@@graft-versus-hostUdisease", "replace_pair": "drug1@@alone@@,@@or@@FK506@@alone@@was@@used@@for@@drug2", "relation": "may_prevent"}, {"head": {"id": "238", "type": "", "word": "Graft-versus-hostUdisease", "begin": "0", "end": "25", "new_begin": "0", "new_end": "25", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "239", "type": "", "word": "cyclosporine", "begin": "56", "end": "68", "new_begin": "63", "new_end": "75", "replace_begin": "43", "replace_end": "48"}, "sentence": "Graft-versus-hostUdisease ( GVHD ) prophylaxis was with cyclosporine alone in 19 ( 58 % ) patients ;", "new_sentence": "Graft-versus-hostUdisease@@(@@GVHD@@)@@prophylaxis@@was@@with@@cyclosporine@@alone@@in@@19@@(@@58@@%@@)@@patients@@;@@", "replace_sentence": "drug1@@(@@GVHD@@)@@prophylaxis@@was@@with@@drug2@@alone@@in@@19@@(@@58@@%@@)@@patients@@;@@", "new_pair": "Graft-versus-hostUdisease@@(@@GVHD@@)@@prophylaxis@@was@@with@@cyclosporine", "replace_pair": "drug1@@(@@GVHD@@)@@prophylaxis@@was@@with@@drug2", "relation": "may_prevent"}, {"head": {"id": "240", "type": "", "word": "miscarriage", "begin": "35", "end": "46", "new_begin": "39", "new_end": "50", "replace_begin": "39", "replace_end": "44"}, "tail": {"id": "241", "type": "", "word": "thyroxine", "begin": "58", "end": "67", "new_begin": "66", "new_end": "75", "replace_begin": "60", "replace_end": "65"}, "sentence": "Thyroid autoimmunity increases the miscarriage rate , and thyroxine treatment does not seem to protect .", "new_sentence": "Thyroid@@autoimmunity@@increases@@the@@miscarriage@@rate@@,@@and@@thyroxine@@treatment@@does@@not@@seem@@to@@protect@@.@@", "replace_sentence": "Thyroid@@autoimmunity@@increases@@the@@drug1@@rate@@,@@and@@drug2@@treatment@@does@@not@@seem@@to@@protect@@.@@", "new_pair": "miscarriage@@rate@@,@@and@@thyroxine", "replace_pair": "drug1@@rate@@,@@and@@drug2", "relation": "NA"}, {"head": {"id": "242", "type": "", "word": "timolol", "begin": "85", "end": "92", "new_begin": "98", "new_end": "105", "replace_begin": "98", "replace_end": "103"}, "tail": {"id": "243", "type": "", "word": "ocularUhypertension", "begin": "150", "end": "169", "new_begin": "175", "new_end": "194", "replace_begin": "173", "replace_end": "178"}, "sentence": "A study was undertaken to compare the ocular haemodynamic effects of dorzolamide and timolol in patients with primary open angle glaucoma ( POAG ) or ocularUhypertension ( OHT ) .", "new_sentence": "A@@study@@was@@undertaken@@to@@compare@@the@@ocular@@haemodynamic@@effects@@of@@dorzolamide@@and@@timolol@@in@@patients@@with@@primary@@open@@angle@@glaucoma@@(@@POAG@@)@@or@@ocularUhypertension@@(@@OHT@@)@@.@@", "replace_sentence": "A@@study@@was@@undertaken@@to@@compare@@the@@ocular@@haemodynamic@@effects@@of@@dorzolamide@@and@@drug1@@in@@patients@@with@@primary@@open@@angle@@glaucoma@@(@@POAG@@)@@or@@drug2@@(@@OHT@@)@@.@@", "new_pair": "timolol@@in@@patients@@with@@primary@@open@@angle@@glaucoma@@(@@POAG@@)@@or@@ocularUhypertension", "replace_pair": "drug1@@in@@patients@@with@@primary@@open@@angle@@glaucoma@@(@@POAG@@)@@or@@drug2", "relation": "NA"}, {"head": {"id": "244", "type": "", "word": "ACDs", "begin": "28", "end": "32", "new_begin": "34", "new_end": "38", "replace_begin": "34", "replace_end": "39"}, "tail": {"id": "245", "type": "", "word": "fluticasone", "begin": "143", "end": "154", "new_begin": "174", "new_end": "185", "replace_begin": "175", "replace_end": "180"}, "sentence": "eNO was both a predictor of ACDs ( P = . 011 ) and a response indicator ( P = . 003 ) in discriminating the difference in ACD response between fluticasone and montelukast .", "new_sentence": "eNO@@was@@both@@a@@predictor@@of@@ACDs@@(@@P@@=@@.@@011@@)@@and@@a@@response@@indicator@@(@@P@@=@@.@@003@@)@@in@@discriminating@@the@@difference@@in@@ACD@@response@@between@@fluticasone@@and@@montelukast@@.@@", "replace_sentence": "eNO@@was@@both@@a@@predictor@@of@@drug1@@(@@P@@=@@.@@011@@)@@and@@a@@response@@indicator@@(@@P@@=@@.@@003@@)@@in@@discriminating@@the@@difference@@in@@ACD@@response@@between@@drug2@@and@@montelukast@@.@@", "new_pair": "ACDs@@(@@P@@=@@.@@011@@)@@and@@a@@response@@indicator@@(@@P@@=@@.@@003@@)@@in@@discriminating@@the@@difference@@in@@ACD@@response@@between@@fluticasone", "replace_pair": "drug1@@(@@P@@=@@.@@011@@)@@and@@a@@response@@indicator@@(@@P@@=@@.@@003@@)@@in@@discriminating@@the@@difference@@in@@ACD@@response@@between@@drug2", "relation": "NA"}, {"head": {"id": "246", "type": "", "word": "vitaminUD", "begin": "21", "end": "30", "new_begin": "24", "new_end": "33", "replace_begin": "24", "replace_end": "29"}, "tail": {"id": "247", "type": "", "word": "osteoporosis", "begin": "60", "end": "72", "new_begin": "69", "new_end": "81", "replace_begin": "65", "replace_end": "70"}, "sentence": "BACKGROUND : Optimal vitaminUD status for the prevention of osteoporosis has been inferred from examinations of the serum 25-hydroxyvitamin D ( 25 ( OH ) D ) concentration below which there is an increase in serum parathyroid hormone ( PTH ) .", "new_sentence": "BACKGROUND@@:@@Optimal@@vitaminUD@@status@@for@@the@@prevention@@of@@osteoporosis@@has@@been@@inferred@@from@@examinations@@of@@the@@serum@@25@@-@@hydroxyvitamin@@D@@(@@25@@(@@OH@@)@@D@@)@@concentration@@below@@which@@there@@is@@an@@increase@@in@@serum@@parathyroid@@hormone@@(@@PTH@@)@@.@@", "replace_sentence": "BACKGROUND@@:@@Optimal@@drug1@@status@@for@@the@@prevention@@of@@drug2@@has@@been@@inferred@@from@@examinations@@of@@the@@serum@@25@@-@@hydroxyvitamin@@D@@(@@25@@(@@OH@@)@@D@@)@@concentration@@below@@which@@there@@is@@an@@increase@@in@@serum@@parathyroid@@hormone@@(@@PTH@@)@@.@@", "new_pair": "vitaminUD@@status@@for@@the@@prevention@@of@@osteoporosis", "replace_pair": "drug1@@status@@for@@the@@prevention@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "248", "type": "", "word": "Dex", "begin": "19", "end": "22", "new_begin": "26", "new_end": "29", "replace_begin": "26", "replace_end": "31"}, "tail": {"id": "249", "type": "", "word": "dermatitis", "begin": "92", "end": "102", "new_begin": "109", "new_end": "119", "replace_begin": "111", "replace_end": "116"}, "sentence": "LXA ( 4 ) and @ or Dex decreased CD11b expression on human neutrophils and suppressed mouse dermatitis induced by LTB ( 4 ) .", "new_sentence": "LXA@@(@@4@@)@@and@@@@@or@@Dex@@decreased@@CD11b@@expression@@on@@human@@neutrophils@@and@@suppressed@@mouse@@dermatitis@@induced@@by@@LTB@@(@@4@@)@@.@@", "replace_sentence": "LXA@@(@@4@@)@@and@@@@@or@@drug1@@decreased@@CD11b@@expression@@on@@human@@neutrophils@@and@@suppressed@@mouse@@drug2@@induced@@by@@LTB@@(@@4@@)@@.@@", "new_pair": "Dex@@decreased@@CD11b@@expression@@on@@human@@neutrophils@@and@@suppressed@@mouse@@dermatitis", "replace_pair": "drug1@@decreased@@CD11b@@expression@@on@@human@@neutrophils@@and@@suppressed@@mouse@@drug2", "relation": "may_prevent"}, {"head": {"id": "250", "type": "", "word": "vivaxUmalaria", "begin": "81", "end": "94", "new_begin": "98", "new_end": "111", "replace_begin": "98", "replace_end": "103"}, "tail": {"id": "251", "type": "", "word": "antimalarial", "begin": "125", "end": "137", "new_begin": "149", "new_end": "161", "replace_begin": "141", "replace_end": "146"}, "sentence": "CONCLUSION : In ROK , the increase in late primary episodes of re - emergent P . vivaxUmalaria is associated with the use of antimalarial chemoprophylaxis .", "new_sentence": "CONCLUSION@@:@@In@@ROK@@,@@the@@increase@@in@@late@@primary@@episodes@@of@@re@@-@@emergent@@P@@.@@vivaxUmalaria@@is@@associated@@with@@the@@use@@of@@antimalarial@@chemoprophylaxis@@.@@", "replace_sentence": "CONCLUSION@@:@@In@@ROK@@,@@the@@increase@@in@@late@@primary@@episodes@@of@@re@@-@@emergent@@P@@.@@drug1@@is@@associated@@with@@the@@use@@of@@drug2@@chemoprophylaxis@@.@@", "new_pair": "vivaxUmalaria@@is@@associated@@with@@the@@use@@of@@antimalarial", "replace_pair": "drug1@@is@@associated@@with@@the@@use@@of@@drug2", "relation": "NA"}, {"head": {"id": "252", "type": "", "word": "asthmatic", "begin": "39", "end": "48", "new_begin": "46", "new_end": "55", "replace_begin": "46", "replace_end": "51"}, "tail": {"id": "253", "type": "", "word": "FP", "begin": "60", "end": "62", "new_begin": "70", "new_end": "72", "replace_begin": "66", "replace_end": "71"}, "sentence": "In conclusion , in young children with asthmatic symptoms , FP at 50 and 125 mcg b . i . d . for 6 months significantly improved respiratory symptoms without causing significant side effects on growth and bone metabolism .", "new_sentence": "In@@conclusion@@,@@in@@young@@children@@with@@asthmatic@@symptoms@@,@@FP@@at@@50@@and@@125@@mcg@@b@@.@@i@@.@@d@@.@@for@@6@@months@@significantly@@improved@@respiratory@@symptoms@@without@@causing@@significant@@side@@effects@@on@@growth@@and@@bone@@metabolism@@.@@", "replace_sentence": "In@@conclusion@@,@@in@@young@@children@@with@@drug1@@symptoms@@,@@drug2@@at@@50@@and@@125@@mcg@@b@@.@@i@@.@@d@@.@@for@@6@@months@@significantly@@improved@@respiratory@@symptoms@@without@@causing@@significant@@side@@effects@@on@@growth@@and@@bone@@metabolism@@.@@", "new_pair": "asthmatic@@symptoms@@,@@FP", "replace_pair": "drug1@@symptoms@@,@@drug2", "relation": "NA"}, {"head": {"id": "254", "type": "", "word": "dexamethasone", "begin": "157", "end": "170", "new_begin": "183", "new_end": "196", "replace_begin": "183", "replace_end": "188"}, "tail": {"id": "255", "type": "", "word": "plaque", "begin": "231", "end": "237", "new_begin": "271", "new_end": "277", "replace_begin": "263", "replace_end": "268"}, "sentence": "Furthermore , adhesion molecules have been exploited as a target for the specific delivery of drug carriers ( e . g . biodegradable particles with entrapped dexamethasone ) or therapeutic compounds ( e . g . dexamethasone ) to the plaque .", "new_sentence": "Furthermore@@,@@adhesion@@molecules@@have@@been@@exploited@@as@@a@@target@@for@@the@@specific@@delivery@@of@@drug@@carriers@@(@@e@@.@@g@@.@@biodegradable@@particles@@with@@entrapped@@dexamethasone@@)@@or@@therapeutic@@compounds@@(@@e@@.@@g@@.@@dexamethasone@@)@@to@@the@@plaque@@.@@", "replace_sentence": "Furthermore@@,@@adhesion@@molecules@@have@@been@@exploited@@as@@a@@target@@for@@the@@specific@@delivery@@of@@drug@@carriers@@(@@e@@.@@g@@.@@biodegradable@@particles@@with@@entrapped@@drug1@@)@@or@@therapeutic@@compounds@@(@@e@@.@@g@@.@@dexamethasone@@)@@to@@the@@drug2@@.@@", "new_pair": "dexamethasone@@)@@or@@therapeutic@@compounds@@(@@e@@.@@g@@.@@dexamethasone@@)@@to@@the@@plaque", "replace_pair": "drug1@@)@@or@@therapeutic@@compounds@@(@@e@@.@@g@@.@@dexamethasone@@)@@to@@the@@drug2", "relation": "NA"}, {"head": {"id": "256", "type": "", "word": "GVHD", "begin": "0", "end": "4", "new_begin": "0", "new_end": "4", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "257", "type": "", "word": "cyclosporine", "begin": "30", "end": "42", "new_begin": "34", "new_end": "46", "replace_begin": "35", "replace_end": "40"}, "sentence": "GVHD prophylaxis consisted of cyclosporine - containing regimens ( 53 % ) , T-cell depletion by elutriation ( 42 % ) , and others ( 2 % ) .", "new_sentence": "GVHD@@prophylaxis@@consisted@@of@@cyclosporine@@-@@containing@@regimens@@(@@53@@%@@)@@,@@T@@-@@cell@@depletion@@by@@elutriation@@(@@42@@%@@)@@,@@and@@others@@(@@2@@%@@)@@.@@", "replace_sentence": "drug1@@prophylaxis@@consisted@@of@@drug2@@-@@containing@@regimens@@(@@53@@%@@)@@,@@T@@-@@cell@@depletion@@by@@elutriation@@(@@42@@%@@)@@,@@and@@others@@(@@2@@%@@)@@.@@", "new_pair": "GVHD@@prophylaxis@@consisted@@of@@cyclosporine", "replace_pair": "drug1@@prophylaxis@@consisted@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "258", "type": "", "word": "iron", "begin": "127", "end": "131", "new_begin": "153", "new_end": "157", "replace_begin": "153", "replace_end": "158"}, "tail": {"id": "259", "type": "", "word": "hepatitisUC", "begin": "220", "end": "231", "new_begin": "263", "new_end": "274", "replace_begin": "264", "replace_end": "269"}, "sentence": "METHODS : We conducted a phase 3 , double-blind , randomized , controlled clinical trial of daily micronutrients with 18 mg of iron ( iron group ) versus micronutrients without iron ( control group ) for 12 months among hepatitisUC - positive female injection drug users in Baltimore , Maryland .", "new_sentence": "METHODS@@:@@We@@conducted@@a@@phase@@3@@,@@double@@-@@blind@@,@@randomized@@,@@controlled@@clinical@@trial@@of@@daily@@micronutrients@@with@@18@@mg@@of@@iron@@(@@iron@@group@@)@@versus@@micronutrients@@without@@iron@@(@@control@@group@@)@@for@@12@@months@@among@@hepatitisUC@@-@@positive@@female@@injection@@drug@@users@@in@@Baltimore@@,@@Maryland@@.@@", "replace_sentence": "METHODS@@:@@We@@conducted@@a@@phase@@3@@,@@double@@-@@blind@@,@@randomized@@,@@controlled@@clinical@@trial@@of@@daily@@micronutrients@@with@@18@@mg@@of@@drug1@@(@@iron@@group@@)@@versus@@micronutrients@@without@@iron@@(@@control@@group@@)@@for@@12@@months@@among@@drug2@@-@@positive@@female@@injection@@drug@@users@@in@@Baltimore@@,@@Maryland@@.@@", "new_pair": "iron@@(@@iron@@group@@)@@versus@@micronutrients@@without@@iron@@(@@control@@group@@)@@for@@12@@months@@among@@hepatitisUC", "replace_pair": "drug1@@(@@iron@@group@@)@@versus@@micronutrients@@without@@iron@@(@@control@@group@@)@@for@@12@@months@@among@@drug2", "relation": "NA"}, {"head": {"id": "260", "type": "", "word": "CMVUinfection", "begin": "46", "end": "59", "new_begin": "50", "new_end": "63", "replace_begin": "50", "replace_end": "55"}, "tail": {"id": "261", "type": "", "word": "aciclovir", "begin": "168", "end": "177", "new_begin": "191", "new_end": "200", "replace_begin": "183", "replace_end": "188"}, "sentence": "Ganciclovir prophylaxis effectively prevented CMVUinfection , especially in higher risk groups , and was associated with a reduced incidence of rejection compared with aciclovir @ no prophylaxis .", "new_sentence": "Ganciclovir@@prophylaxis@@effectively@@prevented@@CMVUinfection@@,@@especially@@in@@higher@@risk@@groups@@,@@and@@was@@associated@@with@@a@@reduced@@incidence@@of@@rejection@@compared@@with@@aciclovir@@@@@no@@prophylaxis@@.@@", "replace_sentence": "Ganciclovir@@prophylaxis@@effectively@@prevented@@drug1@@,@@especially@@in@@higher@@risk@@groups@@,@@and@@was@@associated@@with@@a@@reduced@@incidence@@of@@rejection@@compared@@with@@drug2@@@@@no@@prophylaxis@@.@@", "new_pair": "CMVUinfection@@,@@especially@@in@@higher@@risk@@groups@@,@@and@@was@@associated@@with@@a@@reduced@@incidence@@of@@rejection@@compared@@with@@aciclovir", "replace_pair": "drug1@@,@@especially@@in@@higher@@risk@@groups@@,@@and@@was@@associated@@with@@a@@reduced@@incidence@@of@@rejection@@compared@@with@@drug2", "relation": "NA"}, {"head": {"id": "262", "type": "", "word": "infections", "begin": "13", "end": "23", "new_begin": "16", "new_end": "26", "replace_begin": "16", "replace_end": "21"}, "tail": {"id": "263", "type": "", "word": "basiliximab", "begin": "113", "end": "124", "new_begin": "131", "new_end": "142", "replace_begin": "126", "replace_end": "131"}, "sentence": "The rates of infections , chronic GVHD , malignancy recurrence and 1 - year TRM following immunosuppression with basiliximab were comparable with those found with other treatment modalities for aGVHD .", "new_sentence": "The@@rates@@of@@infections@@,@@chronic@@GVHD@@,@@malignancy@@recurrence@@and@@1@@-@@year@@TRM@@following@@immunosuppression@@with@@basiliximab@@were@@comparable@@with@@those@@found@@with@@other@@treatment@@modalities@@for@@aGVHD@@.@@", "replace_sentence": "The@@rates@@of@@drug1@@,@@chronic@@GVHD@@,@@malignancy@@recurrence@@and@@1@@-@@year@@TRM@@following@@immunosuppression@@with@@drug2@@were@@comparable@@with@@those@@found@@with@@other@@treatment@@modalities@@for@@aGVHD@@.@@", "new_pair": "infections@@,@@chronic@@GVHD@@,@@malignancy@@recurrence@@and@@1@@-@@year@@TRM@@following@@immunosuppression@@with@@basiliximab", "replace_pair": "drug1@@,@@chronic@@GVHD@@,@@malignancy@@recurrence@@and@@1@@-@@year@@TRM@@following@@immunosuppression@@with@@drug2", "relation": "may_prevent"}, {"head": {"id": "264", "type": "", "word": "aspirin", "begin": "30", "end": "37", "new_begin": "34", "new_end": "41", "replace_begin": "34", "replace_end": "39"}, "tail": {"id": "265", "type": "", "word": "stroke", "begin": "70", "end": "76", "new_begin": "80", "new_end": "86", "replace_begin": "78", "replace_end": "83"}, "sentence": "Comparison of warfarin versus aspirin for the prevention of recurrent stroke or death : subgroup analyses from the Warfarin - Aspirin Recurrent Stroke Study .", "new_sentence": "Comparison@@of@@warfarin@@versus@@aspirin@@for@@the@@prevention@@of@@recurrent@@stroke@@or@@death@@:@@subgroup@@analyses@@from@@the@@Warfarin@@-@@Aspirin@@Recurrent@@Stroke@@Study@@.@@", "replace_sentence": "Comparison@@of@@warfarin@@versus@@drug1@@for@@the@@prevention@@of@@recurrent@@drug2@@or@@death@@:@@subgroup@@analyses@@from@@the@@Warfarin@@-@@Aspirin@@Recurrent@@Stroke@@Study@@.@@", "new_pair": "aspirin@@for@@the@@prevention@@of@@recurrent@@stroke", "replace_pair": "drug1@@for@@the@@prevention@@of@@recurrent@@drug2", "relation": "NA"}, {"head": {"id": "266", "type": "", "word": "iron", "begin": "115", "end": "119", "new_begin": "131", "new_end": "135", "replace_begin": "131", "replace_end": "136"}, "tail": {"id": "267", "type": "", "word": "infectious", "begin": "216", "end": "226", "new_begin": "245", "new_end": "255", "replace_begin": "246", "replace_end": "251"}, "sentence": "Our findings provide direct evidence that this promoter polymorphism is functional and support the hypothesis that iron dysregulation mediated by allelic effects of SLC11A1 underlies disease susceptibility linked to infectious and autoimmune conditions .", "new_sentence": "Our@@findings@@provide@@direct@@evidence@@that@@this@@promoter@@polymorphism@@is@@functional@@and@@support@@the@@hypothesis@@that@@iron@@dysregulation@@mediated@@by@@allelic@@effects@@of@@SLC11A1@@underlies@@disease@@susceptibility@@linked@@to@@infectious@@and@@autoimmune@@conditions@@.@@", "replace_sentence": "Our@@findings@@provide@@direct@@evidence@@that@@this@@promoter@@polymorphism@@is@@functional@@and@@support@@the@@hypothesis@@that@@drug1@@dysregulation@@mediated@@by@@allelic@@effects@@of@@SLC11A1@@underlies@@disease@@susceptibility@@linked@@to@@drug2@@and@@autoimmune@@conditions@@.@@", "new_pair": "iron@@dysregulation@@mediated@@by@@allelic@@effects@@of@@SLC11A1@@underlies@@disease@@susceptibility@@linked@@to@@infectious", "replace_pair": "drug1@@dysregulation@@mediated@@by@@allelic@@effects@@of@@SLC11A1@@underlies@@disease@@susceptibility@@linked@@to@@drug2", "relation": "NA"}, {"head": {"id": "268", "type": "", "word": "tetanus", "begin": "102", "end": "109", "new_begin": "117", "new_end": "124", "replace_begin": "117", "replace_end": "122"}, "tail": {"id": "269", "type": "", "word": "pertussisU ( UdTapU ) Uvaccines", "begin": "116", "end": "147", "new_begin": "134", "new_end": "165", "replace_begin": "132", "replace_end": "137"}, "sentence": "Furthermore , the possibility of continuing to vaccinate adolescents and adults with new diphtheria , tetanus , and pertussisU ( UdTapU ) Uvaccines is an important step in achieving control and elimination of the disease .", "new_sentence": "Furthermore@@,@@the@@possibility@@of@@continuing@@to@@vaccinate@@adolescents@@and@@adults@@with@@new@@diphtheria@@,@@tetanus@@,@@and@@pertussisU ( UdTapU ) Uvaccines@@is@@an@@important@@step@@in@@achieving@@control@@and@@elimination@@of@@the@@disease@@.@@", "replace_sentence": "Furthermore@@,@@the@@possibility@@of@@continuing@@to@@vaccinate@@adolescents@@and@@adults@@with@@new@@diphtheria@@,@@drug1@@,@@and@@drug2@@is@@an@@important@@step@@in@@achieving@@control@@and@@elimination@@of@@the@@disease@@.@@", "new_pair": "tetanus@@,@@and@@pertussisU ( UdTapU ) Uvaccines", "replace_pair": "drug1@@,@@and@@drug2", "relation": "NA"}, {"head": {"id": "270", "type": "", "word": "vitaminUD", "begin": "52", "end": "61", "new_begin": "62", "new_end": "71", "replace_begin": "62", "replace_end": "67"}, "tail": {"id": "271", "type": "", "word": "osteoporosis", "begin": "118", "end": "130", "new_begin": "140", "new_end": "152", "replace_begin": "136", "replace_end": "141"}, "sentence": "AIM : To review recent reports on the prevalence of vitaminUD inadequacy among post-menopausal women with and without osteoporosis and @ or other musculoskeletal diseases .", "new_sentence": "AIM@@:@@To@@review@@recent@@reports@@on@@the@@prevalence@@of@@vitaminUD@@inadequacy@@among@@post@@-@@menopausal@@women@@with@@and@@without@@osteoporosis@@and@@@@@or@@other@@musculoskeletal@@diseases@@.@@", "replace_sentence": "AIM@@:@@To@@review@@recent@@reports@@on@@the@@prevalence@@of@@drug1@@inadequacy@@among@@post@@-@@menopausal@@women@@with@@and@@without@@drug2@@and@@@@@or@@other@@musculoskeletal@@diseases@@.@@", "new_pair": "vitaminUD@@inadequacy@@among@@post@@-@@menopausal@@women@@with@@and@@without@@osteoporosis", "replace_pair": "drug1@@inadequacy@@among@@post@@-@@menopausal@@women@@with@@and@@without@@drug2", "relation": "NA"}, {"head": {"id": "272", "type": "", "word": "fluticasone", "begin": "82", "end": "93", "new_begin": "93", "new_end": "104", "replace_begin": "93", "replace_end": "98"}, "tail": {"id": "273", "type": "", "word": "asthma", "begin": "187", "end": "193", "new_begin": "219", "new_end": "225", "replace_begin": "213", "replace_end": "218"}, "sentence": "Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper - responsiveness in mild-to-moderate persistent asthma .", "new_sentence": "Effects@@of@@hydrofluoroalkane@@formulations@@of@@ciclesonide@@400@@microg@@once@@daily@@vs@@fluticasone@@250@@microg@@twice@@daily@@on@@methacholine@@hyper@@-@@responsiveness@@in@@mild@@-@@to@@-@@moderate@@persistent@@asthma@@.@@", "replace_sentence": "Effects@@of@@hydrofluoroalkane@@formulations@@of@@ciclesonide@@400@@microg@@once@@daily@@vs@@drug1@@250@@microg@@twice@@daily@@on@@methacholine@@hyper@@-@@responsiveness@@in@@mild@@-@@to@@-@@moderate@@persistent@@drug2@@.@@", "new_pair": "fluticasone@@250@@microg@@twice@@daily@@on@@methacholine@@hyper@@-@@responsiveness@@in@@mild@@-@@to@@-@@moderate@@persistent@@asthma", "replace_pair": "drug1@@250@@microg@@twice@@daily@@on@@methacholine@@hyper@@-@@responsiveness@@in@@mild@@-@@to@@-@@moderate@@persistent@@drug2", "relation": "NA"}, {"head": {"id": "274", "type": "", "word": "ironUoverload", "begin": "107", "end": "120", "new_begin": "126", "new_end": "139", "replace_begin": "126", "replace_end": "131"}, "tail": {"id": "275", "type": "", "word": "iron-dextran", "begin": "362", "end": "374", "new_begin": "437", "new_end": "449", "replace_begin": "429", "replace_end": "434"}, "sentence": "In vivo preventive effects of a Mangifera indica L extract ( Vimang ) or its major component mangiferin on ironUoverload injury have been studied in rats given respectively , 50 , 100 , 250 mg kg ( - 1 ) body weight of Vimang , or 40 mg kg ( - 1 ) body weight of mangiferin , for 7 days prior to , and for 7 days following the administration of toxic amounts of iron-dextran .", "new_sentence": "In@@vivo@@preventive@@effects@@of@@a@@Mangifera@@indica@@L@@extract@@(@@Vimang@@)@@or@@its@@major@@component@@mangiferin@@on@@ironUoverload@@injury@@have@@been@@studied@@in@@rats@@given@@respectively@@,@@50@@,@@100@@,@@250@@mg@@kg@@(@@-@@1@@)@@body@@weight@@of@@Vimang@@,@@or@@40@@mg@@kg@@(@@-@@1@@)@@body@@weight@@of@@mangiferin@@,@@for@@7@@days@@prior@@to@@,@@and@@for@@7@@days@@following@@the@@administration@@of@@toxic@@amounts@@of@@iron-dextran@@.@@", "replace_sentence": "In@@vivo@@preventive@@effects@@of@@a@@Mangifera@@indica@@L@@extract@@(@@Vimang@@)@@or@@its@@major@@component@@mangiferin@@on@@drug1@@injury@@have@@been@@studied@@in@@rats@@given@@respectively@@,@@50@@,@@100@@,@@250@@mg@@kg@@(@@-@@1@@)@@body@@weight@@of@@Vimang@@,@@or@@40@@mg@@kg@@(@@-@@1@@)@@body@@weight@@of@@mangiferin@@,@@for@@7@@days@@prior@@to@@,@@and@@for@@7@@days@@following@@the@@administration@@of@@toxic@@amounts@@of@@drug2@@.@@", "new_pair": "ironUoverload@@injury@@have@@been@@studied@@in@@rats@@given@@respectively@@,@@50@@,@@100@@,@@250@@mg@@kg@@(@@-@@1@@)@@body@@weight@@of@@Vimang@@,@@or@@40@@mg@@kg@@(@@-@@1@@)@@body@@weight@@of@@mangiferin@@,@@for@@7@@days@@prior@@to@@,@@and@@for@@7@@days@@following@@the@@administration@@of@@toxic@@amounts@@of@@iron-dextran", "replace_pair": "drug1@@injury@@have@@been@@studied@@in@@rats@@given@@respectively@@,@@50@@,@@100@@,@@250@@mg@@kg@@(@@-@@1@@)@@body@@weight@@of@@Vimang@@,@@or@@40@@mg@@kg@@(@@-@@1@@)@@body@@weight@@of@@mangiferin@@,@@for@@7@@days@@prior@@to@@,@@and@@for@@7@@days@@following@@the@@administration@@of@@toxic@@amounts@@of@@drug2", "relation": "NA"}, {"head": {"id": "276", "type": "", "word": "aspirin", "begin": "142", "end": "149", "new_begin": "166", "new_end": "173", "replace_begin": "166", "replace_end": "171"}, "tail": {"id": "277", "type": "", "word": "myocardialUinfarction", "begin": "163", "end": "184", "new_begin": "190", "new_end": "211", "replace_begin": "188", "replace_end": "193"}, "sentence": "These properties indicate that long-term treatment with a low dose of ximelagatran may provide valuable depression of coagulation activity in aspirin treated post myocardialUinfarction patients .", "new_sentence": "These@@properties@@indicate@@that@@long@@-@@term@@treatment@@with@@a@@low@@dose@@of@@ximelagatran@@may@@provide@@valuable@@depression@@of@@coagulation@@activity@@in@@aspirin@@treated@@post@@myocardialUinfarction@@patients@@.@@", "replace_sentence": "These@@properties@@indicate@@that@@long@@-@@term@@treatment@@with@@a@@low@@dose@@of@@ximelagatran@@may@@provide@@valuable@@depression@@of@@coagulation@@activity@@in@@drug1@@treated@@post@@drug2@@patients@@.@@", "new_pair": "aspirin@@treated@@post@@myocardialUinfarction", "replace_pair": "drug1@@treated@@post@@drug2", "relation": "NA"}, {"head": {"id": "278", "type": "", "word": "tumorUlysisUsyndrome", "begin": "49", "end": "69", "new_begin": "57", "new_end": "77", "replace_begin": "57", "replace_end": "62"}, "tail": {"id": "279", "type": "", "word": "allopurinol", "begin": "104", "end": "115", "new_begin": "119", "new_end": "130", "replace_begin": "104", "replace_end": "109"}, "sentence": "The patient s hospital course was complicated by tumorUlysisUsyndrome that was managed by hydration and allopurinol .", "new_sentence": "The@@patient@@s@@hospital@@course@@was@@complicated@@by@@tumorUlysisUsyndrome@@that@@was@@managed@@by@@hydration@@and@@allopurinol@@.@@", "replace_sentence": "The@@patient@@s@@hospital@@course@@was@@complicated@@by@@drug1@@that@@was@@managed@@by@@hydration@@and@@drug2@@.@@", "new_pair": "tumorUlysisUsyndrome@@that@@was@@managed@@by@@hydration@@and@@allopurinol", "replace_pair": "drug1@@that@@was@@managed@@by@@hydration@@and@@drug2", "relation": "NA"}, {"head": {"id": "280", "type": "", "word": "stroke", "begin": "43", "end": "49", "new_begin": "49", "new_end": "55", "replace_begin": "49", "replace_end": "54"}, "tail": {"id": "281", "type": "", "word": "aspirin", "begin": "153", "end": "160", "new_begin": "177", "new_end": "184", "replace_begin": "176", "replace_end": "181"}, "sentence": "Clopidogrel is another option in secondary stroke prevention , especially for aspirin - intolerant patients , but it appears to have less advantage over aspirin than aspirin plus ER-DP , and its combined use with aspirin has only marginally better efficacy and increased bleeding risk .", "new_sentence": "Clopidogrel@@is@@another@@option@@in@@secondary@@stroke@@prevention@@,@@especially@@for@@aspirin@@-@@intolerant@@patients@@,@@but@@it@@appears@@to@@have@@less@@advantage@@over@@aspirin@@than@@aspirin@@plus@@ER@@-@@DP@@,@@and@@its@@combined@@use@@with@@aspirin@@has@@only@@marginally@@better@@efficacy@@and@@increased@@bleeding@@risk@@.@@", "replace_sentence": "Clopidogrel@@is@@another@@option@@in@@secondary@@drug1@@prevention@@,@@especially@@for@@aspirin@@-@@intolerant@@patients@@,@@but@@it@@appears@@to@@have@@less@@advantage@@over@@drug2@@than@@aspirin@@plus@@ER@@-@@DP@@,@@and@@its@@combined@@use@@with@@aspirin@@has@@only@@marginally@@better@@efficacy@@and@@increased@@bleeding@@risk@@.@@", "new_pair": "stroke@@prevention@@,@@especially@@for@@aspirin@@-@@intolerant@@patients@@,@@but@@it@@appears@@to@@have@@less@@advantage@@over@@aspirin", "replace_pair": "drug1@@prevention@@,@@especially@@for@@aspirin@@-@@intolerant@@patients@@,@@but@@it@@appears@@to@@have@@less@@advantage@@over@@drug2", "relation": "may_prevent"}, {"head": {"id": "282", "type": "", "word": "leftUventricularUhypertrophy", "begin": "167", "end": "195", "new_begin": "192", "new_end": "220", "replace_begin": "192", "replace_end": "197"}, "tail": {"id": "283", "type": "", "word": "benazepril", "begin": "244", "end": "254", "new_begin": "276", "new_end": "286", "replace_begin": "253", "replace_end": "258"}, "sentence": "A study of the relationships between angiotensin- converting enzyme gene , chymase gene polymorphisms , pharmacological treatment with ACE inhibitor and regression of leftUventricularUhypertrophy in essential hypertension patients treated with benazepril .", "new_sentence": "A@@study@@of@@the@@relationships@@between@@angiotensin@@-@@converting@@enzyme@@gene@@,@@chymase@@gene@@polymorphisms@@,@@pharmacological@@treatment@@with@@ACE@@inhibitor@@and@@regression@@of@@leftUventricularUhypertrophy@@in@@essential@@hypertension@@patients@@treated@@with@@benazepril@@.@@", "replace_sentence": "A@@study@@of@@the@@relationships@@between@@angiotensin@@-@@converting@@enzyme@@gene@@,@@chymase@@gene@@polymorphisms@@,@@pharmacological@@treatment@@with@@ACE@@inhibitor@@and@@regression@@of@@drug1@@in@@essential@@hypertension@@patients@@treated@@with@@drug2@@.@@", "new_pair": "leftUventricularUhypertrophy@@in@@essential@@hypertension@@patients@@treated@@with@@benazepril", "replace_pair": "drug1@@in@@essential@@hypertension@@patients@@treated@@with@@drug2", "relation": "NA"}, {"head": {"id": "284", "type": "", "word": "estradiol", "begin": "31", "end": "40", "new_begin": "35", "new_end": "44", "replace_begin": "35", "replace_end": "40"}, "tail": {"id": "285", "type": "", "word": "ischemia", "begin": "160", "end": "168", "new_begin": "186", "new_end": "194", "replace_begin": "182", "replace_end": "187"}, "sentence": "The study investigated whether estradiol can prevent release of cytochrome c from mitochondria and induction of apoptosis after 30 and 60 min stop - flow heart ischemia in Langendorff- perfused female rat hearts .", "new_sentence": "The@@study@@investigated@@whether@@estradiol@@can@@prevent@@release@@of@@cytochrome@@c@@from@@mitochondria@@and@@induction@@of@@apoptosis@@after@@30@@and@@60@@min@@stop@@-@@flow@@heart@@ischemia@@in@@Langendorff@@-@@perfused@@female@@rat@@hearts@@.@@", "replace_sentence": "The@@study@@investigated@@whether@@drug1@@can@@prevent@@release@@of@@cytochrome@@c@@from@@mitochondria@@and@@induction@@of@@apoptosis@@after@@30@@and@@60@@min@@stop@@-@@flow@@heart@@drug2@@in@@Langendorff@@-@@perfused@@female@@rat@@hearts@@.@@", "new_pair": "estradiol@@can@@prevent@@release@@of@@cytochrome@@c@@from@@mitochondria@@and@@induction@@of@@apoptosis@@after@@30@@and@@60@@min@@stop@@-@@flow@@heart@@ischemia", "replace_pair": "drug1@@can@@prevent@@release@@of@@cytochrome@@c@@from@@mitochondria@@and@@induction@@of@@apoptosis@@after@@30@@and@@60@@min@@stop@@-@@flow@@heart@@drug2", "relation": "NA"}, {"head": {"id": "286", "type": "", "word": "ganciclovir", "begin": "30", "end": "41", "new_begin": "35", "new_end": "46", "replace_begin": "35", "replace_end": "40"}, "tail": {"id": "287", "type": "", "word": "CMVUinfection", "begin": "81", "end": "94", "new_begin": "92", "new_end": "105", "replace_begin": "86", "replace_end": "91"}, "sentence": "Our results suggest that oral ganciclovir prophylaxis is effective in preventing CMVUinfection during the 3-month period of prophylaxis , that a 3- month period of prophylaxis appears to be sufficient for D ( + ) R ( + ) recipients , but a longer period of oral ganciclovir prophylaxis may be needed in D ( + ) R ( - ) recipients .", "new_sentence": "Our@@results@@suggest@@that@@oral@@ganciclovir@@prophylaxis@@is@@effective@@in@@preventing@@CMVUinfection@@during@@the@@3@@-@@month@@period@@of@@prophylaxis@@,@@that@@a@@3@@-@@month@@period@@of@@prophylaxis@@appears@@to@@be@@sufficient@@for@@D@@(@@+@@)@@R@@(@@+@@)@@recipients@@,@@but@@a@@longer@@period@@of@@oral@@ganciclovir@@prophylaxis@@may@@be@@needed@@in@@D@@(@@+@@)@@R@@(@@-@@)@@recipients@@.@@", "replace_sentence": "Our@@results@@suggest@@that@@oral@@drug1@@prophylaxis@@is@@effective@@in@@preventing@@drug2@@during@@the@@3@@-@@month@@period@@of@@prophylaxis@@,@@that@@a@@3@@-@@month@@period@@of@@prophylaxis@@appears@@to@@be@@sufficient@@for@@D@@(@@+@@)@@R@@(@@+@@)@@recipients@@,@@but@@a@@longer@@period@@of@@oral@@ganciclovir@@prophylaxis@@may@@be@@needed@@in@@D@@(@@+@@)@@R@@(@@-@@)@@recipients@@.@@", "new_pair": "ganciclovir@@prophylaxis@@is@@effective@@in@@preventing@@CMVUinfection", "replace_pair": "drug1@@prophylaxis@@is@@effective@@in@@preventing@@drug2", "relation": "may_prevent"}, {"head": {"id": "288", "type": "", "word": "ganciclovir", "begin": "36", "end": "47", "new_begin": "41", "new_end": "52", "replace_begin": "41", "replace_end": "46"}, "tail": {"id": "289", "type": "", "word": "CMVUdisease", "begin": "91", "end": "102", "new_begin": "104", "new_end": "115", "replace_begin": "98", "replace_end": "103"}, "sentence": "CONCLUSIONS : Valacyclovir and oral ganciclovir are equally effective in the prevention of CMVUdisease after renal transplantation .", "new_sentence": "CONCLUSIONS@@:@@Valacyclovir@@and@@oral@@ganciclovir@@are@@equally@@effective@@in@@the@@prevention@@of@@CMVUdisease@@after@@renal@@transplantation@@.@@", "replace_sentence": "CONCLUSIONS@@:@@Valacyclovir@@and@@oral@@drug1@@are@@equally@@effective@@in@@the@@prevention@@of@@drug2@@after@@renal@@transplantation@@.@@", "new_pair": "ganciclovir@@are@@equally@@effective@@in@@the@@prevention@@of@@CMVUdisease", "replace_pair": "drug1@@are@@equally@@effective@@in@@the@@prevention@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "290", "type": "", "word": "chronicUrenalUinsufficiency", "begin": "60", "end": "87", "new_begin": "71", "new_end": "98", "replace_begin": "71", "replace_end": "76"}, "tail": {"id": "291", "type": "", "word": "NAC", "begin": "270", "end": "273", "new_begin": "317", "new_end": "320", "replace_begin": "295", "replace_end": "300"}, "sentence": "METHODS : One hundred ninety- two consecutive patients with chronicUrenalUinsufficiency , referred to our institution for coronary and @ or peripheral procedures , were assigned randomly to receive 0 . 45 % saline intravenously and NAC ( 1 , 200 mg orally twice daily ; NAC group ; n = 97 ) or fenoldopam ( 0 . 10 microg @ kg @ min ; fenoldopam group ; n = 95 ) before and after a nonionic , iso - osmolality contrast dye administration .", "new_sentence": "METHODS@@:@@One@@hundred@@ninety@@-@@two@@consecutive@@patients@@with@@chronicUrenalUinsufficiency@@,@@referred@@to@@our@@institution@@for@@coronary@@and@@@@@or@@peripheral@@procedures@@,@@were@@assigned@@randomly@@to@@receive@@0@@.@@45@@%@@saline@@intravenously@@and@@NAC@@(@@1@@,@@200@@mg@@orally@@twice@@daily@@;@@NAC@@group@@;@@n@@=@@97@@)@@or@@fenoldopam@@(@@0@@.@@10@@microg@@@@@kg@@@@@min@@;@@fenoldopam@@group@@;@@n@@=@@95@@)@@before@@and@@after@@a@@nonionic@@,@@iso@@-@@osmolality@@contrast@@dye@@administration@@.@@", "replace_sentence": "METHODS@@:@@One@@hundred@@ninety@@-@@two@@consecutive@@patients@@with@@drug1@@,@@referred@@to@@our@@institution@@for@@coronary@@and@@@@@or@@peripheral@@procedures@@,@@were@@assigned@@randomly@@to@@receive@@0@@.@@45@@%@@saline@@intravenously@@and@@NAC@@(@@1@@,@@200@@mg@@orally@@twice@@daily@@;@@drug2@@group@@;@@n@@=@@97@@)@@or@@fenoldopam@@(@@0@@.@@10@@microg@@@@@kg@@@@@min@@;@@fenoldopam@@group@@;@@n@@=@@95@@)@@before@@and@@after@@a@@nonionic@@,@@iso@@-@@osmolality@@contrast@@dye@@administration@@.@@", "new_pair": "chronicUrenalUinsufficiency@@,@@referred@@to@@our@@institution@@for@@coronary@@and@@@@@or@@peripheral@@procedures@@,@@were@@assigned@@randomly@@to@@receive@@0@@.@@45@@%@@saline@@intravenously@@and@@NAC@@(@@1@@,@@200@@mg@@orally@@twice@@daily@@;@@NAC", "replace_pair": "drug1@@,@@referred@@to@@our@@institution@@for@@coronary@@and@@@@@or@@peripheral@@procedures@@,@@were@@assigned@@randomly@@to@@receive@@0@@.@@45@@%@@saline@@intravenously@@and@@NAC@@(@@1@@,@@200@@mg@@orally@@twice@@daily@@;@@drug2", "relation": "NA"}, {"head": {"id": "292", "type": "", "word": "aspirin", "begin": "41", "end": "48", "new_begin": "47", "new_end": "54", "replace_begin": "47", "replace_end": "52"}, "tail": {"id": "293", "type": "", "word": "TIA", "begin": "111", "end": "114", "new_begin": "127", "new_end": "130", "replace_begin": "125", "replace_end": "130"}, "sentence": "Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIA .", "new_sentence": "Dipyridamole@@with@@aspirin@@is@@better@@than@@aspirin@@alone@@in@@preventing@@vascular@@events@@after@@ischaemic@@stroke@@or@@TIA@@.@@", "replace_sentence": "Dipyridamole@@with@@aspirin@@is@@better@@than@@drug1@@alone@@in@@preventing@@vascular@@events@@after@@ischaemic@@stroke@@or@@drug2@@.@@", "new_pair": "aspirin@@alone@@in@@preventing@@vascular@@events@@after@@ischaemic@@stroke@@or@@TIA", "replace_pair": "drug1@@alone@@in@@preventing@@vascular@@events@@after@@ischaemic@@stroke@@or@@drug2", "relation": "NA"}, {"head": {"id": "294", "type": "", "word": "asthmatic", "begin": "130", "end": "139", "new_begin": "158", "new_end": "167", "replace_begin": "158", "replace_end": "163"}, "tail": {"id": "295", "type": "", "word": "beclomethasone", "begin": "179", "end": "193", "new_begin": "218", "new_end": "232", "replace_begin": "214", "replace_end": "219"}, "sentence": "A post hoc analysis was performed , pooling data from four double-blind , placebo-controlled studies randomising 3 , 073 moderate asthmatic adults to montelukast ( n =1 , 439 ) , beclomethasone ( n =894 ) or placebo ( n =740 ) .", "new_sentence": "A@@post@@hoc@@analysis@@was@@performed@@,@@pooling@@data@@from@@four@@double@@-@@blind@@,@@placebo@@-@@controlled@@studies@@randomising@@3@@,@@073@@moderate@@asthmatic@@adults@@to@@montelukast@@(@@n@@=1@@,@@439@@)@@,@@beclomethasone@@(@@n@@=894@@)@@or@@placebo@@(@@n@@=740@@)@@.@@", "replace_sentence": "A@@post@@hoc@@analysis@@was@@performed@@,@@pooling@@data@@from@@four@@double@@-@@blind@@,@@placebo@@-@@controlled@@studies@@randomising@@3@@,@@073@@moderate@@drug1@@adults@@to@@montelukast@@(@@n@@=1@@,@@439@@)@@,@@drug2@@(@@n@@=894@@)@@or@@placebo@@(@@n@@=740@@)@@.@@", "new_pair": "asthmatic@@adults@@to@@montelukast@@(@@n@@=1@@,@@439@@)@@,@@beclomethasone", "replace_pair": "drug1@@adults@@to@@montelukast@@(@@n@@=1@@,@@439@@)@@,@@drug2", "relation": "NA"}, {"head": {"id": "296", "type": "", "word": "malaria", "begin": "129", "end": "136", "new_begin": "146", "new_end": "153", "replace_begin": "146", "replace_end": "151"}, "tail": {"id": "297", "type": "", "word": "CHQ", "begin": "154", "end": "157", "new_begin": "176", "new_end": "179", "replace_begin": "174", "replace_end": "179"}, "sentence": "The findings are in agreement with current recommendations for using artemisinin - based combinations for treating uncomplicated malaria in areas of high CHQ failure such as Ghana .", "new_sentence": "The@@findings@@are@@in@@agreement@@with@@current@@recommendations@@for@@using@@artemisinin@@-@@based@@combinations@@for@@treating@@uncomplicated@@malaria@@in@@areas@@of@@high@@CHQ@@failure@@such@@as@@Ghana@@.@@", "replace_sentence": "The@@findings@@are@@in@@agreement@@with@@current@@recommendations@@for@@using@@artemisinin@@-@@based@@combinations@@for@@treating@@uncomplicated@@drug1@@in@@areas@@of@@high@@drug2@@failure@@such@@as@@Ghana@@.@@", "new_pair": "malaria@@in@@areas@@of@@high@@CHQ", "replace_pair": "drug1@@in@@areas@@of@@high@@drug2", "relation": "NA"}, {"head": {"id": "298", "type": "", "word": "cystitis", "begin": "52", "end": "60", "new_begin": "61", "new_end": "69", "replace_begin": "61", "replace_end": "66"}, "tail": {"id": "299", "type": "", "word": "aspirin", "begin": "90", "end": "97", "new_begin": "106", "new_end": "113", "replace_begin": "103", "replace_end": "108"}, "sentence": "Effects of NSAIDs on bladder function in normal and cystitis rats : a comparison study of aspirin , indomethacin , and ketoprofen .", "new_sentence": "Effects@@of@@NSAIDs@@on@@bladder@@function@@in@@normal@@and@@cystitis@@rats@@:@@a@@comparison@@study@@of@@aspirin@@,@@indomethacin@@,@@and@@ketoprofen@@.@@", "replace_sentence": "Effects@@of@@NSAIDs@@on@@bladder@@function@@in@@normal@@and@@drug1@@rats@@:@@a@@comparison@@study@@of@@drug2@@,@@indomethacin@@,@@and@@ketoprofen@@.@@", "new_pair": "cystitis@@rats@@:@@a@@comparison@@study@@of@@aspirin", "replace_pair": "drug1@@rats@@:@@a@@comparison@@study@@of@@drug2", "relation": "NA"}, {"head": {"id": "300", "type": "", "word": "L-arginine", "begin": "47", "end": "57", "new_begin": "55", "new_end": "65", "replace_begin": "55", "replace_end": "60"}, "tail": {"id": "301", "type": "", "word": "stroke", "begin": "74", "end": "80", "new_begin": "85", "new_end": "91", "replace_begin": "80", "replace_end": "85"}, "sentence": "A systematic review of nitric oxide donors and L-arginine in experimental stroke ;", "new_sentence": "A@@systematic@@review@@of@@nitric@@oxide@@donors@@and@@L-arginine@@in@@experimental@@stroke@@;@@", "replace_sentence": "A@@systematic@@review@@of@@nitric@@oxide@@donors@@and@@drug1@@in@@experimental@@drug2@@;@@", "new_pair": "L-arginine@@in@@experimental@@stroke", "replace_pair": "drug1@@in@@experimental@@drug2", "relation": "NA"}, {"head": {"id": "302", "type": "", "word": "PrimaquineUphosphate", "begin": "0", "end": "20", "new_begin": "0", "new_end": "20", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "303", "type": "", "word": "malaria", "begin": "92", "end": "99", "new_begin": "106", "new_end": "113", "replace_begin": "91", "replace_end": "96"}, "sentence": "PrimaquineUphosphate has been used for preventing relapse of Plasmodium vivax and P . ovale malaria since the early 1950s , based on its ability to kill latent ( hypnozoite ) and developing liver stages of these parasites .", "new_sentence": "PrimaquineUphosphate@@has@@been@@used@@for@@preventing@@relapse@@of@@Plasmodium@@vivax@@and@@P@@.@@ovale@@malaria@@since@@the@@early@@1950s@@,@@based@@on@@its@@ability@@to@@kill@@latent@@(@@hypnozoite@@)@@and@@developing@@liver@@stages@@of@@these@@parasites@@.@@", "replace_sentence": "drug1@@has@@been@@used@@for@@preventing@@relapse@@of@@Plasmodium@@vivax@@and@@P@@.@@ovale@@drug2@@since@@the@@early@@1950s@@,@@based@@on@@its@@ability@@to@@kill@@latent@@(@@hypnozoite@@)@@and@@developing@@liver@@stages@@of@@these@@parasites@@.@@", "new_pair": "PrimaquineUphosphate@@has@@been@@used@@for@@preventing@@relapse@@of@@Plasmodium@@vivax@@and@@P@@.@@ovale@@malaria", "replace_pair": "drug1@@has@@been@@used@@for@@preventing@@relapse@@of@@Plasmodium@@vivax@@and@@P@@.@@ovale@@drug2", "relation": "may_prevent"}, {"head": {"id": "304", "type": "", "word": "hepatitisUBUimmuneUglobulin", "begin": "101", "end": "128", "new_begin": "122", "new_end": "149", "replace_begin": "122", "replace_end": "127"}, "tail": {"id": "305", "type": "", "word": "hepatitisUB", "begin": "219", "end": "230", "new_begin": "255", "new_end": "266", "replace_begin": "233", "replace_end": "238"}, "sentence": "BACKGROUND @ AIMS : We sought to determine the outcomes of long-term use of lamivudine combined with hepatitisUBUimmuneUglobulin according to the titer of antibody to hepatitis B surface antigen in preventing recurrent hepatitisUB in Chinese patients after liver transplantation .", "new_sentence": "BACKGROUND@@@@@AIMS@@:@@We@@sought@@to@@determine@@the@@outcomes@@of@@long@@-@@term@@use@@of@@lamivudine@@combined@@with@@hepatitisUBUimmuneUglobulin@@according@@to@@the@@titer@@of@@antibody@@to@@hepatitis@@B@@surface@@antigen@@in@@preventing@@recurrent@@hepatitisUB@@in@@Chinese@@patients@@after@@liver@@transplantation@@.@@", "replace_sentence": "BACKGROUND@@@@@AIMS@@:@@We@@sought@@to@@determine@@the@@outcomes@@of@@long@@-@@term@@use@@of@@lamivudine@@combined@@with@@drug1@@according@@to@@the@@titer@@of@@antibody@@to@@hepatitis@@B@@surface@@antigen@@in@@preventing@@recurrent@@drug2@@in@@Chinese@@patients@@after@@liver@@transplantation@@.@@", "new_pair": "hepatitisUBUimmuneUglobulin@@according@@to@@the@@titer@@of@@antibody@@to@@hepatitis@@B@@surface@@antigen@@in@@preventing@@recurrent@@hepatitisUB", "replace_pair": "drug1@@according@@to@@the@@titer@@of@@antibody@@to@@hepatitis@@B@@surface@@antigen@@in@@preventing@@recurrent@@drug2", "relation": "may_prevent"}, {"head": {"id": "306", "type": "", "word": "chloroquine", "begin": "180", "end": "191", "new_begin": "211", "new_end": "222", "replace_begin": "211", "replace_end": "216"}, "tail": {"id": "307", "type": "", "word": "malariaUfever", "begin": "214", "end": "227", "new_begin": "249", "new_end": "262", "replace_begin": "243", "replace_end": "248"}, "sentence": "The aim of our present study was to assess and compare the antipruritic efficacy of the micro - opiate receptor antagonist , naltrexone , and the antihistamine , promethazine , in chloroquine treated patients with malariaUfever .", "new_sentence": "The@@aim@@of@@our@@present@@study@@was@@to@@assess@@and@@compare@@the@@antipruritic@@efficacy@@of@@the@@micro@@-@@opiate@@receptor@@antagonist@@,@@naltrexone@@,@@and@@the@@antihistamine@@,@@promethazine@@,@@in@@chloroquine@@treated@@patients@@with@@malariaUfever@@.@@", "replace_sentence": "The@@aim@@of@@our@@present@@study@@was@@to@@assess@@and@@compare@@the@@antipruritic@@efficacy@@of@@the@@micro@@-@@opiate@@receptor@@antagonist@@,@@naltrexone@@,@@and@@the@@antihistamine@@,@@promethazine@@,@@in@@drug1@@treated@@patients@@with@@drug2@@.@@", "new_pair": "chloroquine@@treated@@patients@@with@@malariaUfever", "replace_pair": "drug1@@treated@@patients@@with@@drug2", "relation": "NA"}, {"head": {"id": "308", "type": "", "word": "graft-versus-hostUdisease", "begin": "0", "end": "25", "new_begin": "0", "new_end": "25", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "309", "type": "", "word": "cyclosporine", "begin": "56", "end": "68", "new_begin": "63", "new_end": "75", "replace_begin": "43", "replace_end": "48"}, "sentence": "graft-versus-hostUdisease ( GVHD ) prophylaxis was with cyclosporine and methotrexate .", "new_sentence": "graft-versus-hostUdisease@@(@@GVHD@@)@@prophylaxis@@was@@with@@cyclosporine@@and@@methotrexate@@.@@", "replace_sentence": "drug1@@(@@GVHD@@)@@prophylaxis@@was@@with@@drug2@@and@@methotrexate@@.@@", "new_pair": "graft-versus-hostUdisease@@(@@GVHD@@)@@prophylaxis@@was@@with@@cyclosporine", "replace_pair": "drug1@@(@@GVHD@@)@@prophylaxis@@was@@with@@drug2", "relation": "may_prevent"}, {"head": {"id": "310", "type": "", "word": "ASA", "begin": "165", "end": "168", "new_begin": "197", "new_end": "200", "replace_begin": "197", "replace_end": "202"}, "tail": {"id": "311", "type": "", "word": "transientUischaemicUattack", "begin": "203", "end": "229", "new_begin": "241", "new_end": "267", "replace_begin": "243", "replace_end": "248"}, "sentence": "Clopidogrel is more effective than ASA in preventing a combined end point of ischaemic stroke , MI , or vascular death , but it has not been shown to be superior to ASA in preventing recurrent stroke in transientUischaemicUattack or stroke patients .", "new_sentence": "Clopidogrel@@is@@more@@effective@@than@@ASA@@in@@preventing@@a@@combined@@end@@point@@of@@ischaemic@@stroke@@,@@MI@@,@@or@@vascular@@death@@,@@but@@it@@has@@not@@been@@shown@@to@@be@@superior@@to@@ASA@@in@@preventing@@recurrent@@stroke@@in@@transientUischaemicUattack@@or@@stroke@@patients@@.@@", "replace_sentence": "Clopidogrel@@is@@more@@effective@@than@@ASA@@in@@preventing@@a@@combined@@end@@point@@of@@ischaemic@@stroke@@,@@MI@@,@@or@@vascular@@death@@,@@but@@it@@has@@not@@been@@shown@@to@@be@@superior@@to@@drug1@@in@@preventing@@recurrent@@stroke@@in@@drug2@@or@@stroke@@patients@@.@@", "new_pair": "ASA@@in@@preventing@@recurrent@@stroke@@in@@transientUischaemicUattack", "replace_pair": "drug1@@in@@preventing@@recurrent@@stroke@@in@@drug2", "relation": "may_prevent"}, {"head": {"id": "312", "type": "", "word": "Fluoride", "begin": "0", "end": "8", "new_begin": "0", "new_end": "8", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "313", "type": "", "word": "caries", "begin": "18", "end": "24", "new_begin": "20", "new_end": "26", "replace_begin": "17", "replace_end": "22"}, "sentence": "Fluoride prevents caries among adults of all ages .", "new_sentence": "Fluoride@@prevents@@caries@@among@@adults@@of@@all@@ages@@.@@", "replace_sentence": "drug1@@prevents@@drug2@@among@@adults@@of@@all@@ages@@.@@", "new_pair": "Fluoride@@prevents@@caries", "replace_pair": "drug1@@prevents@@drug2", "relation": "may_prevent"}, {"head": {"id": "314", "type": "", "word": "flurbiprofen", "begin": "59", "end": "71", "new_begin": "73", "new_end": "85", "replace_begin": "73", "replace_end": "78"}, "tail": {"id": "315", "type": "", "word": "AlzheimerUsUdisease", "begin": "93", "end": "112", "new_begin": "112", "new_end": "131", "replace_begin": "105", "replace_end": "110"}, "sentence": "Drug evaluation : ( R ) - flurbiprofen -- an enantiomer of flurbiprofen for the treatment of AlzheimerUsUdisease .", "new_sentence": "Drug@@evaluation@@:@@(@@R@@)@@-@@flurbiprofen@@-@@-@@an@@enantiomer@@of@@flurbiprofen@@for@@the@@treatment@@of@@AlzheimerUsUdisease@@.@@", "replace_sentence": "Drug@@evaluation@@:@@(@@R@@)@@-@@flurbiprofen@@-@@-@@an@@enantiomer@@of@@drug1@@for@@the@@treatment@@of@@drug2@@.@@", "new_pair": "flurbiprofen@@for@@the@@treatment@@of@@AlzheimerUsUdisease", "replace_pair": "drug1@@for@@the@@treatment@@of@@drug2", "relation": "NA"}, {"head": {"id": "316", "type": "", "word": "osteoporosis", "begin": "165", "end": "177", "new_begin": "191", "new_end": "203", "replace_begin": "191", "replace_end": "196"}, "tail": {"id": "317", "type": "", "word": "estrogen", "begin": "260", "end": "268", "new_begin": "298", "new_end": "306", "replace_begin": "291", "replace_end": "296"}, "sentence": "It approaches the screening of hypertension , visual and auditive impairment , breast , colorectal , cervical , prostate cancers , about dyslipidemia , depression , osteoporosis , vaccination against influenza , pneumococcal infection , and chemoprophylaxy by estrogen , raloxifene , acetylsalicylic acid .", "new_sentence": "It@@approaches@@the@@screening@@of@@hypertension@@,@@visual@@and@@auditive@@impairment@@,@@breast@@,@@colorectal@@,@@cervical@@,@@prostate@@cancers@@,@@about@@dyslipidemia@@,@@depression@@,@@osteoporosis@@,@@vaccination@@against@@influenza@@,@@pneumococcal@@infection@@,@@and@@chemoprophylaxy@@by@@estrogen@@,@@raloxifene@@,@@acetylsalicylic@@acid@@.@@", "replace_sentence": "It@@approaches@@the@@screening@@of@@hypertension@@,@@visual@@and@@auditive@@impairment@@,@@breast@@,@@colorectal@@,@@cervical@@,@@prostate@@cancers@@,@@about@@dyslipidemia@@,@@depression@@,@@drug1@@,@@vaccination@@against@@influenza@@,@@pneumococcal@@infection@@,@@and@@chemoprophylaxy@@by@@drug2@@,@@raloxifene@@,@@acetylsalicylic@@acid@@.@@", "new_pair": "osteoporosis@@,@@vaccination@@against@@influenza@@,@@pneumococcal@@infection@@,@@and@@chemoprophylaxy@@by@@estrogen", "replace_pair": "drug1@@,@@vaccination@@against@@influenza@@,@@pneumococcal@@infection@@,@@and@@chemoprophylaxy@@by@@drug2", "relation": "NA"}, {"head": {"id": "318", "type": "", "word": "Tg", "begin": "42", "end": "44", "new_begin": "49", "new_end": "51", "replace_begin": "49", "replace_end": "54"}, "tail": {"id": "319", "type": "", "word": "hypothyroidism", "begin": "88", "end": "102", "new_begin": "106", "new_end": "120", "replace_begin": "109", "replace_end": "114"}, "sentence": "A total of 113 patients with undetectable Tg on T4 and negative US had to be exposed to hypothyroidism in order to diagnose one further case of metastases .", "new_sentence": "A@@total@@of@@113@@patients@@with@@undetectable@@Tg@@on@@T4@@and@@negative@@US@@had@@to@@be@@exposed@@to@@hypothyroidism@@in@@order@@to@@diagnose@@one@@further@@case@@of@@metastases@@.@@", "replace_sentence": "A@@total@@of@@113@@patients@@with@@undetectable@@drug1@@on@@T4@@and@@negative@@US@@had@@to@@be@@exposed@@to@@drug2@@in@@order@@to@@diagnose@@one@@further@@case@@of@@metastases@@.@@", "new_pair": "Tg@@on@@T4@@and@@negative@@US@@had@@to@@be@@exposed@@to@@hypothyroidism", "replace_pair": "drug1@@on@@T4@@and@@negative@@US@@had@@to@@be@@exposed@@to@@drug2", "relation": "NA"}, {"head": {"id": "320", "type": "", "word": "vitaminUE", "begin": "5", "end": "14", "new_begin": "6", "new_end": "15", "replace_begin": "6", "replace_end": "11"}, "tail": {"id": "321", "type": "", "word": "heartUattack", "begin": "45", "end": "57", "new_begin": "52", "new_end": "64", "replace_begin": "48", "replace_end": "53"}, "sentence": "Does vitaminUE help prevent heart disease or heartUattack ?", "new_sentence": "Does@@vitaminUE@@help@@prevent@@heart@@disease@@or@@heartUattack@@?@@", "replace_sentence": "Does@@drug1@@help@@prevent@@heart@@disease@@or@@drug2@@?@@", "new_pair": "vitaminUE@@help@@prevent@@heart@@disease@@or@@heartUattack", "replace_pair": "drug1@@help@@prevent@@heart@@disease@@or@@drug2", "relation": "NA"}, {"head": {"id": "322", "type": "", "word": "Clot", "begin": "0", "end": "4", "new_begin": "0", "new_end": "4", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "323", "type": "", "word": "stroke", "begin": "112", "end": "118", "new_begin": "128", "new_end": "134", "replace_begin": "129", "replace_end": "134"}, "sentence": "Clot prevention with anticoagulant therapy could have a significant impact on patient survival , disability and stroke recurrence .", "new_sentence": "Clot@@prevention@@with@@anticoagulant@@therapy@@could@@have@@a@@significant@@impact@@on@@patient@@survival@@,@@disability@@and@@stroke@@recurrence@@.@@", "replace_sentence": "drug1@@prevention@@with@@anticoagulant@@therapy@@could@@have@@a@@significant@@impact@@on@@patient@@survival@@,@@disability@@and@@drug2@@recurrence@@.@@", "new_pair": "Clot@@prevention@@with@@anticoagulant@@therapy@@could@@have@@a@@significant@@impact@@on@@patient@@survival@@,@@disability@@and@@stroke", "replace_pair": "drug1@@prevention@@with@@anticoagulant@@therapy@@could@@have@@a@@significant@@impact@@on@@patient@@survival@@,@@disability@@and@@drug2", "relation": "NA"}, {"head": {"id": "324", "type": "", "word": "aspirin", "begin": "19", "end": "26", "new_begin": "22", "new_end": "29", "replace_begin": "22", "replace_end": "27"}, "tail": {"id": "325", "type": "", "word": "MI", "begin": "86", "end": "88", "new_begin": "101", "new_end": "103", "replace_begin": "99", "replace_end": "104"}, "sentence": "BACKGROUND : Prior aspirin use is considered a marker of higher risk in patients with MI , yet the prognostic significance of this factor has been debated .", "new_sentence": "BACKGROUND@@:@@Prior@@aspirin@@use@@is@@considered@@a@@marker@@of@@higher@@risk@@in@@patients@@with@@MI@@,@@yet@@the@@prognostic@@significance@@of@@this@@factor@@has@@been@@debated@@.@@", "replace_sentence": "BACKGROUND@@:@@Prior@@drug1@@use@@is@@considered@@a@@marker@@of@@higher@@risk@@in@@patients@@with@@drug2@@,@@yet@@the@@prognostic@@significance@@of@@this@@factor@@has@@been@@debated@@.@@", "new_pair": "aspirin@@use@@is@@considered@@a@@marker@@of@@higher@@risk@@in@@patients@@with@@MI", "replace_pair": "drug1@@use@@is@@considered@@a@@marker@@of@@higher@@risk@@in@@patients@@with@@drug2", "relation": "NA"}, {"head": {"id": "326", "type": "", "word": "itraconazole", "begin": "8", "end": "20", "new_begin": "10", "new_end": "22", "replace_begin": "10", "replace_end": "15"}, "tail": {"id": "327", "type": "", "word": "fungalUinfection", "begin": "78", "end": "94", "new_begin": "90", "new_end": "106", "replace_begin": "83", "replace_end": "88"}, "sentence": "First , itraconazole has proven efficacy for the prophylaxis and treatment of fungalUinfection in immunocompromised individuals such as neutropenic cancer , human immunodeficiency virus ( HIV ) , and solid organ transplant patients .", "new_sentence": "First@@,@@itraconazole@@has@@proven@@efficacy@@for@@the@@prophylaxis@@and@@treatment@@of@@fungalUinfection@@in@@immunocompromised@@individuals@@such@@as@@neutropenic@@cancer@@,@@human@@immunodeficiency@@virus@@(@@HIV@@)@@,@@and@@solid@@organ@@transplant@@patients@@.@@", "replace_sentence": "First@@,@@drug1@@has@@proven@@efficacy@@for@@the@@prophylaxis@@and@@treatment@@of@@drug2@@in@@immunocompromised@@individuals@@such@@as@@neutropenic@@cancer@@,@@human@@immunodeficiency@@virus@@(@@HIV@@)@@,@@and@@solid@@organ@@transplant@@patients@@.@@", "new_pair": "itraconazole@@has@@proven@@efficacy@@for@@the@@prophylaxis@@and@@treatment@@of@@fungalUinfection", "replace_pair": "drug1@@has@@proven@@efficacy@@for@@the@@prophylaxis@@and@@treatment@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "328", "type": "", "word": "RSVUinfection", "begin": "143", "end": "156", "new_begin": "168", "new_end": "181", "replace_begin": "168", "replace_end": "173"}, "tail": {"id": "329", "type": "", "word": "palivizumab", "begin": "184", "end": "195", "new_begin": "215", "new_end": "226", "replace_begin": "207", "replace_end": "212"}, "sentence": "CONCLUSIONS : Specific host @ environmental factors can be used to identify which 33 -35GA infants are at greatest risk of hospitalization for RSVUinfection and likely to benefit from palivizumab prophylaxis .", "new_sentence": "CONCLUSIONS@@:@@Specific@@host@@@@@environmental@@factors@@can@@be@@used@@to@@identify@@which@@33@@-@@35GA@@infants@@are@@at@@greatest@@risk@@of@@hospitalization@@for@@RSVUinfection@@and@@likely@@to@@benefit@@from@@palivizumab@@prophylaxis@@.@@", "replace_sentence": "CONCLUSIONS@@:@@Specific@@host@@@@@environmental@@factors@@can@@be@@used@@to@@identify@@which@@33@@-@@35GA@@infants@@are@@at@@greatest@@risk@@of@@hospitalization@@for@@drug1@@and@@likely@@to@@benefit@@from@@drug2@@prophylaxis@@.@@", "new_pair": "RSVUinfection@@and@@likely@@to@@benefit@@from@@palivizumab", "replace_pair": "drug1@@and@@likely@@to@@benefit@@from@@drug2", "relation": "may_prevent"}, {"head": {"id": "330", "type": "", "word": "fluoride", "begin": "33", "end": "41", "new_begin": "38", "new_end": "46", "replace_begin": "38", "replace_end": "43"}, "tail": {"id": "331", "type": "", "word": "dentalUcaries", "begin": "94", "end": "107", "new_begin": "110", "new_end": "123", "replace_begin": "107", "replace_end": "112"}, "sentence": "Despite the indisputable role of fluoride in the prevention of caries , it has not eliminated dentalUcaries and many communities are not exposed to optimal quantities of fluoride .", "new_sentence": "Despite@@the@@indisputable@@role@@of@@fluoride@@in@@the@@prevention@@of@@caries@@,@@it@@has@@not@@eliminated@@dentalUcaries@@and@@many@@communities@@are@@not@@exposed@@to@@optimal@@quantities@@of@@fluoride@@.@@", "replace_sentence": "Despite@@the@@indisputable@@role@@of@@drug1@@in@@the@@prevention@@of@@caries@@,@@it@@has@@not@@eliminated@@drug2@@and@@many@@communities@@are@@not@@exposed@@to@@optimal@@quantities@@of@@fluoride@@.@@", "new_pair": "fluoride@@in@@the@@prevention@@of@@caries@@,@@it@@has@@not@@eliminated@@dentalUcaries", "replace_pair": "drug1@@in@@the@@prevention@@of@@caries@@,@@it@@has@@not@@eliminated@@drug2", "relation": "NA"}, {"head": {"id": "332", "type": "", "word": "ganciclovir", "begin": "37", "end": "48", "new_begin": "48", "new_end": "59", "replace_begin": "48", "replace_end": "53"}, "tail": {"id": "333", "type": "", "word": "cytomegalovirusUdisease", "begin": "66", "end": "89", "new_begin": "81", "new_end": "104", "replace_begin": "75", "replace_end": "80"}, "sentence": "High-dose acyclovir and pre -emptive ganciclovir in prevention of cytomegalovirusUdisease in pediatric patients following peripheral blood stem cell transplantation .", "new_sentence": "High@@-@@dose@@acyclovir@@and@@pre@@-@@emptive@@ganciclovir@@in@@prevention@@of@@cytomegalovirusUdisease@@in@@pediatric@@patients@@following@@peripheral@@blood@@stem@@cell@@transplantation@@.@@", "replace_sentence": "High@@-@@dose@@acyclovir@@and@@pre@@-@@emptive@@drug1@@in@@prevention@@of@@drug2@@in@@pediatric@@patients@@following@@peripheral@@blood@@stem@@cell@@transplantation@@.@@", "new_pair": "ganciclovir@@in@@prevention@@of@@cytomegalovirusUdisease", "replace_pair": "drug1@@in@@prevention@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "334", "type": "", "word": "myocardialUinfarction", "begin": "137", "end": "158", "new_begin": "161", "new_end": "182", "replace_begin": "161", "replace_end": "166"}, "tail": {"id": "335", "type": "", "word": "aspirin", "begin": "340", "end": "347", "new_begin": "399", "new_end": "406", "replace_begin": "383", "replace_end": "388"}, "sentence": "The 2002 American College of Cardiology @ American Heart Association guidelines for the management of unstable angina and non ST-segment myocardialUinfarction and the 2004 guidelines for ST-segment myocardial infarction assign priority to the long-term administration of four critical classes of drugs : antiplatelet agents , in particular aspirin and clopidogrel , beta-blockers , angiotensin-converting enzyme inhibitors , and statins .", "new_sentence": "The@@2002@@American@@College@@of@@Cardiology@@@@@American@@Heart@@Association@@guidelines@@for@@the@@management@@of@@unstable@@angina@@and@@non@@ST@@-@@segment@@myocardialUinfarction@@and@@the@@2004@@guidelines@@for@@ST@@-@@segment@@myocardial@@infarction@@assign@@priority@@to@@the@@long@@-@@term@@administration@@of@@four@@critical@@classes@@of@@drugs@@:@@antiplatelet@@agents@@,@@in@@particular@@aspirin@@and@@clopidogrel@@,@@beta@@-@@blockers@@,@@angiotensin@@-@@converting@@enzyme@@inhibitors@@,@@and@@statins@@.@@", "replace_sentence": "The@@2002@@American@@College@@of@@Cardiology@@@@@American@@Heart@@Association@@guidelines@@for@@the@@management@@of@@unstable@@angina@@and@@non@@ST@@-@@segment@@drug1@@and@@the@@2004@@guidelines@@for@@ST@@-@@segment@@myocardial@@infarction@@assign@@priority@@to@@the@@long@@-@@term@@administration@@of@@four@@critical@@classes@@of@@drugs@@:@@antiplatelet@@agents@@,@@in@@particular@@drug2@@and@@clopidogrel@@,@@beta@@-@@blockers@@,@@angiotensin@@-@@converting@@enzyme@@inhibitors@@,@@and@@statins@@.@@", "new_pair": "myocardialUinfarction@@and@@the@@2004@@guidelines@@for@@ST@@-@@segment@@myocardial@@infarction@@assign@@priority@@to@@the@@long@@-@@term@@administration@@of@@four@@critical@@classes@@of@@drugs@@:@@antiplatelet@@agents@@,@@in@@particular@@aspirin", "replace_pair": "drug1@@and@@the@@2004@@guidelines@@for@@ST@@-@@segment@@myocardial@@infarction@@assign@@priority@@to@@the@@long@@-@@term@@administration@@of@@four@@critical@@classes@@of@@drugs@@:@@antiplatelet@@agents@@,@@in@@particular@@drug2", "relation": "NA"}, {"head": {"id": "336", "type": "", "word": "glycerol", "begin": "72", "end": "80", "new_begin": "83", "new_end": "91", "replace_begin": "83", "replace_end": "88"}, "tail": {"id": "337", "type": "", "word": "ARF", "begin": "91", "end": "94", "new_begin": "105", "new_end": "108", "replace_begin": "102", "replace_end": "107"}, "sentence": "Hepatic extraction following intra - portal infusion was not altered by glycerol - induced ARF ;", "new_sentence": "Hepatic@@extraction@@following@@intra@@-@@portal@@infusion@@was@@not@@altered@@by@@glycerol@@-@@induced@@ARF@@;@@", "replace_sentence": "Hepatic@@extraction@@following@@intra@@-@@portal@@infusion@@was@@not@@altered@@by@@drug1@@-@@induced@@drug2@@;@@", "new_pair": "glycerol@@-@@induced@@ARF", "replace_pair": "drug1@@-@@induced@@drug2", "relation": "NA"}, {"head": {"id": "338", "type": "", "word": "IFRS", "begin": "119", "end": "123", "new_begin": "141", "new_end": "145", "replace_begin": "141", "replace_end": "146"}, "tail": {"id": "339", "type": "", "word": "caries", "begin": "390", "end": "396", "new_begin": "468", "new_end": "474", "replace_begin": "469", "replace_end": "474"}, "sentence": "The rate of new or recurrent carious lesions in the group treated with the fluoride gel was slightly lower than in the IFRS group , based on carious lesions at the baseline examination ( Poisson mean number of new or recurrent carious lesions for the control group =0 . 55 per year vs . 0 . 83 per year for the study group , p=0 . 705 ; odds ratio of the occurrence of any new or recurrent caries during follow-up for control group vs . the study group =0 . 80 ; p=0 . 781 ) .", "new_sentence": "The@@rate@@of@@new@@or@@recurrent@@carious@@lesions@@in@@the@@group@@treated@@with@@the@@fluoride@@gel@@was@@slightly@@lower@@than@@in@@the@@IFRS@@group@@,@@based@@on@@carious@@lesions@@at@@the@@baseline@@examination@@(@@Poisson@@mean@@number@@of@@new@@or@@recurrent@@carious@@lesions@@for@@the@@control@@group@@=0@@.@@55@@per@@year@@vs@@.@@0@@.@@83@@per@@year@@for@@the@@study@@group@@,@@p=0@@.@@705@@;@@odds@@ratio@@of@@the@@occurrence@@of@@any@@new@@or@@recurrent@@caries@@during@@follow@@-@@up@@for@@control@@group@@vs@@.@@the@@study@@group@@=0@@.@@80@@;@@p=0@@.@@781@@)@@.@@", "replace_sentence": "The@@rate@@of@@new@@or@@recurrent@@carious@@lesions@@in@@the@@group@@treated@@with@@the@@fluoride@@gel@@was@@slightly@@lower@@than@@in@@the@@drug1@@group@@,@@based@@on@@carious@@lesions@@at@@the@@baseline@@examination@@(@@Poisson@@mean@@number@@of@@new@@or@@recurrent@@carious@@lesions@@for@@the@@control@@group@@=0@@.@@55@@per@@year@@vs@@.@@0@@.@@83@@per@@year@@for@@the@@study@@group@@,@@p=0@@.@@705@@;@@odds@@ratio@@of@@the@@occurrence@@of@@any@@new@@or@@recurrent@@drug2@@during@@follow@@-@@up@@for@@control@@group@@vs@@.@@the@@study@@group@@=0@@.@@80@@;@@p=0@@.@@781@@)@@.@@", "new_pair": "IFRS@@group@@,@@based@@on@@carious@@lesions@@at@@the@@baseline@@examination@@(@@Poisson@@mean@@number@@of@@new@@or@@recurrent@@carious@@lesions@@for@@the@@control@@group@@=0@@.@@55@@per@@year@@vs@@.@@0@@.@@83@@per@@year@@for@@the@@study@@group@@,@@p=0@@.@@705@@;@@odds@@ratio@@of@@the@@occurrence@@of@@any@@new@@or@@recurrent@@caries", "replace_pair": "drug1@@group@@,@@based@@on@@carious@@lesions@@at@@the@@baseline@@examination@@(@@Poisson@@mean@@number@@of@@new@@or@@recurrent@@carious@@lesions@@for@@the@@control@@group@@=0@@.@@55@@per@@year@@vs@@.@@0@@.@@83@@per@@year@@for@@the@@study@@group@@,@@p=0@@.@@705@@;@@odds@@ratio@@of@@the@@occurrence@@of@@any@@new@@or@@recurrent@@drug2", "relation": "NA"}, {"head": {"id": "340", "type": "", "word": "palivizumab", "begin": "33", "end": "44", "new_begin": "38", "new_end": "49", "replace_begin": "38", "replace_end": "43"}, "tail": {"id": "341", "type": "", "word": "RSVUinfection", "begin": "306", "end": "319", "new_begin": "360", "new_end": "373", "replace_begin": "354", "replace_end": "359"}, "sentence": "In conclusion , prophylaxis with palivizumab significantly reduces the incidence of RSV - related hospitalization relative to placebo and is generally well tolerated in high-risk infants aged < 2 years , including those with prematurity and BPD @ CLD or HSCHD , which are risk factors for early or serious RSVUinfection .", "new_sentence": "In@@conclusion@@,@@prophylaxis@@with@@palivizumab@@significantly@@reduces@@the@@incidence@@of@@RSV@@-@@related@@hospitalization@@relative@@to@@placebo@@and@@is@@generally@@well@@tolerated@@in@@high@@-@@risk@@infants@@aged@@<@@2@@years@@,@@including@@those@@with@@prematurity@@and@@BPD@@@@@CLD@@or@@HSCHD@@,@@which@@are@@risk@@factors@@for@@early@@or@@serious@@RSVUinfection@@.@@", "replace_sentence": "In@@conclusion@@,@@prophylaxis@@with@@drug1@@significantly@@reduces@@the@@incidence@@of@@RSV@@-@@related@@hospitalization@@relative@@to@@placebo@@and@@is@@generally@@well@@tolerated@@in@@high@@-@@risk@@infants@@aged@@<@@2@@years@@,@@including@@those@@with@@prematurity@@and@@BPD@@@@@CLD@@or@@HSCHD@@,@@which@@are@@risk@@factors@@for@@early@@or@@serious@@drug2@@.@@", "new_pair": "palivizumab@@significantly@@reduces@@the@@incidence@@of@@RSV@@-@@related@@hospitalization@@relative@@to@@placebo@@and@@is@@generally@@well@@tolerated@@in@@high@@-@@risk@@infants@@aged@@<@@2@@years@@,@@including@@those@@with@@prematurity@@and@@BPD@@@@@CLD@@or@@HSCHD@@,@@which@@are@@risk@@factors@@for@@early@@or@@serious@@RSVUinfection", "replace_pair": "drug1@@significantly@@reduces@@the@@incidence@@of@@RSV@@-@@related@@hospitalization@@relative@@to@@placebo@@and@@is@@generally@@well@@tolerated@@in@@high@@-@@risk@@infants@@aged@@<@@2@@years@@,@@including@@those@@with@@prematurity@@and@@BPD@@@@@CLD@@or@@HSCHD@@,@@which@@are@@risk@@factors@@for@@early@@or@@serious@@drug2", "relation": "NA"}, {"head": {"id": "342", "type": "", "word": "ganciclovir", "begin": "84", "end": "95", "new_begin": "99", "new_end": "110", "replace_begin": "99", "replace_end": "104"}, "tail": {"id": "343", "type": "", "word": "CMVUdisease", "begin": "111", "end": "122", "new_begin": "129", "new_end": "140", "replace_begin": "123", "replace_end": "128"}, "sentence": "SUMMARY : Valganciclovir , an oral prodrug of ganciclovir , is as effective as oral ganciclovir for preventing CMVUdisease , although prophylaxis with either agent may delay CMV disease .", "new_sentence": "SUMMARY@@:@@Valganciclovir@@,@@an@@oral@@prodrug@@of@@ganciclovir@@,@@is@@as@@effective@@as@@oral@@ganciclovir@@for@@preventing@@CMVUdisease@@,@@although@@prophylaxis@@with@@either@@agent@@may@@delay@@CMV@@disease@@.@@", "replace_sentence": "SUMMARY@@:@@Valganciclovir@@,@@an@@oral@@prodrug@@of@@ganciclovir@@,@@is@@as@@effective@@as@@oral@@drug1@@for@@preventing@@drug2@@,@@although@@prophylaxis@@with@@either@@agent@@may@@delay@@CMV@@disease@@.@@", "new_pair": "ganciclovir@@for@@preventing@@CMVUdisease", "replace_pair": "drug1@@for@@preventing@@drug2", "relation": "may_prevent"}, {"head": {"id": "344", "type": "", "word": "lisinopril", "begin": "107", "end": "117", "new_begin": "125", "new_end": "135", "replace_begin": "125", "replace_end": "130"}, "tail": {"id": "345", "type": "", "word": "myocardialUinfarction", "begin": "218", "end": "239", "new_begin": "252", "new_end": "273", "replace_begin": "247", "replace_end": "252"}, "sentence": "The results of ALLHAT showed that the diuretic chlorthalidone , the CCB amlodipine , and the ACE inhibitor lisinopril were equally effective in preventing the primary outcome - fatal coronary heart disease or nonfatal myocardialUinfarction .", "new_sentence": "The@@results@@of@@ALLHAT@@showed@@that@@the@@diuretic@@chlorthalidone@@,@@the@@CCB@@amlodipine@@,@@and@@the@@ACE@@inhibitor@@lisinopril@@were@@equally@@effective@@in@@preventing@@the@@primary@@outcome@@-@@fatal@@coronary@@heart@@disease@@or@@nonfatal@@myocardialUinfarction@@.@@", "replace_sentence": "The@@results@@of@@ALLHAT@@showed@@that@@the@@diuretic@@chlorthalidone@@,@@the@@CCB@@amlodipine@@,@@and@@the@@ACE@@inhibitor@@drug1@@were@@equally@@effective@@in@@preventing@@the@@primary@@outcome@@-@@fatal@@coronary@@heart@@disease@@or@@nonfatal@@drug2@@.@@", "new_pair": "lisinopril@@were@@equally@@effective@@in@@preventing@@the@@primary@@outcome@@-@@fatal@@coronary@@heart@@disease@@or@@nonfatal@@myocardialUinfarction", "replace_pair": "drug1@@were@@equally@@effective@@in@@preventing@@the@@primary@@outcome@@-@@fatal@@coronary@@heart@@disease@@or@@nonfatal@@drug2", "relation": "may_prevent"}, {"head": {"id": "346", "type": "", "word": "cavity", "begin": "23", "end": "29", "new_begin": "26", "new_end": "32", "replace_begin": "26", "replace_end": "31"}, "tail": {"id": "347", "type": "", "word": "f", "begin": "99", "end": "100", "new_begin": "114", "new_end": "115", "replace_begin": "113", "replace_end": "118"}, "sentence": "Detuning the microwave cavity several megahertz from resonance reduces this effect to the deltaf @ f = 1o ( -16 ) level .", "new_sentence": "Detuning@@the@@microwave@@cavity@@several@@megahertz@@from@@resonance@@reduces@@this@@effect@@to@@the@@deltaf@@@@@f@@=@@1o@@(@@-@@16@@)@@level@@.@@", "replace_sentence": "Detuning@@the@@microwave@@drug1@@several@@megahertz@@from@@resonance@@reduces@@this@@effect@@to@@the@@deltaf@@@@@drug2@@=@@1o@@(@@-@@16@@)@@level@@.@@", "new_pair": "cavity@@several@@megahertz@@from@@resonance@@reduces@@this@@effect@@to@@the@@deltaf@@@@@f", "replace_pair": "drug1@@several@@megahertz@@from@@resonance@@reduces@@this@@effect@@to@@the@@deltaf@@@@@drug2", "relation": "NA"}, {"head": {"id": "348", "type": "", "word": "osteoporosis", "begin": "76", "end": "88", "new_begin": "88", "new_end": "100", "replace_begin": "88", "replace_end": "93"}, "tail": {"id": "349", "type": "", "word": "methylprednisolone", "begin": "140", "end": "158", "new_begin": "163", "new_end": "181", "replace_begin": "156", "replace_end": "161"}, "sentence": "In conclusion , treatment with repeated HDMP pulses was not associated with osteoporosis in patients with MS who participated in a trial of methylprednisolone .", "new_sentence": "In@@conclusion@@,@@treatment@@with@@repeated@@HDMP@@pulses@@was@@not@@associated@@with@@osteoporosis@@in@@patients@@with@@MS@@who@@participated@@in@@a@@trial@@of@@methylprednisolone@@.@@", "replace_sentence": "In@@conclusion@@,@@treatment@@with@@repeated@@HDMP@@pulses@@was@@not@@associated@@with@@drug1@@in@@patients@@with@@MS@@who@@participated@@in@@a@@trial@@of@@drug2@@.@@", "new_pair": "osteoporosis@@in@@patients@@with@@MS@@who@@participated@@in@@a@@trial@@of@@methylprednisolone", "replace_pair": "drug1@@in@@patients@@with@@MS@@who@@participated@@in@@a@@trial@@of@@drug2", "relation": "NA"}, {"head": {"id": "350", "type": "", "word": "dexamethasone", "begin": "25", "end": "38", "new_begin": "29", "new_end": "42", "replace_begin": "29", "replace_end": "34"}, "tail": {"id": "351", "type": "", "word": "airwayUhyperreactivity", "begin": "143", "end": "165", "new_begin": "163", "new_end": "185", "replace_begin": "155", "replace_end": "160"}, "sentence": "However , treatment with dexamethasone during the delivery of respiratory Ag prevented tolerance , such that allergen sensitization and severe airwayUhyperreactivity subsequently occurred .", "new_sentence": "However@@,@@treatment@@with@@dexamethasone@@during@@the@@delivery@@of@@respiratory@@Ag@@prevented@@tolerance@@,@@such@@that@@allergen@@sensitization@@and@@severe@@airwayUhyperreactivity@@subsequently@@occurred@@.@@", "replace_sentence": "However@@,@@treatment@@with@@drug1@@during@@the@@delivery@@of@@respiratory@@Ag@@prevented@@tolerance@@,@@such@@that@@allergen@@sensitization@@and@@severe@@drug2@@subsequently@@occurred@@.@@", "new_pair": "dexamethasone@@during@@the@@delivery@@of@@respiratory@@Ag@@prevented@@tolerance@@,@@such@@that@@allergen@@sensitization@@and@@severe@@airwayUhyperreactivity", "replace_pair": "drug1@@during@@the@@delivery@@of@@respiratory@@Ag@@prevented@@tolerance@@,@@such@@that@@allergen@@sensitization@@and@@severe@@drug2", "relation": "NA"}, {"head": {"id": "352", "type": "", "word": "toxoplasmosis", "begin": "38", "end": "51", "new_begin": "43", "new_end": "56", "replace_begin": "43", "replace_end": "48"}, "tail": {"id": "353", "type": "", "word": "cyclosporin", "begin": "67", "end": "78", "new_begin": "77", "new_end": "88", "replace_begin": "69", "replace_end": "74"}, "sentence": "Antemortem diagnosis and treatment of toxoplasmosis in two cats on cyclosporin therapy .", "new_sentence": "Antemortem@@diagnosis@@and@@treatment@@of@@toxoplasmosis@@in@@two@@cats@@on@@cyclosporin@@therapy@@.@@", "replace_sentence": "Antemortem@@diagnosis@@and@@treatment@@of@@drug1@@in@@two@@cats@@on@@drug2@@therapy@@.@@", "new_pair": "toxoplasmosis@@in@@two@@cats@@on@@cyclosporin", "replace_pair": "drug1@@in@@two@@cats@@on@@drug2", "relation": "NA"}, {"head": {"id": "354", "type": "", "word": "tyrosine", "begin": "69", "end": "77", "new_begin": "79", "new_end": "87", "replace_begin": "79", "replace_end": "84"}, "tail": {"id": "355", "type": "", "word": "ESRD", "begin": "122", "end": "126", "new_begin": "139", "new_end": "143", "replace_begin": "136", "replace_end": "141"}, "sentence": "CONCLUSION : We conclude that reduced conversion of phenylalanine to tyrosine causes tyrosine deficiency in patients with ESRD prompting to propose that tyrosine replacement is potentially required in patients with ESRD .", "new_sentence": "CONCLUSION@@:@@We@@conclude@@that@@reduced@@conversion@@of@@phenylalanine@@to@@tyrosine@@causes@@tyrosine@@deficiency@@in@@patients@@with@@ESRD@@prompting@@to@@propose@@that@@tyrosine@@replacement@@is@@potentially@@required@@in@@patients@@with@@ESRD@@.@@", "replace_sentence": "CONCLUSION@@:@@We@@conclude@@that@@reduced@@conversion@@of@@phenylalanine@@to@@drug1@@causes@@tyrosine@@deficiency@@in@@patients@@with@@drug2@@prompting@@to@@propose@@that@@tyrosine@@replacement@@is@@potentially@@required@@in@@patients@@with@@ESRD@@.@@", "new_pair": "tyrosine@@causes@@tyrosine@@deficiency@@in@@patients@@with@@ESRD", "replace_pair": "drug1@@causes@@tyrosine@@deficiency@@in@@patients@@with@@drug2", "relation": "NA"}, {"head": {"id": "356", "type": "", "word": "dentalUplaque", "begin": "70", "end": "83", "new_begin": "81", "new_end": "94", "replace_begin": "81", "replace_end": "86"}, "tail": {"id": "357", "type": "", "word": "F", "begin": "206", "end": "207", "new_begin": "238", "new_end": "239", "replace_begin": "230", "replace_end": "235"}, "sentence": "METHODS : Awild strain of mutans streptococci was isolated from human dentalUplaque and a monospecific biofilm adherent to the surfaces of 12 adhesive restorative materials ( F2000 , Dyract AP , Compoglass F , Z100 MP , Filtek Z250 , Clearfil , Ketac-Bond , Ketac-Fil Plus , Ketac-Molar , Fuji Cap II , Fuji Bond LC and Fuji II LC ) were tested .", "new_sentence": "METHODS@@:@@Awild@@strain@@of@@mutans@@streptococci@@was@@isolated@@from@@human@@dentalUplaque@@and@@a@@monospecific@@biofilm@@adherent@@to@@the@@surfaces@@of@@12@@adhesive@@restorative@@materials@@(@@F2000@@,@@Dyract@@AP@@,@@Compoglass@@F@@,@@Z100@@MP@@,@@Filtek@@Z250@@,@@Clearfil@@,@@Ketac@@-@@Bond@@,@@Ketac@@-@@Fil@@Plus@@,@@Ketac@@-@@Molar@@,@@Fuji@@Cap@@II@@,@@Fuji@@Bond@@LC@@and@@Fuji@@II@@LC@@)@@were@@tested@@.@@", "replace_sentence": "METHODS@@:@@Awild@@strain@@of@@mutans@@streptococci@@was@@isolated@@from@@human@@drug1@@and@@a@@monospecific@@biofilm@@adherent@@to@@the@@surfaces@@of@@12@@adhesive@@restorative@@materials@@(@@F2000@@,@@Dyract@@AP@@,@@Compoglass@@drug2@@,@@Z100@@MP@@,@@Filtek@@Z250@@,@@Clearfil@@,@@Ketac@@-@@Bond@@,@@Ketac@@-@@Fil@@Plus@@,@@Ketac@@-@@Molar@@,@@Fuji@@Cap@@II@@,@@Fuji@@Bond@@LC@@and@@Fuji@@II@@LC@@)@@were@@tested@@.@@", "new_pair": "dentalUplaque@@and@@a@@monospecific@@biofilm@@adherent@@to@@the@@surfaces@@of@@12@@adhesive@@restorative@@materials@@(@@F2000@@,@@Dyract@@AP@@,@@Compoglass@@F", "replace_pair": "drug1@@and@@a@@monospecific@@biofilm@@adherent@@to@@the@@surfaces@@of@@12@@adhesive@@restorative@@materials@@(@@F2000@@,@@Dyract@@AP@@,@@Compoglass@@drug2", "relation": "NA"}, {"head": {"id": "358", "type": "", "word": "Acyclovir", "begin": "0", "end": "9", "new_begin": "0", "new_end": "9", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "359", "type": "", "word": "HIVUinfection", "begin": "21", "end": "34", "new_begin": "24", "new_end": "37", "replace_begin": "20", "replace_end": "25"}, "sentence": "Acyclovir to prevent HIVUinfection ?", "new_sentence": "Acyclovir@@to@@prevent@@HIVUinfection@@?@@", "replace_sentence": "drug1@@to@@prevent@@drug2@@?@@", "new_pair": "Acyclovir@@to@@prevent@@HIVUinfection", "replace_pair": "drug1@@to@@prevent@@drug2", "relation": "NA"}, {"head": {"id": "360", "type": "", "word": "Stroke", "begin": "0", "end": "6", "new_begin": "0", "new_end": "6", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "361", "type": "", "word": "enalapril", "begin": "112", "end": "121", "new_begin": "131", "new_end": "140", "replace_begin": "130", "replace_end": "135"}, "sentence": "Stroke - prone spontaneously hypertensive rats ( SHRSP ) were randomly treated with a vehicle , amlodipine , or enalapril while Wistar-Kyoto rats ( WKY ) used as controls were treated with only the vehicle .", "new_sentence": "Stroke@@-@@prone@@spontaneously@@hypertensive@@rats@@(@@SHRSP@@)@@were@@randomly@@treated@@with@@a@@vehicle@@,@@amlodipine@@,@@or@@enalapril@@while@@Wistar@@-@@Kyoto@@rats@@(@@WKY@@)@@used@@as@@controls@@were@@treated@@with@@only@@the@@vehicle@@.@@", "replace_sentence": "drug1@@-@@prone@@spontaneously@@hypertensive@@rats@@(@@SHRSP@@)@@were@@randomly@@treated@@with@@a@@vehicle@@,@@amlodipine@@,@@or@@drug2@@while@@Wistar@@-@@Kyoto@@rats@@(@@WKY@@)@@used@@as@@controls@@were@@treated@@with@@only@@the@@vehicle@@.@@", "new_pair": "Stroke@@-@@prone@@spontaneously@@hypertensive@@rats@@(@@SHRSP@@)@@were@@randomly@@treated@@with@@a@@vehicle@@,@@amlodipine@@,@@or@@enalapril", "replace_pair": "drug1@@-@@prone@@spontaneously@@hypertensive@@rats@@(@@SHRSP@@)@@were@@randomly@@treated@@with@@a@@vehicle@@,@@amlodipine@@,@@or@@drug2", "relation": "NA"}, {"head": {"id": "362", "type": "", "word": "Ketotifen", "begin": "18", "end": "27", "new_begin": "21", "new_end": "30", "replace_begin": "21", "replace_end": "26"}, "tail": {"id": "363", "type": "", "word": "bronchialUasthma", "begin": "97", "end": "113", "new_begin": "112", "new_end": "128", "replace_begin": "108", "replace_end": "113"}, "sentence": "CONCLUSION : Oral Ketotifen is effective and well tolerated for use in prophylactic treatment of bronchialUasthma in children .", "new_sentence": "CONCLUSION@@:@@Oral@@Ketotifen@@is@@effective@@and@@well@@tolerated@@for@@use@@in@@prophylactic@@treatment@@of@@bronchialUasthma@@in@@children@@.@@", "replace_sentence": "CONCLUSION@@:@@Oral@@drug1@@is@@effective@@and@@well@@tolerated@@for@@use@@in@@prophylactic@@treatment@@of@@drug2@@in@@children@@.@@", "new_pair": "Ketotifen@@is@@effective@@and@@well@@tolerated@@for@@use@@in@@prophylactic@@treatment@@of@@bronchialUasthma", "replace_pair": "drug1@@is@@effective@@and@@well@@tolerated@@for@@use@@in@@prophylactic@@treatment@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "364", "type": "", "word": "Fluorides", "begin": "0", "end": "9", "new_begin": "0", "new_end": "9", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "365", "type": "", "word": "caries", "begin": "13", "end": "19", "new_begin": "15", "new_end": "21", "replace_begin": "11", "replace_end": "16"}, "sentence": "Fluorides in caries prevention and control : empiricism or science .", "new_sentence": "Fluorides@@in@@caries@@prevention@@and@@control@@:@@empiricism@@or@@science@@.@@", "replace_sentence": "drug1@@in@@drug2@@prevention@@and@@control@@:@@empiricism@@or@@science@@.@@", "new_pair": "Fluorides@@in@@caries", "replace_pair": "drug1@@in@@drug2", "relation": "may_prevent"}, {"head": {"id": "366", "type": "", "word": "Graft-versus-hostUdisease", "begin": "0", "end": "25", "new_begin": "0", "new_end": "25", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "367", "type": "", "word": "cyclosporine", "begin": "51", "end": "63", "new_begin": "55", "new_end": "67", "replace_begin": "35", "replace_end": "40"}, "sentence": "Graft-versus-hostUdisease prophylaxis consisted of cyclosporine alone .", "new_sentence": "Graft-versus-hostUdisease@@prophylaxis@@consisted@@of@@cyclosporine@@alone@@.@@", "replace_sentence": "drug1@@prophylaxis@@consisted@@of@@drug2@@alone@@.@@", "new_pair": "Graft-versus-hostUdisease@@prophylaxis@@consisted@@of@@cyclosporine", "replace_pair": "drug1@@prophylaxis@@consisted@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "368", "type": "", "word": "fungalUinfection", "begin": "98", "end": "114", "new_begin": "112", "new_end": "128", "replace_begin": "112", "replace_end": "117"}, "tail": {"id": "369", "type": "", "word": "fluconazole", "begin": "132", "end": "143", "new_begin": "150", "new_end": "161", "replace_begin": "139", "replace_end": "144"}, "sentence": "OBJECTIVES : To evaluate the impact of selective fluconazole prophylaxis on incidence of invasive fungalUinfection and emergence of fluconazole resistance in neonatal intensive care .", "new_sentence": "OBJECTIVES@@:@@To@@evaluate@@the@@impact@@of@@selective@@fluconazole@@prophylaxis@@on@@incidence@@of@@invasive@@fungalUinfection@@and@@emergence@@of@@fluconazole@@resistance@@in@@neonatal@@intensive@@care@@.@@", "replace_sentence": "OBJECTIVES@@:@@To@@evaluate@@the@@impact@@of@@selective@@fluconazole@@prophylaxis@@on@@incidence@@of@@invasive@@drug1@@and@@emergence@@of@@drug2@@resistance@@in@@neonatal@@intensive@@care@@.@@", "new_pair": "fungalUinfection@@and@@emergence@@of@@fluconazole", "replace_pair": "drug1@@and@@emergence@@of@@drug2", "relation": "NA"}, {"head": {"id": "370", "type": "", "word": "polioUvaccine", "begin": "117", "end": "130", "new_begin": "136", "new_end": "149", "replace_begin": "136", "replace_end": "141"}, "tail": {"id": "371", "type": "", "word": "polio", "begin": "225", "end": "230", "new_begin": "268", "new_end": "273", "replace_begin": "260", "replace_end": "265"}, "sentence": "Despite increase in number of pulse polio immunization ( PPI ) rounds since year 2000 and introduction of monovalent polioUvaccine type 1 ( mOPV1 ) and type 3 ( mOPV3 ) in Uttar Pradesh in 2005 , there has been no respite in polio incidence in Uttar Pradesh and Bihar .", "new_sentence": "Despite@@increase@@in@@number@@of@@pulse@@polio@@immunization@@(@@PPI@@)@@rounds@@since@@year@@2000@@and@@introduction@@of@@monovalent@@polioUvaccine@@type@@1@@(@@mOPV1@@)@@and@@type@@3@@(@@mOPV3@@)@@in@@Uttar@@Pradesh@@in@@2005@@,@@there@@has@@been@@no@@respite@@in@@polio@@incidence@@in@@Uttar@@Pradesh@@and@@Bihar@@.@@", "replace_sentence": "Despite@@increase@@in@@number@@of@@pulse@@polio@@immunization@@(@@PPI@@)@@rounds@@since@@year@@2000@@and@@introduction@@of@@monovalent@@drug1@@type@@1@@(@@mOPV1@@)@@and@@type@@3@@(@@mOPV3@@)@@in@@Uttar@@Pradesh@@in@@2005@@,@@there@@has@@been@@no@@respite@@in@@drug2@@incidence@@in@@Uttar@@Pradesh@@and@@Bihar@@.@@", "new_pair": "polioUvaccine@@type@@1@@(@@mOPV1@@)@@and@@type@@3@@(@@mOPV3@@)@@in@@Uttar@@Pradesh@@in@@2005@@,@@there@@has@@been@@no@@respite@@in@@polio", "replace_pair": "drug1@@type@@1@@(@@mOPV1@@)@@and@@type@@3@@(@@mOPV3@@)@@in@@Uttar@@Pradesh@@in@@2005@@,@@there@@has@@been@@no@@respite@@in@@drug2", "relation": "NA"}, {"head": {"id": "372", "type": "", "word": "RSVUinfection", "begin": "125", "end": "138", "new_begin": "146", "new_end": "159", "replace_begin": "146", "replace_end": "151"}, "tail": {"id": "373", "type": "", "word": "palivizumab", "begin": "174", "end": "185", "new_begin": "205", "new_end": "216", "replace_begin": "197", "replace_end": "202"}, "sentence": "The data tend to agree , albeit with different levels of evidence , that palivizumab reduces the risk of hospitalisation for RSVUinfection ( 3 . 95 % of infants treated with palivizumab , 13 . 25 % of untreated infants ) , but has no impact on the need for intensive care or on overall mortality .", "new_sentence": "The@@data@@tend@@to@@agree@@,@@albeit@@with@@different@@levels@@of@@evidence@@,@@that@@palivizumab@@reduces@@the@@risk@@of@@hospitalisation@@for@@RSVUinfection@@(@@3@@.@@95@@%@@of@@infants@@treated@@with@@palivizumab@@,@@13@@.@@25@@%@@of@@untreated@@infants@@)@@,@@but@@has@@no@@impact@@on@@the@@need@@for@@intensive@@care@@or@@on@@overall@@mortality@@.@@", "replace_sentence": "The@@data@@tend@@to@@agree@@,@@albeit@@with@@different@@levels@@of@@evidence@@,@@that@@palivizumab@@reduces@@the@@risk@@of@@hospitalisation@@for@@drug1@@(@@3@@.@@95@@%@@of@@infants@@treated@@with@@drug2@@,@@13@@.@@25@@%@@of@@untreated@@infants@@)@@,@@but@@has@@no@@impact@@on@@the@@need@@for@@intensive@@care@@or@@on@@overall@@mortality@@.@@", "new_pair": "RSVUinfection@@(@@3@@.@@95@@%@@of@@infants@@treated@@with@@palivizumab", "replace_pair": "drug1@@(@@3@@.@@95@@%@@of@@infants@@treated@@with@@drug2", "relation": "may_prevent"}, {"head": {"id": "374", "type": "", "word": "stroke", "begin": "111", "end": "117", "new_begin": "128", "new_end": "134", "replace_begin": "128", "replace_end": "133"}, "tail": {"id": "375", "type": "", "word": "folicUacid", "begin": "210", "end": "220", "new_begin": "244", "new_end": "254", "replace_begin": "243", "replace_end": "248"}, "sentence": "Currently , there is insufficient evidence to confirm that homocysteine is a modifiable causal risk factor for stroke , or to recommend routine screening for , or treatment of , raised tHcy concentrations with folicUacid and other vitamins , to prevent ischemic stroke .", "new_sentence": "Currently@@,@@there@@is@@insufficient@@evidence@@to@@confirm@@that@@homocysteine@@is@@a@@modifiable@@causal@@risk@@factor@@for@@stroke@@,@@or@@to@@recommend@@routine@@screening@@for@@,@@or@@treatment@@of@@,@@raised@@tHcy@@concentrations@@with@@folicUacid@@and@@other@@vitamins@@,@@to@@prevent@@ischemic@@stroke@@.@@", "replace_sentence": "Currently@@,@@there@@is@@insufficient@@evidence@@to@@confirm@@that@@homocysteine@@is@@a@@modifiable@@causal@@risk@@factor@@for@@drug1@@,@@or@@to@@recommend@@routine@@screening@@for@@,@@or@@treatment@@of@@,@@raised@@tHcy@@concentrations@@with@@drug2@@and@@other@@vitamins@@,@@to@@prevent@@ischemic@@stroke@@.@@", "new_pair": "stroke@@,@@or@@to@@recommend@@routine@@screening@@for@@,@@or@@treatment@@of@@,@@raised@@tHcy@@concentrations@@with@@folicUacid", "replace_pair": "drug1@@,@@or@@to@@recommend@@routine@@screening@@for@@,@@or@@treatment@@of@@,@@raised@@tHcy@@concentrations@@with@@drug2", "relation": "NA"}, {"head": {"id": "376", "type": "", "word": "iron", "begin": "188", "end": "192", "new_begin": "220", "new_end": "224", "replace_begin": "220", "replace_end": "225"}, "tail": {"id": "377", "type": "", "word": "ironUoverload", "begin": "224", "end": "237", "new_begin": "264", "new_end": "277", "replace_begin": "265", "replace_end": "270"}, "sentence": "Recent discoveries have led to the identification of hepcidin as a key regulator of iron metabolism and to the association of non - transferrin bound iron moieties , such as labile plasma iron , with the end organ damage in ironUoverload states .", "new_sentence": "Recent@@discoveries@@have@@led@@to@@the@@identification@@of@@hepcidin@@as@@a@@key@@regulator@@of@@iron@@metabolism@@and@@to@@the@@association@@of@@non@@-@@transferrin@@bound@@iron@@moieties@@,@@such@@as@@labile@@plasma@@iron@@,@@with@@the@@end@@organ@@damage@@in@@ironUoverload@@states@@.@@", "replace_sentence": "Recent@@discoveries@@have@@led@@to@@the@@identification@@of@@hepcidin@@as@@a@@key@@regulator@@of@@iron@@metabolism@@and@@to@@the@@association@@of@@non@@-@@transferrin@@bound@@iron@@moieties@@,@@such@@as@@labile@@plasma@@drug1@@,@@with@@the@@end@@organ@@damage@@in@@drug2@@states@@.@@", "new_pair": "iron@@,@@with@@the@@end@@organ@@damage@@in@@ironUoverload", "replace_pair": "drug1@@,@@with@@the@@end@@organ@@damage@@in@@drug2", "relation": "NA"}, {"head": {"id": "378", "type": "", "word": "LAH", "begin": "0", "end": "3", "new_begin": "0", "new_end": "3", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "379", "type": "", "word": "iron", "begin": "191", "end": "195", "new_begin": "228", "new_end": "232", "replace_begin": "230", "replace_end": "235"}, "sentence": "LAH was prevented by laryngeal application of either dimethylthiourea ( DMTU ; a @ OH scavenger ) or deferoxamine ( DEF ; an antioxidant for @ OH ) , but was unaltered by the DMTU vehicle or iron - saturated DEF ( ineffective DEF ) .", "new_sentence": "LAH@@was@@prevented@@by@@laryngeal@@application@@of@@either@@dimethylthiourea@@(@@DMTU@@;@@a@@@@@OH@@scavenger@@)@@or@@deferoxamine@@(@@DEF@@;@@an@@antioxidant@@for@@@@@OH@@)@@,@@but@@was@@unaltered@@by@@the@@DMTU@@vehicle@@or@@iron@@-@@saturated@@DEF@@(@@ineffective@@DEF@@)@@.@@", "replace_sentence": "drug1@@was@@prevented@@by@@laryngeal@@application@@of@@either@@dimethylthiourea@@(@@DMTU@@;@@a@@@@@OH@@scavenger@@)@@or@@deferoxamine@@(@@DEF@@;@@an@@antioxidant@@for@@@@@OH@@)@@,@@but@@was@@unaltered@@by@@the@@DMTU@@vehicle@@or@@drug2@@-@@saturated@@DEF@@(@@ineffective@@DEF@@)@@.@@", "new_pair": "LAH@@was@@prevented@@by@@laryngeal@@application@@of@@either@@dimethylthiourea@@(@@DMTU@@;@@a@@@@@OH@@scavenger@@)@@or@@deferoxamine@@(@@DEF@@;@@an@@antioxidant@@for@@@@@OH@@)@@,@@but@@was@@unaltered@@by@@the@@DMTU@@vehicle@@or@@iron", "replace_pair": "drug1@@was@@prevented@@by@@laryngeal@@application@@of@@either@@dimethylthiourea@@(@@DMTU@@;@@a@@@@@OH@@scavenger@@)@@or@@deferoxamine@@(@@DEF@@;@@an@@antioxidant@@for@@@@@OH@@)@@,@@but@@was@@unaltered@@by@@the@@DMTU@@vehicle@@or@@drug2", "relation": "NA"}, {"head": {"id": "380", "type": "", "word": "fluconazole", "begin": "62", "end": "73", "new_begin": "70", "new_end": "81", "replace_begin": "70", "replace_end": "75"}, "tail": {"id": "381", "type": "", "word": "infections", "begin": "126", "end": "136", "new_begin": "142", "new_end": "152", "replace_begin": "136", "replace_end": "141"}, "sentence": "Although invasive candidiasis was the principal IFI predating fluconazole prophylaxis , invasive aspergillosis and other mold infections now cause most deaths from fungal infection in this patient population .", "new_sentence": "Although@@invasive@@candidiasis@@was@@the@@principal@@IFI@@predating@@fluconazole@@prophylaxis@@,@@invasive@@aspergillosis@@and@@other@@mold@@infections@@now@@cause@@most@@deaths@@from@@fungal@@infection@@in@@this@@patient@@population@@.@@", "replace_sentence": "Although@@invasive@@candidiasis@@was@@the@@principal@@IFI@@predating@@drug1@@prophylaxis@@,@@invasive@@aspergillosis@@and@@other@@mold@@drug2@@now@@cause@@most@@deaths@@from@@fungal@@infection@@in@@this@@patient@@population@@.@@", "new_pair": "fluconazole@@prophylaxis@@,@@invasive@@aspergillosis@@and@@other@@mold@@infections", "replace_pair": "drug1@@prophylaxis@@,@@invasive@@aspergillosis@@and@@other@@mold@@drug2", "relation": "NA"}, {"head": {"id": "382", "type": "", "word": "CHF", "begin": "38", "end": "41", "new_begin": "44", "new_end": "47", "replace_begin": "44", "replace_end": "49"}, "tail": {"id": "383", "type": "", "word": "iron", "begin": "235", "end": "239", "new_begin": "280", "new_end": "284", "replace_begin": "282", "replace_end": "287"}, "sentence": "CONCLUSIONS : In anemic patients with CHF , correction of anemia with EPO and oral iron over 1 year lead to an improvement in LV systolic function , LV remodeling , BNP levels , and PAP compared with a control group in which only oral iron was used .", "new_sentence": "CONCLUSIONS@@:@@In@@anemic@@patients@@with@@CHF@@,@@correction@@of@@anemia@@with@@EPO@@and@@oral@@iron@@over@@1@@year@@lead@@to@@an@@improvement@@in@@LV@@systolic@@function@@,@@LV@@remodeling@@,@@BNP@@levels@@,@@and@@PAP@@compared@@with@@a@@control@@group@@in@@which@@only@@oral@@iron@@was@@used@@.@@", "replace_sentence": "CONCLUSIONS@@:@@In@@anemic@@patients@@with@@drug1@@,@@correction@@of@@anemia@@with@@EPO@@and@@oral@@iron@@over@@1@@year@@lead@@to@@an@@improvement@@in@@LV@@systolic@@function@@,@@LV@@remodeling@@,@@BNP@@levels@@,@@and@@PAP@@compared@@with@@a@@control@@group@@in@@which@@only@@oral@@drug2@@was@@used@@.@@", "new_pair": "CHF@@,@@correction@@of@@anemia@@with@@EPO@@and@@oral@@iron@@over@@1@@year@@lead@@to@@an@@improvement@@in@@LV@@systolic@@function@@,@@LV@@remodeling@@,@@BNP@@levels@@,@@and@@PAP@@compared@@with@@a@@control@@group@@in@@which@@only@@oral@@iron", "replace_pair": "drug1@@,@@correction@@of@@anemia@@with@@EPO@@and@@oral@@iron@@over@@1@@year@@lead@@to@@an@@improvement@@in@@LV@@systolic@@function@@,@@LV@@remodeling@@,@@BNP@@levels@@,@@and@@PAP@@compared@@with@@a@@control@@group@@in@@which@@only@@oral@@drug2", "relation": "NA"}, {"head": {"id": "384", "type": "", "word": "GVHD", "begin": "56", "end": "60", "new_begin": "64", "new_end": "68", "replace_begin": "64", "replace_end": "69"}, "tail": {"id": "385", "type": "", "word": "CSP", "begin": "95", "end": "98", "new_begin": "110", "new_end": "113", "replace_begin": "111", "replace_end": "116"}, "sentence": "Although a significant improvement in the prevention of GVHD was not suggested , compared with CSP and MTX , MMF in combination with CSP could be considered in cases in which MTX is contraindicated .", "new_sentence": "Although@@a@@significant@@improvement@@in@@the@@prevention@@of@@GVHD@@was@@not@@suggested@@,@@compared@@with@@CSP@@and@@MTX@@,@@MMF@@in@@combination@@with@@CSP@@could@@be@@considered@@in@@cases@@in@@which@@MTX@@is@@contraindicated@@.@@", "replace_sentence": "Although@@a@@significant@@improvement@@in@@the@@prevention@@of@@drug1@@was@@not@@suggested@@,@@compared@@with@@drug2@@and@@MTX@@,@@MMF@@in@@combination@@with@@CSP@@could@@be@@considered@@in@@cases@@in@@which@@MTX@@is@@contraindicated@@.@@", "new_pair": "GVHD@@was@@not@@suggested@@,@@compared@@with@@CSP", "replace_pair": "drug1@@was@@not@@suggested@@,@@compared@@with@@drug2", "relation": "may_prevent"}, {"head": {"id": "386", "type": "", "word": "fluoride", "begin": "33", "end": "41", "new_begin": "38", "new_end": "46", "replace_begin": "38", "replace_end": "43"}, "tail": {"id": "387", "type": "", "word": "caries", "begin": "145", "end": "151", "new_begin": "166", "new_end": "172", "replace_begin": "163", "replace_end": "168"}, "sentence": "CONCLUSIONS : Even prophylaxis , fluoride gel application and complete surgical treatment of caries at baseline were insufficient to prevent new caries in over 60 % of the patients in these high caries risk infants .", "new_sentence": "CONCLUSIONS@@:@@Even@@prophylaxis@@,@@fluoride@@gel@@application@@and@@complete@@surgical@@treatment@@of@@caries@@at@@baseline@@were@@insufficient@@to@@prevent@@new@@caries@@in@@over@@60@@%@@of@@the@@patients@@in@@these@@high@@caries@@risk@@infants@@.@@", "replace_sentence": "CONCLUSIONS@@:@@Even@@prophylaxis@@,@@drug1@@gel@@application@@and@@complete@@surgical@@treatment@@of@@caries@@at@@baseline@@were@@insufficient@@to@@prevent@@new@@drug2@@in@@over@@60@@%@@of@@the@@patients@@in@@these@@high@@caries@@risk@@infants@@.@@", "new_pair": "fluoride@@gel@@application@@and@@complete@@surgical@@treatment@@of@@caries@@at@@baseline@@were@@insufficient@@to@@prevent@@new@@caries", "replace_pair": "drug1@@gel@@application@@and@@complete@@surgical@@treatment@@of@@caries@@at@@baseline@@were@@insufficient@@to@@prevent@@new@@drug2", "relation": "NA"}, {"head": {"id": "388", "type": "", "word": "iron", "begin": "102", "end": "106", "new_begin": "117", "new_end": "121", "replace_begin": "117", "replace_end": "122"}, "tail": {"id": "389", "type": "", "word": "HIVUinfection", "begin": "119", "end": "132", "new_begin": "137", "new_end": "150", "replace_begin": "138", "replace_end": "143"}, "sentence": "CONCLUSION : Prevention of infantile anemia should include efforts to increase the birth endowment of iron and prevent HIVUinfection .", "new_sentence": "CONCLUSION@@:@@Prevention@@of@@infantile@@anemia@@should@@include@@efforts@@to@@increase@@the@@birth@@endowment@@of@@iron@@and@@prevent@@HIVUinfection@@.@@", "replace_sentence": "CONCLUSION@@:@@Prevention@@of@@infantile@@anemia@@should@@include@@efforts@@to@@increase@@the@@birth@@endowment@@of@@drug1@@and@@prevent@@drug2@@.@@", "new_pair": "iron@@and@@prevent@@HIVUinfection", "replace_pair": "drug1@@and@@prevent@@drug2", "relation": "NA"}, {"head": {"id": "390", "type": "", "word": "AIR", "begin": "84", "end": "87", "new_begin": "98", "new_end": "101", "replace_begin": "98", "replace_end": "103"}, "tail": {"id": "391", "type": "", "word": "MEL", "begin": "90", "end": "93", "new_begin": "106", "new_end": "109", "replace_begin": "108", "replace_end": "113"}, "sentence": "Treating rat with MEL significantly decreased MDA levels as well as MPO activity in AIR + MEL group when compared to AIR group ( P < 0 . 05 ) .", "new_sentence": "Treating@@rat@@with@@MEL@@significantly@@decreased@@MDA@@levels@@as@@well@@as@@MPO@@activity@@in@@AIR@@+@@MEL@@group@@when@@compared@@to@@AIR@@group@@(@@P@@<@@0@@.@@05@@)@@.@@", "replace_sentence": "Treating@@rat@@with@@MEL@@significantly@@decreased@@MDA@@levels@@as@@well@@as@@MPO@@activity@@in@@drug1@@+@@drug2@@group@@when@@compared@@to@@AIR@@group@@(@@P@@<@@0@@.@@05@@)@@.@@", "new_pair": "AIR@@+@@MEL", "replace_pair": "drug1@@+@@drug2", "relation": "NA"}, {"head": {"id": "392", "type": "", "word": "aspirin", "begin": "35", "end": "42", "new_begin": "41", "new_end": "48", "replace_begin": "41", "replace_end": "46"}, "tail": {"id": "393", "type": "", "word": "myocardialUinfarction", "begin": "77", "end": "98", "new_begin": "92", "new_end": "113", "replace_begin": "90", "replace_end": "95"}, "sentence": "In men the primary prevention with aspirin reduced the risk of a non - fatal myocardialUinfarction with an annual numbers needed to treat of about 670 .", "new_sentence": "In@@men@@the@@primary@@prevention@@with@@aspirin@@reduced@@the@@risk@@of@@a@@non@@-@@fatal@@myocardialUinfarction@@with@@an@@annual@@numbers@@needed@@to@@treat@@of@@about@@670@@.@@", "replace_sentence": "In@@men@@the@@primary@@prevention@@with@@drug1@@reduced@@the@@risk@@of@@a@@non@@-@@fatal@@drug2@@with@@an@@annual@@numbers@@needed@@to@@treat@@of@@about@@670@@.@@", "new_pair": "aspirin@@reduced@@the@@risk@@of@@a@@non@@-@@fatal@@myocardialUinfarction", "replace_pair": "drug1@@reduced@@the@@risk@@of@@a@@non@@-@@fatal@@drug2", "relation": "may_prevent"}, {"head": {"id": "394", "type": "", "word": "cyclosporine", "begin": "53", "end": "65", "new_begin": "61", "new_end": "73", "replace_begin": "61", "replace_end": "66"}, "tail": {"id": "395", "type": "", "word": "graft-versus-hostUdisease", "begin": "292", "end": "317", "new_begin": "340", "new_end": "365", "replace_begin": "333", "replace_end": "338"}, "sentence": "We retrospectively evaluated the effect of the blood cyclosporine ( CsA ) concentration on the outcome of allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor in 171 patients who received a continuous infusion of CsA and short - course methotrexate to prevent graft-versus-hostUdisease ( GVHD ) .", "new_sentence": "We@@retrospectively@@evaluated@@the@@effect@@of@@the@@blood@@cyclosporine@@(@@CsA@@)@@concentration@@on@@the@@outcome@@of@@allogeneic@@hematopoietic@@stem@@cell@@transplantation@@from@@an@@HLA@@-@@matched@@sibling@@donor@@in@@171@@patients@@who@@received@@a@@continuous@@infusion@@of@@CsA@@and@@short@@-@@course@@methotrexate@@to@@prevent@@graft-versus-hostUdisease@@(@@GVHD@@)@@.@@", "replace_sentence": "We@@retrospectively@@evaluated@@the@@effect@@of@@the@@blood@@drug1@@(@@CsA@@)@@concentration@@on@@the@@outcome@@of@@allogeneic@@hematopoietic@@stem@@cell@@transplantation@@from@@an@@HLA@@-@@matched@@sibling@@donor@@in@@171@@patients@@who@@received@@a@@continuous@@infusion@@of@@CsA@@and@@short@@-@@course@@methotrexate@@to@@prevent@@drug2@@(@@GVHD@@)@@.@@", "new_pair": "cyclosporine@@(@@CsA@@)@@concentration@@on@@the@@outcome@@of@@allogeneic@@hematopoietic@@stem@@cell@@transplantation@@from@@an@@HLA@@-@@matched@@sibling@@donor@@in@@171@@patients@@who@@received@@a@@continuous@@infusion@@of@@CsA@@and@@short@@-@@course@@methotrexate@@to@@prevent@@graft-versus-hostUdisease", "replace_pair": "drug1@@(@@CsA@@)@@concentration@@on@@the@@outcome@@of@@allogeneic@@hematopoietic@@stem@@cell@@transplantation@@from@@an@@HLA@@-@@matched@@sibling@@donor@@in@@171@@patients@@who@@received@@a@@continuous@@infusion@@of@@CsA@@and@@short@@-@@course@@methotrexate@@to@@prevent@@drug2", "relation": "NA"}, {"head": {"id": "396", "type": "", "word": "warfarin", "begin": "42", "end": "50", "new_begin": "50", "new_end": "58", "replace_begin": "50", "replace_end": "55"}, "tail": {"id": "397", "type": "", "word": "myocardialUinfarction", "begin": "168", "end": "189", "new_begin": "198", "new_end": "219", "replace_begin": "195", "replace_end": "200"}, "sentence": "PATIENTS : A total of 1435 outpatients on warfarin for a total of 1613 patient years , treated to prevent the target events recurrent venous thromboembolism ( VTE ) or myocardialUinfarction ( MI ) , and stroke in patients with atrial fibrillation ( AF ) or mechanical heart valves .", "new_sentence": "PATIENTS@@:@@A@@total@@of@@1435@@outpatients@@on@@warfarin@@for@@a@@total@@of@@1613@@patient@@years@@,@@treated@@to@@prevent@@the@@target@@events@@recurrent@@venous@@thromboembolism@@(@@VTE@@)@@or@@myocardialUinfarction@@(@@MI@@)@@,@@and@@stroke@@in@@patients@@with@@atrial@@fibrillation@@(@@AF@@)@@or@@mechanical@@heart@@valves@@.@@", "replace_sentence": "PATIENTS@@:@@A@@total@@of@@1435@@outpatients@@on@@drug1@@for@@a@@total@@of@@1613@@patient@@years@@,@@treated@@to@@prevent@@the@@target@@events@@recurrent@@venous@@thromboembolism@@(@@VTE@@)@@or@@drug2@@(@@MI@@)@@,@@and@@stroke@@in@@patients@@with@@atrial@@fibrillation@@(@@AF@@)@@or@@mechanical@@heart@@valves@@.@@", "new_pair": "warfarin@@for@@a@@total@@of@@1613@@patient@@years@@,@@treated@@to@@prevent@@the@@target@@events@@recurrent@@venous@@thromboembolism@@(@@VTE@@)@@or@@myocardialUinfarction", "replace_pair": "drug1@@for@@a@@total@@of@@1613@@patient@@years@@,@@treated@@to@@prevent@@the@@target@@events@@recurrent@@venous@@thromboembolism@@(@@VTE@@)@@or@@drug2", "relation": "may_prevent"}, {"head": {"id": "398", "type": "", "word": "azathioprine", "begin": "123", "end": "135", "new_begin": "142", "new_end": "154", "replace_begin": "142", "replace_end": "147"}, "tail": {"id": "399", "type": "", "word": "infections", "begin": "273", "end": "283", "new_begin": "322", "new_end": "332", "replace_begin": "315", "replace_end": "320"}, "sentence": "In addition , we discuss the evidence for Pneumocystis and other infections in IBD patients treated with corticosteroids , azathioprine @ 6-MP , biologic agents and other therapies , and we present the case for various antibiotic ( and antiviral ) regimens to prevent such infections .", "new_sentence": "In@@addition@@,@@we@@discuss@@the@@evidence@@for@@Pneumocystis@@and@@other@@infections@@in@@IBD@@patients@@treated@@with@@corticosteroids@@,@@azathioprine@@@@@6@@-@@MP@@,@@biologic@@agents@@and@@other@@therapies@@,@@and@@we@@present@@the@@case@@for@@various@@antibiotic@@(@@and@@antiviral@@)@@regimens@@to@@prevent@@such@@infections@@.@@", "replace_sentence": "In@@addition@@,@@we@@discuss@@the@@evidence@@for@@Pneumocystis@@and@@other@@infections@@in@@IBD@@patients@@treated@@with@@corticosteroids@@,@@drug1@@@@@6@@-@@MP@@,@@biologic@@agents@@and@@other@@therapies@@,@@and@@we@@present@@the@@case@@for@@various@@antibiotic@@(@@and@@antiviral@@)@@regimens@@to@@prevent@@such@@drug2@@.@@", "new_pair": "azathioprine@@@@@6@@-@@MP@@,@@biologic@@agents@@and@@other@@therapies@@,@@and@@we@@present@@the@@case@@for@@various@@antibiotic@@(@@and@@antiviral@@)@@regimens@@to@@prevent@@such@@infections", "replace_pair": "drug1@@@@@6@@-@@MP@@,@@biologic@@agents@@and@@other@@therapies@@,@@and@@we@@present@@the@@case@@for@@various@@antibiotic@@(@@and@@antiviral@@)@@regimens@@to@@prevent@@such@@drug2", "relation": "NA"}, {"head": {"id": "400", "type": "", "word": "ASA", "begin": "83", "end": "86", "new_begin": "99", "new_end": "102", "replace_begin": "99", "replace_end": "104"}, "tail": {"id": "401", "type": "", "word": "stroke", "begin": "104", "end": "110", "new_begin": "125", "new_end": "131", "replace_begin": "127", "replace_end": "132"}, "sentence": "A total of 33 stroke patients had to be treated with this combination , instead of ASA , to prevent one stroke .", "new_sentence": "A@@total@@of@@33@@stroke@@patients@@had@@to@@be@@treated@@with@@this@@combination@@,@@instead@@of@@ASA@@,@@to@@prevent@@one@@stroke@@.@@", "replace_sentence": "A@@total@@of@@33@@stroke@@patients@@had@@to@@be@@treated@@with@@this@@combination@@,@@instead@@of@@drug1@@,@@to@@prevent@@one@@drug2@@.@@", "new_pair": "ASA@@,@@to@@prevent@@one@@stroke", "replace_pair": "drug1@@,@@to@@prevent@@one@@drug2", "relation": "NA"}, {"head": {"id": "402", "type": "", "word": "caries", "begin": "121", "end": "127", "new_begin": "139", "new_end": "145", "replace_begin": "139", "replace_end": "144"}, "tail": {"id": "403", "type": "", "word": "fluoride", "begin": "136", "end": "144", "new_begin": "157", "new_end": "165", "replace_begin": "156", "replace_end": "161"}, "sentence": "to assess the relationship between fluorosis and the fluoride content of the drinking water and the relationship between caries and the fluoride content of the water ;", "new_sentence": "to@@assess@@the@@relationship@@between@@fluorosis@@and@@the@@fluoride@@content@@of@@the@@drinking@@water@@and@@the@@relationship@@between@@caries@@and@@the@@fluoride@@content@@of@@the@@water@@;@@", "replace_sentence": "to@@assess@@the@@relationship@@between@@fluorosis@@and@@the@@fluoride@@content@@of@@the@@drinking@@water@@and@@the@@relationship@@between@@drug1@@and@@the@@drug2@@content@@of@@the@@water@@;@@", "new_pair": "caries@@and@@the@@fluoride", "replace_pair": "drug1@@and@@the@@drug2", "relation": "NA"}, {"head": {"id": "404", "type": "", "word": "iron", "begin": "149", "end": "153", "new_begin": "174", "new_end": "178", "replace_begin": "174", "replace_end": "179"}, "tail": {"id": "405", "type": "", "word": "excessiveUiron", "begin": "176", "end": "190", "new_begin": "206", "new_end": "220", "replace_begin": "207", "replace_end": "212"}, "sentence": "Thus , for A549 cells , different mechanisms influencing IRP - IRE interaction allow ferritin translation in the presence of TfR mRNA to provide for iron needs and yet prevent excessiveUiron uptake .", "new_sentence": "Thus@@,@@for@@A549@@cells@@,@@different@@mechanisms@@influencing@@IRP@@-@@IRE@@interaction@@allow@@ferritin@@translation@@in@@the@@presence@@of@@TfR@@mRNA@@to@@provide@@for@@iron@@needs@@and@@yet@@prevent@@excessiveUiron@@uptake@@.@@", "replace_sentence": "Thus@@,@@for@@A549@@cells@@,@@different@@mechanisms@@influencing@@IRP@@-@@IRE@@interaction@@allow@@ferritin@@translation@@in@@the@@presence@@of@@TfR@@mRNA@@to@@provide@@for@@drug1@@needs@@and@@yet@@prevent@@drug2@@uptake@@.@@", "new_pair": "iron@@needs@@and@@yet@@prevent@@excessiveUiron", "replace_pair": "drug1@@needs@@and@@yet@@prevent@@drug2", "relation": "NA"}, {"head": {"id": "406", "type": "", "word": "GVHD", "begin": "0", "end": "4", "new_begin": "0", "new_end": "4", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "407", "type": "", "word": "cyclosporineUA", "begin": "56", "end": "70", "new_begin": "65", "new_end": "79", "replace_begin": "66", "replace_end": "71"}, "sentence": "GVHD prophylaxis consisted of 6- methylprednisolone and cyclosporineUA .", "new_sentence": "GVHD@@prophylaxis@@consisted@@of@@6@@-@@methylprednisolone@@and@@cyclosporineUA@@.@@", "replace_sentence": "drug1@@prophylaxis@@consisted@@of@@6@@-@@methylprednisolone@@and@@drug2@@.@@", "new_pair": "GVHD@@prophylaxis@@consisted@@of@@6@@-@@methylprednisolone@@and@@cyclosporineUA", "replace_pair": "drug1@@prophylaxis@@consisted@@of@@6@@-@@methylprednisolone@@and@@drug2", "relation": "may_prevent"}, {"head": {"id": "408", "type": "", "word": "hepatitisUBUimmuneUglobulin", "begin": "22", "end": "49", "new_begin": "25", "new_end": "52", "replace_begin": "25", "replace_end": "30"}, "tail": {"id": "409", "type": "", "word": "hepatitisUB", "begin": "110", "end": "121", "new_begin": "125", "new_end": "136", "replace_begin": "103", "replace_end": "108"}, "sentence": "BACKGROUND : Combined hepatitisUBUimmuneUglobulin ( HBIg ) and lamivudine in prophylaxis of the recurrence of hepatitisUB after liver transplantation has significantly improved the survival of HBsAg positive patients .", "new_sentence": "BACKGROUND@@:@@Combined@@hepatitisUBUimmuneUglobulin@@(@@HBIg@@)@@and@@lamivudine@@in@@prophylaxis@@of@@the@@recurrence@@of@@hepatitisUB@@after@@liver@@transplantation@@has@@significantly@@improved@@the@@survival@@of@@HBsAg@@positive@@patients@@.@@", "replace_sentence": "BACKGROUND@@:@@Combined@@drug1@@(@@HBIg@@)@@and@@lamivudine@@in@@prophylaxis@@of@@the@@recurrence@@of@@drug2@@after@@liver@@transplantation@@has@@significantly@@improved@@the@@survival@@of@@HBsAg@@positive@@patients@@.@@", "new_pair": "hepatitisUBUimmuneUglobulin@@(@@HBIg@@)@@and@@lamivudine@@in@@prophylaxis@@of@@the@@recurrence@@of@@hepatitisUB", "replace_pair": "drug1@@(@@HBIg@@)@@and@@lamivudine@@in@@prophylaxis@@of@@the@@recurrence@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "410", "type": "", "word": "clotrimazole", "begin": "176", "end": "188", "new_begin": "208", "new_end": "220", "replace_begin": "208", "replace_end": "213"}, "tail": {"id": "411", "type": "", "word": "mycosis", "begin": "374", "end": "381", "new_begin": "439", "new_end": "446", "replace_begin": "432", "replace_end": "437"}, "sentence": "Two topical formats containing clotrimazole ( 500 mg single dose vaginal tablet ( VT ) or 10 % single dose vaginal cream ( VC ) for intravaginal use ) combined with additional clotrimazole cream for topical application to the vulval area ( Canesten 1 Combi , Bayer AG , Leverkusen , Germany ) were compared with oral fluconazole 150 mg single dose treatment of vulvovaginal mycosis ( VVM ) in a single-blind clinical study .", "new_sentence": "Two@@topical@@formats@@containing@@clotrimazole@@(@@500@@mg@@single@@dose@@vaginal@@tablet@@(@@VT@@)@@or@@10@@%@@single@@dose@@vaginal@@cream@@(@@VC@@)@@for@@intravaginal@@use@@)@@combined@@with@@additional@@clotrimazole@@cream@@for@@topical@@application@@to@@the@@vulval@@area@@(@@Canesten@@1@@Combi@@,@@Bayer@@AG@@,@@Leverkusen@@,@@Germany@@)@@were@@compared@@with@@oral@@fluconazole@@150@@mg@@single@@dose@@treatment@@of@@vulvovaginal@@mycosis@@(@@VVM@@)@@in@@a@@single@@-@@blind@@clinical@@study@@.@@", "replace_sentence": "Two@@topical@@formats@@containing@@clotrimazole@@(@@500@@mg@@single@@dose@@vaginal@@tablet@@(@@VT@@)@@or@@10@@%@@single@@dose@@vaginal@@cream@@(@@VC@@)@@for@@intravaginal@@use@@)@@combined@@with@@additional@@drug1@@cream@@for@@topical@@application@@to@@the@@vulval@@area@@(@@Canesten@@1@@Combi@@,@@Bayer@@AG@@,@@Leverkusen@@,@@Germany@@)@@were@@compared@@with@@oral@@fluconazole@@150@@mg@@single@@dose@@treatment@@of@@vulvovaginal@@drug2@@(@@VVM@@)@@in@@a@@single@@-@@blind@@clinical@@study@@.@@", "new_pair": "clotrimazole@@cream@@for@@topical@@application@@to@@the@@vulval@@area@@(@@Canesten@@1@@Combi@@,@@Bayer@@AG@@,@@Leverkusen@@,@@Germany@@)@@were@@compared@@with@@oral@@fluconazole@@150@@mg@@single@@dose@@treatment@@of@@vulvovaginal@@mycosis", "replace_pair": "drug1@@cream@@for@@topical@@application@@to@@the@@vulval@@area@@(@@Canesten@@1@@Combi@@,@@Bayer@@AG@@,@@Leverkusen@@,@@Germany@@)@@were@@compared@@with@@oral@@fluconazole@@150@@mg@@single@@dose@@treatment@@of@@vulvovaginal@@drug2", "relation": "NA"}, {"head": {"id": "412", "type": "", "word": "CyclosporineUA", "begin": "0", "end": "14", "new_begin": "0", "new_end": "14", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "413", "type": "", "word": "graft-versus-hostUdisease", "begin": "73", "end": "98", "new_begin": "90", "new_end": "115", "replace_begin": "81", "replace_end": "86"}, "sentence": "CyclosporineUA ( CsA ) and short-term methotrexate ( MTX ) were used for graft-versus-hostUdisease prevention .", "new_sentence": "CyclosporineUA@@(@@CsA@@)@@and@@short@@-@@term@@methotrexate@@(@@MTX@@)@@were@@used@@for@@graft-versus-hostUdisease@@prevention@@.@@", "replace_sentence": "drug1@@(@@CsA@@)@@and@@short@@-@@term@@methotrexate@@(@@MTX@@)@@were@@used@@for@@drug2@@prevention@@.@@", "new_pair": "CyclosporineUA@@(@@CsA@@)@@and@@short@@-@@term@@methotrexate@@(@@MTX@@)@@were@@used@@for@@graft-versus-hostUdisease", "replace_pair": "drug1@@(@@CsA@@)@@and@@short@@-@@term@@methotrexate@@(@@MTX@@)@@were@@used@@for@@drug2", "relation": "may_prevent"}, {"head": {"id": "414", "type": "", "word": "aspirin", "begin": "6", "end": "13", "new_begin": "7", "new_end": "14", "replace_begin": "7", "replace_end": "12"}, "tail": {"id": "415", "type": "", "word": "myocardialUinfarction", "begin": "103", "end": "124", "new_begin": "120", "new_end": "141", "replace_begin": "118", "replace_end": "123"}, "sentence": "While aspirin as a first choice antiplatelet therapy cannot be discussed in coronary disease , after a myocardialUinfarction , or in cerebrovascular disease , its use in lower limb occlusive arterial disease does not enable a reduction in morbi- mortality .", "new_sentence": "While@@aspirin@@as@@a@@first@@choice@@antiplatelet@@therapy@@cannot@@be@@discussed@@in@@coronary@@disease@@,@@after@@a@@myocardialUinfarction@@,@@or@@in@@cerebrovascular@@disease@@,@@its@@use@@in@@lower@@limb@@occlusive@@arterial@@disease@@does@@not@@enable@@a@@reduction@@in@@morbi@@-@@mortality@@.@@", "replace_sentence": "While@@drug1@@as@@a@@first@@choice@@antiplatelet@@therapy@@cannot@@be@@discussed@@in@@coronary@@disease@@,@@after@@a@@drug2@@,@@or@@in@@cerebrovascular@@disease@@,@@its@@use@@in@@lower@@limb@@occlusive@@arterial@@disease@@does@@not@@enable@@a@@reduction@@in@@morbi@@-@@mortality@@.@@", "new_pair": "aspirin@@as@@a@@first@@choice@@antiplatelet@@therapy@@cannot@@be@@discussed@@in@@coronary@@disease@@,@@after@@a@@myocardialUinfarction", "replace_pair": "drug1@@as@@a@@first@@choice@@antiplatelet@@therapy@@cannot@@be@@discussed@@in@@coronary@@disease@@,@@after@@a@@drug2", "relation": "NA"}, {"head": {"id": "416", "type": "", "word": "MethenamineUhippurate", "begin": "0", "end": "21", "new_begin": "0", "new_end": "21", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "417", "type": "", "word": "urinaryUtractUinfections", "begin": "37", "end": "61", "new_begin": "40", "new_end": "64", "replace_begin": "24", "replace_end": "29"}, "sentence": "MethenamineUhippurate for preventing urinaryUtractUinfections .", "new_sentence": "MethenamineUhippurate@@for@@preventing@@urinaryUtractUinfections@@.@@", "replace_sentence": "drug1@@for@@preventing@@drug2@@.@@", "new_pair": "MethenamineUhippurate@@for@@preventing@@urinaryUtractUinfections", "replace_pair": "drug1@@for@@preventing@@drug2", "relation": "may_prevent"}, {"head": {"id": "418", "type": "", "word": "HIVUproteaseUinhibitors", "begin": "0", "end": "23", "new_begin": "0", "new_end": "23", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "419", "type": "", "word": "infectious", "begin": "79", "end": "89", "new_begin": "88", "new_end": "98", "replace_begin": "70", "replace_end": "75"}, "sentence": "HIVUproteaseUinhibitors are antiretroviral drugs able to prevent production of infectious particles .", "new_sentence": "HIVUproteaseUinhibitors@@are@@antiretroviral@@drugs@@able@@to@@prevent@@production@@of@@infectious@@particles@@.@@", "replace_sentence": "drug1@@are@@antiretroviral@@drugs@@able@@to@@prevent@@production@@of@@drug2@@particles@@.@@", "new_pair": "HIVUproteaseUinhibitors@@are@@antiretroviral@@drugs@@able@@to@@prevent@@production@@of@@infectious", "replace_pair": "drug1@@are@@antiretroviral@@drugs@@able@@to@@prevent@@production@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "420", "type": "", "word": "MyocardialUinfarction", "begin": "0", "end": "21", "new_begin": "0", "new_end": "21", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "421", "type": "", "word": "aspirin", "begin": "28", "end": "35", "new_begin": "30", "new_end": "37", "replace_begin": "14", "replace_end": "19"}, "sentence": "MyocardialUinfarction after aspirin treatment , and Kounis syndrome .", "new_sentence": "MyocardialUinfarction@@after@@aspirin@@treatment@@,@@and@@Kounis@@syndrome@@.@@", "replace_sentence": "drug1@@after@@drug2@@treatment@@,@@and@@Kounis@@syndrome@@.@@", "new_pair": "MyocardialUinfarction@@after@@aspirin", "replace_pair": "drug1@@after@@drug2", "relation": "NA"}, {"head": {"id": "422", "type": "", "word": "pulmonaryUembolism", "begin": "57", "end": "75", "new_begin": "71", "new_end": "89", "replace_begin": "71", "replace_end": "76"}, "tail": {"id": "423", "type": "", "word": "lepirudin", "begin": "250", "end": "259", "new_begin": "292", "new_end": "301", "replace_begin": "279", "replace_end": "284"}, "sentence": "We report the case of 64- year - old female patient with pulmonaryUembolism and bilateral femoropopliteal deep vein thrombosis caused by heparin-induced thrombocytopenia type II ( HIT II ) resistant to danaparoid sodium and subsequently administered lepirudin in whom a single late plasmapheresis performed on day 6 of the initiation of treatment of HIT reversed the course of the disease , preventing its highly potential fatal outcome .", "new_sentence": "We@@report@@the@@case@@of@@64@@-@@year@@-@@old@@female@@patient@@with@@pulmonaryUembolism@@and@@bilateral@@femoropopliteal@@deep@@vein@@thrombosis@@caused@@by@@heparin@@-@@induced@@thrombocytopenia@@type@@II@@(@@HIT@@II@@)@@resistant@@to@@danaparoid@@sodium@@and@@subsequently@@administered@@lepirudin@@in@@whom@@a@@single@@late@@plasmapheresis@@performed@@on@@day@@6@@of@@the@@initiation@@of@@treatment@@of@@HIT@@reversed@@the@@course@@of@@the@@disease@@,@@preventing@@its@@highly@@potential@@fatal@@outcome@@.@@", "replace_sentence": "We@@report@@the@@case@@of@@64@@-@@year@@-@@old@@female@@patient@@with@@drug1@@and@@bilateral@@femoropopliteal@@deep@@vein@@thrombosis@@caused@@by@@heparin@@-@@induced@@thrombocytopenia@@type@@II@@(@@HIT@@II@@)@@resistant@@to@@danaparoid@@sodium@@and@@subsequently@@administered@@drug2@@in@@whom@@a@@single@@late@@plasmapheresis@@performed@@on@@day@@6@@of@@the@@initiation@@of@@treatment@@of@@HIT@@reversed@@the@@course@@of@@the@@disease@@,@@preventing@@its@@highly@@potential@@fatal@@outcome@@.@@", "new_pair": "pulmonaryUembolism@@and@@bilateral@@femoropopliteal@@deep@@vein@@thrombosis@@caused@@by@@heparin@@-@@induced@@thrombocytopenia@@type@@II@@(@@HIT@@II@@)@@resistant@@to@@danaparoid@@sodium@@and@@subsequently@@administered@@lepirudin", "replace_pair": "drug1@@and@@bilateral@@femoropopliteal@@deep@@vein@@thrombosis@@caused@@by@@heparin@@-@@induced@@thrombocytopenia@@type@@II@@(@@HIT@@II@@)@@resistant@@to@@danaparoid@@sodium@@and@@subsequently@@administered@@drug2", "relation": "NA"}, {"head": {"id": "424", "type": "", "word": "caries", "begin": "103", "end": "109", "new_begin": "119", "new_end": "125", "replace_begin": "119", "replace_end": "124"}, "tail": {"id": "425", "type": "", "word": "fluoride", "begin": "133", "end": "141", "new_begin": "154", "new_end": "162", "replace_begin": "153", "replace_end": "158"}, "sentence": "There are still important questions open that need to be answered despite existing knowledge about the caries - preventive effect of fluoride .", "new_sentence": "There@@are@@still@@important@@questions@@open@@that@@need@@to@@be@@answered@@despite@@existing@@knowledge@@about@@the@@caries@@-@@preventive@@effect@@of@@fluoride@@.@@", "replace_sentence": "There@@are@@still@@important@@questions@@open@@that@@need@@to@@be@@answered@@despite@@existing@@knowledge@@about@@the@@drug1@@-@@preventive@@effect@@of@@drug2@@.@@", "new_pair": "caries@@-@@preventive@@effect@@of@@fluoride", "replace_pair": "drug1@@-@@preventive@@effect@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "426", "type": "", "word": "HumanURabiesUImmuneUGlobulin", "begin": "12", "end": "40", "new_begin": "14", "new_end": "42", "replace_begin": "14", "replace_end": "19"}, "tail": {"id": "427", "type": "", "word": "rabies", "begin": "90", "end": "96", "new_begin": "105", "new_end": "111", "replace_begin": "82", "replace_end": "87"}, "sentence": "Even though HumanURabiesUImmuneUGlobulin ( HRIG ) is the ideal product for post- exposure rabies treatment it , like most biological , can cause very rare adverse reactions .", "new_sentence": "Even@@though@@HumanURabiesUImmuneUGlobulin@@(@@HRIG@@)@@is@@the@@ideal@@product@@for@@post@@-@@exposure@@rabies@@treatment@@it@@,@@like@@most@@biological@@,@@can@@cause@@very@@rare@@adverse@@reactions@@.@@", "replace_sentence": "Even@@though@@drug1@@(@@HRIG@@)@@is@@the@@ideal@@product@@for@@post@@-@@exposure@@drug2@@treatment@@it@@,@@like@@most@@biological@@,@@can@@cause@@very@@rare@@adverse@@reactions@@.@@", "new_pair": "HumanURabiesUImmuneUGlobulin@@(@@HRIG@@)@@is@@the@@ideal@@product@@for@@post@@-@@exposure@@rabies", "replace_pair": "drug1@@(@@HRIG@@)@@is@@the@@ideal@@product@@for@@post@@-@@exposure@@drug2", "relation": "NA"}, {"head": {"id": "428", "type": "", "word": "L-arginine", "begin": "0", "end": "10", "new_begin": "0", "new_end": "10", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "429", "type": "", "word": "ischemia", "begin": "119", "end": "127", "new_begin": "134", "new_end": "142", "replace_begin": "129", "replace_end": "134"}, "sentence": "L-arginine administration attenuated cardio - and hemodynamic disturbances , that substantially improved the course of ischemia @ reperfusion , diminished the ultrastructural changes in myocardium and prevented development of autophagic programmed cell death .", "new_sentence": "L-arginine@@administration@@attenuated@@cardio@@-@@and@@hemodynamic@@disturbances@@,@@that@@substantially@@improved@@the@@course@@of@@ischemia@@@@@reperfusion@@,@@diminished@@the@@ultrastructural@@changes@@in@@myocardium@@and@@prevented@@development@@of@@autophagic@@programmed@@cell@@death@@.@@", "replace_sentence": "drug1@@administration@@attenuated@@cardio@@-@@and@@hemodynamic@@disturbances@@,@@that@@substantially@@improved@@the@@course@@of@@drug2@@@@@reperfusion@@,@@diminished@@the@@ultrastructural@@changes@@in@@myocardium@@and@@prevented@@development@@of@@autophagic@@programmed@@cell@@death@@.@@", "new_pair": "L-arginine@@administration@@attenuated@@cardio@@-@@and@@hemodynamic@@disturbances@@,@@that@@substantially@@improved@@the@@course@@of@@ischemia", "replace_pair": "drug1@@administration@@attenuated@@cardio@@-@@and@@hemodynamic@@disturbances@@,@@that@@substantially@@improved@@the@@course@@of@@drug2", "relation": "NA"}, {"head": {"id": "430", "type": "", "word": "osteoporosis", "begin": "30", "end": "42", "new_begin": "35", "new_end": "47", "replace_begin": "35", "replace_end": "40"}, "tail": {"id": "431", "type": "", "word": "risedronate", "begin": "68", "end": "79", "new_begin": "78", "new_end": "89", "replace_begin": "71", "replace_end": "76"}, "sentence": "To prevent the progression of osteoporosis , oral administration of risedronate and alfacalcidol was started for this patient .", "new_sentence": "To@@prevent@@the@@progression@@of@@osteoporosis@@,@@oral@@administration@@of@@risedronate@@and@@alfacalcidol@@was@@started@@for@@this@@patient@@.@@", "replace_sentence": "To@@prevent@@the@@progression@@of@@drug1@@,@@oral@@administration@@of@@drug2@@and@@alfacalcidol@@was@@started@@for@@this@@patient@@.@@", "new_pair": "osteoporosis@@,@@oral@@administration@@of@@risedronate", "replace_pair": "drug1@@,@@oral@@administration@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "432", "type": "", "word": "aspirin", "begin": "50", "end": "57", "new_begin": "57", "new_end": "64", "replace_begin": "57", "replace_end": "62"}, "tail": {"id": "433", "type": "", "word": "myocardialUinfarction", "begin": "102", "end": "123", "new_begin": "117", "new_end": "138", "replace_begin": "115", "replace_end": "120"}, "sentence": "Clinical trials have demonstrated the efficacy of aspirin in both primary and secondary prevention of myocardialUinfarction , stroke , and cardiovascular death .", "new_sentence": "Clinical@@trials@@have@@demonstrated@@the@@efficacy@@of@@aspirin@@in@@both@@primary@@and@@secondary@@prevention@@of@@myocardialUinfarction@@,@@stroke@@,@@and@@cardiovascular@@death@@.@@", "replace_sentence": "Clinical@@trials@@have@@demonstrated@@the@@efficacy@@of@@drug1@@in@@both@@primary@@and@@secondary@@prevention@@of@@drug2@@,@@stroke@@,@@and@@cardiovascular@@death@@.@@", "new_pair": "aspirin@@in@@both@@primary@@and@@secondary@@prevention@@of@@myocardialUinfarction", "replace_pair": "drug1@@in@@both@@primary@@and@@secondary@@prevention@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "434", "type": "", "word": "mefloquine", "begin": "31", "end": "41", "new_begin": "34", "new_end": "44", "replace_begin": "34", "replace_end": "39"}, "tail": {"id": "435", "type": "", "word": "malaria", "begin": "88", "end": "95", "new_begin": "98", "new_end": "105", "replace_begin": "93", "replace_end": "98"}, "sentence": "Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment .", "new_sentence": "Population@@pharmacokinetics@@of@@mefloquine@@in@@military@@personnel@@for@@prophylaxis@@against@@malaria@@infection@@during@@field@@deployment@@.@@", "replace_sentence": "Population@@pharmacokinetics@@of@@drug1@@in@@military@@personnel@@for@@prophylaxis@@against@@drug2@@infection@@during@@field@@deployment@@.@@", "new_pair": "mefloquine@@in@@military@@personnel@@for@@prophylaxis@@against@@malaria", "replace_pair": "drug1@@in@@military@@personnel@@for@@prophylaxis@@against@@drug2", "relation": "may_prevent"}, {"head": {"id": "436", "type": "", "word": "triamcinoloneUacetonide", "begin": "13", "end": "36", "new_begin": "14", "new_end": "37", "replace_begin": "14", "replace_end": "19"}, "tail": {"id": "437", "type": "", "word": "cystoidUmacularUedema", "begin": "41", "end": "62", "new_begin": "44", "new_end": "65", "replace_begin": "26", "replace_end": "31"}, "sentence": "Intravitreal triamcinoloneUacetonide for cystoidUmacularUedema in nonischemic central retinal vein occlusion .", "new_sentence": "Intravitreal@@triamcinoloneUacetonide@@for@@cystoidUmacularUedema@@in@@nonischemic@@central@@retinal@@vein@@occlusion@@.@@", "replace_sentence": "Intravitreal@@drug1@@for@@drug2@@in@@nonischemic@@central@@retinal@@vein@@occlusion@@.@@", "new_pair": "triamcinoloneUacetonide@@for@@cystoidUmacularUedema", "replace_pair": "drug1@@for@@drug2", "relation": "NA"}, {"head": {"id": "438", "type": "", "word": "clopidogrel", "begin": "39", "end": "50", "new_begin": "48", "new_end": "59", "replace_begin": "48", "replace_end": "53"}, "tail": {"id": "439", "type": "", "word": "stroke", "begin": "228", "end": "234", "new_begin": "278", "new_end": "284", "replace_begin": "272", "replace_end": "277"}, "sentence": "Five agents -- aspirin , ticlopidine , clopidogrel , extended-release dipyridamole ( ER-DP ) , and triflusal --have demonstrated efficacy in large - scale clinical studies in the prevention of recurrent vascular events and @ or stroke in patients with a history of stroke .", "new_sentence": "Five@@agents@@-@@-@@aspirin@@,@@ticlopidine@@,@@clopidogrel@@,@@extended@@-@@release@@dipyridamole@@(@@ER@@-@@DP@@)@@,@@and@@triflusal@@-@@-@@have@@demonstrated@@efficacy@@in@@large@@-@@scale@@clinical@@studies@@in@@the@@prevention@@of@@recurrent@@vascular@@events@@and@@@@@or@@stroke@@in@@patients@@with@@a@@history@@of@@stroke@@.@@", "replace_sentence": "Five@@agents@@-@@-@@aspirin@@,@@ticlopidine@@,@@drug1@@,@@extended@@-@@release@@dipyridamole@@(@@ER@@-@@DP@@)@@,@@and@@triflusal@@-@@-@@have@@demonstrated@@efficacy@@in@@large@@-@@scale@@clinical@@studies@@in@@the@@prevention@@of@@recurrent@@vascular@@events@@and@@@@@or@@drug2@@in@@patients@@with@@a@@history@@of@@stroke@@.@@", "new_pair": "clopidogrel@@,@@extended@@-@@release@@dipyridamole@@(@@ER@@-@@DP@@)@@,@@and@@triflusal@@-@@-@@have@@demonstrated@@efficacy@@in@@large@@-@@scale@@clinical@@studies@@in@@the@@prevention@@of@@recurrent@@vascular@@events@@and@@@@@or@@stroke", "replace_pair": "drug1@@,@@extended@@-@@release@@dipyridamole@@(@@ER@@-@@DP@@)@@,@@and@@triflusal@@-@@-@@have@@demonstrated@@efficacy@@in@@large@@-@@scale@@clinical@@studies@@in@@the@@prevention@@of@@recurrent@@vascular@@events@@and@@@@@or@@drug2", "relation": "may_prevent"}, {"head": {"id": "440", "type": "", "word": "fluoride", "begin": "113", "end": "121", "new_begin": "127", "new_end": "135", "replace_begin": "127", "replace_end": "132"}, "tail": {"id": "441", "type": "", "word": "caries", "begin": "220", "end": "226", "new_begin": "249", "new_end": "255", "replace_begin": "246", "replace_end": "251"}, "sentence": "Several studies conducted in fluoridated and nonfluoridated communities suggested that this method of delivering fluoride may be unnecessary for caries prevention , particularly in the industrialized countries where the caries level has became low .", "new_sentence": "Several@@studies@@conducted@@in@@fluoridated@@and@@nonfluoridated@@communities@@suggested@@that@@this@@method@@of@@delivering@@fluoride@@may@@be@@unnecessary@@for@@caries@@prevention@@,@@particularly@@in@@the@@industrialized@@countries@@where@@the@@caries@@level@@has@@became@@low@@.@@", "replace_sentence": "Several@@studies@@conducted@@in@@fluoridated@@and@@nonfluoridated@@communities@@suggested@@that@@this@@method@@of@@delivering@@drug1@@may@@be@@unnecessary@@for@@caries@@prevention@@,@@particularly@@in@@the@@industrialized@@countries@@where@@the@@drug2@@level@@has@@became@@low@@.@@", "new_pair": "fluoride@@may@@be@@unnecessary@@for@@caries@@prevention@@,@@particularly@@in@@the@@industrialized@@countries@@where@@the@@caries", "replace_pair": "drug1@@may@@be@@unnecessary@@for@@caries@@prevention@@,@@particularly@@in@@the@@industrialized@@countries@@where@@the@@drug2", "relation": "NA"}, {"head": {"id": "442", "type": "", "word": "perindopril", "begin": "99", "end": "110", "new_begin": "122", "new_end": "133", "replace_begin": "122", "replace_end": "127"}, "tail": {"id": "443", "type": "", "word": "hyperlipidemia", "begin": "254", "end": "268", "new_begin": "306", "new_end": "320", "replace_begin": "300", "replace_end": "305"}, "sentence": "We thus investigated the long-term effects of an angiotensin-converting enzyme ( ACE ) inhibitor ( perindopril ) @ diuretic ( indapamide ) combination ( per @ ind ) in the Zucker rat , a classical model of chronic renal failure associated with obesity , hyperlipidemia , and insulin resistance .", "new_sentence": "We@@thus@@investigated@@the@@long@@-@@term@@effects@@of@@an@@angiotensin@@-@@converting@@enzyme@@(@@ACE@@)@@inhibitor@@(@@perindopril@@)@@@@@diuretic@@(@@indapamide@@)@@combination@@(@@per@@@@@ind@@)@@in@@the@@Zucker@@rat@@,@@a@@classical@@model@@of@@chronic@@renal@@failure@@associated@@with@@obesity@@,@@hyperlipidemia@@,@@and@@insulin@@resistance@@.@@", "replace_sentence": "We@@thus@@investigated@@the@@long@@-@@term@@effects@@of@@an@@angiotensin@@-@@converting@@enzyme@@(@@ACE@@)@@inhibitor@@(@@drug1@@)@@@@@diuretic@@(@@indapamide@@)@@combination@@(@@per@@@@@ind@@)@@in@@the@@Zucker@@rat@@,@@a@@classical@@model@@of@@chronic@@renal@@failure@@associated@@with@@obesity@@,@@drug2@@,@@and@@insulin@@resistance@@.@@", "new_pair": "perindopril@@)@@@@@diuretic@@(@@indapamide@@)@@combination@@(@@per@@@@@ind@@)@@in@@the@@Zucker@@rat@@,@@a@@classical@@model@@of@@chronic@@renal@@failure@@associated@@with@@obesity@@,@@hyperlipidemia", "replace_pair": "drug1@@)@@@@@diuretic@@(@@indapamide@@)@@combination@@(@@per@@@@@ind@@)@@in@@the@@Zucker@@rat@@,@@a@@classical@@model@@of@@chronic@@renal@@failure@@associated@@with@@obesity@@,@@drug2", "relation": "NA"}, {"head": {"id": "444", "type": "", "word": "hypothyroidism", "begin": "39", "end": "53", "new_begin": "47", "new_end": "61", "replace_begin": "47", "replace_end": "52"}, "tail": {"id": "445", "type": "", "word": "carnitine", "begin": "79", "end": "88", "new_begin": "95", "new_end": "104", "replace_begin": "86", "replace_end": "91"}, "sentence": "Weakness is common in both hyper - and hypothyroidism , and skeletal muscle L- carnitine may play a role in this regard , as suggested by studies indicating abnormal levels of carnitine in serum and urine of patients with thyroid dysfunction .", "new_sentence": "Weakness@@is@@common@@in@@both@@hyper@@-@@and@@hypothyroidism@@,@@and@@skeletal@@muscle@@L@@-@@carnitine@@may@@play@@a@@role@@in@@this@@regard@@,@@as@@suggested@@by@@studies@@indicating@@abnormal@@levels@@of@@carnitine@@in@@serum@@and@@urine@@of@@patients@@with@@thyroid@@dysfunction@@.@@", "replace_sentence": "Weakness@@is@@common@@in@@both@@hyper@@-@@and@@drug1@@,@@and@@skeletal@@muscle@@L@@-@@drug2@@may@@play@@a@@role@@in@@this@@regard@@,@@as@@suggested@@by@@studies@@indicating@@abnormal@@levels@@of@@carnitine@@in@@serum@@and@@urine@@of@@patients@@with@@thyroid@@dysfunction@@.@@", "new_pair": "hypothyroidism@@,@@and@@skeletal@@muscle@@L@@-@@carnitine", "replace_pair": "drug1@@,@@and@@skeletal@@muscle@@L@@-@@drug2", "relation": "NA"}, {"head": {"id": "446", "type": "", "word": "Graft-versus-hostUdisease", "begin": "0", "end": "25", "new_begin": "0", "new_end": "25", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "447", "type": "", "word": "cyclosporine", "begin": "51", "end": "63", "new_begin": "55", "new_end": "67", "replace_begin": "35", "replace_end": "40"}, "sentence": "Graft-versus-hostUdisease prophylaxis consisted of cyclosporine plus methotrexate or prednisolone .", "new_sentence": "Graft-versus-hostUdisease@@prophylaxis@@consisted@@of@@cyclosporine@@plus@@methotrexate@@or@@prednisolone@@.@@", "replace_sentence": "drug1@@prophylaxis@@consisted@@of@@drug2@@plus@@methotrexate@@or@@prednisolone@@.@@", "new_pair": "Graft-versus-hostUdisease@@prophylaxis@@consisted@@of@@cyclosporine", "replace_pair": "drug1@@prophylaxis@@consisted@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "448", "type": "", "word": "hepatitisUBUimmunoglobulin", "begin": "52", "end": "78", "new_begin": "74", "new_end": "100", "replace_begin": "74", "replace_end": "79"}, "tail": {"id": "449", "type": "", "word": "hepatitisUB", "begin": "122", "end": "133", "new_begin": "150", "new_end": "161", "replace_begin": "129", "replace_end": "134"}, "sentence": "Short-term high-dose followed by long-term low-dose hepatitisUBUimmunoglobulin and lamivudine therapy prevented recurrent hepatitisUB after liver transplantation .", "new_sentence": "Short@@-@@term@@high@@-@@dose@@followed@@by@@long@@-@@term@@low@@-@@dose@@hepatitisUBUimmunoglobulin@@and@@lamivudine@@therapy@@prevented@@recurrent@@hepatitisUB@@after@@liver@@transplantation@@.@@", "replace_sentence": "Short@@-@@term@@high@@-@@dose@@followed@@by@@long@@-@@term@@low@@-@@dose@@drug1@@and@@lamivudine@@therapy@@prevented@@recurrent@@drug2@@after@@liver@@transplantation@@.@@", "new_pair": "hepatitisUBUimmunoglobulin@@and@@lamivudine@@therapy@@prevented@@recurrent@@hepatitisUB", "replace_pair": "drug1@@and@@lamivudine@@therapy@@prevented@@recurrent@@drug2", "relation": "may_prevent"}, {"head": {"id": "450", "type": "", "word": "fluoride", "begin": "226", "end": "234", "new_begin": "279", "new_end": "287", "replace_begin": "279", "replace_end": "284"}, "tail": {"id": "451", "type": "", "word": "caries", "begin": "262", "end": "268", "new_begin": "320", "new_end": "326", "replace_begin": "317", "replace_end": "322"}, "sentence": "Almost all ( 89 % ) prescribed fluoride supplements and those younger ( p = 0 . 016 ) , with a higher number of patients seen in workday ( p = 0 . 001 ) , with longer practice activity ( p = 0 . 004 ) , those who believe that fluoride is effective in preventing caries ( p < 0 . 0001 ) , and who learned about prevention from scientific sources ( p = 0 . 002 ) were more likely to prescribe fluoride .", "new_sentence": "Almost@@all@@(@@89@@%@@)@@prescribed@@fluoride@@supplements@@and@@those@@younger@@(@@p@@=@@0@@.@@016@@)@@,@@with@@a@@higher@@number@@of@@patients@@seen@@in@@workday@@(@@p@@=@@0@@.@@001@@)@@,@@with@@longer@@practice@@activity@@(@@p@@=@@0@@.@@004@@)@@,@@those@@who@@believe@@that@@fluoride@@is@@effective@@in@@preventing@@caries@@(@@p@@<@@0@@.@@0001@@)@@,@@and@@who@@learned@@about@@prevention@@from@@scientific@@sources@@(@@p@@=@@0@@.@@002@@)@@were@@more@@likely@@to@@prescribe@@fluoride@@.@@", "replace_sentence": "Almost@@all@@(@@89@@%@@)@@prescribed@@fluoride@@supplements@@and@@those@@younger@@(@@p@@=@@0@@.@@016@@)@@,@@with@@a@@higher@@number@@of@@patients@@seen@@in@@workday@@(@@p@@=@@0@@.@@001@@)@@,@@with@@longer@@practice@@activity@@(@@p@@=@@0@@.@@004@@)@@,@@those@@who@@believe@@that@@drug1@@is@@effective@@in@@preventing@@drug2@@(@@p@@<@@0@@.@@0001@@)@@,@@and@@who@@learned@@about@@prevention@@from@@scientific@@sources@@(@@p@@=@@0@@.@@002@@)@@were@@more@@likely@@to@@prescribe@@fluoride@@.@@", "new_pair": "fluoride@@is@@effective@@in@@preventing@@caries", "replace_pair": "drug1@@is@@effective@@in@@preventing@@drug2", "relation": "NA"}, {"head": {"id": "452", "type": "", "word": "aspirin", "begin": "25", "end": "32", "new_begin": "30", "new_end": "37", "replace_begin": "30", "replace_end": "35"}, "tail": {"id": "453", "type": "", "word": "stroke", "begin": "156", "end": "162", "new_begin": "186", "new_end": "192", "replace_begin": "184", "replace_end": "189"}, "sentence": "Just because you can buy aspirin without a prescription ( and for pennies a tablet ) doesn t mean everyone should be taking it to prevent a heart attack or stroke .", "new_sentence": "Just@@because@@you@@can@@buy@@aspirin@@without@@a@@prescription@@(@@and@@for@@pennies@@a@@tablet@@)@@doesn@@t@@mean@@everyone@@should@@be@@taking@@it@@to@@prevent@@a@@heart@@attack@@or@@stroke@@.@@", "replace_sentence": "Just@@because@@you@@can@@buy@@drug1@@without@@a@@prescription@@(@@and@@for@@pennies@@a@@tablet@@)@@doesn@@t@@mean@@everyone@@should@@be@@taking@@it@@to@@prevent@@a@@heart@@attack@@or@@drug2@@.@@", "new_pair": "aspirin@@without@@a@@prescription@@(@@and@@for@@pennies@@a@@tablet@@)@@doesn@@t@@mean@@everyone@@should@@be@@taking@@it@@to@@prevent@@a@@heart@@attack@@or@@stroke", "replace_pair": "drug1@@without@@a@@prescription@@(@@and@@for@@pennies@@a@@tablet@@)@@doesn@@t@@mean@@everyone@@should@@be@@taking@@it@@to@@prevent@@a@@heart@@attack@@or@@drug2", "relation": "NA"}, {"head": {"id": "454", "type": "", "word": "acyclovir", "begin": "23", "end": "32", "new_begin": "30", "new_end": "39", "replace_begin": "30", "replace_end": "35"}, "tail": {"id": "455", "type": "", "word": "CMVUdisease", "begin": "83", "end": "94", "new_begin": "102", "new_end": "113", "replace_begin": "98", "replace_end": "103"}, "sentence": "We evaluated high-dose acyclovir ( HDACV ) and pre -emptive ganciclovir to prevent CMVUdisease in 76 children who underwent peripheral blood stem cell transplantation ( PBSCT ) and were at risk for CMV reactivation and disease ( both recipient and donor seropositive ) from May 1998 to April 2003 .", "new_sentence": "We@@evaluated@@high@@-@@dose@@acyclovir@@(@@HDACV@@)@@and@@pre@@-@@emptive@@ganciclovir@@to@@prevent@@CMVUdisease@@in@@76@@children@@who@@underwent@@peripheral@@blood@@stem@@cell@@transplantation@@(@@PBSCT@@)@@and@@were@@at@@risk@@for@@CMV@@reactivation@@and@@disease@@(@@both@@recipient@@and@@donor@@seropositive@@)@@from@@May@@1998@@to@@April@@2003@@.@@", "replace_sentence": "We@@evaluated@@high@@-@@dose@@drug1@@(@@HDACV@@)@@and@@pre@@-@@emptive@@ganciclovir@@to@@prevent@@drug2@@in@@76@@children@@who@@underwent@@peripheral@@blood@@stem@@cell@@transplantation@@(@@PBSCT@@)@@and@@were@@at@@risk@@for@@CMV@@reactivation@@and@@disease@@(@@both@@recipient@@and@@donor@@seropositive@@)@@from@@May@@1998@@to@@April@@2003@@.@@", "new_pair": "acyclovir@@(@@HDACV@@)@@and@@pre@@-@@emptive@@ganciclovir@@to@@prevent@@CMVUdisease", "replace_pair": "drug1@@(@@HDACV@@)@@and@@pre@@-@@emptive@@ganciclovir@@to@@prevent@@drug2", "relation": "NA"}, {"head": {"id": "456", "type": "", "word": "myocardialUinfarction", "begin": "102", "end": "123", "new_begin": "119", "new_end": "140", "replace_begin": "119", "replace_end": "124"}, "tail": {"id": "457", "type": "", "word": "clopidogrel", "begin": "142", "end": "153", "new_begin": "163", "new_end": "174", "replace_begin": "147", "replace_end": "152"}, "sentence": "Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardialUinfarction also treated with clopidogrel .", "new_sentence": "Efficacy@@and@@safety@@of@@enoxaparin@@versus@@unfractionated@@heparin@@in@@patients@@with@@ST@@-@@segment@@elevation@@myocardialUinfarction@@also@@treated@@with@@clopidogrel@@.@@", "replace_sentence": "Efficacy@@and@@safety@@of@@enoxaparin@@versus@@unfractionated@@heparin@@in@@patients@@with@@ST@@-@@segment@@elevation@@drug1@@also@@treated@@with@@drug2@@.@@", "new_pair": "myocardialUinfarction@@also@@treated@@with@@clopidogrel", "replace_pair": "drug1@@also@@treated@@with@@drug2", "relation": "NA"}, {"head": {"id": "458", "type": "", "word": "acetylsalicylicUacid", "begin": "14", "end": "34", "new_begin": "16", "new_end": "36", "replace_begin": "16", "replace_end": "21"}, "tail": {"id": "459", "type": "", "word": "stroke", "begin": "111", "end": "117", "new_begin": "129", "new_end": "135", "replace_begin": "114", "replace_end": "119"}, "sentence": "Hydrolysis of acetylsalicylicUacid ( ASA , aspirin ) , an antiplatelet drug commonly used in the prevention of stroke and myocardial infarction , seems to play a crucial role in its pharmacological action .", "new_sentence": "Hydrolysis@@of@@acetylsalicylicUacid@@(@@ASA@@,@@aspirin@@)@@,@@an@@antiplatelet@@drug@@commonly@@used@@in@@the@@prevention@@of@@stroke@@and@@myocardial@@infarction@@,@@seems@@to@@play@@a@@crucial@@role@@in@@its@@pharmacological@@action@@.@@", "replace_sentence": "Hydrolysis@@of@@drug1@@(@@ASA@@,@@aspirin@@)@@,@@an@@antiplatelet@@drug@@commonly@@used@@in@@the@@prevention@@of@@drug2@@and@@myocardial@@infarction@@,@@seems@@to@@play@@a@@crucial@@role@@in@@its@@pharmacological@@action@@.@@", "new_pair": "acetylsalicylicUacid@@(@@ASA@@,@@aspirin@@)@@,@@an@@antiplatelet@@drug@@commonly@@used@@in@@the@@prevention@@of@@stroke", "replace_pair": "drug1@@(@@ASA@@,@@aspirin@@)@@,@@an@@antiplatelet@@drug@@commonly@@used@@in@@the@@prevention@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "460", "type": "", "word": "ranitidine", "begin": "63", "end": "73", "new_begin": "76", "new_end": "86", "replace_begin": "76", "replace_end": "81"}, "tail": {"id": "461", "type": "", "word": "sepsis", "begin": "105", "end": "111", "new_begin": "125", "new_end": "131", "replace_begin": "120", "replace_end": "125"}, "sentence": "AIMS : The objective of the study was to examine the effect of ranitidine on the incidence of late onset sepsis .", "new_sentence": "AIMS@@:@@The@@objective@@of@@the@@study@@was@@to@@examine@@the@@effect@@of@@ranitidine@@on@@the@@incidence@@of@@late@@onset@@sepsis@@.@@", "replace_sentence": "AIMS@@:@@The@@objective@@of@@the@@study@@was@@to@@examine@@the@@effect@@of@@drug1@@on@@the@@incidence@@of@@late@@onset@@drug2@@.@@", "new_pair": "ranitidine@@on@@the@@incidence@@of@@late@@onset@@sepsis", "replace_pair": "drug1@@on@@the@@incidence@@of@@late@@onset@@drug2", "relation": "NA"}, {"head": {"id": "462", "type": "", "word": "caries", "begin": "62", "end": "68", "new_begin": "74", "new_end": "80", "replace_begin": "74", "replace_end": "79"}, "tail": {"id": "463", "type": "", "word": "F", "begin": "86", "end": "87", "new_begin": "103", "new_end": "104", "replace_begin": "102", "replace_end": "107"}, "sentence": "Despite fluoride s ( F ) well - documented ability to prevent caries , the effects of F concentrations on enamel and dentin apatite crystals are unknown .", "new_sentence": "Despite@@fluoride@@s@@(@@F@@)@@well@@-@@documented@@ability@@to@@prevent@@caries@@,@@the@@effects@@of@@F@@concentrations@@on@@enamel@@and@@dentin@@apatite@@crystals@@are@@unknown@@.@@", "replace_sentence": "Despite@@fluoride@@s@@(@@F@@)@@well@@-@@documented@@ability@@to@@prevent@@drug1@@,@@the@@effects@@of@@drug2@@concentrations@@on@@enamel@@and@@dentin@@apatite@@crystals@@are@@unknown@@.@@", "new_pair": "caries@@,@@the@@effects@@of@@F", "replace_pair": "drug1@@,@@the@@effects@@of@@drug2", "relation": "NA"}, {"head": {"id": "464", "type": "", "word": "IronUoverload", "begin": "0", "end": "13", "new_begin": "0", "new_end": "13", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "465", "type": "", "word": "iron", "begin": "81", "end": "85", "new_begin": "93", "new_end": "97", "replace_begin": "85", "replace_end": "90"}, "sentence": "IronUoverload , oxidative stress , and inflammation were lower in the moderately iron - deficient group compared with the other 3 groups .", "new_sentence": "IronUoverload@@,@@oxidative@@stress@@,@@and@@inflammation@@were@@lower@@in@@the@@moderately@@iron@@-@@deficient@@group@@compared@@with@@the@@other@@3@@groups@@.@@", "replace_sentence": "drug1@@,@@oxidative@@stress@@,@@and@@inflammation@@were@@lower@@in@@the@@moderately@@drug2@@-@@deficient@@group@@compared@@with@@the@@other@@3@@groups@@.@@", "new_pair": "IronUoverload@@,@@oxidative@@stress@@,@@and@@inflammation@@were@@lower@@in@@the@@moderately@@iron", "replace_pair": "drug1@@,@@oxidative@@stress@@,@@and@@inflammation@@were@@lower@@in@@the@@moderately@@drug2", "relation": "NA"}, {"head": {"id": "466", "type": "", "word": "hepatitisUB", "begin": "38", "end": "49", "new_begin": "44", "new_end": "55", "replace_begin": "44", "replace_end": "49"}, "tail": {"id": "467", "type": "", "word": "HBsAg", "begin": "73", "end": "78", "new_begin": "84", "new_end": "89", "replace_begin": "78", "replace_end": "83"}, "sentence": "RESULTS : The following occurrence of hepatitisUB markers was observed : HBsAg - 3 . 2 % , anti-HBs ( total ) - 36 . 2 % , anti-HBc IgG - 30 . 3 % , anti-HBc IgM - 1 . 6 % .", "new_sentence": "RESULTS@@:@@The@@following@@occurrence@@of@@hepatitisUB@@markers@@was@@observed@@:@@HBsAg@@-@@3@@.@@2@@%@@,@@anti@@-@@HBs@@(@@total@@)@@-@@36@@.@@2@@%@@,@@anti@@-@@HBc@@IgG@@-@@30@@.@@3@@%@@,@@anti@@-@@HBc@@IgM@@-@@1@@.@@6@@%@@.@@", "replace_sentence": "RESULTS@@:@@The@@following@@occurrence@@of@@drug1@@markers@@was@@observed@@:@@drug2@@-@@3@@.@@2@@%@@,@@anti@@-@@HBs@@(@@total@@)@@-@@36@@.@@2@@%@@,@@anti@@-@@HBc@@IgG@@-@@30@@.@@3@@%@@,@@anti@@-@@HBc@@IgM@@-@@1@@.@@6@@%@@.@@", "new_pair": "hepatitisUB@@markers@@was@@observed@@:@@HBsAg", "replace_pair": "drug1@@markers@@was@@observed@@:@@drug2", "relation": "NA"}, {"head": {"id": "468", "type": "", "word": "antimycobacterial", "begin": "57", "end": "74", "new_begin": "67", "new_end": "84", "replace_begin": "67", "replace_end": "72"}, "tail": {"id": "469", "type": "", "word": "tuberculosis", "begin": "209", "end": "221", "new_begin": "239", "new_end": "251", "replace_begin": "227", "replace_end": "232"}, "sentence": "In this review , we describe selected recent progress in antimycobacterial drug design , illustrating the strengths and limitations of current structural bioinformatic approaches as tools in the fight against tuberculosis .", "new_sentence": "In@@this@@review@@,@@we@@describe@@selected@@recent@@progress@@in@@antimycobacterial@@drug@@design@@,@@illustrating@@the@@strengths@@and@@limitations@@of@@current@@structural@@bioinformatic@@approaches@@as@@tools@@in@@the@@fight@@against@@tuberculosis@@.@@", "replace_sentence": "In@@this@@review@@,@@we@@describe@@selected@@recent@@progress@@in@@drug1@@drug@@design@@,@@illustrating@@the@@strengths@@and@@limitations@@of@@current@@structural@@bioinformatic@@approaches@@as@@tools@@in@@the@@fight@@against@@drug2@@.@@", "new_pair": "antimycobacterial@@drug@@design@@,@@illustrating@@the@@strengths@@and@@limitations@@of@@current@@structural@@bioinformatic@@approaches@@as@@tools@@in@@the@@fight@@against@@tuberculosis", "replace_pair": "drug1@@drug@@design@@,@@illustrating@@the@@strengths@@and@@limitations@@of@@current@@structural@@bioinformatic@@approaches@@as@@tools@@in@@the@@fight@@against@@drug2", "relation": "NA"}, {"head": {"id": "470", "type": "", "word": "fluticasoneUpropionate", "begin": "27", "end": "49", "new_begin": "32", "new_end": "54", "replace_begin": "32", "replace_end": "37"}, "tail": {"id": "471", "type": "", "word": "asthma", "begin": "89", "end": "95", "new_begin": "101", "new_end": "107", "replace_begin": "84", "replace_end": "89"}, "sentence": "The efficacy and safety of fluticasoneUpropionate in very young children with persistent asthma symptoms .", "new_sentence": "The@@efficacy@@and@@safety@@of@@fluticasoneUpropionate@@in@@very@@young@@children@@with@@persistent@@asthma@@symptoms@@.@@", "replace_sentence": "The@@efficacy@@and@@safety@@of@@drug1@@in@@very@@young@@children@@with@@persistent@@drug2@@symptoms@@.@@", "new_pair": "fluticasoneUpropionate@@in@@very@@young@@children@@with@@persistent@@asthma", "replace_pair": "drug1@@in@@very@@young@@children@@with@@persistent@@drug2", "relation": "NA"}, {"head": {"id": "472", "type": "", "word": "Ganciclovir", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "473", "type": "", "word": "cytomegalovirusU ( UCMVU ) Uinfection", "begin": "95", "end": "132", "new_begin": "109", "new_end": "146", "replace_begin": "103", "replace_end": "108"}, "sentence": "Ganciclovir and its prodrug , valganciclovir , are more effective than acyclovir in preventing cytomegalovirusU ( UCMVU ) Uinfection and disease in solid-organ transplant recipients .", "new_sentence": "Ganciclovir@@and@@its@@prodrug@@,@@valganciclovir@@,@@are@@more@@effective@@than@@acyclovir@@in@@preventing@@cytomegalovirusU ( UCMVU ) Uinfection@@and@@disease@@in@@solid@@-@@organ@@transplant@@recipients@@.@@", "replace_sentence": "drug1@@and@@its@@prodrug@@,@@valganciclovir@@,@@are@@more@@effective@@than@@acyclovir@@in@@preventing@@drug2@@and@@disease@@in@@solid@@-@@organ@@transplant@@recipients@@.@@", "new_pair": "Ganciclovir@@and@@its@@prodrug@@,@@valganciclovir@@,@@are@@more@@effective@@than@@acyclovir@@in@@preventing@@cytomegalovirusU ( UCMVU ) Uinfection", "replace_pair": "drug1@@and@@its@@prodrug@@,@@valganciclovir@@,@@are@@more@@effective@@than@@acyclovir@@in@@preventing@@drug2", "relation": "may_prevent"}, {"head": {"id": "474", "type": "", "word": "tacrolimus", "begin": "78", "end": "88", "new_begin": "90", "new_end": "100", "replace_begin": "90", "replace_end": "95"}, "tail": {"id": "475", "type": "", "word": "CMVUinfection", "begin": "270", "end": "283", "new_begin": "315", "new_end": "328", "replace_begin": "310", "replace_end": "315"}, "sentence": "The correlations between the incidence of CMV infection and acute rejection , tacrolimus versus cyclosporine regimens , dual versus triple immunosupressive schemes were not statistically significant , whereas anti- IL-2R -ab antibodies markedly reduced the incidence of CMVUinfection ( P < . 05 ) .", "new_sentence": "The@@correlations@@between@@the@@incidence@@of@@CMV@@infection@@and@@acute@@rejection@@,@@tacrolimus@@versus@@cyclosporine@@regimens@@,@@dual@@versus@@triple@@immunosupressive@@schemes@@were@@not@@statistically@@significant@@,@@whereas@@anti@@-@@IL@@-@@2R@@-@@ab@@antibodies@@markedly@@reduced@@the@@incidence@@of@@CMVUinfection@@(@@P@@<@@.@@05@@)@@.@@", "replace_sentence": "The@@correlations@@between@@the@@incidence@@of@@CMV@@infection@@and@@acute@@rejection@@,@@drug1@@versus@@cyclosporine@@regimens@@,@@dual@@versus@@triple@@immunosupressive@@schemes@@were@@not@@statistically@@significant@@,@@whereas@@anti@@-@@IL@@-@@2R@@-@@ab@@antibodies@@markedly@@reduced@@the@@incidence@@of@@drug2@@(@@P@@<@@.@@05@@)@@.@@", "new_pair": "tacrolimus@@versus@@cyclosporine@@regimens@@,@@dual@@versus@@triple@@immunosupressive@@schemes@@were@@not@@statistically@@significant@@,@@whereas@@anti@@-@@IL@@-@@2R@@-@@ab@@antibodies@@markedly@@reduced@@the@@incidence@@of@@CMVUinfection", "replace_pair": "drug1@@versus@@cyclosporine@@regimens@@,@@dual@@versus@@triple@@immunosupressive@@schemes@@were@@not@@statistically@@significant@@,@@whereas@@anti@@-@@IL@@-@@2R@@-@@ab@@antibodies@@markedly@@reduced@@the@@incidence@@of@@drug2", "relation": "NA"}, {"head": {"id": "476", "type": "", "word": "valacyclovir", "begin": "54", "end": "66", "new_begin": "61", "new_end": "73", "replace_begin": "61", "replace_end": "66"}, "tail": {"id": "477", "type": "", "word": "CMVUdisease", "begin": "122", "end": "133", "new_begin": "138", "new_end": "149", "replace_begin": "131", "replace_end": "136"}, "sentence": "In conclusion , preemptive valganciclovir therapy and valacyclovir prophylaxis are equally effective in the prevention of CMVUdisease after renal transplantation .", "new_sentence": "In@@conclusion@@,@@preemptive@@valganciclovir@@therapy@@and@@valacyclovir@@prophylaxis@@are@@equally@@effective@@in@@the@@prevention@@of@@CMVUdisease@@after@@renal@@transplantation@@.@@", "replace_sentence": "In@@conclusion@@,@@preemptive@@valganciclovir@@therapy@@and@@drug1@@prophylaxis@@are@@equally@@effective@@in@@the@@prevention@@of@@drug2@@after@@renal@@transplantation@@.@@", "new_pair": "valacyclovir@@prophylaxis@@are@@equally@@effective@@in@@the@@prevention@@of@@CMVUdisease", "replace_pair": "drug1@@prophylaxis@@are@@equally@@effective@@in@@the@@prevention@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "478", "type": "", "word": "ranitidine", "begin": "68", "end": "78", "new_begin": "78", "new_end": "88", "replace_begin": "78", "replace_end": "83"}, "tail": {"id": "479", "type": "", "word": "gastricUulcer", "begin": "175", "end": "188", "new_begin": "209", "new_end": "222", "replace_begin": "204", "replace_end": "209"}, "sentence": "We randomly assigned 69 consecutive patients with gastric ulcers to ranitidine ( n = 34 ) or famotidine ( n = 35 ) for 12 weeks , with endoscopic assessment of the quality of gastricUulcer healing and histological assessment of gastric mucosa 12 weeks after treatment started .", "new_sentence": "We@@randomly@@assigned@@69@@consecutive@@patients@@with@@gastric@@ulcers@@to@@ranitidine@@(@@n@@=@@34@@)@@or@@famotidine@@(@@n@@=@@35@@)@@for@@12@@weeks@@,@@with@@endoscopic@@assessment@@of@@the@@quality@@of@@gastricUulcer@@healing@@and@@histological@@assessment@@of@@gastric@@mucosa@@12@@weeks@@after@@treatment@@started@@.@@", "replace_sentence": "We@@randomly@@assigned@@69@@consecutive@@patients@@with@@gastric@@ulcers@@to@@drug1@@(@@n@@=@@34@@)@@or@@famotidine@@(@@n@@=@@35@@)@@for@@12@@weeks@@,@@with@@endoscopic@@assessment@@of@@the@@quality@@of@@drug2@@healing@@and@@histological@@assessment@@of@@gastric@@mucosa@@12@@weeks@@after@@treatment@@started@@.@@", "new_pair": "ranitidine@@(@@n@@=@@34@@)@@or@@famotidine@@(@@n@@=@@35@@)@@for@@12@@weeks@@,@@with@@endoscopic@@assessment@@of@@the@@quality@@of@@gastricUulcer", "replace_pair": "drug1@@(@@n@@=@@34@@)@@or@@famotidine@@(@@n@@=@@35@@)@@for@@12@@weeks@@,@@with@@endoscopic@@assessment@@of@@the@@quality@@of@@drug2", "relation": "NA"}, {"head": {"id": "480", "type": "", "word": "cavity", "begin": "57", "end": "63", "new_begin": "65", "new_end": "71", "replace_begin": "65", "replace_end": "70"}, "tail": {"id": "481", "type": "", "word": "heparin", "begin": "80", "end": "87", "new_begin": "92", "new_end": "99", "replace_begin": "91", "replace_end": "96"}, "sentence": "The percentages of organized areas occupying the luminal cavity in unmodified , heparin - coated , bFGF -coated , and TNC - coated groups were 4 . 8 + @ - 4 . 6 , 1 . 6 + @ - 1 . 1 , 17 . 9 + @ - 10 . 7 , and 93 . 4 + @ - 6 . 9 % , respectively .", "new_sentence": "The@@percentages@@of@@organized@@areas@@occupying@@the@@luminal@@cavity@@in@@unmodified@@,@@heparin@@-@@coated@@,@@bFGF@@-@@coated@@,@@and@@TNC@@-@@coated@@groups@@were@@4@@.@@8@@+@@@@@-@@4@@.@@6@@,@@1@@.@@6@@+@@@@@-@@1@@.@@1@@,@@17@@.@@9@@+@@@@@-@@10@@.@@7@@,@@and@@93@@.@@4@@+@@@@@-@@6@@.@@9@@%@@,@@respectively@@.@@", "replace_sentence": "The@@percentages@@of@@organized@@areas@@occupying@@the@@luminal@@drug1@@in@@unmodified@@,@@drug2@@-@@coated@@,@@bFGF@@-@@coated@@,@@and@@TNC@@-@@coated@@groups@@were@@4@@.@@8@@+@@@@@-@@4@@.@@6@@,@@1@@.@@6@@+@@@@@-@@1@@.@@1@@,@@17@@.@@9@@+@@@@@-@@10@@.@@7@@,@@and@@93@@.@@4@@+@@@@@-@@6@@.@@9@@%@@,@@respectively@@.@@", "new_pair": "cavity@@in@@unmodified@@,@@heparin", "replace_pair": "drug1@@in@@unmodified@@,@@drug2", "relation": "NA"}, {"head": {"id": "482", "type": "", "word": "ulcersUinUtheUstomach", "begin": "113", "end": "134", "new_begin": "131", "new_end": "152", "replace_begin": "131", "replace_end": "136"}, "tail": {"id": "483", "type": "", "word": "NSARUagents", "begin": "158", "end": "169", "new_begin": "181", "new_end": "192", "replace_begin": "165", "replace_end": "170"}, "sentence": "Optimized inhibition of acid secretion with proton pump inhibitors has made it possible to both prevent and cure ulcersUinUtheUstomach and duodenum caused by NSARUagents .", "new_sentence": "Optimized@@inhibition@@of@@acid@@secretion@@with@@proton@@pump@@inhibitors@@has@@made@@it@@possible@@to@@both@@prevent@@and@@cure@@ulcersUinUtheUstomach@@and@@duodenum@@caused@@by@@NSARUagents@@.@@", "replace_sentence": "Optimized@@inhibition@@of@@acid@@secretion@@with@@proton@@pump@@inhibitors@@has@@made@@it@@possible@@to@@both@@prevent@@and@@cure@@drug1@@and@@duodenum@@caused@@by@@drug2@@.@@", "new_pair": "ulcersUinUtheUstomach@@and@@duodenum@@caused@@by@@NSARUagents", "replace_pair": "drug1@@and@@duodenum@@caused@@by@@drug2", "relation": "NA"}, {"head": {"id": "484", "type": "", "word": "aspirin", "begin": "27", "end": "34", "new_begin": "30", "new_end": "37", "replace_begin": "30", "replace_end": "35"}, "tail": {"id": "485", "type": "", "word": "stroke", "begin": "91", "end": "97", "new_begin": "104", "new_end": "110", "replace_begin": "102", "replace_end": "107"}, "sentence": "Combination therapies with aspirin and warfarin show no additional benefits with regard to stroke prevention and carry higher risks of hemorrhage .", "new_sentence": "Combination@@therapies@@with@@aspirin@@and@@warfarin@@show@@no@@additional@@benefits@@with@@regard@@to@@stroke@@prevention@@and@@carry@@higher@@risks@@of@@hemorrhage@@.@@", "replace_sentence": "Combination@@therapies@@with@@drug1@@and@@warfarin@@show@@no@@additional@@benefits@@with@@regard@@to@@drug2@@prevention@@and@@carry@@higher@@risks@@of@@hemorrhage@@.@@", "new_pair": "aspirin@@and@@warfarin@@show@@no@@additional@@benefits@@with@@regard@@to@@stroke", "replace_pair": "drug1@@and@@warfarin@@show@@no@@additional@@benefits@@with@@regard@@to@@drug2", "relation": "NA"}, {"head": {"id": "486", "type": "", "word": "dexamethasone", "begin": "35", "end": "48", "new_begin": "42", "new_end": "55", "replace_begin": "42", "replace_end": "47"}, "tail": {"id": "487", "type": "", "word": "cavities", "begin": "121", "end": "129", "new_begin": "144", "new_end": "152", "replace_begin": "136", "replace_end": "141"}, "sentence": "Two per cent glacial acetic acid , dexamethasone and neomycin sulphate resolved only 30 % ( 8 @ 27 ) of infected mastoid cavities compared to only 10 % ( 3 @ 29 ) on glacial acetic acid ( P < 0 . 07 ) .", "new_sentence": "Two@@per@@cent@@glacial@@acetic@@acid@@,@@dexamethasone@@and@@neomycin@@sulphate@@resolved@@only@@30@@%@@(@@8@@@@@27@@)@@of@@infected@@mastoid@@cavities@@compared@@to@@only@@10@@%@@(@@3@@@@@29@@)@@on@@glacial@@acetic@@acid@@(@@P@@<@@0@@.@@07@@)@@.@@", "replace_sentence": "Two@@per@@cent@@glacial@@acetic@@acid@@,@@drug1@@and@@neomycin@@sulphate@@resolved@@only@@30@@%@@(@@8@@@@@27@@)@@of@@infected@@mastoid@@drug2@@compared@@to@@only@@10@@%@@(@@3@@@@@29@@)@@on@@glacial@@acetic@@acid@@(@@P@@<@@0@@.@@07@@)@@.@@", "new_pair": "dexamethasone@@and@@neomycin@@sulphate@@resolved@@only@@30@@%@@(@@8@@@@@27@@)@@of@@infected@@mastoid@@cavities", "replace_pair": "drug1@@and@@neomycin@@sulphate@@resolved@@only@@30@@%@@(@@8@@@@@27@@)@@of@@infected@@mastoid@@drug2", "relation": "NA"}, {"head": {"id": "488", "type": "", "word": "17beta-estradiol", "begin": "19", "end": "35", "new_begin": "21", "new_end": "37", "replace_begin": "21", "replace_end": "26"}, "tail": {"id": "489", "type": "", "word": "postmenopausalUosteoporosis", "begin": "78", "end": "105", "new_begin": "87", "new_end": "114", "replace_begin": "76", "replace_end": "81"}, "sentence": "Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausalUosteoporosis .", "new_sentence": "Levonorgestrel@@and@@17beta-estradiol@@given@@transdermally@@for@@the@@prevention@@of@@postmenopausalUosteoporosis@@.@@", "replace_sentence": "Levonorgestrel@@and@@drug1@@given@@transdermally@@for@@the@@prevention@@of@@drug2@@.@@", "new_pair": "17beta-estradiol@@given@@transdermally@@for@@the@@prevention@@of@@postmenopausalUosteoporosis", "replace_pair": "drug1@@given@@transdermally@@for@@the@@prevention@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "490", "type": "", "word": "Plaque", "begin": "0", "end": "6", "new_begin": "0", "new_end": "6", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "491", "type": "", "word": "fluoride", "begin": "7", "end": "15", "new_begin": "8", "new_end": "16", "replace_begin": "7", "replace_end": "12"}, "sentence": "Plaque fluoride concentrations ( ( F ) ) are directly related to plaque calcium concentrations ( Ca ) .", "new_sentence": "Plaque@@fluoride@@concentrations@@(@@(@@F@@)@@)@@are@@directly@@related@@to@@plaque@@calcium@@concentrations@@(@@Ca@@)@@.@@", "replace_sentence": "drug1@@drug2@@concentrations@@(@@(@@F@@)@@)@@are@@directly@@related@@to@@plaque@@calcium@@concentrations@@(@@Ca@@)@@.@@", "new_pair": "Plaque@@fluoride", "replace_pair": "drug1@@drug2", "relation": "NA"}, {"head": {"id": "492", "type": "", "word": "Septicaemia", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "493", "type": "", "word": "lysine", "begin": "257", "end": "263", "new_begin": "306", "new_end": "312", "replace_begin": "300", "replace_end": "305"}, "sentence": "Septicaemia significantly ( P < 0 . 0001 ) elevated 2-aminoadipic acid in non - diabetic , but not diabetic individuals , and mildly correlated with other glycoxidation markers , carboxymethyl-lysine and the methylglyoxal - derived products , carboxyethyl- lysine , argpyrimidine and MODIC ( methylglyoxal - derived imidazolium cross-link ) .", "new_sentence": "Septicaemia@@significantly@@(@@P@@<@@0@@.@@0001@@)@@elevated@@2@@-@@aminoadipic@@acid@@in@@non@@-@@diabetic@@,@@but@@not@@diabetic@@individuals@@,@@and@@mildly@@correlated@@with@@other@@glycoxidation@@markers@@,@@carboxymethyl@@-@@lysine@@and@@the@@methylglyoxal@@-@@derived@@products@@,@@carboxyethyl@@-@@lysine@@,@@argpyrimidine@@and@@MODIC@@(@@methylglyoxal@@-@@derived@@imidazolium@@cross@@-@@link@@)@@.@@", "replace_sentence": "drug1@@significantly@@(@@P@@<@@0@@.@@0001@@)@@elevated@@2@@-@@aminoadipic@@acid@@in@@non@@-@@diabetic@@,@@but@@not@@diabetic@@individuals@@,@@and@@mildly@@correlated@@with@@other@@glycoxidation@@markers@@,@@carboxymethyl@@-@@lysine@@and@@the@@methylglyoxal@@-@@derived@@products@@,@@carboxyethyl@@-@@drug2@@,@@argpyrimidine@@and@@MODIC@@(@@methylglyoxal@@-@@derived@@imidazolium@@cross@@-@@link@@)@@.@@", "new_pair": "Septicaemia@@significantly@@(@@P@@<@@0@@.@@0001@@)@@elevated@@2@@-@@aminoadipic@@acid@@in@@non@@-@@diabetic@@,@@but@@not@@diabetic@@individuals@@,@@and@@mildly@@correlated@@with@@other@@glycoxidation@@markers@@,@@carboxymethyl@@-@@lysine@@and@@the@@methylglyoxal@@-@@derived@@products@@,@@carboxyethyl@@-@@lysine", "replace_pair": "drug1@@significantly@@(@@P@@<@@0@@.@@0001@@)@@elevated@@2@@-@@aminoadipic@@acid@@in@@non@@-@@diabetic@@,@@but@@not@@diabetic@@individuals@@,@@and@@mildly@@correlated@@with@@other@@glycoxidation@@markers@@,@@carboxymethyl@@-@@lysine@@and@@the@@methylglyoxal@@-@@derived@@products@@,@@carboxyethyl@@-@@drug2", "relation": "NA"}, {"head": {"id": "494", "type": "", "word": "GCV", "begin": "53", "end": "56", "new_begin": "61", "new_end": "64", "replace_begin": "61", "replace_end": "66"}, "tail": {"id": "495", "type": "", "word": "GVHD", "begin": "213", "end": "217", "new_begin": "251", "new_end": "255", "replace_begin": "253", "replace_end": "258"}, "sentence": "By 60 days after transplantation , mice administered GCV had T-cell repertoires that were virtually indistinguishable from those of mice that underwent transplantation with T cell- depleted bone marrow alone ( no GVHD controls ) when assayed by T-cell receptor ( TCR ) spectratyping .", "new_sentence": "By@@60@@days@@after@@transplantation@@,@@mice@@administered@@GCV@@had@@T@@-@@cell@@repertoires@@that@@were@@virtually@@indistinguishable@@from@@those@@of@@mice@@that@@underwent@@transplantation@@with@@T@@cell@@-@@depleted@@bone@@marrow@@alone@@(@@no@@GVHD@@controls@@)@@when@@assayed@@by@@T@@-@@cell@@receptor@@(@@TCR@@)@@spectratyping@@.@@", "replace_sentence": "By@@60@@days@@after@@transplantation@@,@@mice@@administered@@drug1@@had@@T@@-@@cell@@repertoires@@that@@were@@virtually@@indistinguishable@@from@@those@@of@@mice@@that@@underwent@@transplantation@@with@@T@@cell@@-@@depleted@@bone@@marrow@@alone@@(@@no@@drug2@@controls@@)@@when@@assayed@@by@@T@@-@@cell@@receptor@@(@@TCR@@)@@spectratyping@@.@@", "new_pair": "GCV@@had@@T@@-@@cell@@repertoires@@that@@were@@virtually@@indistinguishable@@from@@those@@of@@mice@@that@@underwent@@transplantation@@with@@T@@cell@@-@@depleted@@bone@@marrow@@alone@@(@@no@@GVHD", "replace_pair": "drug1@@had@@T@@-@@cell@@repertoires@@that@@were@@virtually@@indistinguishable@@from@@those@@of@@mice@@that@@underwent@@transplantation@@with@@T@@cell@@-@@depleted@@bone@@marrow@@alone@@(@@no@@drug2", "relation": "NA"}, {"head": {"id": "496", "type": "", "word": "malaria", "begin": "53", "end": "60", "new_begin": "61", "new_end": "68", "replace_begin": "61", "replace_end": "66"}, "tail": {"id": "497", "type": "", "word": "chloroquine", "begin": "72", "end": "83", "new_begin": "84", "new_end": "95", "replace_begin": "82", "replace_end": "87"}, "sentence": "In 2002 , the investigators identified patients with malaria , made its chloroquine eliminating treatment , seasonal chemoprevention of some 5000 dwellers of the Leilek District of the Batken Region contiguous with Tadjikistan , and larvicidal treatments of water reservoirs and rice checks with dimilin .", "new_sentence": "In@@2002@@,@@the@@investigators@@identified@@patients@@with@@malaria@@,@@made@@its@@chloroquine@@eliminating@@treatment@@,@@seasonal@@chemoprevention@@of@@some@@5000@@dwellers@@of@@the@@Leilek@@District@@of@@the@@Batken@@Region@@contiguous@@with@@Tadjikistan@@,@@and@@larvicidal@@treatments@@of@@water@@reservoirs@@and@@rice@@checks@@with@@dimilin@@.@@", "replace_sentence": "In@@2002@@,@@the@@investigators@@identified@@patients@@with@@drug1@@,@@made@@its@@drug2@@eliminating@@treatment@@,@@seasonal@@chemoprevention@@of@@some@@5000@@dwellers@@of@@the@@Leilek@@District@@of@@the@@Batken@@Region@@contiguous@@with@@Tadjikistan@@,@@and@@larvicidal@@treatments@@of@@water@@reservoirs@@and@@rice@@checks@@with@@dimilin@@.@@", "new_pair": "malaria@@,@@made@@its@@chloroquine", "replace_pair": "drug1@@,@@made@@its@@drug2", "relation": "NA"}, {"head": {"id": "498", "type": "", "word": "aspirin", "begin": "21", "end": "28", "new_begin": "24", "new_end": "31", "replace_begin": "24", "replace_end": "29"}, "tail": {"id": "499", "type": "", "word": "transientUischemicUattack", "begin": "126", "end": "151", "new_begin": "153", "new_end": "178", "replace_begin": "151", "replace_end": "156"}, "sentence": "Neither warfarin nor aspirin were prescribed in 21 % of high-risk patients , including 18 % of those with a previous stroke , transientUischemicUattack , or systemic embolic event .", "new_sentence": "Neither@@warfarin@@nor@@aspirin@@were@@prescribed@@in@@21@@%@@of@@high@@-@@risk@@patients@@,@@including@@18@@%@@of@@those@@with@@a@@previous@@stroke@@,@@transientUischemicUattack@@,@@or@@systemic@@embolic@@event@@.@@", "replace_sentence": "Neither@@warfarin@@nor@@drug1@@were@@prescribed@@in@@21@@%@@of@@high@@-@@risk@@patients@@,@@including@@18@@%@@of@@those@@with@@a@@previous@@stroke@@,@@drug2@@,@@or@@systemic@@embolic@@event@@.@@", "new_pair": "aspirin@@were@@prescribed@@in@@21@@%@@of@@high@@-@@risk@@patients@@,@@including@@18@@%@@of@@those@@with@@a@@previous@@stroke@@,@@transientUischemicUattack", "replace_pair": "drug1@@were@@prescribed@@in@@21@@%@@of@@high@@-@@risk@@patients@@,@@including@@18@@%@@of@@those@@with@@a@@previous@@stroke@@,@@drug2", "relation": "NA"}, {"head": {"id": "500", "type": "", "word": "CMVUinfections", "begin": "32", "end": "46", "new_begin": "35", "new_end": "49", "replace_begin": "35", "replace_end": "40"}, "tail": {"id": "501", "type": "", "word": "acyclovir", "begin": "191", "end": "200", "new_begin": "225", "new_end": "234", "replace_begin": "216", "replace_end": "221"}, "sentence": "Statistically significant fewer CMVUinfections occurred among patients who received ganciclovir ( 22 % ) than those who did not receive prophylaxis ( 42 % ; P = . 0075 ) or were treated with acyclovir ( 43 % ; P = . 0066 ) .", "new_sentence": "Statistically@@significant@@fewer@@CMVUinfections@@occurred@@among@@patients@@who@@received@@ganciclovir@@(@@22@@%@@)@@than@@those@@who@@did@@not@@receive@@prophylaxis@@(@@42@@%@@;@@P@@=@@.@@0075@@)@@or@@were@@treated@@with@@acyclovir@@(@@43@@%@@;@@P@@=@@.@@0066@@)@@.@@", "replace_sentence": "Statistically@@significant@@fewer@@drug1@@occurred@@among@@patients@@who@@received@@ganciclovir@@(@@22@@%@@)@@than@@those@@who@@did@@not@@receive@@prophylaxis@@(@@42@@%@@;@@P@@=@@.@@0075@@)@@or@@were@@treated@@with@@drug2@@(@@43@@%@@;@@P@@=@@.@@0066@@)@@.@@", "new_pair": "CMVUinfections@@occurred@@among@@patients@@who@@received@@ganciclovir@@(@@22@@%@@)@@than@@those@@who@@did@@not@@receive@@prophylaxis@@(@@42@@%@@;@@P@@=@@.@@0075@@)@@or@@were@@treated@@with@@acyclovir", "replace_pair": "drug1@@occurred@@among@@patients@@who@@received@@ganciclovir@@(@@22@@%@@)@@than@@those@@who@@did@@not@@receive@@prophylaxis@@(@@42@@%@@;@@P@@=@@.@@0075@@)@@or@@were@@treated@@with@@drug2", "relation": "NA"}, {"head": {"id": "502", "type": "", "word": "vitaminUB12Udeficiency", "begin": "56", "end": "78", "new_begin": "66", "new_end": "88", "replace_begin": "66", "replace_end": "71"}, "tail": {"id": "503", "type": "", "word": "vitaminUB12", "begin": "93", "end": "104", "new_begin": "106", "new_end": "117", "replace_begin": "89", "replace_end": "94"}, "sentence": "This study suggests that it is necessary to monitor the vitaminUB12Udeficiency and advocates vitaminUB12 supplementation with folate prevention program .", "new_sentence": "This@@study@@suggests@@that@@it@@is@@necessary@@to@@monitor@@the@@vitaminUB12Udeficiency@@and@@advocates@@vitaminUB12@@supplementation@@with@@folate@@prevention@@program@@.@@", "replace_sentence": "This@@study@@suggests@@that@@it@@is@@necessary@@to@@monitor@@the@@drug1@@and@@advocates@@drug2@@supplementation@@with@@folate@@prevention@@program@@.@@", "new_pair": "vitaminUB12Udeficiency@@and@@advocates@@vitaminUB12", "replace_pair": "drug1@@and@@advocates@@drug2", "relation": "may_prevent"}, {"head": {"id": "504", "type": "", "word": "urticaria", "begin": "35", "end": "44", "new_begin": "42", "new_end": "51", "replace_begin": "42", "replace_end": "47"}, "tail": {"id": "505", "type": "", "word": "intravenousUimmunoglobulins", "begin": "57", "end": "84", "new_begin": "67", "new_end": "94", "replace_begin": "63", "replace_end": "68"}, "sentence": "We report the second case of solar urticaria improved by intravenousUimmunoglobulins .", "new_sentence": "We@@report@@the@@second@@case@@of@@solar@@urticaria@@improved@@by@@intravenousUimmunoglobulins@@.@@", "replace_sentence": "We@@report@@the@@second@@case@@of@@solar@@drug1@@improved@@by@@drug2@@.@@", "new_pair": "urticaria@@improved@@by@@intravenousUimmunoglobulins", "replace_pair": "drug1@@improved@@by@@drug2", "relation": "NA"}, {"head": {"id": "506", "type": "", "word": "dentalUcaries", "begin": "98", "end": "111", "new_begin": "112", "new_end": "125", "replace_begin": "112", "replace_end": "117"}, "tail": {"id": "507", "type": "", "word": "fluoride", "begin": "147", "end": "155", "new_begin": "168", "new_end": "176", "replace_begin": "160", "replace_end": "165"}, "sentence": "Similarly , although inorganic fluorides have long been recognized for their potential to prevent dentalUcaries , exposure to excessive amounts of fluoride when enamel is forming often leads to a type of enamel hypoplasia referred to as dental fluorosis or mottled enamel .", "new_sentence": "Similarly@@,@@although@@inorganic@@fluorides@@have@@long@@been@@recognized@@for@@their@@potential@@to@@prevent@@dentalUcaries@@,@@exposure@@to@@excessive@@amounts@@of@@fluoride@@when@@enamel@@is@@forming@@often@@leads@@to@@a@@type@@of@@enamel@@hypoplasia@@referred@@to@@as@@dental@@fluorosis@@or@@mottled@@enamel@@.@@", "replace_sentence": "Similarly@@,@@although@@inorganic@@fluorides@@have@@long@@been@@recognized@@for@@their@@potential@@to@@prevent@@drug1@@,@@exposure@@to@@excessive@@amounts@@of@@drug2@@when@@enamel@@is@@forming@@often@@leads@@to@@a@@type@@of@@enamel@@hypoplasia@@referred@@to@@as@@dental@@fluorosis@@or@@mottled@@enamel@@.@@", "new_pair": "dentalUcaries@@,@@exposure@@to@@excessive@@amounts@@of@@fluoride", "replace_pair": "drug1@@,@@exposure@@to@@excessive@@amounts@@of@@drug2", "relation": "NA"}, {"head": {"id": "508", "type": "", "word": "cyclosporine", "begin": "68", "end": "80", "new_begin": "81", "new_end": "93", "replace_begin": "81", "replace_end": "86"}, "tail": {"id": "509", "type": "", "word": "graft-versus-hostUdisease", "begin": "236", "end": "261", "new_begin": "278", "new_end": "303", "replace_begin": "271", "replace_end": "276"}, "sentence": "Because the symptoms of HHV-6 meningoencephalitis mimicked those of cyclosporine - or tacrolimus - induced encephalopathy , the drugs were withdrawn at the onset of CNS symptoms in 10 patients , resulting in the development of grade IV graft-versus-hostUdisease ( GVHD ) in 5 patients .", "new_sentence": "Because@@the@@symptoms@@of@@HHV@@-@@6@@meningoencephalitis@@mimicked@@those@@of@@cyclosporine@@-@@or@@tacrolimus@@-@@induced@@encephalopathy@@,@@the@@drugs@@were@@withdrawn@@at@@the@@onset@@of@@CNS@@symptoms@@in@@10@@patients@@,@@resulting@@in@@the@@development@@of@@grade@@IV@@graft-versus-hostUdisease@@(@@GVHD@@)@@in@@5@@patients@@.@@", "replace_sentence": "Because@@the@@symptoms@@of@@HHV@@-@@6@@meningoencephalitis@@mimicked@@those@@of@@drug1@@-@@or@@tacrolimus@@-@@induced@@encephalopathy@@,@@the@@drugs@@were@@withdrawn@@at@@the@@onset@@of@@CNS@@symptoms@@in@@10@@patients@@,@@resulting@@in@@the@@development@@of@@grade@@IV@@drug2@@(@@GVHD@@)@@in@@5@@patients@@.@@", "new_pair": "cyclosporine@@-@@or@@tacrolimus@@-@@induced@@encephalopathy@@,@@the@@drugs@@were@@withdrawn@@at@@the@@onset@@of@@CNS@@symptoms@@in@@10@@patients@@,@@resulting@@in@@the@@development@@of@@grade@@IV@@graft-versus-hostUdisease", "replace_pair": "drug1@@-@@or@@tacrolimus@@-@@induced@@encephalopathy@@,@@the@@drugs@@were@@withdrawn@@at@@the@@onset@@of@@CNS@@symptoms@@in@@10@@patients@@,@@resulting@@in@@the@@development@@of@@grade@@IV@@drug2", "relation": "NA"}, {"head": {"id": "510", "type": "", "word": "bronchopulmonaryUdysplasia", "begin": "152", "end": "178", "new_begin": "180", "new_end": "206", "replace_begin": "180", "replace_end": "185"}, "tail": {"id": "511", "type": "", "word": "DEX", "begin": "222", "end": "225", "new_begin": "259", "new_end": "262", "replace_begin": "238", "replace_end": "243"}, "sentence": "Growth , bone , and body composition were studied at prepuberty in former very low birth weight ( VLBW ) infants who received dexamethasone ( DEX ) for bronchopulmonaryUdysplasia ( BPD ) compared with VLBW infants without DEX and term-born infants ( TERM ) to identify early life risk factors for later low bone mass .", "new_sentence": "Growth@@,@@bone@@,@@and@@body@@composition@@were@@studied@@at@@prepuberty@@in@@former@@very@@low@@birth@@weight@@(@@VLBW@@)@@infants@@who@@received@@dexamethasone@@(@@DEX@@)@@for@@bronchopulmonaryUdysplasia@@(@@BPD@@)@@compared@@with@@VLBW@@infants@@without@@DEX@@and@@term@@-@@born@@infants@@(@@TERM@@)@@to@@identify@@early@@life@@risk@@factors@@for@@later@@low@@bone@@mass@@.@@", "replace_sentence": "Growth@@,@@bone@@,@@and@@body@@composition@@were@@studied@@at@@prepuberty@@in@@former@@very@@low@@birth@@weight@@(@@VLBW@@)@@infants@@who@@received@@dexamethasone@@(@@DEX@@)@@for@@drug1@@(@@BPD@@)@@compared@@with@@VLBW@@infants@@without@@drug2@@and@@term@@-@@born@@infants@@(@@TERM@@)@@to@@identify@@early@@life@@risk@@factors@@for@@later@@low@@bone@@mass@@.@@", "new_pair": "bronchopulmonaryUdysplasia@@(@@BPD@@)@@compared@@with@@VLBW@@infants@@without@@DEX", "replace_pair": "drug1@@(@@BPD@@)@@compared@@with@@VLBW@@infants@@without@@drug2", "relation": "NA"}, {"head": {"id": "512", "type": "", "word": "iron", "begin": "14", "end": "18", "new_begin": "16", "new_end": "20", "replace_begin": "16", "replace_end": "21"}, "tail": {"id": "513", "type": "", "word": "hepatitisUC", "begin": "86", "end": "97", "new_begin": "99", "new_end": "110", "replace_begin": "100", "replace_end": "105"}, "sentence": "Screening for iron parameters and HFE mutations should be considered in patients with hepatitisUC .", "new_sentence": "Screening@@for@@iron@@parameters@@and@@HFE@@mutations@@should@@be@@considered@@in@@patients@@with@@hepatitisUC@@.@@", "replace_sentence": "Screening@@for@@drug1@@parameters@@and@@HFE@@mutations@@should@@be@@considered@@in@@patients@@with@@drug2@@.@@", "new_pair": "iron@@parameters@@and@@HFE@@mutations@@should@@be@@considered@@in@@patients@@with@@hepatitisUC", "replace_pair": "drug1@@parameters@@and@@HFE@@mutations@@should@@be@@considered@@in@@patients@@with@@drug2", "relation": "NA"}, {"head": {"id": "514", "type": "", "word": "TgAA", "begin": "147", "end": "151", "new_begin": "167", "new_end": "171", "replace_begin": "167", "replace_end": "172"}, "tail": {"id": "515", "type": "", "word": "hypothyroid", "begin": "207", "end": "218", "new_begin": "238", "new_end": "249", "replace_begin": "239", "replace_end": "244"}, "sentence": "Circulating thyroglobulin autoantibody ( TgAA ) was analyzed using the Western immunoblot for determination of the dominant epitopes recognized by TgAA on tryptic peptides of canine thyroglobulin ( cTg ) in hypothyroid dogs .", "new_sentence": "Circulating@@thyroglobulin@@autoantibody@@(@@TgAA@@)@@was@@analyzed@@using@@the@@Western@@immunoblot@@for@@determination@@of@@the@@dominant@@epitopes@@recognized@@by@@TgAA@@on@@tryptic@@peptides@@of@@canine@@thyroglobulin@@(@@cTg@@)@@in@@hypothyroid@@dogs@@.@@", "replace_sentence": "Circulating@@thyroglobulin@@autoantibody@@(@@TgAA@@)@@was@@analyzed@@using@@the@@Western@@immunoblot@@for@@determination@@of@@the@@dominant@@epitopes@@recognized@@by@@drug1@@on@@tryptic@@peptides@@of@@canine@@thyroglobulin@@(@@cTg@@)@@in@@drug2@@dogs@@.@@", "new_pair": "TgAA@@on@@tryptic@@peptides@@of@@canine@@thyroglobulin@@(@@cTg@@)@@in@@hypothyroid", "replace_pair": "drug1@@on@@tryptic@@peptides@@of@@canine@@thyroglobulin@@(@@cTg@@)@@in@@drug2", "relation": "NA"}, {"head": {"id": "516", "type": "", "word": "cavity", "begin": "125", "end": "131", "new_begin": "148", "new_end": "154", "replace_begin": "148", "replace_end": "153"}, "tail": {"id": "517", "type": "", "word": "F", "begin": "187", "end": "188", "new_begin": "223", "new_end": "224", "replace_begin": "222", "replace_end": "227"}, "sentence": "The results suggest that conserved hydrophobic residues in the beta-5 hairpin help define the shape of the substrate binding cavity and that this structure interacts with Phe -248 in the F - helix .", "new_sentence": "The@@results@@suggest@@that@@conserved@@hydrophobic@@residues@@in@@the@@beta@@-@@5@@hairpin@@help@@define@@the@@shape@@of@@the@@substrate@@binding@@cavity@@and@@that@@this@@structure@@interacts@@with@@Phe@@-@@248@@in@@the@@F@@-@@helix@@.@@", "replace_sentence": "The@@results@@suggest@@that@@conserved@@hydrophobic@@residues@@in@@the@@beta@@-@@5@@hairpin@@help@@define@@the@@shape@@of@@the@@substrate@@binding@@drug1@@and@@that@@this@@structure@@interacts@@with@@Phe@@-@@248@@in@@the@@drug2@@-@@helix@@.@@", "new_pair": "cavity@@and@@that@@this@@structure@@interacts@@with@@Phe@@-@@248@@in@@the@@F", "replace_pair": "drug1@@and@@that@@this@@structure@@interacts@@with@@Phe@@-@@248@@in@@the@@drug2", "relation": "NA"}, {"head": {"id": "518", "type": "", "word": "glutamicUacid", "begin": "103", "end": "116", "new_begin": "121", "new_end": "134", "replace_begin": "121", "replace_end": "126"}, "tail": {"id": "519", "type": "", "word": "PEST", "begin": "155", "end": "159", "new_begin": "184", "new_end": "188", "replace_begin": "176", "replace_end": "181"}, "sentence": "Of two potential caspase consensus motifs in HDAC4 , both lying within a region containing proline - , glutamicUacid - , serine - , and threonine - rich ( PEST ) sequences , we identified , by site-directed mutagenesis , Asp -289 as the prime cleavage site .", "new_sentence": "Of@@two@@potential@@caspase@@consensus@@motifs@@in@@HDAC4@@,@@both@@lying@@within@@a@@region@@containing@@proline@@-@@,@@glutamicUacid@@-@@,@@serine@@-@@,@@and@@threonine@@-@@rich@@(@@PEST@@)@@sequences@@,@@we@@identified@@,@@by@@site@@-@@directed@@mutagenesis@@,@@Asp@@-@@289@@as@@the@@prime@@cleavage@@site@@.@@", "replace_sentence": "Of@@two@@potential@@caspase@@consensus@@motifs@@in@@HDAC4@@,@@both@@lying@@within@@a@@region@@containing@@proline@@-@@,@@drug1@@-@@,@@serine@@-@@,@@and@@threonine@@-@@rich@@(@@drug2@@)@@sequences@@,@@we@@identified@@,@@by@@site@@-@@directed@@mutagenesis@@,@@Asp@@-@@289@@as@@the@@prime@@cleavage@@site@@.@@", "new_pair": "glutamicUacid@@-@@,@@serine@@-@@,@@and@@threonine@@-@@rich@@(@@PEST", "replace_pair": "drug1@@-@@,@@serine@@-@@,@@and@@threonine@@-@@rich@@(@@drug2", "relation": "NA"}, {"head": {"id": "520", "type": "", "word": "cyclosporinUA", "begin": "47", "end": "60", "new_begin": "53", "new_end": "66", "replace_begin": "53", "replace_end": "58"}, "tail": {"id": "521", "type": "", "word": "graft-versus-hostUdisease", "begin": "115", "end": "140", "new_begin": "134", "new_end": "159", "replace_begin": "126", "replace_end": "131"}, "sentence": "All patients received mycophenolate mofetile , cyclosporinUA and short-term methotrexate with CD25 antibody as the graft-versus-hostUdisease ( GVHD ) prophylaxis .", "new_sentence": "All@@patients@@received@@mycophenolate@@mofetile@@,@@cyclosporinUA@@and@@short@@-@@term@@methotrexate@@with@@CD25@@antibody@@as@@the@@graft-versus-hostUdisease@@(@@GVHD@@)@@prophylaxis@@.@@", "replace_sentence": "All@@patients@@received@@mycophenolate@@mofetile@@,@@drug1@@and@@short@@-@@term@@methotrexate@@with@@CD25@@antibody@@as@@the@@drug2@@(@@GVHD@@)@@prophylaxis@@.@@", "new_pair": "cyclosporinUA@@and@@short@@-@@term@@methotrexate@@with@@CD25@@antibody@@as@@the@@graft-versus-hostUdisease", "replace_pair": "drug1@@and@@short@@-@@term@@methotrexate@@with@@CD25@@antibody@@as@@the@@drug2", "relation": "may_prevent"}, {"head": {"id": "522", "type": "", "word": "clopidogrel", "begin": "89", "end": "100", "new_begin": "101", "new_end": "112", "replace_begin": "101", "replace_end": "106"}, "tail": {"id": "523", "type": "", "word": "stroke", "begin": "118", "end": "124", "new_begin": "134", "new_end": "140", "replace_begin": "128", "replace_end": "133"}, "sentence": "Unacceptable bleeding risks without additional efficacy weigh against the routine use of clopidogrel with aspirin for stroke prophylaxis .", "new_sentence": "Unacceptable@@bleeding@@risks@@without@@additional@@efficacy@@weigh@@against@@the@@routine@@use@@of@@clopidogrel@@with@@aspirin@@for@@stroke@@prophylaxis@@.@@", "replace_sentence": "Unacceptable@@bleeding@@risks@@without@@additional@@efficacy@@weigh@@against@@the@@routine@@use@@of@@drug1@@with@@aspirin@@for@@drug2@@prophylaxis@@.@@", "new_pair": "clopidogrel@@with@@aspirin@@for@@stroke", "replace_pair": "drug1@@with@@aspirin@@for@@drug2", "relation": "NA"}, {"head": {"id": "524", "type": "", "word": "malaria", "begin": "37", "end": "44", "new_begin": "42", "new_end": "49", "replace_begin": "42", "replace_end": "47"}, "tail": {"id": "525", "type": "", "word": "chloroquine", "begin": "127", "end": "138", "new_begin": "150", "new_end": "161", "replace_begin": "148", "replace_end": "153"}, "sentence": "( Molecular epidemiology of imported malaria in Italy : the use of genetic markers and in vitro sensitivity test in a study of chloroquine resistance in Plasmodium falciparum ) .", "new_sentence": "(@@Molecular@@epidemiology@@of@@imported@@malaria@@in@@Italy@@:@@the@@use@@of@@genetic@@markers@@and@@in@@vitro@@sensitivity@@test@@in@@a@@study@@of@@chloroquine@@resistance@@in@@Plasmodium@@falciparum@@)@@.@@", "replace_sentence": "(@@Molecular@@epidemiology@@of@@imported@@drug1@@in@@Italy@@:@@the@@use@@of@@genetic@@markers@@and@@in@@vitro@@sensitivity@@test@@in@@a@@study@@of@@drug2@@resistance@@in@@Plasmodium@@falciparum@@)@@.@@", "new_pair": "malaria@@in@@Italy@@:@@the@@use@@of@@genetic@@markers@@and@@in@@vitro@@sensitivity@@test@@in@@a@@study@@of@@chloroquine", "replace_pair": "drug1@@in@@Italy@@:@@the@@use@@of@@genetic@@markers@@and@@in@@vitro@@sensitivity@@test@@in@@a@@study@@of@@drug2", "relation": "NA"}, {"head": {"id": "526", "type": "", "word": "GraftUvsU . UhostUdisease", "begin": "0", "end": "25", "new_begin": "0", "new_end": "25", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "527", "type": "", "word": "cyclosporineUa", "begin": "56", "end": "70", "new_begin": "62", "new_end": "76", "replace_begin": "42", "replace_end": "47"}, "sentence": "GraftUvsU . UhostUdisease ( GVHD ) prophylaxis included cyclosporineUa and methotrexate .", "new_sentence": "GraftUvsU . UhostUdisease@@(@@GVHD@@)@@prophylaxis@@included@@cyclosporineUa@@and@@methotrexate@@.@@", "replace_sentence": "drug1@@(@@GVHD@@)@@prophylaxis@@included@@drug2@@and@@methotrexate@@.@@", "new_pair": "GraftUvsU . UhostUdisease@@(@@GVHD@@)@@prophylaxis@@included@@cyclosporineUa", "replace_pair": "drug1@@(@@GVHD@@)@@prophylaxis@@included@@drug2", "relation": "may_prevent"}, {"head": {"id": "528", "type": "", "word": "Graft-versus-hostUdisease", "begin": "0", "end": "25", "new_begin": "0", "new_end": "25", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "529", "type": "", "word": "cyclosporine", "begin": "60", "end": "72", "new_begin": "67", "new_end": "79", "replace_begin": "47", "replace_end": "52"}, "sentence": "Graft-versus-hostUdisease ( GVHD ) prophylaxis consisted of cyclosporine and prednisolone .", "new_sentence": "Graft-versus-hostUdisease@@(@@GVHD@@)@@prophylaxis@@consisted@@of@@cyclosporine@@and@@prednisolone@@.@@", "replace_sentence": "drug1@@(@@GVHD@@)@@prophylaxis@@consisted@@of@@drug2@@and@@prednisolone@@.@@", "new_pair": "Graft-versus-hostUdisease@@(@@GVHD@@)@@prophylaxis@@consisted@@of@@cyclosporine", "replace_pair": "drug1@@(@@GVHD@@)@@prophylaxis@@consisted@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "530", "type": "", "word": "MMF", "begin": "82", "end": "85", "new_begin": "100", "new_end": "103", "replace_begin": "100", "replace_end": "105"}, "tail": {"id": "531", "type": "", "word": "infections", "begin": "235", "end": "245", "new_begin": "286", "new_end": "296", "replace_begin": "288", "replace_end": "293"}, "sentence": "The incidence of all safety parameters was similar in the EC-MPS patients and the MMF - treated patients in the RAD B201 and RAD B251 studies during the 12- to 36- month posttransplant period , as was the frequency of adverse events , infections , malignancies , and hematological abnormalities .", "new_sentence": "The@@incidence@@of@@all@@safety@@parameters@@was@@similar@@in@@the@@EC@@-@@MPS@@patients@@and@@the@@MMF@@-@@treated@@patients@@in@@the@@RAD@@B201@@and@@RAD@@B251@@studies@@during@@the@@12@@-@@to@@36@@-@@month@@posttransplant@@period@@,@@as@@was@@the@@frequency@@of@@adverse@@events@@,@@infections@@,@@malignancies@@,@@and@@hematological@@abnormalities@@.@@", "replace_sentence": "The@@incidence@@of@@all@@safety@@parameters@@was@@similar@@in@@the@@EC@@-@@MPS@@patients@@and@@the@@drug1@@-@@treated@@patients@@in@@the@@RAD@@B201@@and@@RAD@@B251@@studies@@during@@the@@12@@-@@to@@36@@-@@month@@posttransplant@@period@@,@@as@@was@@the@@frequency@@of@@adverse@@events@@,@@drug2@@,@@malignancies@@,@@and@@hematological@@abnormalities@@.@@", "new_pair": "MMF@@-@@treated@@patients@@in@@the@@RAD@@B201@@and@@RAD@@B251@@studies@@during@@the@@12@@-@@to@@36@@-@@month@@posttransplant@@period@@,@@as@@was@@the@@frequency@@of@@adverse@@events@@,@@infections", "replace_pair": "drug1@@-@@treated@@patients@@in@@the@@RAD@@B201@@and@@RAD@@B251@@studies@@during@@the@@12@@-@@to@@36@@-@@month@@posttransplant@@period@@,@@as@@was@@the@@frequency@@of@@adverse@@events@@,@@drug2", "relation": "NA"}, {"head": {"id": "532", "type": "", "word": "aspirin", "begin": "31", "end": "38", "new_begin": "36", "new_end": "43", "replace_begin": "36", "replace_end": "41"}, "tail": {"id": "533", "type": "", "word": "stroke", "begin": "116", "end": "122", "new_begin": "134", "new_end": "140", "replace_begin": "132", "replace_end": "137"}, "sentence": "Many patients are treated with aspirin to prevent a serious vascular event , most notably myocardial infarction and stroke .", "new_sentence": "Many@@patients@@are@@treated@@with@@aspirin@@to@@prevent@@a@@serious@@vascular@@event@@,@@most@@notably@@myocardial@@infarction@@and@@stroke@@.@@", "replace_sentence": "Many@@patients@@are@@treated@@with@@drug1@@to@@prevent@@a@@serious@@vascular@@event@@,@@most@@notably@@myocardial@@infarction@@and@@drug2@@.@@", "new_pair": "aspirin@@to@@prevent@@a@@serious@@vascular@@event@@,@@most@@notably@@myocardial@@infarction@@and@@stroke", "replace_pair": "drug1@@to@@prevent@@a@@serious@@vascular@@event@@,@@most@@notably@@myocardial@@infarction@@and@@drug2", "relation": "may_prevent"}, {"head": {"id": "534", "type": "", "word": "Ganciclovir", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "535", "type": "", "word": "CMVUdisease", "begin": "35", "end": "46", "new_begin": "39", "new_end": "50", "replace_begin": "33", "replace_end": "38"}, "sentence": "Ganciclovir prophylaxis to prevent CMVUdisease in kidney recipients undergoing anti- lymphocyte globulin treatment for acute rejection .", "new_sentence": "Ganciclovir@@prophylaxis@@to@@prevent@@CMVUdisease@@in@@kidney@@recipients@@undergoing@@anti@@-@@lymphocyte@@globulin@@treatment@@for@@acute@@rejection@@.@@", "replace_sentence": "drug1@@prophylaxis@@to@@prevent@@drug2@@in@@kidney@@recipients@@undergoing@@anti@@-@@lymphocyte@@globulin@@treatment@@for@@acute@@rejection@@.@@", "new_pair": "Ganciclovir@@prophylaxis@@to@@prevent@@CMVUdisease", "replace_pair": "drug1@@prophylaxis@@to@@prevent@@drug2", "relation": "may_prevent"}, {"head": {"id": "536", "type": "", "word": "EIA", "begin": "32", "end": "35", "new_begin": "39", "new_end": "42", "replace_begin": "39", "replace_end": "44"}, "tail": {"id": "537", "type": "", "word": "albuterol", "begin": "244", "end": "253", "new_begin": "288", "new_end": "297", "replace_begin": "290", "replace_end": "295"}, "sentence": "In study 2 , five subjects with EIA performed three treadmill exercise tests while breathing cold air : one test using the heat exchanger mask , one test without the mask but with albuterol pretreatment , and one test with neither the mask nor albuterol pretreatment ( unprotected exercise ) .", "new_sentence": "In@@study@@2@@,@@five@@subjects@@with@@EIA@@performed@@three@@treadmill@@exercise@@tests@@while@@breathing@@cold@@air@@:@@one@@test@@using@@the@@heat@@exchanger@@mask@@,@@one@@test@@without@@the@@mask@@but@@with@@albuterol@@pretreatment@@,@@and@@one@@test@@with@@neither@@the@@mask@@nor@@albuterol@@pretreatment@@(@@unprotected@@exercise@@)@@.@@", "replace_sentence": "In@@study@@2@@,@@five@@subjects@@with@@drug1@@performed@@three@@treadmill@@exercise@@tests@@while@@breathing@@cold@@air@@:@@one@@test@@using@@the@@heat@@exchanger@@mask@@,@@one@@test@@without@@the@@mask@@but@@with@@albuterol@@pretreatment@@,@@and@@one@@test@@with@@neither@@the@@mask@@nor@@drug2@@pretreatment@@(@@unprotected@@exercise@@)@@.@@", "new_pair": "EIA@@performed@@three@@treadmill@@exercise@@tests@@while@@breathing@@cold@@air@@:@@one@@test@@using@@the@@heat@@exchanger@@mask@@,@@one@@test@@without@@the@@mask@@but@@with@@albuterol@@pretreatment@@,@@and@@one@@test@@with@@neither@@the@@mask@@nor@@albuterol", "replace_pair": "drug1@@performed@@three@@treadmill@@exercise@@tests@@while@@breathing@@cold@@air@@:@@one@@test@@using@@the@@heat@@exchanger@@mask@@,@@one@@test@@without@@the@@mask@@but@@with@@albuterol@@pretreatment@@,@@and@@one@@test@@with@@neither@@the@@mask@@nor@@drug2", "relation": "NA"}, {"head": {"id": "538", "type": "", "word": "acetylsalicylicUacid", "begin": "43", "end": "63", "new_begin": "52", "new_end": "72", "replace_begin": "52", "replace_end": "57"}, "tail": {"id": "539", "type": "", "word": "CRI", "begin": "193", "end": "196", "new_begin": "226", "new_end": "229", "replace_begin": "211", "replace_end": "216"}, "sentence": "Medical interventions with beta-blockers , acetylsalicylicUacid , lipid-lowering therapy , and thrombolysis and surgical intervention were significantly less likely to be used in patients with CRI .", "new_sentence": "Medical@@interventions@@with@@beta@@-@@blockers@@,@@acetylsalicylicUacid@@,@@lipid@@-@@lowering@@therapy@@,@@and@@thrombolysis@@and@@surgical@@intervention@@were@@significantly@@less@@likely@@to@@be@@used@@in@@patients@@with@@CRI@@.@@", "replace_sentence": "Medical@@interventions@@with@@beta@@-@@blockers@@,@@drug1@@,@@lipid@@-@@lowering@@therapy@@,@@and@@thrombolysis@@and@@surgical@@intervention@@were@@significantly@@less@@likely@@to@@be@@used@@in@@patients@@with@@drug2@@.@@", "new_pair": "acetylsalicylicUacid@@,@@lipid@@-@@lowering@@therapy@@,@@and@@thrombolysis@@and@@surgical@@intervention@@were@@significantly@@less@@likely@@to@@be@@used@@in@@patients@@with@@CRI", "replace_pair": "drug1@@,@@lipid@@-@@lowering@@therapy@@,@@and@@thrombolysis@@and@@surgical@@intervention@@were@@significantly@@less@@likely@@to@@be@@used@@in@@patients@@with@@drug2", "relation": "NA"}, {"head": {"id": "540", "type": "", "word": "fluticasoneUpropionate", "begin": "31", "end": "53", "new_begin": "36", "new_end": "58", "replace_begin": "36", "replace_end": "41"}, "tail": {"id": "541", "type": "", "word": "bronchialUasthma", "begin": "194", "end": "210", "new_begin": "226", "new_end": "242", "replace_begin": "209", "replace_end": "214"}, "sentence": "Recent studies have shown that fluticasoneUpropionate ( FP ) was more effective than beclomethasone dipropionate ( BDP ) inhalation even at a dose reduced by twofold or more in the treatment of bronchialUasthma .", "new_sentence": "Recent@@studies@@have@@shown@@that@@fluticasoneUpropionate@@(@@FP@@)@@was@@more@@effective@@than@@beclomethasone@@dipropionate@@(@@BDP@@)@@inhalation@@even@@at@@a@@dose@@reduced@@by@@twofold@@or@@more@@in@@the@@treatment@@of@@bronchialUasthma@@.@@", "replace_sentence": "Recent@@studies@@have@@shown@@that@@drug1@@(@@FP@@)@@was@@more@@effective@@than@@beclomethasone@@dipropionate@@(@@BDP@@)@@inhalation@@even@@at@@a@@dose@@reduced@@by@@twofold@@or@@more@@in@@the@@treatment@@of@@drug2@@.@@", "new_pair": "fluticasoneUpropionate@@(@@FP@@)@@was@@more@@effective@@than@@beclomethasone@@dipropionate@@(@@BDP@@)@@inhalation@@even@@at@@a@@dose@@reduced@@by@@twofold@@or@@more@@in@@the@@treatment@@of@@bronchialUasthma", "replace_pair": "drug1@@(@@FP@@)@@was@@more@@effective@@than@@beclomethasone@@dipropionate@@(@@BDP@@)@@inhalation@@even@@at@@a@@dose@@reduced@@by@@twofold@@or@@more@@in@@the@@treatment@@of@@drug2", "relation": "NA"}, {"head": {"id": "542", "type": "", "word": "fungalUinfections", "begin": "22", "end": "39", "new_begin": "24", "new_end": "41", "replace_begin": "24", "replace_end": "29"}, "tail": {"id": "543", "type": "", "word": "fluconazole", "begin": "123", "end": "134", "new_begin": "148", "new_end": "159", "replace_begin": "136", "replace_end": "141"}, "sentence": "Breakthrough invasive fungalUinfections of the sinus ( n =1 ) , lung ( n =3 ) , and pericardium ( n =1 ) developed despite fluconazole prophylaxis and failed to respond to treatment with other licensed antifungal therapies , including amphotericin B ( n =3 ) , caspofungin ( n =2 ) , and voriconazole ( n =3 ) , and surgical intervention ( n =2 ) .", "new_sentence": "Breakthrough@@invasive@@fungalUinfections@@of@@the@@sinus@@(@@n@@=1@@)@@,@@lung@@(@@n@@=3@@)@@,@@and@@pericardium@@(@@n@@=1@@)@@developed@@despite@@fluconazole@@prophylaxis@@and@@failed@@to@@respond@@to@@treatment@@with@@other@@licensed@@antifungal@@therapies@@,@@including@@amphotericin@@B@@(@@n@@=3@@)@@,@@caspofungin@@(@@n@@=2@@)@@,@@and@@voriconazole@@(@@n@@=3@@)@@,@@and@@surgical@@intervention@@(@@n@@=2@@)@@.@@", "replace_sentence": "Breakthrough@@invasive@@drug1@@of@@the@@sinus@@(@@n@@=1@@)@@,@@lung@@(@@n@@=3@@)@@,@@and@@pericardium@@(@@n@@=1@@)@@developed@@despite@@drug2@@prophylaxis@@and@@failed@@to@@respond@@to@@treatment@@with@@other@@licensed@@antifungal@@therapies@@,@@including@@amphotericin@@B@@(@@n@@=3@@)@@,@@caspofungin@@(@@n@@=2@@)@@,@@and@@voriconazole@@(@@n@@=3@@)@@,@@and@@surgical@@intervention@@(@@n@@=2@@)@@.@@", "new_pair": "fungalUinfections@@of@@the@@sinus@@(@@n@@=1@@)@@,@@lung@@(@@n@@=3@@)@@,@@and@@pericardium@@(@@n@@=1@@)@@developed@@despite@@fluconazole", "replace_pair": "drug1@@of@@the@@sinus@@(@@n@@=1@@)@@,@@lung@@(@@n@@=3@@)@@,@@and@@pericardium@@(@@n@@=1@@)@@developed@@despite@@drug2", "relation": "NA"}, {"head": {"id": "544", "type": "", "word": "osteoporosis", "begin": "5", "end": "17", "new_begin": "6", "new_end": "18", "replace_begin": "6", "replace_end": "11"}, "tail": {"id": "545", "type": "", "word": "vitaminUD", "begin": "61", "end": "70", "new_begin": "68", "new_end": "77", "replace_begin": "61", "replace_end": "66"}, "sentence": "Some osteoporosis treatments , including bisphosphonates and vitaminUD , seem to have a beneficial effect on osteoarthritis as well .", "new_sentence": "Some@@osteoporosis@@treatments@@,@@including@@bisphosphonates@@and@@vitaminUD@@,@@seem@@to@@have@@a@@beneficial@@effect@@on@@osteoarthritis@@as@@well@@.@@", "replace_sentence": "Some@@drug1@@treatments@@,@@including@@bisphosphonates@@and@@drug2@@,@@seem@@to@@have@@a@@beneficial@@effect@@on@@osteoarthritis@@as@@well@@.@@", "new_pair": "osteoporosis@@treatments@@,@@including@@bisphosphonates@@and@@vitaminUD", "replace_pair": "drug1@@treatments@@,@@including@@bisphosphonates@@and@@drug2", "relation": "NA"}, {"head": {"id": "546", "type": "", "word": "iron-overload", "begin": "79", "end": "92", "new_begin": "90", "new_end": "103", "replace_begin": "90", "replace_end": "95"}, "tail": {"id": "547", "type": "", "word": "iron", "begin": "205", "end": "209", "new_begin": "240", "new_end": "244", "replace_begin": "232", "replace_end": "237"}, "sentence": "This study suggests that the iron chelator Desferal is neuroprotective against iron-overload , so iron chelators that can cross the blood-brain barrier may have the potential to treat cases where abnormal iron accumulation in the brain is associated with the degenerative processes , as in Parkinson s disease .", "new_sentence": "This@@study@@suggests@@that@@the@@iron@@chelator@@Desferal@@is@@neuroprotective@@against@@iron-overload@@,@@so@@iron@@chelators@@that@@can@@cross@@the@@blood@@-@@brain@@barrier@@may@@have@@the@@potential@@to@@treat@@cases@@where@@abnormal@@iron@@accumulation@@in@@the@@brain@@is@@associated@@with@@the@@degenerative@@processes@@,@@as@@in@@Parkinson@@s@@disease@@.@@", "replace_sentence": "This@@study@@suggests@@that@@the@@iron@@chelator@@Desferal@@is@@neuroprotective@@against@@drug1@@,@@so@@iron@@chelators@@that@@can@@cross@@the@@blood@@-@@brain@@barrier@@may@@have@@the@@potential@@to@@treat@@cases@@where@@abnormal@@drug2@@accumulation@@in@@the@@brain@@is@@associated@@with@@the@@degenerative@@processes@@,@@as@@in@@Parkinson@@s@@disease@@.@@", "new_pair": "iron-overload@@,@@so@@iron@@chelators@@that@@can@@cross@@the@@blood@@-@@brain@@barrier@@may@@have@@the@@potential@@to@@treat@@cases@@where@@abnormal@@iron", "replace_pair": "drug1@@,@@so@@iron@@chelators@@that@@can@@cross@@the@@blood@@-@@brain@@barrier@@may@@have@@the@@potential@@to@@treat@@cases@@where@@abnormal@@drug2", "relation": "NA"}, {"head": {"id": "548", "type": "", "word": "ischemia", "begin": "33", "end": "41", "new_begin": "39", "new_end": "47", "replace_begin": "39", "replace_end": "44"}, "tail": {"id": "549", "type": "", "word": "oxygen", "begin": "89", "end": "95", "new_begin": "104", "new_end": "110", "replace_begin": "101", "replace_end": "106"}, "sentence": "We utilized two model systems of ischemia , middle cerebral artery occlusion in vivo and oxygen - glucose deprivation in vitro , to delineate changes in AMPK activity incurred from a metabolic stress .", "new_sentence": "We@@utilized@@two@@model@@systems@@of@@ischemia@@,@@middle@@cerebral@@artery@@occlusion@@in@@vivo@@and@@oxygen@@-@@glucose@@deprivation@@in@@vitro@@,@@to@@delineate@@changes@@in@@AMPK@@activity@@incurred@@from@@a@@metabolic@@stress@@.@@", "replace_sentence": "We@@utilized@@two@@model@@systems@@of@@drug1@@,@@middle@@cerebral@@artery@@occlusion@@in@@vivo@@and@@drug2@@-@@glucose@@deprivation@@in@@vitro@@,@@to@@delineate@@changes@@in@@AMPK@@activity@@incurred@@from@@a@@metabolic@@stress@@.@@", "new_pair": "ischemia@@,@@middle@@cerebral@@artery@@occlusion@@in@@vivo@@and@@oxygen", "replace_pair": "drug1@@,@@middle@@cerebral@@artery@@occlusion@@in@@vivo@@and@@drug2", "relation": "NA"}, {"head": {"id": "550", "type": "", "word": "triiodothyronine", "begin": "26", "end": "42", "new_begin": "34", "new_end": "50", "replace_begin": "34", "replace_end": "39"}, "tail": {"id": "551", "type": "", "word": "hypothyroid", "begin": "86", "end": "97", "new_begin": "103", "new_end": "114", "replace_begin": "92", "replace_end": "97"}, "sentence": "( 3 ) The rate of loss of triiodothyronine from the brain tissue is slowed down under hypothyroid conditions as evidenced by our hormone kinetic studies .", "new_sentence": "(@@3@@)@@The@@rate@@of@@loss@@of@@triiodothyronine@@from@@the@@brain@@tissue@@is@@slowed@@down@@under@@hypothyroid@@conditions@@as@@evidenced@@by@@our@@hormone@@kinetic@@studies@@.@@", "replace_sentence": "(@@3@@)@@The@@rate@@of@@loss@@of@@drug1@@from@@the@@brain@@tissue@@is@@slowed@@down@@under@@drug2@@conditions@@as@@evidenced@@by@@our@@hormone@@kinetic@@studies@@.@@", "new_pair": "triiodothyronine@@from@@the@@brain@@tissue@@is@@slowed@@down@@under@@hypothyroid", "replace_pair": "drug1@@from@@the@@brain@@tissue@@is@@slowed@@down@@under@@drug2", "relation": "NA"}, {"head": {"id": "552", "type": "", "word": "Ganciclovir", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "553", "type": "", "word": "CMVUinfections", "begin": "155", "end": "169", "new_begin": "183", "new_end": "197", "replace_begin": "177", "replace_end": "182"}, "sentence": "Ganciclovir was re - started , and the patient improved , but 6 months later he relapsed , and chorioretinitis lesions compatible both with T . gondii and CMVUinfections appeared .", "new_sentence": "Ganciclovir@@was@@re@@-@@started@@,@@and@@the@@patient@@improved@@,@@but@@6@@months@@later@@he@@relapsed@@,@@and@@chorioretinitis@@lesions@@compatible@@both@@with@@T@@.@@gondii@@and@@CMVUinfections@@appeared@@.@@", "replace_sentence": "drug1@@was@@re@@-@@started@@,@@and@@the@@patient@@improved@@,@@but@@6@@months@@later@@he@@relapsed@@,@@and@@chorioretinitis@@lesions@@compatible@@both@@with@@T@@.@@gondii@@and@@drug2@@appeared@@.@@", "new_pair": "Ganciclovir@@was@@re@@-@@started@@,@@and@@the@@patient@@improved@@,@@but@@6@@months@@later@@he@@relapsed@@,@@and@@chorioretinitis@@lesions@@compatible@@both@@with@@T@@.@@gondii@@and@@CMVUinfections", "replace_pair": "drug1@@was@@re@@-@@started@@,@@and@@the@@patient@@improved@@,@@but@@6@@months@@later@@he@@relapsed@@,@@and@@chorioretinitis@@lesions@@compatible@@both@@with@@T@@.@@gondii@@and@@drug2", "relation": "NA"}, {"head": {"id": "554", "type": "", "word": "asthma", "begin": "143", "end": "149", "new_begin": "179", "new_end": "185", "replace_begin": "179", "replace_end": "184"}, "tail": {"id": "555", "type": "", "word": "dexamethasone", "begin": "224", "end": "237", "new_begin": "275", "new_end": "288", "replace_begin": "274", "replace_end": "279"}, "sentence": "METHODS : Totally 80 male Sprague-Dawlay rats ( 6-8 weeks old , weighing about 120 g ) were randomly divided into control groups ( 30 rats ) , asthma groups ( 30 rats ) and treated groups ( including a group intervened with dexamethasone ( DM group ) and budesonide ( BUD group ) , each had 10 rats ) .", "new_sentence": "METHODS@@:@@Totally@@80@@male@@Sprague@@-@@Dawlay@@rats@@(@@6@@-@@8@@weeks@@old@@,@@weighing@@about@@120@@g@@)@@were@@randomly@@divided@@into@@control@@groups@@(@@30@@rats@@)@@,@@asthma@@groups@@(@@30@@rats@@)@@and@@treated@@groups@@(@@including@@a@@group@@intervened@@with@@dexamethasone@@(@@DM@@group@@)@@and@@budesonide@@(@@BUD@@group@@)@@,@@each@@had@@10@@rats@@)@@.@@", "replace_sentence": "METHODS@@:@@Totally@@80@@male@@Sprague@@-@@Dawlay@@rats@@(@@6@@-@@8@@weeks@@old@@,@@weighing@@about@@120@@g@@)@@were@@randomly@@divided@@into@@control@@groups@@(@@30@@rats@@)@@,@@drug1@@groups@@(@@30@@rats@@)@@and@@treated@@groups@@(@@including@@a@@group@@intervened@@with@@drug2@@(@@DM@@group@@)@@and@@budesonide@@(@@BUD@@group@@)@@,@@each@@had@@10@@rats@@)@@.@@", "new_pair": "asthma@@groups@@(@@30@@rats@@)@@and@@treated@@groups@@(@@including@@a@@group@@intervened@@with@@dexamethasone", "replace_pair": "drug1@@groups@@(@@30@@rats@@)@@and@@treated@@groups@@(@@including@@a@@group@@intervened@@with@@drug2", "relation": "NA"}, {"head": {"id": "556", "type": "", "word": "retinol", "begin": "21", "end": "28", "new_begin": "24", "new_end": "31", "replace_begin": "24", "replace_end": "29"}, "tail": {"id": "557", "type": "", "word": "infections", "begin": "53", "end": "63", "new_begin": "60", "new_end": "70", "replace_begin": "58", "replace_end": "63"}, "sentence": "Serum carotenoid and retinol levels during childhood infections .", "new_sentence": "Serum@@carotenoid@@and@@retinol@@levels@@during@@childhood@@infections@@.@@", "replace_sentence": "Serum@@carotenoid@@and@@drug1@@levels@@during@@childhood@@drug2@@.@@", "new_pair": "retinol@@levels@@during@@childhood@@infections", "replace_pair": "drug1@@levels@@during@@childhood@@drug2", "relation": "NA"}, {"head": {"id": "558", "type": "", "word": "Aspirin", "begin": "14", "end": "21", "new_begin": "16", "new_end": "23", "replace_begin": "16", "replace_end": "21"}, "tail": {"id": "559", "type": "", "word": "thromboembolism", "begin": "100", "end": "115", "new_begin": "118", "new_end": "133", "replace_begin": "116", "replace_end": "121"}, "sentence": "CONCLUSIONS : Aspirin -plus- clopidogrel and warfarin were equally safe and effective in preventing thromboembolism in this small group of patients with non - high - risk AF .", "new_sentence": "CONCLUSIONS@@:@@Aspirin@@-@@plus@@-@@clopidogrel@@and@@warfarin@@were@@equally@@safe@@and@@effective@@in@@preventing@@thromboembolism@@in@@this@@small@@group@@of@@patients@@with@@non@@-@@high@@-@@risk@@AF@@.@@", "replace_sentence": "CONCLUSIONS@@:@@drug1@@-@@plus@@-@@clopidogrel@@and@@warfarin@@were@@equally@@safe@@and@@effective@@in@@preventing@@drug2@@in@@this@@small@@group@@of@@patients@@with@@non@@-@@high@@-@@risk@@AF@@.@@", "new_pair": "Aspirin@@-@@plus@@-@@clopidogrel@@and@@warfarin@@were@@equally@@safe@@and@@effective@@in@@preventing@@thromboembolism", "replace_pair": "drug1@@-@@plus@@-@@clopidogrel@@and@@warfarin@@were@@equally@@safe@@and@@effective@@in@@preventing@@drug2", "relation": "may_prevent"}, {"head": {"id": "560", "type": "", "word": "folicUacid", "begin": "60", "end": "70", "new_begin": "70", "new_end": "80", "replace_begin": "70", "replace_end": "75"}, "tail": {"id": "561", "type": "", "word": "stroke", "begin": "80", "end": "86", "new_begin": "93", "new_end": "99", "replace_begin": "88", "replace_end": "93"}, "sentence": "METHODS : We collected data from eight randomised trials of folicUacid that had stroke reported as one of the endpoints .", "new_sentence": "METHODS@@:@@We@@collected@@data@@from@@eight@@randomised@@trials@@of@@folicUacid@@that@@had@@stroke@@reported@@as@@one@@of@@the@@endpoints@@.@@", "replace_sentence": "METHODS@@:@@We@@collected@@data@@from@@eight@@randomised@@trials@@of@@drug1@@that@@had@@drug2@@reported@@as@@one@@of@@the@@endpoints@@.@@", "new_pair": "folicUacid@@that@@had@@stroke", "replace_pair": "drug1@@that@@had@@drug2", "relation": "NA"}, {"head": {"id": "562", "type": "", "word": "lisinopril", "begin": "52", "end": "62", "new_begin": "60", "new_end": "70", "replace_begin": "60", "replace_end": "65"}, "tail": {"id": "563", "type": "", "word": "leftUventricularUhypertrophy", "begin": "145", "end": "173", "new_begin": "169", "new_end": "197", "replace_begin": "164", "replace_end": "169"}, "sentence": "There are plenty of evidence which demonstrate that lisinopril , a first line antihypertensive agent , has a positive effect in the treatment of leftUventricularUhypertrophy , retinopathy and nephropathy , and also has a favourable outcome after myocardial infarction and in heart failure .", "new_sentence": "There@@are@@plenty@@of@@evidence@@which@@demonstrate@@that@@lisinopril@@,@@a@@first@@line@@antihypertensive@@agent@@,@@has@@a@@positive@@effect@@in@@the@@treatment@@of@@leftUventricularUhypertrophy@@,@@retinopathy@@and@@nephropathy@@,@@and@@also@@has@@a@@favourable@@outcome@@after@@myocardial@@infarction@@and@@in@@heart@@failure@@.@@", "replace_sentence": "There@@are@@plenty@@of@@evidence@@which@@demonstrate@@that@@drug1@@,@@a@@first@@line@@antihypertensive@@agent@@,@@has@@a@@positive@@effect@@in@@the@@treatment@@of@@drug2@@,@@retinopathy@@and@@nephropathy@@,@@and@@also@@has@@a@@favourable@@outcome@@after@@myocardial@@infarction@@and@@in@@heart@@failure@@.@@", "new_pair": "lisinopril@@,@@a@@first@@line@@antihypertensive@@agent@@,@@has@@a@@positive@@effect@@in@@the@@treatment@@of@@leftUventricularUhypertrophy", "replace_pair": "drug1@@,@@a@@first@@line@@antihypertensive@@agent@@,@@has@@a@@positive@@effect@@in@@the@@treatment@@of@@drug2", "relation": "NA"}, {"head": {"id": "564", "type": "", "word": "ganciclovir", "begin": "58", "end": "69", "new_begin": "70", "new_end": "81", "replace_begin": "70", "replace_end": "75"}, "tail": {"id": "565", "type": "", "word": "CMVUdisease", "begin": "196", "end": "207", "new_begin": "231", "new_end": "242", "replace_begin": "225", "replace_end": "230"}, "sentence": "AIMS : To compare the efficacy , costs and safety of oral ganciclovir and valacyclovir in the prophylaxis of cytomegalovirus ( CMV ) disease in renal transplant ( RTx ) recipients at high risk of CMVUdisease .", "new_sentence": "AIMS@@:@@To@@compare@@the@@efficacy@@,@@costs@@and@@safety@@of@@oral@@ganciclovir@@and@@valacyclovir@@in@@the@@prophylaxis@@of@@cytomegalovirus@@(@@CMV@@)@@disease@@in@@renal@@transplant@@(@@RTx@@)@@recipients@@at@@high@@risk@@of@@CMVUdisease@@.@@", "replace_sentence": "AIMS@@:@@To@@compare@@the@@efficacy@@,@@costs@@and@@safety@@of@@oral@@drug1@@and@@valacyclovir@@in@@the@@prophylaxis@@of@@cytomegalovirus@@(@@CMV@@)@@disease@@in@@renal@@transplant@@(@@RTx@@)@@recipients@@at@@high@@risk@@of@@drug2@@.@@", "new_pair": "ganciclovir@@and@@valacyclovir@@in@@the@@prophylaxis@@of@@cytomegalovirus@@(@@CMV@@)@@disease@@in@@renal@@transplant@@(@@RTx@@)@@recipients@@at@@high@@risk@@of@@CMVUdisease", "replace_pair": "drug1@@and@@valacyclovir@@in@@the@@prophylaxis@@of@@cytomegalovirus@@(@@CMV@@)@@disease@@in@@renal@@transplant@@(@@RTx@@)@@recipients@@at@@high@@risk@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "566", "type": "", "word": "heparin", "begin": "106", "end": "113", "new_begin": "121", "new_end": "128", "replace_begin": "121", "replace_end": "126"}, "tail": {"id": "567", "type": "", "word": "sepsis", "begin": "154", "end": "160", "new_begin": "177", "new_end": "183", "replace_begin": "175", "replace_end": "180"}, "sentence": "CONCLUSION : The practice of locking newly inserted tunneled central venous catheters with gentamicin and heparin is an effective strategy to reduce line sepsis rates , and is associated with beneficial effects on epoetin requirements .", "new_sentence": "CONCLUSION@@:@@The@@practice@@of@@locking@@newly@@inserted@@tunneled@@central@@venous@@catheters@@with@@gentamicin@@and@@heparin@@is@@an@@effective@@strategy@@to@@reduce@@line@@sepsis@@rates@@,@@and@@is@@associated@@with@@beneficial@@effects@@on@@epoetin@@requirements@@.@@", "replace_sentence": "CONCLUSION@@:@@The@@practice@@of@@locking@@newly@@inserted@@tunneled@@central@@venous@@catheters@@with@@gentamicin@@and@@drug1@@is@@an@@effective@@strategy@@to@@reduce@@line@@drug2@@rates@@,@@and@@is@@associated@@with@@beneficial@@effects@@on@@epoetin@@requirements@@.@@", "new_pair": "heparin@@is@@an@@effective@@strategy@@to@@reduce@@line@@sepsis", "replace_pair": "drug1@@is@@an@@effective@@strategy@@to@@reduce@@line@@drug2", "relation": "may_prevent"}, {"head": {"id": "568", "type": "", "word": "osteoporosis", "begin": "107", "end": "119", "new_begin": "130", "new_end": "142", "replace_begin": "130", "replace_end": "135"}, "tail": {"id": "569", "type": "", "word": "raloxifene", "begin": "140", "end": "150", "new_begin": "167", "new_end": "177", "replace_begin": "160", "replace_end": "165"}, "sentence": "METHODS : Our study included 178 consecutive patients aged 67 . 41 + @ - 8 . 52 years who were treated for osteoporosis with alendronate or raloxifene in the Metabolic Bone Diseases Unit .", "new_sentence": "METHODS@@:@@Our@@study@@included@@178@@consecutive@@patients@@aged@@67@@.@@41@@+@@@@@-@@8@@.@@52@@years@@who@@were@@treated@@for@@osteoporosis@@with@@alendronate@@or@@raloxifene@@in@@the@@Metabolic@@Bone@@Diseases@@Unit@@.@@", "replace_sentence": "METHODS@@:@@Our@@study@@included@@178@@consecutive@@patients@@aged@@67@@.@@41@@+@@@@@-@@8@@.@@52@@years@@who@@were@@treated@@for@@drug1@@with@@alendronate@@or@@drug2@@in@@the@@Metabolic@@Bone@@Diseases@@Unit@@.@@", "new_pair": "osteoporosis@@with@@alendronate@@or@@raloxifene", "replace_pair": "drug1@@with@@alendronate@@or@@drug2", "relation": "NA"}, {"head": {"id": "570", "type": "", "word": "raloxifene", "begin": "20", "end": "30", "new_begin": "24", "new_end": "34", "replace_begin": "24", "replace_end": "29"}, "tail": {"id": "571", "type": "", "word": "GIOP", "begin": "51", "end": "55", "new_begin": "60", "new_end": "64", "replace_begin": "55", "replace_end": "60"}, "sentence": "Data using the SERM raloxifene to treat or prevent GIOP are lacking , as are data using the promising bone anabolic agent strontium ranelate .", "new_sentence": "Data@@using@@the@@SERM@@raloxifene@@to@@treat@@or@@prevent@@GIOP@@are@@lacking@@,@@as@@are@@data@@using@@the@@promising@@bone@@anabolic@@agent@@strontium@@ranelate@@.@@", "replace_sentence": "Data@@using@@the@@SERM@@drug1@@to@@treat@@or@@prevent@@drug2@@are@@lacking@@,@@as@@are@@data@@using@@the@@promising@@bone@@anabolic@@agent@@strontium@@ranelate@@.@@", "new_pair": "raloxifene@@to@@treat@@or@@prevent@@GIOP", "replace_pair": "drug1@@to@@treat@@or@@prevent@@drug2", "relation": "NA"}, {"head": {"id": "572", "type": "", "word": "CMVUinfections", "begin": "32", "end": "46", "new_begin": "35", "new_end": "49", "replace_begin": "35", "replace_end": "40"}, "tail": {"id": "573", "type": "", "word": "ganciclovir", "begin": "84", "end": "95", "new_begin": "93", "new_end": "104", "replace_begin": "84", "replace_end": "89"}, "sentence": "Statistically significant fewer CMVUinfections occurred among patients who received ganciclovir ( 22 % ) than those who did not receive prophylaxis ( 42 % ; P = . 0075 ) or were treated with acyclovir ( 43 % ; P = . 0066 ) .", "new_sentence": "Statistically@@significant@@fewer@@CMVUinfections@@occurred@@among@@patients@@who@@received@@ganciclovir@@(@@22@@%@@)@@than@@those@@who@@did@@not@@receive@@prophylaxis@@(@@42@@%@@;@@P@@=@@.@@0075@@)@@or@@were@@treated@@with@@acyclovir@@(@@43@@%@@;@@P@@=@@.@@0066@@)@@.@@", "replace_sentence": "Statistically@@significant@@fewer@@drug1@@occurred@@among@@patients@@who@@received@@drug2@@(@@22@@%@@)@@than@@those@@who@@did@@not@@receive@@prophylaxis@@(@@42@@%@@;@@P@@=@@.@@0075@@)@@or@@were@@treated@@with@@acyclovir@@(@@43@@%@@;@@P@@=@@.@@0066@@)@@.@@", "new_pair": "CMVUinfections@@occurred@@among@@patients@@who@@received@@ganciclovir", "replace_pair": "drug1@@occurred@@among@@patients@@who@@received@@drug2", "relation": "may_prevent"}, {"head": {"id": "574", "type": "", "word": "triiodothyronine", "begin": "37", "end": "53", "new_begin": "42", "new_end": "58", "replace_begin": "42", "replace_end": "47"}, "tail": {"id": "575", "type": "", "word": "hypothyroidism", "begin": "152", "end": "166", "new_begin": "180", "new_end": "194", "replace_begin": "169", "replace_end": "174"}, "sentence": "Hyperthyroid state was maintained by triiodothyronine ( T ( 3 ) ) or thyroxine ( T ( 4 ) ) administration , while methimazole was employed for inducing hypothyroidism .", "new_sentence": "Hyperthyroid@@state@@was@@maintained@@by@@triiodothyronine@@(@@T@@(@@3@@)@@)@@or@@thyroxine@@(@@T@@(@@4@@)@@)@@administration@@,@@while@@methimazole@@was@@employed@@for@@inducing@@hypothyroidism@@.@@", "replace_sentence": "Hyperthyroid@@state@@was@@maintained@@by@@drug1@@(@@T@@(@@3@@)@@)@@or@@thyroxine@@(@@T@@(@@4@@)@@)@@administration@@,@@while@@methimazole@@was@@employed@@for@@inducing@@drug2@@.@@", "new_pair": "triiodothyronine@@(@@T@@(@@3@@)@@)@@or@@thyroxine@@(@@T@@(@@4@@)@@)@@administration@@,@@while@@methimazole@@was@@employed@@for@@inducing@@hypothyroidism", "replace_pair": "drug1@@(@@T@@(@@3@@)@@)@@or@@thyroxine@@(@@T@@(@@4@@)@@)@@administration@@,@@while@@methimazole@@was@@employed@@for@@inducing@@drug2", "relation": "NA"}, {"head": {"id": "576", "type": "", "word": "Isoniazid", "begin": "0", "end": "9", "new_begin": "0", "new_end": "9", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "577", "type": "", "word": "infections", "begin": "135", "end": "145", "new_begin": "154", "new_end": "164", "replace_begin": "150", "replace_end": "155"}, "sentence": "Isoniazid preventive therapy ( IPT ) for HIV - TB coinfected individuals reduces the reactivation of latent Mycobacterium tuberculosis infections and is being evaluated as a potential community - wide strategy for improving TB control .", "new_sentence": "Isoniazid@@preventive@@therapy@@(@@IPT@@)@@for@@HIV@@-@@TB@@coinfected@@individuals@@reduces@@the@@reactivation@@of@@latent@@Mycobacterium@@tuberculosis@@infections@@and@@is@@being@@evaluated@@as@@a@@potential@@community@@-@@wide@@strategy@@for@@improving@@TB@@control@@.@@", "replace_sentence": "drug1@@preventive@@therapy@@(@@IPT@@)@@for@@HIV@@-@@TB@@coinfected@@individuals@@reduces@@the@@reactivation@@of@@latent@@Mycobacterium@@tuberculosis@@drug2@@and@@is@@being@@evaluated@@as@@a@@potential@@community@@-@@wide@@strategy@@for@@improving@@TB@@control@@.@@", "new_pair": "Isoniazid@@preventive@@therapy@@(@@IPT@@)@@for@@HIV@@-@@TB@@coinfected@@individuals@@reduces@@the@@reactivation@@of@@latent@@Mycobacterium@@tuberculosis@@infections", "replace_pair": "drug1@@preventive@@therapy@@(@@IPT@@)@@for@@HIV@@-@@TB@@coinfected@@individuals@@reduces@@the@@reactivation@@of@@latent@@Mycobacterium@@tuberculosis@@drug2", "relation": "may_prevent"}, {"head": {"id": "578", "type": "", "word": "asthma", "begin": "395", "end": "401", "new_begin": "467", "new_end": "473", "replace_begin": "467", "replace_end": "472"}, "tail": {"id": "579", "type": "", "word": "FP", "begin": "458", "end": "460", "new_begin": "541", "new_end": "543", "replace_begin": "540", "replace_end": "545"}, "sentence": "OBJECTIVE : This study compared the efficacy and tolerability of the combination of fluticasone propionate ( FP ) and salmeterol ( SAL ) delivered via a single hydrofluoroalkane ( HFA ) 134a metered-dose inhaler ( MDI ) with those of its 2 components alone delivered via a chlorofluorocarbon ( CFC ) MDI and placebo ( PLA ) delivered via HFA MDI in adolescent and adult patients with persistent asthma that was not controlled by medium doses ( equivalent to FP 440-660 microg @ d ) of inhaled corticosteroids ( ICSs ) .", "new_sentence": "OBJECTIVE@@:@@This@@study@@compared@@the@@efficacy@@and@@tolerability@@of@@the@@combination@@of@@fluticasone@@propionate@@(@@FP@@)@@and@@salmeterol@@(@@SAL@@)@@delivered@@via@@a@@single@@hydrofluoroalkane@@(@@HFA@@)@@134a@@metered@@-@@dose@@inhaler@@(@@MDI@@)@@with@@those@@of@@its@@2@@components@@alone@@delivered@@via@@a@@chlorofluorocarbon@@(@@CFC@@)@@MDI@@and@@placebo@@(@@PLA@@)@@delivered@@via@@HFA@@MDI@@in@@adolescent@@and@@adult@@patients@@with@@persistent@@asthma@@that@@was@@not@@controlled@@by@@medium@@doses@@(@@equivalent@@to@@FP@@440@@-@@660@@microg@@@@@d@@)@@of@@inhaled@@corticosteroids@@(@@ICSs@@)@@.@@", "replace_sentence": "OBJECTIVE@@:@@This@@study@@compared@@the@@efficacy@@and@@tolerability@@of@@the@@combination@@of@@fluticasone@@propionate@@(@@FP@@)@@and@@salmeterol@@(@@SAL@@)@@delivered@@via@@a@@single@@hydrofluoroalkane@@(@@HFA@@)@@134a@@metered@@-@@dose@@inhaler@@(@@MDI@@)@@with@@those@@of@@its@@2@@components@@alone@@delivered@@via@@a@@chlorofluorocarbon@@(@@CFC@@)@@MDI@@and@@placebo@@(@@PLA@@)@@delivered@@via@@HFA@@MDI@@in@@adolescent@@and@@adult@@patients@@with@@persistent@@drug1@@that@@was@@not@@controlled@@by@@medium@@doses@@(@@equivalent@@to@@drug2@@440@@-@@660@@microg@@@@@d@@)@@of@@inhaled@@corticosteroids@@(@@ICSs@@)@@.@@", "new_pair": "asthma@@that@@was@@not@@controlled@@by@@medium@@doses@@(@@equivalent@@to@@FP", "replace_pair": "drug1@@that@@was@@not@@controlled@@by@@medium@@doses@@(@@equivalent@@to@@drug2", "relation": "NA"}, {"head": {"id": "580", "type": "", "word": "oxygen", "begin": "146", "end": "152", "new_begin": "167", "new_end": "173", "replace_begin": "167", "replace_end": "172"}, "tail": {"id": "581", "type": "", "word": "respiratoryUdistressUsyndrome", "begin": "184", "end": "213", "new_begin": "211", "new_end": "240", "replace_begin": "210", "replace_end": "215"}, "sentence": "Apoptosis and proliferation and the effect of exogenous surfactant on these processes were investigated in the lungs of mechanically ventilated @ oxygen - treated preterm infants with respiratoryUdistressUsyndrome and stillborn foetuses .", "new_sentence": "Apoptosis@@and@@proliferation@@and@@the@@effect@@of@@exogenous@@surfactant@@on@@these@@processes@@were@@investigated@@in@@the@@lungs@@of@@mechanically@@ventilated@@@@@oxygen@@-@@treated@@preterm@@infants@@with@@respiratoryUdistressUsyndrome@@and@@stillborn@@foetuses@@.@@", "replace_sentence": "Apoptosis@@and@@proliferation@@and@@the@@effect@@of@@exogenous@@surfactant@@on@@these@@processes@@were@@investigated@@in@@the@@lungs@@of@@mechanically@@ventilated@@@@@drug1@@-@@treated@@preterm@@infants@@with@@drug2@@and@@stillborn@@foetuses@@.@@", "new_pair": "oxygen@@-@@treated@@preterm@@infants@@with@@respiratoryUdistressUsyndrome", "replace_pair": "drug1@@-@@treated@@preterm@@infants@@with@@drug2", "relation": "NA"}, {"head": {"id": "582", "type": "", "word": "fluticasoneUpropionate", "begin": "139", "end": "161", "new_begin": "164", "new_end": "186", "replace_begin": "164", "replace_end": "169"}, "tail": {"id": "583", "type": "", "word": "asthma", "begin": "256", "end": "262", "new_begin": "296", "new_end": "302", "replace_begin": "279", "replace_end": "284"}, "sentence": "METHODS : A multicentre , randomised , placebo controlled , parallel group study was performed to compare the anti-inflammatory effects of fluticasoneUpropionate and montelukast as measured by sputum eosinophils in 50 adults with symptomatic steroid naive asthma and sputum eosinophilia of > or = 3 . 5 % .", "new_sentence": "METHODS@@:@@A@@multicentre@@,@@randomised@@,@@placebo@@controlled@@,@@parallel@@group@@study@@was@@performed@@to@@compare@@the@@anti@@-@@inflammatory@@effects@@of@@fluticasoneUpropionate@@and@@montelukast@@as@@measured@@by@@sputum@@eosinophils@@in@@50@@adults@@with@@symptomatic@@steroid@@naive@@asthma@@and@@sputum@@eosinophilia@@of@@>@@or@@=@@3@@.@@5@@%@@.@@", "replace_sentence": "METHODS@@:@@A@@multicentre@@,@@randomised@@,@@placebo@@controlled@@,@@parallel@@group@@study@@was@@performed@@to@@compare@@the@@anti@@-@@inflammatory@@effects@@of@@drug1@@and@@montelukast@@as@@measured@@by@@sputum@@eosinophils@@in@@50@@adults@@with@@symptomatic@@steroid@@naive@@drug2@@and@@sputum@@eosinophilia@@of@@>@@or@@=@@3@@.@@5@@%@@.@@", "new_pair": "fluticasoneUpropionate@@and@@montelukast@@as@@measured@@by@@sputum@@eosinophils@@in@@50@@adults@@with@@symptomatic@@steroid@@naive@@asthma", "replace_pair": "drug1@@and@@montelukast@@as@@measured@@by@@sputum@@eosinophils@@in@@50@@adults@@with@@symptomatic@@steroid@@naive@@drug2", "relation": "NA"}, {"head": {"id": "584", "type": "", "word": "cavity", "begin": "90", "end": "96", "new_begin": "103", "new_end": "109", "replace_begin": "103", "replace_end": "108"}, "tail": {"id": "585", "type": "", "word": "iron", "begin": "105", "end": "109", "new_begin": "121", "new_end": "125", "replace_begin": "120", "replace_end": "125"}, "sentence": "Dimers have a decreased protection efficiency due to disruption of the dodecamer internal cavity , where iron is deposited and mineralized after oxidation at the ferroxidase center .", "new_sentence": "Dimers@@have@@a@@decreased@@protection@@efficiency@@due@@to@@disruption@@of@@the@@dodecamer@@internal@@cavity@@,@@where@@iron@@is@@deposited@@and@@mineralized@@after@@oxidation@@at@@the@@ferroxidase@@center@@.@@", "replace_sentence": "Dimers@@have@@a@@decreased@@protection@@efficiency@@due@@to@@disruption@@of@@the@@dodecamer@@internal@@drug1@@,@@where@@drug2@@is@@deposited@@and@@mineralized@@after@@oxidation@@at@@the@@ferroxidase@@center@@.@@", "new_pair": "cavity@@,@@where@@iron", "replace_pair": "drug1@@,@@where@@drug2", "relation": "NA"}, {"head": {"id": "586", "type": "", "word": "ON", "begin": "69", "end": "71", "new_begin": "79", "new_end": "81", "replace_begin": "79", "replace_end": "84"}, "tail": {"id": "587", "type": "", "word": "antisepticUagents", "begin": "136", "end": "153", "new_begin": "157", "new_end": "174", "replace_begin": "160", "replace_end": "165"}, "sentence": "Chlamydia trachomatis has become the most common infectious cause of ON in developed countries . A number of prophylactic antibiotic or antisepticUagents have been used to prevent ON .", "new_sentence": "Chlamydia@@trachomatis@@has@@become@@the@@most@@common@@infectious@@cause@@of@@ON@@in@@developed@@countries@@.@@A@@number@@of@@prophylactic@@antibiotic@@or@@antisepticUagents@@have@@been@@used@@to@@prevent@@ON@@.@@", "replace_sentence": "Chlamydia@@trachomatis@@has@@become@@the@@most@@common@@infectious@@cause@@of@@drug1@@in@@developed@@countries@@.@@A@@number@@of@@prophylactic@@antibiotic@@or@@drug2@@have@@been@@used@@to@@prevent@@ON@@.@@", "new_pair": "ON@@in@@developed@@countries@@.@@A@@number@@of@@prophylactic@@antibiotic@@or@@antisepticUagents", "replace_pair": "drug1@@in@@developed@@countries@@.@@A@@number@@of@@prophylactic@@antibiotic@@or@@drug2", "relation": "NA"}, {"head": {"id": "588", "type": "", "word": "fluoride", "begin": "61", "end": "69", "new_begin": "71", "new_end": "79", "replace_begin": "71", "replace_end": "76"}, "tail": {"id": "589", "type": "", "word": "caries", "begin": "91", "end": "97", "new_begin": "106", "new_end": "112", "replace_begin": "103", "replace_end": "108"}, "sentence": "This combination along with the well - established effect of fluoride in the prevention of caries , presents an important contribution to dental public health .", "new_sentence": "This@@combination@@along@@with@@the@@well@@-@@established@@effect@@of@@fluoride@@in@@the@@prevention@@of@@caries@@,@@presents@@an@@important@@contribution@@to@@dental@@public@@health@@.@@", "replace_sentence": "This@@combination@@along@@with@@the@@well@@-@@established@@effect@@of@@drug1@@in@@the@@prevention@@of@@drug2@@,@@presents@@an@@important@@contribution@@to@@dental@@public@@health@@.@@", "new_pair": "fluoride@@in@@the@@prevention@@of@@caries", "replace_pair": "drug1@@in@@the@@prevention@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "590", "type": "", "word": "fluoride", "begin": "157", "end": "165", "new_begin": "187", "new_end": "195", "replace_begin": "187", "replace_end": "192"}, "tail": {"id": "591", "type": "", "word": "caries", "begin": "274", "end": "280", "new_begin": "320", "new_end": "326", "replace_begin": "317", "replace_end": "322"}, "sentence": "The deterioration in dental health of 5- year - olds after 1997 was associated with a reduction in the sale of fluoride tablets , whereas increased sales of fluoride tablets after 1998 reflect improved caries prevention among preschool children and may explain the improved caries status of these children in 2003 .", "new_sentence": "The@@deterioration@@in@@dental@@health@@of@@5@@-@@year@@-@@olds@@after@@1997@@was@@associated@@with@@a@@reduction@@in@@the@@sale@@of@@fluoride@@tablets@@,@@whereas@@increased@@sales@@of@@fluoride@@tablets@@after@@1998@@reflect@@improved@@caries@@prevention@@among@@preschool@@children@@and@@may@@explain@@the@@improved@@caries@@status@@of@@these@@children@@in@@2003@@.@@", "replace_sentence": "The@@deterioration@@in@@dental@@health@@of@@5@@-@@year@@-@@olds@@after@@1997@@was@@associated@@with@@a@@reduction@@in@@the@@sale@@of@@fluoride@@tablets@@,@@whereas@@increased@@sales@@of@@drug1@@tablets@@after@@1998@@reflect@@improved@@caries@@prevention@@among@@preschool@@children@@and@@may@@explain@@the@@improved@@drug2@@status@@of@@these@@children@@in@@2003@@.@@", "new_pair": "fluoride@@tablets@@after@@1998@@reflect@@improved@@caries@@prevention@@among@@preschool@@children@@and@@may@@explain@@the@@improved@@caries", "replace_pair": "drug1@@tablets@@after@@1998@@reflect@@improved@@caries@@prevention@@among@@preschool@@children@@and@@may@@explain@@the@@improved@@drug2", "relation": "may_prevent"}, {"head": {"id": "592", "type": "", "word": "pneumococcalUinfection", "begin": "212", "end": "234", "new_begin": "244", "new_end": "266", "replace_begin": "244", "replace_end": "249"}, "tail": {"id": "593", "type": "", "word": "acetylsalicylicUacid", "begin": "284", "end": "304", "new_begin": "325", "new_end": "345", "replace_begin": "308", "replace_end": "313"}, "sentence": "It approaches the screening of hypertension , visual and auditive impairment , breast , colorectal , cervical , prostate cancers , about dyslipidemia , depression , osteoporosis , vaccination against influenza , pneumococcalUinfection , and chemoprophylaxy by estrogen , raloxifene , acetylsalicylicUacid .", "new_sentence": "It@@approaches@@the@@screening@@of@@hypertension@@,@@visual@@and@@auditive@@impairment@@,@@breast@@,@@colorectal@@,@@cervical@@,@@prostate@@cancers@@,@@about@@dyslipidemia@@,@@depression@@,@@osteoporosis@@,@@vaccination@@against@@influenza@@,@@pneumococcalUinfection@@,@@and@@chemoprophylaxy@@by@@estrogen@@,@@raloxifene@@,@@acetylsalicylicUacid@@.@@", "replace_sentence": "It@@approaches@@the@@screening@@of@@hypertension@@,@@visual@@and@@auditive@@impairment@@,@@breast@@,@@colorectal@@,@@cervical@@,@@prostate@@cancers@@,@@about@@dyslipidemia@@,@@depression@@,@@osteoporosis@@,@@vaccination@@against@@influenza@@,@@drug1@@,@@and@@chemoprophylaxy@@by@@estrogen@@,@@raloxifene@@,@@drug2@@.@@", "new_pair": "pneumococcalUinfection@@,@@and@@chemoprophylaxy@@by@@estrogen@@,@@raloxifene@@,@@acetylsalicylicUacid", "replace_pair": "drug1@@,@@and@@chemoprophylaxy@@by@@estrogen@@,@@raloxifene@@,@@drug2", "relation": "NA"}, {"head": {"id": "594", "type": "", "word": "worm", "begin": "4", "end": "8", "new_begin": "5", "new_end": "9", "replace_begin": "5", "replace_end": "10"}, "tail": {"id": "595", "type": "", "word": "ketotifen", "begin": "59", "end": "68", "new_begin": "70", "new_end": "79", "replace_begin": "71", "replace_end": "76"}, "sentence": "The worm recovery rate was higher and lasted longer in the ketotifen - treated mice in comparison to the untreated mice .", "new_sentence": "The@@worm@@recovery@@rate@@was@@higher@@and@@lasted@@longer@@in@@the@@ketotifen@@-@@treated@@mice@@in@@comparison@@to@@the@@untreated@@mice@@.@@", "replace_sentence": "The@@drug1@@recovery@@rate@@was@@higher@@and@@lasted@@longer@@in@@the@@drug2@@-@@treated@@mice@@in@@comparison@@to@@the@@untreated@@mice@@.@@", "new_pair": "worm@@recovery@@rate@@was@@higher@@and@@lasted@@longer@@in@@the@@ketotifen", "replace_pair": "drug1@@recovery@@rate@@was@@higher@@and@@lasted@@longer@@in@@the@@drug2", "relation": "NA"}, {"head": {"id": "596", "type": "", "word": "cyclosporineUA", "begin": "26", "end": "40", "new_begin": "30", "new_end": "44", "replace_begin": "30", "replace_end": "35"}, "tail": {"id": "597", "type": "", "word": "graft-versus-hostUdisease", "begin": "89", "end": "114", "new_begin": "104", "new_end": "129", "replace_begin": "95", "replace_end": "100"}, "sentence": "All the patients received cyclosporineUA , short term MTX and MMF for the prophylaxis of graft-versus-hostUdisease ( GVHD ) .", "new_sentence": "All@@the@@patients@@received@@cyclosporineUA@@,@@short@@term@@MTX@@and@@MMF@@for@@the@@prophylaxis@@of@@graft-versus-hostUdisease@@(@@GVHD@@)@@.@@", "replace_sentence": "All@@the@@patients@@received@@drug1@@,@@short@@term@@MTX@@and@@MMF@@for@@the@@prophylaxis@@of@@drug2@@(@@GVHD@@)@@.@@", "new_pair": "cyclosporineUA@@,@@short@@term@@MTX@@and@@MMF@@for@@the@@prophylaxis@@of@@graft-versus-hostUdisease", "replace_pair": "drug1@@,@@short@@term@@MTX@@and@@MMF@@for@@the@@prophylaxis@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "598", "type": "", "word": "vitaminUBU ( U12", "begin": "117", "end": "133", "new_begin": "134", "new_end": "150", "replace_begin": "134", "replace_end": "139"}, "tail": {"id": "599", "type": "", "word": "folateUdeficiencies", "begin": "140", "end": "159", "new_begin": "160", "new_end": "179", "replace_begin": "149", "replace_end": "154"}, "sentence": "The higher prevalence of undernutritional states and parasitic infestations in many of these countries could lead to vitaminUBU ( U12 ) and folateUdeficiencies .", "new_sentence": "The@@higher@@prevalence@@of@@undernutritional@@states@@and@@parasitic@@infestations@@in@@many@@of@@these@@countries@@could@@lead@@to@@vitaminUBU ( U12@@)@@and@@folateUdeficiencies@@.@@", "replace_sentence": "The@@higher@@prevalence@@of@@undernutritional@@states@@and@@parasitic@@infestations@@in@@many@@of@@these@@countries@@could@@lead@@to@@drug1@@)@@and@@drug2@@.@@", "new_pair": "vitaminUBU ( U12@@)@@and@@folateUdeficiencies", "replace_pair": "drug1@@)@@and@@drug2", "relation": "NA"}, {"head": {"id": "600", "type": "", "word": "aspirin", "begin": "71", "end": "78", "new_begin": "82", "new_end": "89", "replace_begin": "82", "replace_end": "87"}, "tail": {"id": "601", "type": "", "word": "myocardialUinfarction", "begin": "120", "end": "141", "new_begin": "140", "new_end": "161", "replace_begin": "138", "replace_end": "143"}, "sentence": "BACKGROUND : Platelet glycoprotein IIb @ IIIa inhibitors are used with aspirin and heparin to decrease rates of death , myocardialUinfarction , and urgent revascularization in patients with acute coronary syndromes .", "new_sentence": "BACKGROUND@@:@@Platelet@@glycoprotein@@IIb@@@@@IIIa@@inhibitors@@are@@used@@with@@aspirin@@and@@heparin@@to@@decrease@@rates@@of@@death@@,@@myocardialUinfarction@@,@@and@@urgent@@revascularization@@in@@patients@@with@@acute@@coronary@@syndromes@@.@@", "replace_sentence": "BACKGROUND@@:@@Platelet@@glycoprotein@@IIb@@@@@IIIa@@inhibitors@@are@@used@@with@@drug1@@and@@heparin@@to@@decrease@@rates@@of@@death@@,@@drug2@@,@@and@@urgent@@revascularization@@in@@patients@@with@@acute@@coronary@@syndromes@@.@@", "new_pair": "aspirin@@and@@heparin@@to@@decrease@@rates@@of@@death@@,@@myocardialUinfarction", "replace_pair": "drug1@@and@@heparin@@to@@decrease@@rates@@of@@death@@,@@drug2", "relation": "may_prevent"}, {"head": {"id": "602", "type": "", "word": "mumps", "begin": "47", "end": "52", "new_begin": "56", "new_end": "61", "replace_begin": "56", "replace_end": "61"}, "tail": {"id": "603", "type": "", "word": "rubella-UcontainingUvaccines", "begin": "59", "end": "87", "new_begin": "71", "new_end": "99", "replace_begin": "71", "replace_end": "76"}, "sentence": "Most were vaccinated with 2 doses of measles , mumps , and rubella-UcontainingUvaccines .", "new_sentence": "Most@@were@@vaccinated@@with@@2@@doses@@of@@measles@@,@@mumps@@,@@and@@rubella-UcontainingUvaccines@@.@@", "replace_sentence": "Most@@were@@vaccinated@@with@@2@@doses@@of@@measles@@,@@drug1@@,@@and@@drug2@@.@@", "new_pair": "mumps@@,@@and@@rubella-UcontainingUvaccines", "replace_pair": "drug1@@,@@and@@drug2", "relation": "NA"}, {"head": {"id": "604", "type": "", "word": "dipyridamole", "begin": "46", "end": "58", "new_begin": "53", "new_end": "65", "replace_begin": "53", "replace_end": "58"}, "tail": {"id": "605", "type": "", "word": "stroke", "begin": "174", "end": "180", "new_begin": "200", "new_end": "206", "replace_begin": "193", "replace_end": "198"}, "sentence": "CONCLUSIONS : The combination of aspirin plus dipyridamole is more effective than aspirin alone in preventing stroke and other serious vascular events in patients with minor stroke and TIAs .", "new_sentence": "CONCLUSIONS@@:@@The@@combination@@of@@aspirin@@plus@@dipyridamole@@is@@more@@effective@@than@@aspirin@@alone@@in@@preventing@@stroke@@and@@other@@serious@@vascular@@events@@in@@patients@@with@@minor@@stroke@@and@@TIAs@@.@@", "replace_sentence": "CONCLUSIONS@@:@@The@@combination@@of@@aspirin@@plus@@drug1@@is@@more@@effective@@than@@aspirin@@alone@@in@@preventing@@stroke@@and@@other@@serious@@vascular@@events@@in@@patients@@with@@minor@@drug2@@and@@TIAs@@.@@", "new_pair": "dipyridamole@@is@@more@@effective@@than@@aspirin@@alone@@in@@preventing@@stroke@@and@@other@@serious@@vascular@@events@@in@@patients@@with@@minor@@stroke", "replace_pair": "drug1@@is@@more@@effective@@than@@aspirin@@alone@@in@@preventing@@stroke@@and@@other@@serious@@vascular@@events@@in@@patients@@with@@minor@@drug2", "relation": "may_prevent"}, {"head": {"id": "606", "type": "", "word": "perindopril", "begin": "165", "end": "176", "new_begin": "200", "new_end": "211", "replace_begin": "200", "replace_end": "205"}, "tail": {"id": "607", "type": "", "word": "stroke", "begin": "228", "end": "234", "new_begin": "274", "new_end": "280", "replace_begin": "268", "replace_end": "273"}, "sentence": "METHODS : Nested case-control study of ischemic ( n =472 ) and hemorrhagic ( n =83 ) strokes occurring during a randomized , placebo-controlled multicenter trial of perindopril - based therapy in 6105 patients with a history of stroke or transient ischemic attack .", "new_sentence": "METHODS@@:@@Nested@@case@@-@@control@@study@@of@@ischemic@@(@@n@@=472@@)@@and@@hemorrhagic@@(@@n@@=83@@)@@strokes@@occurring@@during@@a@@randomized@@,@@placebo@@-@@controlled@@multicenter@@trial@@of@@perindopril@@-@@based@@therapy@@in@@6105@@patients@@with@@a@@history@@of@@stroke@@or@@transient@@ischemic@@attack@@.@@", "replace_sentence": "METHODS@@:@@Nested@@case@@-@@control@@study@@of@@ischemic@@(@@n@@=472@@)@@and@@hemorrhagic@@(@@n@@=83@@)@@strokes@@occurring@@during@@a@@randomized@@,@@placebo@@-@@controlled@@multicenter@@trial@@of@@drug1@@-@@based@@therapy@@in@@6105@@patients@@with@@a@@history@@of@@drug2@@or@@transient@@ischemic@@attack@@.@@", "new_pair": "perindopril@@-@@based@@therapy@@in@@6105@@patients@@with@@a@@history@@of@@stroke", "replace_pair": "drug1@@-@@based@@therapy@@in@@6105@@patients@@with@@a@@history@@of@@drug2", "relation": "NA"}, {"head": {"id": "608", "type": "", "word": "fluconazole", "begin": "27", "end": "38", "new_begin": "30", "new_end": "41", "replace_begin": "30", "replace_end": "35"}, "tail": {"id": "609", "type": "", "word": "mycoses", "begin": "72", "end": "79", "new_begin": "80", "new_end": "87", "replace_begin": "74", "replace_end": "79"}, "sentence": "CONCLUSIONS : Prophylactic fluconazole administration for prevention of mycoses in SICU patients appears to successfully decrease the rate of these infections , but this strategy does not improve survival .", "new_sentence": "CONCLUSIONS@@:@@Prophylactic@@fluconazole@@administration@@for@@prevention@@of@@mycoses@@in@@SICU@@patients@@appears@@to@@successfully@@decrease@@the@@rate@@of@@these@@infections@@,@@but@@this@@strategy@@does@@not@@improve@@survival@@.@@", "replace_sentence": "CONCLUSIONS@@:@@Prophylactic@@drug1@@administration@@for@@prevention@@of@@drug2@@in@@SICU@@patients@@appears@@to@@successfully@@decrease@@the@@rate@@of@@these@@infections@@,@@but@@this@@strategy@@does@@not@@improve@@survival@@.@@", "new_pair": "fluconazole@@administration@@for@@prevention@@of@@mycoses", "replace_pair": "drug1@@administration@@for@@prevention@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "610", "type": "", "word": "fluticasoneUpropionate", "begin": "194", "end": "216", "new_begin": "228", "new_end": "250", "replace_begin": "228", "replace_end": "233"}, "tail": {"id": "611", "type": "", "word": "asthmatic", "begin": "502", "end": "511", "new_begin": "587", "new_end": "596", "replace_begin": "570", "replace_end": "575"}, "sentence": "OBJECTIVE : Because the clinical efficacy of inhaled corticosteroids combined with long - acting beta 2 - agonists has been widely demonstrated in asthma , we studied , in vitro , the effect of fluticasoneUpropionate ( FP ) and salmeterol alone and in combination on the activation and apoptosis of peripheral blood T cells ( PBTs ) , on the expression of phosphorylated nuclear factor kappaB inhibitor ( IkappaBalpha ) , and on the nuclear translocation of glucocorticoid receptor ( GR ) in PBTs from asthmatic subjects .", "new_sentence": "OBJECTIVE@@:@@Because@@the@@clinical@@efficacy@@of@@inhaled@@corticosteroids@@combined@@with@@long@@-@@acting@@beta@@2@@-@@agonists@@has@@been@@widely@@demonstrated@@in@@asthma@@,@@we@@studied@@,@@in@@vitro@@,@@the@@effect@@of@@fluticasoneUpropionate@@(@@FP@@)@@and@@salmeterol@@alone@@and@@in@@combination@@on@@the@@activation@@and@@apoptosis@@of@@peripheral@@blood@@T@@cells@@(@@PBTs@@)@@,@@on@@the@@expression@@of@@phosphorylated@@nuclear@@factor@@kappaB@@inhibitor@@(@@IkappaBalpha@@)@@,@@and@@on@@the@@nuclear@@translocation@@of@@glucocorticoid@@receptor@@(@@GR@@)@@in@@PBTs@@from@@asthmatic@@subjects@@.@@", "replace_sentence": "OBJECTIVE@@:@@Because@@the@@clinical@@efficacy@@of@@inhaled@@corticosteroids@@combined@@with@@long@@-@@acting@@beta@@2@@-@@agonists@@has@@been@@widely@@demonstrated@@in@@asthma@@,@@we@@studied@@,@@in@@vitro@@,@@the@@effect@@of@@drug1@@(@@FP@@)@@and@@salmeterol@@alone@@and@@in@@combination@@on@@the@@activation@@and@@apoptosis@@of@@peripheral@@blood@@T@@cells@@(@@PBTs@@)@@,@@on@@the@@expression@@of@@phosphorylated@@nuclear@@factor@@kappaB@@inhibitor@@(@@IkappaBalpha@@)@@,@@and@@on@@the@@nuclear@@translocation@@of@@glucocorticoid@@receptor@@(@@GR@@)@@in@@PBTs@@from@@drug2@@subjects@@.@@", "new_pair": "fluticasoneUpropionate@@(@@FP@@)@@and@@salmeterol@@alone@@and@@in@@combination@@on@@the@@activation@@and@@apoptosis@@of@@peripheral@@blood@@T@@cells@@(@@PBTs@@)@@,@@on@@the@@expression@@of@@phosphorylated@@nuclear@@factor@@kappaB@@inhibitor@@(@@IkappaBalpha@@)@@,@@and@@on@@the@@nuclear@@translocation@@of@@glucocorticoid@@receptor@@(@@GR@@)@@in@@PBTs@@from@@asthmatic", "replace_pair": "drug1@@(@@FP@@)@@and@@salmeterol@@alone@@and@@in@@combination@@on@@the@@activation@@and@@apoptosis@@of@@peripheral@@blood@@T@@cells@@(@@PBTs@@)@@,@@on@@the@@expression@@of@@phosphorylated@@nuclear@@factor@@kappaB@@inhibitor@@(@@IkappaBalpha@@)@@,@@and@@on@@the@@nuclear@@translocation@@of@@glucocorticoid@@receptor@@(@@GR@@)@@in@@PBTs@@from@@drug2", "relation": "NA"}, {"head": {"id": "612", "type": "", "word": "Aciclovir", "begin": "0", "end": "9", "new_begin": "0", "new_end": "9", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "613", "type": "", "word": "cytomegalovirusUinfection", "begin": "50", "end": "75", "new_begin": "56", "new_end": "81", "replace_begin": "52", "replace_end": "57"}, "sentence": "Aciclovir or ganciclovir universal prophylaxis of cytomegalovirusUinfection in liver transplantation : an economic analysis .", "new_sentence": "Aciclovir@@or@@ganciclovir@@universal@@prophylaxis@@of@@cytomegalovirusUinfection@@in@@liver@@transplantation@@:@@an@@economic@@analysis@@.@@", "replace_sentence": "drug1@@or@@ganciclovir@@universal@@prophylaxis@@of@@drug2@@in@@liver@@transplantation@@:@@an@@economic@@analysis@@.@@", "new_pair": "Aciclovir@@or@@ganciclovir@@universal@@prophylaxis@@of@@cytomegalovirusUinfection", "replace_pair": "drug1@@or@@ganciclovir@@universal@@prophylaxis@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "614", "type": "", "word": "ironUoxide", "begin": "91", "end": "101", "new_begin": "107", "new_end": "117", "replace_begin": "107", "replace_end": "112"}, "tail": {"id": "615", "type": "", "word": "chronicUkidneyUdisease", "begin": "156", "end": "178", "new_begin": "180", "new_end": "202", "replace_begin": "175", "replace_end": "180"}, "sentence": "This phase II clinical trial studied ferumoxytol , a semi- synthetic carbohydrate - coated ironUoxide administered by rapid intravenous injection to anemic chronicUkidneyUdisease patients ( predialysis or undergoing peritoneal dialysis ) .", "new_sentence": "This@@phase@@II@@clinical@@trial@@studied@@ferumoxytol@@,@@a@@semi@@-@@synthetic@@carbohydrate@@-@@coated@@ironUoxide@@administered@@by@@rapid@@intravenous@@injection@@to@@anemic@@chronicUkidneyUdisease@@patients@@(@@predialysis@@or@@undergoing@@peritoneal@@dialysis@@)@@.@@", "replace_sentence": "This@@phase@@II@@clinical@@trial@@studied@@ferumoxytol@@,@@a@@semi@@-@@synthetic@@carbohydrate@@-@@coated@@drug1@@administered@@by@@rapid@@intravenous@@injection@@to@@anemic@@drug2@@patients@@(@@predialysis@@or@@undergoing@@peritoneal@@dialysis@@)@@.@@", "new_pair": "ironUoxide@@administered@@by@@rapid@@intravenous@@injection@@to@@anemic@@chronicUkidneyUdisease", "replace_pair": "drug1@@administered@@by@@rapid@@intravenous@@injection@@to@@anemic@@drug2", "relation": "NA"}, {"head": {"id": "616", "type": "", "word": "infectiousUdisease", "begin": "79", "end": "97", "new_begin": "92", "new_end": "110", "replace_begin": "92", "replace_end": "97"}, "tail": {"id": "617", "type": "", "word": "hepatitisUBUsurfaceUantigen", "begin": "147", "end": "174", "new_begin": "177", "new_end": "204", "replace_begin": "164", "replace_end": "169"}, "sentence": "The blood donations were analysed for the presence or absence of the following infectiousUdisease markers : anti- hepatitis C virus ( anti-HCV ) , hepatitisUBUsurfaceUantigen ( HBsAg ) , anti- human immunodeficiency virus ( anti-HIV ( 1 ) @ ( 2 ) ) and syphilis .", "new_sentence": "The@@blood@@donations@@were@@analysed@@for@@the@@presence@@or@@absence@@of@@the@@following@@infectiousUdisease@@markers@@:@@anti@@-@@hepatitis@@C@@virus@@(@@anti@@-@@HCV@@)@@,@@hepatitisUBUsurfaceUantigen@@(@@HBsAg@@)@@,@@anti@@-@@human@@immunodeficiency@@virus@@(@@anti@@-@@HIV@@(@@1@@)@@@@@(@@2@@)@@)@@and@@syphilis@@.@@", "replace_sentence": "The@@blood@@donations@@were@@analysed@@for@@the@@presence@@or@@absence@@of@@the@@following@@drug1@@markers@@:@@anti@@-@@hepatitis@@C@@virus@@(@@anti@@-@@HCV@@)@@,@@drug2@@(@@HBsAg@@)@@,@@anti@@-@@human@@immunodeficiency@@virus@@(@@anti@@-@@HIV@@(@@1@@)@@@@@(@@2@@)@@)@@and@@syphilis@@.@@", "new_pair": "infectiousUdisease@@markers@@:@@anti@@-@@hepatitis@@C@@virus@@(@@anti@@-@@HCV@@)@@,@@hepatitisUBUsurfaceUantigen", "replace_pair": "drug1@@markers@@:@@anti@@-@@hepatitis@@C@@virus@@(@@anti@@-@@HCV@@)@@,@@drug2", "relation": "NA"}, {"head": {"id": "618", "type": "", "word": "albuterol", "begin": "27", "end": "36", "new_begin": "31", "new_end": "40", "replace_begin": "31", "replace_end": "36"}, "tail": {"id": "619", "type": "", "word": "exercise-inducedUasthma", "begin": "149", "end": "172", "new_begin": "175", "new_end": "198", "replace_begin": "171", "replace_end": "176"}, "sentence": "In conclusion , intranasal albuterol may offer an alternative to metered-dose inhalers for the treatment of acute bronchospasm and for prevention of exercise-inducedUasthma , especially for children and the elderly .", "new_sentence": "In@@conclusion@@,@@intranasal@@albuterol@@may@@offer@@an@@alternative@@to@@metered@@-@@dose@@inhalers@@for@@the@@treatment@@of@@acute@@bronchospasm@@and@@for@@prevention@@of@@exercise-inducedUasthma@@,@@especially@@for@@children@@and@@the@@elderly@@.@@", "replace_sentence": "In@@conclusion@@,@@intranasal@@drug1@@may@@offer@@an@@alternative@@to@@metered@@-@@dose@@inhalers@@for@@the@@treatment@@of@@acute@@bronchospasm@@and@@for@@prevention@@of@@drug2@@,@@especially@@for@@children@@and@@the@@elderly@@.@@", "new_pair": "albuterol@@may@@offer@@an@@alternative@@to@@metered@@-@@dose@@inhalers@@for@@the@@treatment@@of@@acute@@bronchospasm@@and@@for@@prevention@@of@@exercise-inducedUasthma", "replace_pair": "drug1@@may@@offer@@an@@alternative@@to@@metered@@-@@dose@@inhalers@@for@@the@@treatment@@of@@acute@@bronchospasm@@and@@for@@prevention@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "620", "type": "", "word": "CQR", "begin": "157", "end": "160", "new_begin": "186", "new_end": "189", "replace_begin": "186", "replace_end": "191"}, "tail": {"id": "621", "type": "", "word": "malaria", "begin": "257", "end": "264", "new_begin": "302", "new_end": "309", "replace_begin": "304", "replace_end": "309"}, "sentence": "Further analyses showed that one of the three haplotypes present in the early 1980 s samples has become the predominant haplotype ( frequency = 0 . 901 ) in CQR parasite populations collected after 1995 from three PNG sites , when CQR had spread throughout malaria - endemic regions of PNG .", "new_sentence": "Further@@analyses@@showed@@that@@one@@of@@the@@three@@haplotypes@@present@@in@@the@@early@@1980@@s@@samples@@has@@become@@the@@predominant@@haplotype@@(@@frequency@@=@@0@@.@@901@@)@@in@@CQR@@parasite@@populations@@collected@@after@@1995@@from@@three@@PNG@@sites@@,@@when@@CQR@@had@@spread@@throughout@@malaria@@-@@endemic@@regions@@of@@PNG@@.@@", "replace_sentence": "Further@@analyses@@showed@@that@@one@@of@@the@@three@@haplotypes@@present@@in@@the@@early@@1980@@s@@samples@@has@@become@@the@@predominant@@haplotype@@(@@frequency@@=@@0@@.@@901@@)@@in@@drug1@@parasite@@populations@@collected@@after@@1995@@from@@three@@PNG@@sites@@,@@when@@CQR@@had@@spread@@throughout@@drug2@@-@@endemic@@regions@@of@@PNG@@.@@", "new_pair": "CQR@@parasite@@populations@@collected@@after@@1995@@from@@three@@PNG@@sites@@,@@when@@CQR@@had@@spread@@throughout@@malaria", "replace_pair": "drug1@@parasite@@populations@@collected@@after@@1995@@from@@three@@PNG@@sites@@,@@when@@CQR@@had@@spread@@throughout@@drug2", "relation": "NA"}, {"head": {"id": "622", "type": "", "word": "Scopolamine", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "623", "type": "", "word": "motionUsickness", "begin": "53", "end": "68", "new_begin": "61", "new_end": "76", "replace_begin": "55", "replace_end": "60"}, "sentence": "Scopolamine ( hyoscine ) for preventing and treating motionUsickness .", "new_sentence": "Scopolamine@@(@@hyoscine@@)@@for@@preventing@@and@@treating@@motionUsickness@@.@@", "replace_sentence": "drug1@@(@@hyoscine@@)@@for@@preventing@@and@@treating@@drug2@@.@@", "new_pair": "Scopolamine@@(@@hyoscine@@)@@for@@preventing@@and@@treating@@motionUsickness", "replace_pair": "drug1@@(@@hyoscine@@)@@for@@preventing@@and@@treating@@drug2", "relation": "may_prevent"}, {"head": {"id": "624", "type": "", "word": "fluticasoneUpropionate", "begin": "50", "end": "72", "new_begin": "57", "new_end": "79", "replace_begin": "57", "replace_end": "62"}, "tail": {"id": "625", "type": "", "word": "asthma", "begin": "113", "end": "119", "new_begin": "127", "new_end": "133", "replace_begin": "110", "replace_end": "115"}, "sentence": "Similar efficacy of ciclesonide once daily versus fluticasoneUpropionate twice daily in patients with persistent asthma .", "new_sentence": "Similar@@efficacy@@of@@ciclesonide@@once@@daily@@versus@@fluticasoneUpropionate@@twice@@daily@@in@@patients@@with@@persistent@@asthma@@.@@", "replace_sentence": "Similar@@efficacy@@of@@ciclesonide@@once@@daily@@versus@@drug1@@twice@@daily@@in@@patients@@with@@persistent@@drug2@@.@@", "new_pair": "fluticasoneUpropionate@@twice@@daily@@in@@patients@@with@@persistent@@asthma", "replace_pair": "drug1@@twice@@daily@@in@@patients@@with@@persistent@@drug2", "relation": "NA"}, {"head": {"id": "626", "type": "", "word": "fluvastatin", "begin": "12", "end": "23", "new_begin": "15", "new_end": "26", "replace_begin": "15", "replace_end": "20"}, "tail": {"id": "627", "type": "", "word": "hyperlipidemia", "begin": "137", "end": "151", "new_begin": "163", "new_end": "177", "replace_begin": "157", "replace_end": "162"}, "sentence": "( Effect of fluvastatin extended release on the protein- lipid structure of erythrocyte membrane and C-reactive protein in patients with hyperlipidemia ) .", "new_sentence": "(@@Effect@@of@@fluvastatin@@extended@@release@@on@@the@@protein@@-@@lipid@@structure@@of@@erythrocyte@@membrane@@and@@C@@-@@reactive@@protein@@in@@patients@@with@@hyperlipidemia@@)@@.@@", "replace_sentence": "(@@Effect@@of@@drug1@@extended@@release@@on@@the@@protein@@-@@lipid@@structure@@of@@erythrocyte@@membrane@@and@@C@@-@@reactive@@protein@@in@@patients@@with@@drug2@@)@@.@@", "new_pair": "fluvastatin@@extended@@release@@on@@the@@protein@@-@@lipid@@structure@@of@@erythrocyte@@membrane@@and@@C@@-@@reactive@@protein@@in@@patients@@with@@hyperlipidemia", "replace_pair": "drug1@@extended@@release@@on@@the@@protein@@-@@lipid@@structure@@of@@erythrocyte@@membrane@@and@@C@@-@@reactive@@protein@@in@@patients@@with@@drug2", "relation": "NA"}, {"head": {"id": "628", "type": "", "word": "caries", "begin": "17", "end": "23", "new_begin": "20", "new_end": "26", "replace_begin": "20", "replace_end": "25"}, "tail": {"id": "629", "type": "", "word": "fluorides", "begin": "58", "end": "67", "new_begin": "67", "new_end": "76", "replace_begin": "66", "replace_end": "71"}, "sentence": "The mainstays of caries prevention , topical and systemic fluorides and pit and fissure sealants , are technologies developed in the 1950s and 1960s .", "new_sentence": "The@@mainstays@@of@@caries@@prevention@@,@@topical@@and@@systemic@@fluorides@@and@@pit@@and@@fissure@@sealants@@,@@are@@technologies@@developed@@in@@the@@1950s@@and@@1960s@@.@@", "replace_sentence": "The@@mainstays@@of@@drug1@@prevention@@,@@topical@@and@@systemic@@drug2@@and@@pit@@and@@fissure@@sealants@@,@@are@@technologies@@developed@@in@@the@@1950s@@and@@1960s@@.@@", "new_pair": "caries@@prevention@@,@@topical@@and@@systemic@@fluorides", "replace_pair": "drug1@@prevention@@,@@topical@@and@@systemic@@drug2", "relation": "may_prevent"}, {"head": {"id": "630", "type": "", "word": "GVHD", "begin": "0", "end": "4", "new_begin": "0", "new_end": "4", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "631", "type": "", "word": "cyclosporinUA", "begin": "30", "end": "43", "new_begin": "34", "new_end": "47", "replace_begin": "35", "replace_end": "40"}, "sentence": "GVHD prophylaxis consisted of cyclosporinUA and a short course of methotrexate .", "new_sentence": "GVHD@@prophylaxis@@consisted@@of@@cyclosporinUA@@and@@a@@short@@course@@of@@methotrexate@@.@@", "replace_sentence": "drug1@@prophylaxis@@consisted@@of@@drug2@@and@@a@@short@@course@@of@@methotrexate@@.@@", "new_pair": "GVHD@@prophylaxis@@consisted@@of@@cyclosporinUA", "replace_pair": "drug1@@prophylaxis@@consisted@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "632", "type": "", "word": "hepatitisUB", "begin": "98", "end": "109", "new_begin": "115", "new_end": "126", "replace_begin": "115", "replace_end": "120"}, "tail": {"id": "633", "type": "", "word": "hepatitisUBUhyperimmuneUglobulin", "begin": "142", "end": "174", "new_begin": "165", "new_end": "197", "replace_begin": "159", "replace_end": "164"}, "sentence": "METHOD : A bibliographic search was carried out using Pubmed , entering the following key words : hepatitisUB and liver transplantation and ( hepatitisUBUhyperimmuneUglobulin and lamivudine and adefovir dipivoxil ) up to June 2006 .", "new_sentence": "METHOD@@:@@A@@bibliographic@@search@@was@@carried@@out@@using@@Pubmed@@,@@entering@@the@@following@@key@@words@@:@@hepatitisUB@@and@@liver@@transplantation@@and@@(@@hepatitisUBUhyperimmuneUglobulin@@and@@lamivudine@@and@@adefovir@@dipivoxil@@)@@up@@to@@June@@2006@@.@@", "replace_sentence": "METHOD@@:@@A@@bibliographic@@search@@was@@carried@@out@@using@@Pubmed@@,@@entering@@the@@following@@key@@words@@:@@drug1@@and@@liver@@transplantation@@and@@(@@drug2@@and@@lamivudine@@and@@adefovir@@dipivoxil@@)@@up@@to@@June@@2006@@.@@", "new_pair": "hepatitisUB@@and@@liver@@transplantation@@and@@(@@hepatitisUBUhyperimmuneUglobulin", "replace_pair": "drug1@@and@@liver@@transplantation@@and@@(@@drug2", "relation": "NA"}, {"head": {"id": "634", "type": "", "word": "atorvastatin", "begin": "38", "end": "50", "new_begin": "44", "new_end": "56", "replace_begin": "44", "replace_end": "49"}, "tail": {"id": "635", "type": "", "word": "ischemia", "begin": "125", "end": "133", "new_begin": "153", "new_end": "161", "replace_begin": "146", "replace_end": "151"}, "sentence": "Experimental group 2 was treated with atorvastatin ( 10 mg @ Kg @ d , p . o . ) during two weeks before the induction of the ischemia .", "new_sentence": "Experimental@@group@@2@@was@@treated@@with@@atorvastatin@@(@@10@@mg@@@@@Kg@@@@@d@@,@@p@@.@@o@@.@@)@@during@@two@@weeks@@before@@the@@induction@@of@@the@@ischemia@@.@@", "replace_sentence": "Experimental@@group@@2@@was@@treated@@with@@drug1@@(@@10@@mg@@@@@Kg@@@@@d@@,@@p@@.@@o@@.@@)@@during@@two@@weeks@@before@@the@@induction@@of@@the@@drug2@@.@@", "new_pair": "atorvastatin@@(@@10@@mg@@@@@Kg@@@@@d@@,@@p@@.@@o@@.@@)@@during@@two@@weeks@@before@@the@@induction@@of@@the@@ischemia", "replace_pair": "drug1@@(@@10@@mg@@@@@Kg@@@@@d@@,@@p@@.@@o@@.@@)@@during@@two@@weeks@@before@@the@@induction@@of@@the@@drug2", "relation": "NA"}, {"head": {"id": "636", "type": "", "word": "Infections", "begin": "0", "end": "10", "new_begin": "0", "new_end": "10", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "637", "type": "", "word": "VAD", "begin": "57", "end": "60", "new_begin": "68", "new_end": "71", "replace_begin": "63", "replace_end": "68"}, "sentence": "Infections ( all grades ) were more commonly seen in the VAD arm ( P = 0 . 001 ) although grade III @ IV infections were not significantly different between the two groups ( P = 0 . 081 ) .", "new_sentence": "Infections@@(@@all@@grades@@)@@were@@more@@commonly@@seen@@in@@the@@VAD@@arm@@(@@P@@=@@0@@.@@001@@)@@although@@grade@@III@@@@@IV@@infections@@were@@not@@significantly@@different@@between@@the@@two@@groups@@(@@P@@=@@0@@.@@081@@)@@.@@", "replace_sentence": "drug1@@(@@all@@grades@@)@@were@@more@@commonly@@seen@@in@@the@@drug2@@arm@@(@@P@@=@@0@@.@@001@@)@@although@@grade@@III@@@@@IV@@infections@@were@@not@@significantly@@different@@between@@the@@two@@groups@@(@@P@@=@@0@@.@@081@@)@@.@@", "new_pair": "Infections@@(@@all@@grades@@)@@were@@more@@commonly@@seen@@in@@the@@VAD", "replace_pair": "drug1@@(@@all@@grades@@)@@were@@more@@commonly@@seen@@in@@the@@drug2", "relation": "NA"}, {"head": {"id": "638", "type": "", "word": "ganciclovir", "begin": "59", "end": "70", "new_begin": "70", "new_end": "81", "replace_begin": "70", "replace_end": "75"}, "tail": {"id": "639", "type": "", "word": "CMVUinfection", "begin": "106", "end": "119", "new_begin": "122", "new_end": "135", "replace_begin": "116", "replace_end": "121"}, "sentence": "This approach could prove to be more cost - effective than ganciclovir universal prophylaxis for treating CMVUinfection .", "new_sentence": "This@@approach@@could@@prove@@to@@be@@more@@cost@@-@@effective@@than@@ganciclovir@@universal@@prophylaxis@@for@@treating@@CMVUinfection@@.@@", "replace_sentence": "This@@approach@@could@@prove@@to@@be@@more@@cost@@-@@effective@@than@@drug1@@universal@@prophylaxis@@for@@treating@@drug2@@.@@", "new_pair": "ganciclovir@@universal@@prophylaxis@@for@@treating@@CMVUinfection", "replace_pair": "drug1@@universal@@prophylaxis@@for@@treating@@drug2", "relation": "may_prevent"}, {"head": {"id": "640", "type": "", "word": "asthma", "begin": "86", "end": "92", "new_begin": "100", "new_end": "106", "replace_begin": "100", "replace_end": "105"}, "tail": {"id": "641", "type": "", "word": "DXM", "begin": "238", "end": "241", "new_begin": "296", "new_end": "299", "replace_begin": "295", "replace_end": "300"}, "sentence": "In situ hybridization showed that the mRNA expression of STAT6 around the bronchus of asthma group ( 0 . 180 + @ - 0 . 013 ) was significantly higher than that of the control group ( 0 . 091 + @ - 0 . 012 ) ( P < 0 . 01 ) , while that of DXM group ( 0 . 114 + @ - 0 . 010 ) was significantly lower than that of asthma group .", "new_sentence": "In@@situ@@hybridization@@showed@@that@@the@@mRNA@@expression@@of@@STAT6@@around@@the@@bronchus@@of@@asthma@@group@@(@@0@@.@@180@@+@@@@@-@@0@@.@@013@@)@@was@@significantly@@higher@@than@@that@@of@@the@@control@@group@@(@@0@@.@@091@@+@@@@@-@@0@@.@@012@@)@@(@@P@@<@@0@@.@@01@@)@@,@@while@@that@@of@@DXM@@group@@(@@0@@.@@114@@+@@@@@-@@0@@.@@010@@)@@was@@significantly@@lower@@than@@that@@of@@asthma@@group@@.@@", "replace_sentence": "In@@situ@@hybridization@@showed@@that@@the@@mRNA@@expression@@of@@STAT6@@around@@the@@bronchus@@of@@drug1@@group@@(@@0@@.@@180@@+@@@@@-@@0@@.@@013@@)@@was@@significantly@@higher@@than@@that@@of@@the@@control@@group@@(@@0@@.@@091@@+@@@@@-@@0@@.@@012@@)@@(@@P@@<@@0@@.@@01@@)@@,@@while@@that@@of@@drug2@@group@@(@@0@@.@@114@@+@@@@@-@@0@@.@@010@@)@@was@@significantly@@lower@@than@@that@@of@@asthma@@group@@.@@", "new_pair": "asthma@@group@@(@@0@@.@@180@@+@@@@@-@@0@@.@@013@@)@@was@@significantly@@higher@@than@@that@@of@@the@@control@@group@@(@@0@@.@@091@@+@@@@@-@@0@@.@@012@@)@@(@@P@@<@@0@@.@@01@@)@@,@@while@@that@@of@@DXM", "replace_pair": "drug1@@group@@(@@0@@.@@180@@+@@@@@-@@0@@.@@013@@)@@was@@significantly@@higher@@than@@that@@of@@the@@control@@group@@(@@0@@.@@091@@+@@@@@-@@0@@.@@012@@)@@(@@P@@<@@0@@.@@01@@)@@,@@while@@that@@of@@drug2", "relation": "NA"}, {"head": {"id": "642", "type": "", "word": "graft-versus-hostUdisease", "begin": "20", "end": "45", "new_begin": "22", "new_end": "47", "replace_begin": "22", "replace_end": "27"}, "tail": {"id": "643", "type": "", "word": "cyclosporine", "begin": "68", "end": "80", "new_begin": "76", "new_end": "88", "replace_begin": "56", "replace_end": "61"}, "sentence": "Prophylaxis against graft-versus-hostUdisease ( GVHD ) consisted of cyclosporine ( CsA ) and short-term methotrexate .", "new_sentence": "Prophylaxis@@against@@graft-versus-hostUdisease@@(@@GVHD@@)@@consisted@@of@@cyclosporine@@(@@CsA@@)@@and@@short@@-@@term@@methotrexate@@.@@", "replace_sentence": "Prophylaxis@@against@@drug1@@(@@GVHD@@)@@consisted@@of@@drug2@@(@@CsA@@)@@and@@short@@-@@term@@methotrexate@@.@@", "new_pair": "graft-versus-hostUdisease@@(@@GVHD@@)@@consisted@@of@@cyclosporine", "replace_pair": "drug1@@(@@GVHD@@)@@consisted@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "644", "type": "", "word": "N-acetylcysteine", "begin": "0", "end": "16", "new_begin": "0", "new_end": "16", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "645", "type": "", "word": "acuteUkidneyUinjury", "begin": "32", "end": "51", "new_begin": "35", "new_end": "54", "replace_begin": "24", "replace_end": "29"}, "sentence": "N-acetylcysteine for preventing acuteUkidneyUinjury in cardiac surgery patients with pre-existing moderate renal insufficiency .", "new_sentence": "N-acetylcysteine@@for@@preventing@@acuteUkidneyUinjury@@in@@cardiac@@surgery@@patients@@with@@pre@@-@@existing@@moderate@@renal@@insufficiency@@.@@", "replace_sentence": "drug1@@for@@preventing@@drug2@@in@@cardiac@@surgery@@patients@@with@@pre@@-@@existing@@moderate@@renal@@insufficiency@@.@@", "new_pair": "N-acetylcysteine@@for@@preventing@@acuteUkidneyUinjury", "replace_pair": "drug1@@for@@preventing@@drug2", "relation": "may_prevent"}, {"head": {"id": "646", "type": "", "word": "tyrosine", "begin": "71", "end": "79", "new_begin": "84", "new_end": "92", "replace_begin": "84", "replace_end": "89"}, "tail": {"id": "647", "type": "", "word": "IR", "begin": "136", "end": "138", "new_begin": "160", "new_end": "162", "replace_begin": "157", "replace_end": "162"}, "sentence": "However , it is not clear if hypothyroidism is able to prevent protein tyrosine nitration , an index of nitrosative stress , induced by IR or if antioxidant enzymes have involved in this protective effect .", "new_sentence": "However@@,@@it@@is@@not@@clear@@if@@hypothyroidism@@is@@able@@to@@prevent@@protein@@tyrosine@@nitration@@,@@an@@index@@of@@nitrosative@@stress@@,@@induced@@by@@IR@@or@@if@@antioxidant@@enzymes@@have@@involved@@in@@this@@protective@@effect@@.@@", "replace_sentence": "However@@,@@it@@is@@not@@clear@@if@@hypothyroidism@@is@@able@@to@@prevent@@protein@@drug1@@nitration@@,@@an@@index@@of@@nitrosative@@stress@@,@@induced@@by@@drug2@@or@@if@@antioxidant@@enzymes@@have@@involved@@in@@this@@protective@@effect@@.@@", "new_pair": "tyrosine@@nitration@@,@@an@@index@@of@@nitrosative@@stress@@,@@induced@@by@@IR", "replace_pair": "drug1@@nitration@@,@@an@@index@@of@@nitrosative@@stress@@,@@induced@@by@@drug2", "relation": "NA"}, {"head": {"id": "648", "type": "", "word": "caries", "begin": "39", "end": "45", "new_begin": "45", "new_end": "51", "replace_begin": "45", "replace_end": "50"}, "tail": {"id": "649", "type": "", "word": "fluoride", "begin": "67", "end": "75", "new_begin": "78", "new_end": "86", "replace_begin": "77", "replace_end": "82"}, "sentence": "The first concerns the most successful caries - preventive agent : fluoride .", "new_sentence": "The@@first@@concerns@@the@@most@@successful@@caries@@-@@preventive@@agent@@:@@fluoride@@.@@", "replace_sentence": "The@@first@@concerns@@the@@most@@successful@@drug1@@-@@preventive@@agent@@:@@drug2@@.@@", "new_pair": "caries@@-@@preventive@@agent@@:@@fluoride", "replace_pair": "drug1@@-@@preventive@@agent@@:@@drug2", "relation": "may_prevent"}, {"head": {"id": "650", "type": "", "word": "cyclosporine", "begin": "22", "end": "34", "new_begin": "25", "new_end": "37", "replace_begin": "25", "replace_end": "30"}, "tail": {"id": "651", "type": "", "word": "graft-versus-hostUdisease", "begin": "54", "end": "79", "new_begin": "61", "new_end": "86", "replace_begin": "54", "replace_end": "59"}, "sentence": "All patients received cyclosporine as prophylaxis for graft-versus-hostUdisease .", "new_sentence": "All@@patients@@received@@cyclosporine@@as@@prophylaxis@@for@@graft-versus-hostUdisease@@.@@", "replace_sentence": "All@@patients@@received@@drug1@@as@@prophylaxis@@for@@drug2@@.@@", "new_pair": "cyclosporine@@as@@prophylaxis@@for@@graft-versus-hostUdisease", "replace_pair": "drug1@@as@@prophylaxis@@for@@drug2", "relation": "may_prevent"}, {"head": {"id": "652", "type": "", "word": "fluoride", "begin": "79", "end": "87", "new_begin": "92", "new_end": "100", "replace_begin": "92", "replace_end": "97"}, "tail": {"id": "653", "type": "", "word": "dentalUcaries", "begin": "99", "end": "112", "new_begin": "115", "new_end": "128", "replace_begin": "112", "replace_end": "117"}, "sentence": "( National committee for oral health impulsed the study and promotion of using fluoride to prevent dentalUcaries in China ) .", "new_sentence": "(@@National@@committee@@for@@oral@@health@@impulsed@@the@@study@@and@@promotion@@of@@using@@fluoride@@to@@prevent@@dentalUcaries@@in@@China@@)@@.@@", "replace_sentence": "(@@National@@committee@@for@@oral@@health@@impulsed@@the@@study@@and@@promotion@@of@@using@@drug1@@to@@prevent@@drug2@@in@@China@@)@@.@@", "new_pair": "fluoride@@to@@prevent@@dentalUcaries", "replace_pair": "drug1@@to@@prevent@@drug2", "relation": "may_prevent"}, {"head": {"id": "654", "type": "", "word": "Gemfibrozil", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "655", "type": "", "word": "chronicUrenalUinsufficiency", "begin": "82", "end": "109", "new_begin": "93", "new_end": "120", "replace_begin": "87", "replace_end": "92"}, "sentence": "Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronicUrenalUinsufficiency .", "new_sentence": "Gemfibrozil@@for@@secondary@@prevention@@of@@cardiovascular@@events@@in@@mild@@to@@moderate@@chronicUrenalUinsufficiency@@.@@", "replace_sentence": "drug1@@for@@secondary@@prevention@@of@@cardiovascular@@events@@in@@mild@@to@@moderate@@drug2@@.@@", "new_pair": "Gemfibrozil@@for@@secondary@@prevention@@of@@cardiovascular@@events@@in@@mild@@to@@moderate@@chronicUrenalUinsufficiency", "replace_pair": "drug1@@for@@secondary@@prevention@@of@@cardiovascular@@events@@in@@mild@@to@@moderate@@drug2", "relation": "may_prevent"}, {"head": {"id": "656", "type": "", "word": "RSVUinfection", "begin": "63", "end": "76", "new_begin": "73", "new_end": "86", "replace_begin": "73", "replace_end": "78"}, "tail": {"id": "657", "type": "", "word": "palivizumab", "begin": "130", "end": "141", "new_begin": "148", "new_end": "159", "replace_begin": "140", "replace_end": "145"}, "sentence": "Although there is not currently a vaccine available to prevent RSVUinfection , prophylaxis with the humanized monoclonal antibody palivizumab has been shown to reduce the rate of RSV hospitalization in premature infants and those infants with chronic lung disease or congenital heart disease .", "new_sentence": "Although@@there@@is@@not@@currently@@a@@vaccine@@available@@to@@prevent@@RSVUinfection@@,@@prophylaxis@@with@@the@@humanized@@monoclonal@@antibody@@palivizumab@@has@@been@@shown@@to@@reduce@@the@@rate@@of@@RSV@@hospitalization@@in@@premature@@infants@@and@@those@@infants@@with@@chronic@@lung@@disease@@or@@congenital@@heart@@disease@@.@@", "replace_sentence": "Although@@there@@is@@not@@currently@@a@@vaccine@@available@@to@@prevent@@drug1@@,@@prophylaxis@@with@@the@@humanized@@monoclonal@@antibody@@drug2@@has@@been@@shown@@to@@reduce@@the@@rate@@of@@RSV@@hospitalization@@in@@premature@@infants@@and@@those@@infants@@with@@chronic@@lung@@disease@@or@@congenital@@heart@@disease@@.@@", "new_pair": "RSVUinfection@@,@@prophylaxis@@with@@the@@humanized@@monoclonal@@antibody@@palivizumab", "replace_pair": "drug1@@,@@prophylaxis@@with@@the@@humanized@@monoclonal@@antibody@@drug2", "relation": "NA"}, {"head": {"id": "658", "type": "", "word": "acyclovir", "begin": "13", "end": "22", "new_begin": "15", "new_end": "24", "replace_begin": "15", "replace_end": "20"}, "tail": {"id": "659", "type": "", "word": "HZ", "begin": "105", "end": "107", "new_begin": "125", "new_end": "127", "replace_begin": "121", "replace_end": "126"}, "sentence": "Therapy with acyclovir and the use of corticosteroids have been reported to prevent PHN in up to 60 % of HZ patients .", "new_sentence": "Therapy@@with@@acyclovir@@and@@the@@use@@of@@corticosteroids@@have@@been@@reported@@to@@prevent@@PHN@@in@@up@@to@@60@@%@@of@@HZ@@patients@@.@@", "replace_sentence": "Therapy@@with@@drug1@@and@@the@@use@@of@@corticosteroids@@have@@been@@reported@@to@@prevent@@PHN@@in@@up@@to@@60@@%@@of@@drug2@@patients@@.@@", "new_pair": "acyclovir@@and@@the@@use@@of@@corticosteroids@@have@@been@@reported@@to@@prevent@@PHN@@in@@up@@to@@60@@%@@of@@HZ", "replace_pair": "drug1@@and@@the@@use@@of@@corticosteroids@@have@@been@@reported@@to@@prevent@@PHN@@in@@up@@to@@60@@%@@of@@drug2", "relation": "NA"}, {"head": {"id": "660", "type": "", "word": "Risedronate", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "661", "type": "", "word": "osteoporosis", "begin": "44", "end": "56", "new_begin": "50", "new_end": "62", "replace_begin": "44", "replace_end": "49"}, "sentence": "Risedronate for prevention and treatment of osteoporosis in postmenopausal women .", "new_sentence": "Risedronate@@for@@prevention@@and@@treatment@@of@@osteoporosis@@in@@postmenopausal@@women@@.@@", "replace_sentence": "drug1@@for@@prevention@@and@@treatment@@of@@drug2@@in@@postmenopausal@@women@@.@@", "new_pair": "Risedronate@@for@@prevention@@and@@treatment@@of@@osteoporosis", "replace_pair": "drug1@@for@@prevention@@and@@treatment@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "662", "type": "", "word": "F", "begin": "100", "end": "101", "new_begin": "118", "new_end": "119", "replace_begin": "118", "replace_end": "123"}, "tail": {"id": "663", "type": "", "word": "plaque", "begin": "248", "end": "254", "new_begin": "296", "new_end": "302", "replace_begin": "300", "replace_end": "305"}, "sentence": "After using 0 . 2 % sodium fluoride mouthwash solution , a significant increase was observed in the F 2 ion concentration both plaque ( P P < 0 . 000 ) of all the studied subjects , while the concentration of phosphate decreased in both saliva and plaque ;", "new_sentence": "After@@using@@0@@.@@2@@%@@sodium@@fluoride@@mouthwash@@solution@@,@@a@@significant@@increase@@was@@observed@@in@@the@@F@@2@@ion@@concentration@@both@@plaque@@(@@P@@P@@<@@0@@.@@000@@)@@of@@all@@the@@studied@@subjects@@,@@while@@the@@concentration@@of@@phosphate@@decreased@@in@@both@@saliva@@and@@plaque@@;@@", "replace_sentence": "After@@using@@0@@.@@2@@%@@sodium@@fluoride@@mouthwash@@solution@@,@@a@@significant@@increase@@was@@observed@@in@@the@@drug1@@2@@ion@@concentration@@both@@plaque@@(@@P@@P@@<@@0@@.@@000@@)@@of@@all@@the@@studied@@subjects@@,@@while@@the@@concentration@@of@@phosphate@@decreased@@in@@both@@saliva@@and@@drug2@@;@@", "new_pair": "F@@2@@ion@@concentration@@both@@plaque@@(@@P@@P@@<@@0@@.@@000@@)@@of@@all@@the@@studied@@subjects@@,@@while@@the@@concentration@@of@@phosphate@@decreased@@in@@both@@saliva@@and@@plaque", "replace_pair": "drug1@@2@@ion@@concentration@@both@@plaque@@(@@P@@P@@<@@0@@.@@000@@)@@of@@all@@the@@studied@@subjects@@,@@while@@the@@concentration@@of@@phosphate@@decreased@@in@@both@@saliva@@and@@drug2", "relation": "NA"}, {"head": {"id": "664", "type": "", "word": "danaparoidUsodium", "begin": "60", "end": "77", "new_begin": "70", "new_end": "87", "replace_begin": "70", "replace_end": "75"}, "tail": {"id": "665", "type": "", "word": "ischemia", "begin": "202", "end": "210", "new_begin": "237", "new_end": "245", "replace_begin": "225", "replace_end": "230"}, "sentence": "This study was undertaken to examine the mechanism by which danaparoidUsodium ( DS ) , a heparinoid that contains mainly heparan sulfate , prevents reperfusion- induced hepatic damage in a rat model of ischemia @ reperfusion ( I @ R ) -induced liver injury .", "new_sentence": "This@@study@@was@@undertaken@@to@@examine@@the@@mechanism@@by@@which@@danaparoidUsodium@@(@@DS@@)@@,@@a@@heparinoid@@that@@contains@@mainly@@heparan@@sulfate@@,@@prevents@@reperfusion@@-@@induced@@hepatic@@damage@@in@@a@@rat@@model@@of@@ischemia@@@@@reperfusion@@(@@I@@@@@R@@)@@-@@induced@@liver@@injury@@.@@", "replace_sentence": "This@@study@@was@@undertaken@@to@@examine@@the@@mechanism@@by@@which@@drug1@@(@@DS@@)@@,@@a@@heparinoid@@that@@contains@@mainly@@heparan@@sulfate@@,@@prevents@@reperfusion@@-@@induced@@hepatic@@damage@@in@@a@@rat@@model@@of@@drug2@@@@@reperfusion@@(@@I@@@@@R@@)@@-@@induced@@liver@@injury@@.@@", "new_pair": "danaparoidUsodium@@(@@DS@@)@@,@@a@@heparinoid@@that@@contains@@mainly@@heparan@@sulfate@@,@@prevents@@reperfusion@@-@@induced@@hepatic@@damage@@in@@a@@rat@@model@@of@@ischemia", "replace_pair": "drug1@@(@@DS@@)@@,@@a@@heparinoid@@that@@contains@@mainly@@heparan@@sulfate@@,@@prevents@@reperfusion@@-@@induced@@hepatic@@damage@@in@@a@@rat@@model@@of@@drug2", "relation": "NA"}, {"head": {"id": "666", "type": "", "word": "vitaminUE", "begin": "49", "end": "58", "new_begin": "56", "new_end": "65", "replace_begin": "56", "replace_end": "61"}, "tail": {"id": "667", "type": "", "word": "asthma", "begin": "164", "end": "170", "new_begin": "188", "new_end": "194", "replace_begin": "184", "replace_end": "189"}, "sentence": "CONCLUSION : Maternal intake of foods containing vitaminUE and zinc during pregnancy is associated with differences in the risks of developing childhood wheeze and asthma .", "new_sentence": "CONCLUSION@@:@@Maternal@@intake@@of@@foods@@containing@@vitaminUE@@and@@zinc@@during@@pregnancy@@is@@associated@@with@@differences@@in@@the@@risks@@of@@developing@@childhood@@wheeze@@and@@asthma@@.@@", "replace_sentence": "CONCLUSION@@:@@Maternal@@intake@@of@@foods@@containing@@drug1@@and@@zinc@@during@@pregnancy@@is@@associated@@with@@differences@@in@@the@@risks@@of@@developing@@childhood@@wheeze@@and@@drug2@@.@@", "new_pair": "vitaminUE@@and@@zinc@@during@@pregnancy@@is@@associated@@with@@differences@@in@@the@@risks@@of@@developing@@childhood@@wheeze@@and@@asthma", "replace_pair": "drug1@@and@@zinc@@during@@pregnancy@@is@@associated@@with@@differences@@in@@the@@risks@@of@@developing@@childhood@@wheeze@@and@@drug2", "relation": "NA"}, {"head": {"id": "668", "type": "", "word": "Simvastatin", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "669", "type": "", "word": "chronicUkidneyUdisease", "begin": "149", "end": "171", "new_begin": "175", "new_end": "197", "replace_begin": "169", "replace_end": "174"}, "sentence": "Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide ( LPS ) stimulated production by isolated human monocytes from chronicUkidneyUdisease patients .", "new_sentence": "Simvastatin@@and@@fluvastatin@@reduce@@interleukin@@-@@6@@and@@interleukin@@-@@8@@lipopolysaccharide@@(@@LPS@@)@@stimulated@@production@@by@@isolated@@human@@monocytes@@from@@chronicUkidneyUdisease@@patients@@.@@", "replace_sentence": "drug1@@and@@fluvastatin@@reduce@@interleukin@@-@@6@@and@@interleukin@@-@@8@@lipopolysaccharide@@(@@LPS@@)@@stimulated@@production@@by@@isolated@@human@@monocytes@@from@@drug2@@patients@@.@@", "new_pair": "Simvastatin@@and@@fluvastatin@@reduce@@interleukin@@-@@6@@and@@interleukin@@-@@8@@lipopolysaccharide@@(@@LPS@@)@@stimulated@@production@@by@@isolated@@human@@monocytes@@from@@chronicUkidneyUdisease", "replace_pair": "drug1@@and@@fluvastatin@@reduce@@interleukin@@-@@6@@and@@interleukin@@-@@8@@lipopolysaccharide@@(@@LPS@@)@@stimulated@@production@@by@@isolated@@human@@monocytes@@from@@drug2", "relation": "NA"}, {"head": {"id": "670", "type": "", "word": "Graft-versus-hostUdisease", "begin": "0", "end": "25", "new_begin": "0", "new_end": "25", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "671", "type": "", "word": "cyclosporine", "begin": "122", "end": "134", "new_begin": "139", "new_end": "151", "replace_begin": "119", "replace_end": "124"}, "sentence": "Graft-versus-hostUdisease prophylaxis was provided with cyclosporine + methotrexate + @ - prednisone for the CMR and with cyclosporine + mycophenolate + @ - methotrexate for the RIR .", "new_sentence": "Graft-versus-hostUdisease@@prophylaxis@@was@@provided@@with@@cyclosporine@@+@@methotrexate@@+@@@@@-@@prednisone@@for@@the@@CMR@@and@@with@@cyclosporine@@+@@mycophenolate@@+@@@@@-@@methotrexate@@for@@the@@RIR@@.@@", "replace_sentence": "drug1@@prophylaxis@@was@@provided@@with@@cyclosporine@@+@@methotrexate@@+@@@@@-@@prednisone@@for@@the@@CMR@@and@@with@@drug2@@+@@mycophenolate@@+@@@@@-@@methotrexate@@for@@the@@RIR@@.@@", "new_pair": "Graft-versus-hostUdisease@@prophylaxis@@was@@provided@@with@@cyclosporine@@+@@methotrexate@@+@@@@@-@@prednisone@@for@@the@@CMR@@and@@with@@cyclosporine", "replace_pair": "drug1@@prophylaxis@@was@@provided@@with@@cyclosporine@@+@@methotrexate@@+@@@@@-@@prednisone@@for@@the@@CMR@@and@@with@@drug2", "relation": "may_prevent"}, {"head": {"id": "672", "type": "", "word": "fluticasone", "begin": "25", "end": "36", "new_begin": "30", "new_end": "41", "replace_begin": "30", "replace_end": "35"}, "tail": {"id": "673", "type": "", "word": "asthmatic", "begin": "162", "end": "171", "new_begin": "190", "new_end": "199", "replace_begin": "184", "replace_end": "189"}, "sentence": "RESULTS : In contrast to fluticasone , treatment with the A ( 2A ) - receptor agonist neither significantly protect against the allergen - induced early and late asthmatic reaction , nor the accompanying inflammatory response as measured by sputum total cell counts , number of EG2 + cells , and the concentration of interleukin-8 and eosinophil cationic protein .", "new_sentence": "RESULTS@@:@@In@@contrast@@to@@fluticasone@@,@@treatment@@with@@the@@A@@(@@2A@@)@@-@@receptor@@agonist@@neither@@significantly@@protect@@against@@the@@allergen@@-@@induced@@early@@and@@late@@asthmatic@@reaction@@,@@nor@@the@@accompanying@@inflammatory@@response@@as@@measured@@by@@sputum@@total@@cell@@counts@@,@@number@@of@@EG2@@+@@cells@@,@@and@@the@@concentration@@of@@interleukin@@-@@8@@and@@eosinophil@@cationic@@protein@@.@@", "replace_sentence": "RESULTS@@:@@In@@contrast@@to@@drug1@@,@@treatment@@with@@the@@A@@(@@2A@@)@@-@@receptor@@agonist@@neither@@significantly@@protect@@against@@the@@allergen@@-@@induced@@early@@and@@late@@drug2@@reaction@@,@@nor@@the@@accompanying@@inflammatory@@response@@as@@measured@@by@@sputum@@total@@cell@@counts@@,@@number@@of@@EG2@@+@@cells@@,@@and@@the@@concentration@@of@@interleukin@@-@@8@@and@@eosinophil@@cationic@@protein@@.@@", "new_pair": "fluticasone@@,@@treatment@@with@@the@@A@@(@@2A@@)@@-@@receptor@@agonist@@neither@@significantly@@protect@@against@@the@@allergen@@-@@induced@@early@@and@@late@@asthmatic", "replace_pair": "drug1@@,@@treatment@@with@@the@@A@@(@@2A@@)@@-@@receptor@@agonist@@neither@@significantly@@protect@@against@@the@@allergen@@-@@induced@@early@@and@@late@@drug2", "relation": "may_prevent"}, {"head": {"id": "674", "type": "", "word": "aspirin", "begin": "79", "end": "86", "new_begin": "91", "new_end": "98", "replace_begin": "91", "replace_end": "96"}, "tail": {"id": "675", "type": "", "word": "TIA", "begin": "137", "end": "140", "new_begin": "157", "new_end": "160", "replace_begin": "155", "replace_end": "160"}, "sentence": "CONCLUSIONS : This pilot trial has not found differences between triflusal and aspirin in the prevention of vascular complications after TIA or ischemic stroke , although given the wide CI , potentially important group differences could not be ruled out .", "new_sentence": "CONCLUSIONS@@:@@This@@pilot@@trial@@has@@not@@found@@differences@@between@@triflusal@@and@@aspirin@@in@@the@@prevention@@of@@vascular@@complications@@after@@TIA@@or@@ischemic@@stroke@@,@@although@@given@@the@@wide@@CI@@,@@potentially@@important@@group@@differences@@could@@not@@be@@ruled@@out@@.@@", "replace_sentence": "CONCLUSIONS@@:@@This@@pilot@@trial@@has@@not@@found@@differences@@between@@triflusal@@and@@drug1@@in@@the@@prevention@@of@@vascular@@complications@@after@@drug2@@or@@ischemic@@stroke@@,@@although@@given@@the@@wide@@CI@@,@@potentially@@important@@group@@differences@@could@@not@@be@@ruled@@out@@.@@", "new_pair": "aspirin@@in@@the@@prevention@@of@@vascular@@complications@@after@@TIA", "replace_pair": "drug1@@in@@the@@prevention@@of@@vascular@@complications@@after@@drug2", "relation": "NA"}, {"head": {"id": "676", "type": "", "word": "vitaminUD", "begin": "64", "end": "73", "new_begin": "75", "new_end": "84", "replace_begin": "75", "replace_end": "80"}, "tail": {"id": "677", "type": "", "word": "Osteoporosis", "begin": "356", "end": "368", "new_begin": "415", "new_end": "427", "replace_begin": "411", "replace_end": "416"}, "sentence": "Its implications for the use of oral supplements of calcium and vitaminUD in the prevention and treatment of osteoporosis were discussed at a meeting organized with the help of the World Health Organization ( WHO ) Collaborating Center for Public Health Aspects of Rheumatic Diseases ( Liege , Belgium ) and the support of the WHO Collaborating Center for Osteoporosis Prevention ( Geneva , Switzerland ) .", "new_sentence": "Its@@implications@@for@@the@@use@@of@@oral@@supplements@@of@@calcium@@and@@vitaminUD@@in@@the@@prevention@@and@@treatment@@of@@osteoporosis@@were@@discussed@@at@@a@@meeting@@organized@@with@@the@@help@@of@@the@@World@@Health@@Organization@@(@@WHO@@)@@Collaborating@@Center@@for@@Public@@Health@@Aspects@@of@@Rheumatic@@Diseases@@(@@Liege@@,@@Belgium@@)@@and@@the@@support@@of@@the@@WHO@@Collaborating@@Center@@for@@Osteoporosis@@Prevention@@(@@Geneva@@,@@Switzerland@@)@@.@@", "replace_sentence": "Its@@implications@@for@@the@@use@@of@@oral@@supplements@@of@@calcium@@and@@drug1@@in@@the@@prevention@@and@@treatment@@of@@osteoporosis@@were@@discussed@@at@@a@@meeting@@organized@@with@@the@@help@@of@@the@@World@@Health@@Organization@@(@@WHO@@)@@Collaborating@@Center@@for@@Public@@Health@@Aspects@@of@@Rheumatic@@Diseases@@(@@Liege@@,@@Belgium@@)@@and@@the@@support@@of@@the@@WHO@@Collaborating@@Center@@for@@drug2@@Prevention@@(@@Geneva@@,@@Switzerland@@)@@.@@", "new_pair": "vitaminUD@@in@@the@@prevention@@and@@treatment@@of@@osteoporosis@@were@@discussed@@at@@a@@meeting@@organized@@with@@the@@help@@of@@the@@World@@Health@@Organization@@(@@WHO@@)@@Collaborating@@Center@@for@@Public@@Health@@Aspects@@of@@Rheumatic@@Diseases@@(@@Liege@@,@@Belgium@@)@@and@@the@@support@@of@@the@@WHO@@Collaborating@@Center@@for@@Osteoporosis", "replace_pair": "drug1@@in@@the@@prevention@@and@@treatment@@of@@osteoporosis@@were@@discussed@@at@@a@@meeting@@organized@@with@@the@@help@@of@@the@@World@@Health@@Organization@@(@@WHO@@)@@Collaborating@@Center@@for@@Public@@Health@@Aspects@@of@@Rheumatic@@Diseases@@(@@Liege@@,@@Belgium@@)@@and@@the@@support@@of@@the@@WHO@@Collaborating@@Center@@for@@drug2", "relation": "NA"}, {"head": {"id": "678", "type": "", "word": "myocardialUnecrosis", "begin": "190", "end": "209", "new_begin": "222", "new_end": "241", "replace_begin": "222", "replace_end": "227"}, "tail": {"id": "679", "type": "", "word": "aspirin", "begin": "234", "end": "241", "new_begin": "271", "new_end": "278", "replace_begin": "257", "replace_end": "262"}, "sentence": "CONCLUSIONS : In patients with NSTE-ACS undergoing early invasive strategy , the adjunctive administration of upstream tirofiban did not reduce the peak values and the cumulative release of myocardialUnecrosis markers , compared with aspirin , heparin , and clopidogrel given on admission and associated with selective use of abciximab just before PCI .", "new_sentence": "CONCLUSIONS@@:@@In@@patients@@with@@NSTE@@-@@ACS@@undergoing@@early@@invasive@@strategy@@,@@the@@adjunctive@@administration@@of@@upstream@@tirofiban@@did@@not@@reduce@@the@@peak@@values@@and@@the@@cumulative@@release@@of@@myocardialUnecrosis@@markers@@,@@compared@@with@@aspirin@@,@@heparin@@,@@and@@clopidogrel@@given@@on@@admission@@and@@associated@@with@@selective@@use@@of@@abciximab@@just@@before@@PCI@@.@@", "replace_sentence": "CONCLUSIONS@@:@@In@@patients@@with@@NSTE@@-@@ACS@@undergoing@@early@@invasive@@strategy@@,@@the@@adjunctive@@administration@@of@@upstream@@tirofiban@@did@@not@@reduce@@the@@peak@@values@@and@@the@@cumulative@@release@@of@@drug1@@markers@@,@@compared@@with@@drug2@@,@@heparin@@,@@and@@clopidogrel@@given@@on@@admission@@and@@associated@@with@@selective@@use@@of@@abciximab@@just@@before@@PCI@@.@@", "new_pair": "myocardialUnecrosis@@markers@@,@@compared@@with@@aspirin", "replace_pair": "drug1@@markers@@,@@compared@@with@@drug2", "relation": "may_prevent"}, {"head": {"id": "680", "type": "", "word": "F", "begin": "41", "end": "42", "new_begin": "46", "new_end": "47", "replace_begin": "46", "replace_end": "51"}, "tail": {"id": "681", "type": "", "word": "caries", "begin": "150", "end": "156", "new_begin": "172", "new_end": "178", "replace_begin": "176", "replace_end": "181"}, "sentence": "Significant differences were observed in F response between shallow and deep lesions , suggesting that this parameter should be included when testing caries - preventive products .", "new_sentence": "Significant@@differences@@were@@observed@@in@@F@@response@@between@@shallow@@and@@deep@@lesions@@,@@suggesting@@that@@this@@parameter@@should@@be@@included@@when@@testing@@caries@@-@@preventive@@products@@.@@", "replace_sentence": "Significant@@differences@@were@@observed@@in@@drug1@@response@@between@@shallow@@and@@deep@@lesions@@,@@suggesting@@that@@this@@parameter@@should@@be@@included@@when@@testing@@drug2@@-@@preventive@@products@@.@@", "new_pair": "F@@response@@between@@shallow@@and@@deep@@lesions@@,@@suggesting@@that@@this@@parameter@@should@@be@@included@@when@@testing@@caries", "replace_pair": "drug1@@response@@between@@shallow@@and@@deep@@lesions@@,@@suggesting@@that@@this@@parameter@@should@@be@@included@@when@@testing@@drug2", "relation": "NA"}, {"head": {"id": "682", "type": "", "word": "CMVUinfection", "begin": "23", "end": "36", "new_begin": "26", "new_end": "39", "replace_begin": "26", "replace_end": "31"}, "tail": {"id": "683", "type": "", "word": "ganciclovir", "begin": "85", "end": "96", "new_begin": "95", "new_end": "106", "replace_begin": "87", "replace_end": "92"}, "sentence": "Strict surveillance of CMVUinfection , preemptive antiviral treatment or concomitant ganciclovir and ALA use are proposed as an attempt to prevent related clinical complications .", "new_sentence": "Strict@@surveillance@@of@@CMVUinfection@@,@@preemptive@@antiviral@@treatment@@or@@concomitant@@ganciclovir@@and@@ALA@@use@@are@@proposed@@as@@an@@attempt@@to@@prevent@@related@@clinical@@complications@@.@@", "replace_sentence": "Strict@@surveillance@@of@@drug1@@,@@preemptive@@antiviral@@treatment@@or@@concomitant@@drug2@@and@@ALA@@use@@are@@proposed@@as@@an@@attempt@@to@@prevent@@related@@clinical@@complications@@.@@", "new_pair": "CMVUinfection@@,@@preemptive@@antiviral@@treatment@@or@@concomitant@@ganciclovir", "replace_pair": "drug1@@,@@preemptive@@antiviral@@treatment@@or@@concomitant@@drug2", "relation": "NA"}, {"head": {"id": "684", "type": "", "word": "VitaminUE", "begin": "0", "end": "9", "new_begin": "0", "new_end": "9", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "685", "type": "", "word": "theUpreventionUofUcoronaryUheartUdisease", "begin": "69", "end": "109", "new_begin": "81", "new_end": "121", "replace_begin": "77", "replace_end": "82"}, "sentence": "VitaminUE is a fat - soluble antioxidant and is possibly involved in theUpreventionUofUcoronaryUheartUdisease by inhibiting oxidative modification of LDL cholesterol .", "new_sentence": "VitaminUE@@is@@a@@fat@@-@@soluble@@antioxidant@@and@@is@@possibly@@involved@@in@@theUpreventionUofUcoronaryUheartUdisease@@by@@inhibiting@@oxidative@@modification@@of@@LDL@@cholesterol@@.@@", "replace_sentence": "drug1@@is@@a@@fat@@-@@soluble@@antioxidant@@and@@is@@possibly@@involved@@in@@drug2@@by@@inhibiting@@oxidative@@modification@@of@@LDL@@cholesterol@@.@@", "new_pair": "VitaminUE@@is@@a@@fat@@-@@soluble@@antioxidant@@and@@is@@possibly@@involved@@in@@theUpreventionUofUcoronaryUheartUdisease", "replace_pair": "drug1@@is@@a@@fat@@-@@soluble@@antioxidant@@and@@is@@possibly@@involved@@in@@drug2", "relation": "NA"}, {"head": {"id": "686", "type": "", "word": "IDA", "begin": "90", "end": "93", "new_begin": "105", "new_end": "108", "replace_begin": "105", "replace_end": "110"}, "tail": {"id": "687", "type": "", "word": "vitUB12", "begin": "225", "end": "232", "new_begin": "265", "new_end": "272", "replace_begin": "267", "replace_end": "272"}, "sentence": "The authors recommend the utilization of Ferro -Folgamma for treatment and prophylaxis of IDA in pregnant women , because of its good gastric acceptance , a few side undesired reactions , and the supplement of Folic acid and vitUB12 increases the iron resorbtion .", "new_sentence": "The@@authors@@recommend@@the@@utilization@@of@@Ferro@@-@@Folgamma@@for@@treatment@@and@@prophylaxis@@of@@IDA@@in@@pregnant@@women@@,@@because@@of@@its@@good@@gastric@@acceptance@@,@@a@@few@@side@@undesired@@reactions@@,@@and@@the@@supplement@@of@@Folic@@acid@@and@@vitUB12@@increases@@the@@iron@@resorbtion@@.@@", "replace_sentence": "The@@authors@@recommend@@the@@utilization@@of@@Ferro@@-@@Folgamma@@for@@treatment@@and@@prophylaxis@@of@@drug1@@in@@pregnant@@women@@,@@because@@of@@its@@good@@gastric@@acceptance@@,@@a@@few@@side@@undesired@@reactions@@,@@and@@the@@supplement@@of@@Folic@@acid@@and@@drug2@@increases@@the@@iron@@resorbtion@@.@@", "new_pair": "IDA@@in@@pregnant@@women@@,@@because@@of@@its@@good@@gastric@@acceptance@@,@@a@@few@@side@@undesired@@reactions@@,@@and@@the@@supplement@@of@@Folic@@acid@@and@@vitUB12", "replace_pair": "drug1@@in@@pregnant@@women@@,@@because@@of@@its@@good@@gastric@@acceptance@@,@@a@@few@@side@@undesired@@reactions@@,@@and@@the@@supplement@@of@@Folic@@acid@@and@@drug2", "relation": "NA"}, {"head": {"id": "688", "type": "", "word": "CSP", "begin": "231", "end": "234", "new_begin": "268", "new_end": "271", "replace_begin": "268", "replace_end": "273"}, "tail": {"id": "689", "type": "", "word": "graft-versus-hostUdisease", "begin": "277", "end": "302", "new_begin": "323", "new_end": "348", "replace_begin": "325", "replace_end": "330"}, "sentence": "The first cohort of 21 patients were given cyclosporine ( CSP ) and mycophenolate mofetil ( MMF ) as postgrafting immunosuppression , whereas the subsequent cohort was given additional methotrexate ( MTX ) and extended duration of CSP @ MMF prophylaxis in an attempt to reduce graft-versus-hostUdisease ( GVHD ) .", "new_sentence": "The@@first@@cohort@@of@@21@@patients@@were@@given@@cyclosporine@@(@@CSP@@)@@and@@mycophenolate@@mofetil@@(@@MMF@@)@@as@@postgrafting@@immunosuppression@@,@@whereas@@the@@subsequent@@cohort@@was@@given@@additional@@methotrexate@@(@@MTX@@)@@and@@extended@@duration@@of@@CSP@@@@@MMF@@prophylaxis@@in@@an@@attempt@@to@@reduce@@graft-versus-hostUdisease@@(@@GVHD@@)@@.@@", "replace_sentence": "The@@first@@cohort@@of@@21@@patients@@were@@given@@cyclosporine@@(@@CSP@@)@@and@@mycophenolate@@mofetil@@(@@MMF@@)@@as@@postgrafting@@immunosuppression@@,@@whereas@@the@@subsequent@@cohort@@was@@given@@additional@@methotrexate@@(@@MTX@@)@@and@@extended@@duration@@of@@drug1@@@@@MMF@@prophylaxis@@in@@an@@attempt@@to@@reduce@@drug2@@(@@GVHD@@)@@.@@", "new_pair": "CSP@@@@@MMF@@prophylaxis@@in@@an@@attempt@@to@@reduce@@graft-versus-hostUdisease", "replace_pair": "drug1@@@@@MMF@@prophylaxis@@in@@an@@attempt@@to@@reduce@@drug2", "relation": "may_prevent"}, {"head": {"id": "690", "type": "", "word": "ASA", "begin": "14", "end": "17", "new_begin": "17", "new_end": "20", "replace_begin": "17", "replace_end": "22"}, "tail": {"id": "691", "type": "", "word": "ischemia", "begin": "39", "end": "47", "new_begin": "46", "new_end": "54", "replace_begin": "48", "replace_end": "53"}, "sentence": "In contrast , ASA therapy in temporary ischemia ( 87 . 2 + @ -6 . 2 mm3 ) reduced infarct size significantly compared to placebo ( 155 . 6 + @ -4 . 8 mm3 , p < 0 . 0001 ) .", "new_sentence": "In@@contrast@@,@@ASA@@therapy@@in@@temporary@@ischemia@@(@@87@@.@@2@@+@@@@@-@@6@@.@@2@@mm3@@)@@reduced@@infarct@@size@@significantly@@compared@@to@@placebo@@(@@155@@.@@6@@+@@@@@-@@4@@.@@8@@mm3@@,@@p@@<@@0@@.@@0001@@)@@.@@", "replace_sentence": "In@@contrast@@,@@drug1@@therapy@@in@@temporary@@drug2@@(@@87@@.@@2@@+@@@@@-@@6@@.@@2@@mm3@@)@@reduced@@infarct@@size@@significantly@@compared@@to@@placebo@@(@@155@@.@@6@@+@@@@@-@@4@@.@@8@@mm3@@,@@p@@<@@0@@.@@0001@@)@@.@@", "new_pair": "ASA@@therapy@@in@@temporary@@ischemia", "replace_pair": "drug1@@therapy@@in@@temporary@@drug2", "relation": "NA"}, {"head": {"id": "692", "type": "", "word": "perindopril", "begin": "50", "end": "61", "new_begin": "55", "new_end": "66", "replace_begin": "55", "replace_end": "60"}, "tail": {"id": "693", "type": "", "word": "stroke", "begin": "217", "end": "223", "new_begin": "245", "new_end": "251", "replace_begin": "239", "replace_end": "244"}, "sentence": "The multifactorial antiatherosclerotic profile of perindopril suggests a beneficial effect not only in patients with uncomplicated hypertension but also in patients with established coronary heart disease or previous stroke , as exemplified by the EUropean trial on Reduction Of coronary events with Perindopril in stable coronary Artery disease ( EUROPA ) and the Perindopril pROtection aGainst REcurrent Stroke Study ( PROGRESS ) .", "new_sentence": "The@@multifactorial@@antiatherosclerotic@@profile@@of@@perindopril@@suggests@@a@@beneficial@@effect@@not@@only@@in@@patients@@with@@uncomplicated@@hypertension@@but@@also@@in@@patients@@with@@established@@coronary@@heart@@disease@@or@@previous@@stroke@@,@@as@@exemplified@@by@@the@@EUropean@@trial@@on@@Reduction@@Of@@coronary@@events@@with@@Perindopril@@in@@stable@@coronary@@Artery@@disease@@(@@EUROPA@@)@@and@@the@@Perindopril@@pROtection@@aGainst@@REcurrent@@Stroke@@Study@@(@@PROGRESS@@)@@.@@", "replace_sentence": "The@@multifactorial@@antiatherosclerotic@@profile@@of@@drug1@@suggests@@a@@beneficial@@effect@@not@@only@@in@@patients@@with@@uncomplicated@@hypertension@@but@@also@@in@@patients@@with@@established@@coronary@@heart@@disease@@or@@previous@@drug2@@,@@as@@exemplified@@by@@the@@EUropean@@trial@@on@@Reduction@@Of@@coronary@@events@@with@@Perindopril@@in@@stable@@coronary@@Artery@@disease@@(@@EUROPA@@)@@and@@the@@Perindopril@@pROtection@@aGainst@@REcurrent@@Stroke@@Study@@(@@PROGRESS@@)@@.@@", "new_pair": "perindopril@@suggests@@a@@beneficial@@effect@@not@@only@@in@@patients@@with@@uncomplicated@@hypertension@@but@@also@@in@@patients@@with@@established@@coronary@@heart@@disease@@or@@previous@@stroke", "replace_pair": "drug1@@suggests@@a@@beneficial@@effect@@not@@only@@in@@patients@@with@@uncomplicated@@hypertension@@but@@also@@in@@patients@@with@@established@@coronary@@heart@@disease@@or@@previous@@drug2", "relation": "NA"}, {"head": {"id": "694", "type": "", "word": "Aspirin", "begin": "0", "end": "7", "new_begin": "0", "new_end": "7", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "695", "type": "", "word": "heartUdisease", "begin": "51", "end": "64", "new_begin": "59", "new_end": "72", "replace_begin": "57", "replace_end": "62"}, "sentence": "Aspirin use for the primary prevention of coronary heartUdisease : a population-based study in Switzerland .", "new_sentence": "Aspirin@@use@@for@@the@@primary@@prevention@@of@@coronary@@heartUdisease@@:@@a@@population@@-@@based@@study@@in@@Switzerland@@.@@", "replace_sentence": "drug1@@use@@for@@the@@primary@@prevention@@of@@coronary@@drug2@@:@@a@@population@@-@@based@@study@@in@@Switzerland@@.@@", "new_pair": "Aspirin@@use@@for@@the@@primary@@prevention@@of@@coronary@@heartUdisease", "replace_pair": "drug1@@use@@for@@the@@primary@@prevention@@of@@coronary@@drug2", "relation": "NA"}, {"head": {"id": "696", "type": "", "word": "Melatonin", "begin": "0", "end": "9", "new_begin": "0", "new_end": "9", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "697", "type": "", "word": "sepsis", "begin": "28", "end": "34", "new_begin": "31", "new_end": "37", "replace_begin": "27", "replace_end": "32"}, "sentence": "Melatonin treatment blunted sepsis - induced inducible nitric oxide synthase @ inducible mitochondrial nitric oxide synthase isoforms , prevented the impairment of mitochondrial homeostasis under sepsis , and restored ATP production .", "new_sentence": "Melatonin@@treatment@@blunted@@sepsis@@-@@induced@@inducible@@nitric@@oxide@@synthase@@@@@inducible@@mitochondrial@@nitric@@oxide@@synthase@@isoforms@@,@@prevented@@the@@impairment@@of@@mitochondrial@@homeostasis@@under@@sepsis@@,@@and@@restored@@ATP@@production@@.@@", "replace_sentence": "drug1@@treatment@@blunted@@drug2@@-@@induced@@inducible@@nitric@@oxide@@synthase@@@@@inducible@@mitochondrial@@nitric@@oxide@@synthase@@isoforms@@,@@prevented@@the@@impairment@@of@@mitochondrial@@homeostasis@@under@@sepsis@@,@@and@@restored@@ATP@@production@@.@@", "new_pair": "Melatonin@@treatment@@blunted@@sepsis", "replace_pair": "drug1@@treatment@@blunted@@drug2", "relation": "NA"}, {"head": {"id": "698", "type": "", "word": "aspirin", "begin": "40", "end": "47", "new_begin": "46", "new_end": "53", "replace_begin": "46", "replace_end": "51"}, "tail": {"id": "699", "type": "", "word": "stroke", "begin": "64", "end": "70", "new_begin": "74", "new_end": "80", "replace_begin": "72", "replace_end": "77"}, "sentence": "Aspirin failures , clopidogrel added to aspirin , and secondary stroke prevention in veterans presenting with TIA or mild-to-moderate ischemic stroke .", "new_sentence": "Aspirin@@failures@@,@@clopidogrel@@added@@to@@aspirin@@,@@and@@secondary@@stroke@@prevention@@in@@veterans@@presenting@@with@@TIA@@or@@mild@@-@@to@@-@@moderate@@ischemic@@stroke@@.@@", "replace_sentence": "Aspirin@@failures@@,@@clopidogrel@@added@@to@@drug1@@,@@and@@secondary@@drug2@@prevention@@in@@veterans@@presenting@@with@@TIA@@or@@mild@@-@@to@@-@@moderate@@ischemic@@stroke@@.@@", "new_pair": "aspirin@@,@@and@@secondary@@stroke", "replace_pair": "drug1@@,@@and@@secondary@@drug2", "relation": "NA"}, {"head": {"id": "700", "type": "", "word": "Captopril", "begin": "0", "end": "9", "new_begin": "0", "new_end": "9", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "701", "type": "", "word": "LVH", "begin": "66", "end": "69", "new_begin": "80", "new_end": "83", "replace_begin": "76", "replace_end": "81"}, "sentence": "Captopril normalized BP in HT and HT + AR , but could not prevent LVH in HT + AR as well as it did in isolated HT .", "new_sentence": "Captopril@@normalized@@BP@@in@@HT@@and@@HT@@+@@AR@@,@@but@@could@@not@@prevent@@LVH@@in@@HT@@+@@AR@@as@@well@@as@@it@@did@@in@@isolated@@HT@@.@@", "replace_sentence": "drug1@@normalized@@BP@@in@@HT@@and@@HT@@+@@AR@@,@@but@@could@@not@@prevent@@drug2@@in@@HT@@+@@AR@@as@@well@@as@@it@@did@@in@@isolated@@HT@@.@@", "new_pair": "Captopril@@normalized@@BP@@in@@HT@@and@@HT@@+@@AR@@,@@but@@could@@not@@prevent@@LVH", "replace_pair": "drug1@@normalized@@BP@@in@@HT@@and@@HT@@+@@AR@@,@@but@@could@@not@@prevent@@drug2", "relation": "may_prevent"}, {"head": {"id": "702", "type": "", "word": "CMVUdisease", "begin": "0", "end": "11", "new_begin": "0", "new_end": "11", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "703", "type": "", "word": "ganciclovir", "begin": "62", "end": "73", "new_begin": "72", "new_end": "83", "replace_begin": "66", "replace_end": "71"}, "sentence": "CMVUdisease was observed in only one patient belonging to the ganciclovir group , who developed enterocolitis 6 months post - transplantation .", "new_sentence": "CMVUdisease@@was@@observed@@in@@only@@one@@patient@@belonging@@to@@the@@ganciclovir@@group@@,@@who@@developed@@enterocolitis@@6@@months@@post@@-@@transplantation@@.@@", "replace_sentence": "drug1@@was@@observed@@in@@only@@one@@patient@@belonging@@to@@the@@drug2@@group@@,@@who@@developed@@enterocolitis@@6@@months@@post@@-@@transplantation@@.@@", "new_pair": "CMVUdisease@@was@@observed@@in@@only@@one@@patient@@belonging@@to@@the@@ganciclovir", "replace_pair": "drug1@@was@@observed@@in@@only@@one@@patient@@belonging@@to@@the@@drug2", "relation": "NA"}, {"head": {"id": "704", "type": "", "word": "folicUacid", "begin": "46", "end": "56", "new_begin": "54", "new_end": "64", "replace_begin": "54", "replace_end": "59"}, "tail": {"id": "705", "type": "", "word": "cobalaminUdeficiency", "begin": "108", "end": "128", "new_begin": "125", "new_end": "145", "replace_begin": "120", "replace_end": "125"}, "sentence": "There is concern that exposure of patients to folicUacid may prevent the development of the macrocytosis of cobalaminUdeficiency and thus delay the detection of the neurological complications .", "new_sentence": "There@@is@@concern@@that@@exposure@@of@@patients@@to@@folicUacid@@may@@prevent@@the@@development@@of@@the@@macrocytosis@@of@@cobalaminUdeficiency@@and@@thus@@delay@@the@@detection@@of@@the@@neurological@@complications@@.@@", "replace_sentence": "There@@is@@concern@@that@@exposure@@of@@patients@@to@@drug1@@may@@prevent@@the@@development@@of@@the@@macrocytosis@@of@@drug2@@and@@thus@@delay@@the@@detection@@of@@the@@neurological@@complications@@.@@", "new_pair": "folicUacid@@may@@prevent@@the@@development@@of@@the@@macrocytosis@@of@@cobalaminUdeficiency", "replace_pair": "drug1@@may@@prevent@@the@@development@@of@@the@@macrocytosis@@of@@drug2", "relation": "NA"}, {"head": {"id": "706", "type": "", "word": "PCP", "begin": "3", "end": "6", "new_begin": "4", "new_end": "7", "replace_begin": "4", "replace_end": "9"}, "tail": {"id": "707", "type": "", "word": "AZA", "begin": "91", "end": "94", "new_begin": "106", "new_end": "109", "replace_begin": "108", "replace_end": "113"}, "sentence": "No PCP occurred either in patients under MMF without TMS prophylaxis nor in patients under AZA .", "new_sentence": "No@@PCP@@occurred@@either@@in@@patients@@under@@MMF@@without@@TMS@@prophylaxis@@nor@@in@@patients@@under@@AZA@@.@@", "replace_sentence": "No@@drug1@@occurred@@either@@in@@patients@@under@@MMF@@without@@TMS@@prophylaxis@@nor@@in@@patients@@under@@drug2@@.@@", "new_pair": "PCP@@occurred@@either@@in@@patients@@under@@MMF@@without@@TMS@@prophylaxis@@nor@@in@@patients@@under@@AZA", "replace_pair": "drug1@@occurred@@either@@in@@patients@@under@@MMF@@without@@TMS@@prophylaxis@@nor@@in@@patients@@under@@drug2", "relation": "may_prevent"}, {"head": {"id": "708", "type": "", "word": "Melatonin", "begin": "0", "end": "9", "new_begin": "0", "new_end": "9", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "709", "type": "", "word": "IU @ UR", "begin": "92", "end": "99", "new_begin": "108", "new_end": "115", "replace_begin": "104", "replace_end": "109"}, "sentence": "Melatonin administration to L-NAME rats significantly reduced the MDA values resulting from IU @ UR .", "new_sentence": "Melatonin@@administration@@to@@L@@-@@NAME@@rats@@significantly@@reduced@@the@@MDA@@values@@resulting@@from@@IU @ UR@@.@@", "replace_sentence": "drug1@@administration@@to@@L@@-@@NAME@@rats@@significantly@@reduced@@the@@MDA@@values@@resulting@@from@@drug2@@.@@", "new_pair": "Melatonin@@administration@@to@@L@@-@@NAME@@rats@@significantly@@reduced@@the@@MDA@@values@@resulting@@from@@IU @ UR", "replace_pair": "drug1@@administration@@to@@L@@-@@NAME@@rats@@significantly@@reduced@@the@@MDA@@values@@resulting@@from@@drug2", "relation": "NA"}, {"head": {"id": "710", "type": "", "word": "glycerol", "begin": "63", "end": "71", "new_begin": "76", "new_end": "84", "replace_begin": "76", "replace_end": "81"}, "tail": {"id": "711", "type": "", "word": "acuteUrenalUfailure", "begin": "82", "end": "101", "new_begin": "98", "new_end": "117", "replace_begin": "95", "replace_end": "100"}, "sentence": "Pre - or post-treatment with hepatocyte growth factor prevents glycerol - induced acuteUrenalUfailure .", "new_sentence": "Pre@@-@@or@@post@@-@@treatment@@with@@hepatocyte@@growth@@factor@@prevents@@glycerol@@-@@induced@@acuteUrenalUfailure@@.@@", "replace_sentence": "Pre@@-@@or@@post@@-@@treatment@@with@@hepatocyte@@growth@@factor@@prevents@@drug1@@-@@induced@@drug2@@.@@", "new_pair": "glycerol@@-@@induced@@acuteUrenalUfailure", "replace_pair": "drug1@@-@@induced@@drug2", "relation": "NA"}, {"head": {"id": "712", "type": "", "word": "probucol", "begin": "25", "end": "33", "new_begin": "32", "new_end": "40", "replace_begin": "32", "replace_end": "37"}, "tail": {"id": "713", "type": "", "word": "leftUventricularUhypertrophy", "begin": "166", "end": "194", "new_begin": "193", "new_end": "221", "replace_begin": "190", "replace_end": "195"}, "sentence": "The lipid-lowering agent probucol may be efficacious , through its antioxidant properties , to limit and reverse the vascular endothelial dysfunction associated with leftUventricularUhypertrophy ( LVH ) .", "new_sentence": "The@@lipid@@-@@lowering@@agent@@probucol@@may@@be@@efficacious@@,@@through@@its@@antioxidant@@properties@@,@@to@@limit@@and@@reverse@@the@@vascular@@endothelial@@dysfunction@@associated@@with@@leftUventricularUhypertrophy@@(@@LVH@@)@@.@@", "replace_sentence": "The@@lipid@@-@@lowering@@agent@@drug1@@may@@be@@efficacious@@,@@through@@its@@antioxidant@@properties@@,@@to@@limit@@and@@reverse@@the@@vascular@@endothelial@@dysfunction@@associated@@with@@drug2@@(@@LVH@@)@@.@@", "new_pair": "probucol@@may@@be@@efficacious@@,@@through@@its@@antioxidant@@properties@@,@@to@@limit@@and@@reverse@@the@@vascular@@endothelial@@dysfunction@@associated@@with@@leftUventricularUhypertrophy", "replace_pair": "drug1@@may@@be@@efficacious@@,@@through@@its@@antioxidant@@properties@@,@@to@@limit@@and@@reverse@@the@@vascular@@endothelial@@dysfunction@@associated@@with@@drug2", "relation": "NA"}, {"head": {"id": "714", "type": "", "word": "B-vitamin", "begin": "96", "end": "105", "new_begin": "113", "new_end": "122", "replace_begin": "113", "replace_end": "118"}, "tail": {"id": "715", "type": "", "word": "stroke", "begin": "168", "end": "174", "new_begin": "195", "new_end": "201", "replace_begin": "191", "replace_end": "196"}, "sentence": "VITATOPS , the VITAmins TO prevent stroke trial : rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke ( NCT00097669 ) ( ISRCTN74743444 ) .", "new_sentence": "VITATOPS@@,@@the@@VITAmins@@TO@@prevent@@stroke@@trial@@:@@rationale@@and@@design@@of@@a@@randomised@@trial@@of@@B-vitamin@@therapy@@in@@patients@@with@@recent@@transient@@ischaemic@@attack@@or@@stroke@@(@@NCT00097669@@)@@(@@ISRCTN74743444@@)@@.@@", "replace_sentence": "VITATOPS@@,@@the@@VITAmins@@TO@@prevent@@stroke@@trial@@:@@rationale@@and@@design@@of@@a@@randomised@@trial@@of@@drug1@@therapy@@in@@patients@@with@@recent@@transient@@ischaemic@@attack@@or@@drug2@@(@@NCT00097669@@)@@(@@ISRCTN74743444@@)@@.@@", "new_pair": "B-vitamin@@therapy@@in@@patients@@with@@recent@@transient@@ischaemic@@attack@@or@@stroke", "replace_pair": "drug1@@therapy@@in@@patients@@with@@recent@@transient@@ischaemic@@attack@@or@@drug2", "relation": "NA"}, {"head": {"id": "716", "type": "", "word": "aspirin", "begin": "70", "end": "77", "new_begin": "85", "new_end": "92", "replace_begin": "85", "replace_end": "90"}, "tail": {"id": "717", "type": "", "word": "TIA", "begin": "168", "end": "171", "new_begin": "199", "new_end": "202", "replace_begin": "197", "replace_end": "202"}, "sentence": "Currently available clinical trial data support the use of ER-DP plus aspirin , but not clopidogrel plus aspirin , to prevent secondary vascular events after stroke or TIA .", "new_sentence": "Currently@@available@@clinical@@trial@@data@@support@@the@@use@@of@@ER@@-@@DP@@plus@@aspirin@@,@@but@@not@@clopidogrel@@plus@@aspirin@@,@@to@@prevent@@secondary@@vascular@@events@@after@@stroke@@or@@TIA@@.@@", "replace_sentence": "Currently@@available@@clinical@@trial@@data@@support@@the@@use@@of@@ER@@-@@DP@@plus@@drug1@@,@@but@@not@@clopidogrel@@plus@@aspirin@@,@@to@@prevent@@secondary@@vascular@@events@@after@@stroke@@or@@drug2@@.@@", "new_pair": "aspirin@@,@@but@@not@@clopidogrel@@plus@@aspirin@@,@@to@@prevent@@secondary@@vascular@@events@@after@@stroke@@or@@TIA", "replace_pair": "drug1@@,@@but@@not@@clopidogrel@@plus@@aspirin@@,@@to@@prevent@@secondary@@vascular@@events@@after@@stroke@@or@@drug2", "relation": "NA"}, {"head": {"id": "718", "type": "", "word": "GVHD", "begin": "59", "end": "63", "new_begin": "71", "new_end": "75", "replace_begin": "71", "replace_end": "76"}, "tail": {"id": "719", "type": "", "word": "cyclosporine", "begin": "158", "end": "170", "new_begin": "187", "new_end": "199", "replace_begin": "188", "replace_end": "193"}, "sentence": "In this study , patients were randomized to receive 1 of 2 GVHD prophylaxis strategies , marrow T cell depletion , and cyclosporine ( TCD ) or methotrexate @ cyclosporine ( M @ C ) after transplantation .", "new_sentence": "In@@this@@study@@,@@patients@@were@@randomized@@to@@receive@@1@@of@@2@@GVHD@@prophylaxis@@strategies@@,@@marrow@@T@@cell@@depletion@@,@@and@@cyclosporine@@(@@TCD@@)@@or@@methotrexate@@@@@cyclosporine@@(@@M@@@@@C@@)@@after@@transplantation@@.@@", "replace_sentence": "In@@this@@study@@,@@patients@@were@@randomized@@to@@receive@@1@@of@@2@@drug1@@prophylaxis@@strategies@@,@@marrow@@T@@cell@@depletion@@,@@and@@cyclosporine@@(@@TCD@@)@@or@@methotrexate@@@@@drug2@@(@@M@@@@@C@@)@@after@@transplantation@@.@@", "new_pair": "GVHD@@prophylaxis@@strategies@@,@@marrow@@T@@cell@@depletion@@,@@and@@cyclosporine@@(@@TCD@@)@@or@@methotrexate@@@@@cyclosporine", "replace_pair": "drug1@@prophylaxis@@strategies@@,@@marrow@@T@@cell@@depletion@@,@@and@@cyclosporine@@(@@TCD@@)@@or@@methotrexate@@@@@drug2", "relation": "NA"}, {"head": {"id": "720", "type": "", "word": "perindopril", "begin": "14", "end": "25", "new_begin": "17", "new_end": "28", "replace_begin": "17", "replace_end": "22"}, "tail": {"id": "721", "type": "", "word": "CKD", "begin": "100", "end": "103", "new_begin": "115", "new_end": "118", "replace_begin": "109", "replace_end": "114"}, "sentence": "We found that perindopril - based BP lowering effectively prevented recurrent stroke in people with CKD , across a wide range of BP levels , without evidence of an increased risk of stroke in people with low BP levels .", "new_sentence": "We@@found@@that@@perindopril@@-@@based@@BP@@lowering@@effectively@@prevented@@recurrent@@stroke@@in@@people@@with@@CKD@@,@@across@@a@@wide@@range@@of@@BP@@levels@@,@@without@@evidence@@of@@an@@increased@@risk@@of@@stroke@@in@@people@@with@@low@@BP@@levels@@.@@", "replace_sentence": "We@@found@@that@@drug1@@-@@based@@BP@@lowering@@effectively@@prevented@@recurrent@@stroke@@in@@people@@with@@drug2@@,@@across@@a@@wide@@range@@of@@BP@@levels@@,@@without@@evidence@@of@@an@@increased@@risk@@of@@stroke@@in@@people@@with@@low@@BP@@levels@@.@@", "new_pair": "perindopril@@-@@based@@BP@@lowering@@effectively@@prevented@@recurrent@@stroke@@in@@people@@with@@CKD", "replace_pair": "drug1@@-@@based@@BP@@lowering@@effectively@@prevented@@recurrent@@stroke@@in@@people@@with@@drug2", "relation": "NA"}, {"head": {"id": "722", "type": "", "word": "essentialUaminoUacid", "begin": "37", "end": "57", "new_begin": "48", "new_end": "68", "replace_begin": "48", "replace_end": "53"}, "tail": {"id": "723", "type": "", "word": "herpesUsimplex", "begin": "132", "end": "146", "new_begin": "160", "new_end": "174", "replace_begin": "145", "replace_end": "150"}, "sentence": "L-Lysine hydrochloride ( Lys ) is an essentialUaminoUacid in humans and animals , and it is used in animal feeds , in prevention of herpesUsimplex recurrence , and cereal fortification in some developing countries .", "new_sentence": "L@@-@@Lysine@@hydrochloride@@(@@Lys@@)@@is@@an@@essentialUaminoUacid@@in@@humans@@and@@animals@@,@@and@@it@@is@@used@@in@@animal@@feeds@@,@@in@@prevention@@of@@herpesUsimplex@@recurrence@@,@@and@@cereal@@fortification@@in@@some@@developing@@countries@@.@@", "replace_sentence": "L@@-@@Lysine@@hydrochloride@@(@@Lys@@)@@is@@an@@drug1@@in@@humans@@and@@animals@@,@@and@@it@@is@@used@@in@@animal@@feeds@@,@@in@@prevention@@of@@drug2@@recurrence@@,@@and@@cereal@@fortification@@in@@some@@developing@@countries@@.@@", "new_pair": "essentialUaminoUacid@@in@@humans@@and@@animals@@,@@and@@it@@is@@used@@in@@animal@@feeds@@,@@in@@prevention@@of@@herpesUsimplex", "replace_pair": "drug1@@in@@humans@@and@@animals@@,@@and@@it@@is@@used@@in@@animal@@feeds@@,@@in@@prevention@@of@@drug2", "relation": "NA"}, {"head": {"id": "724", "type": "", "word": "hyperlipidemic", "begin": "80", "end": "94", "new_begin": "98", "new_end": "112", "replace_begin": "98", "replace_end": "103"}, "tail": {"id": "725", "type": "", "word": "pravastatin", "begin": "173", "end": "184", "new_begin": "207", "new_end": "218", "replace_begin": "198", "replace_end": "203"}, "sentence": "METHODS AND RESULTS : In a double-blind , multicenter trial , we randomized 615 hyperlipidemic , postmenopausal women to intensive ( atorvastatin 80 mg @ d ) and moderate ( pravastatin 40 mg @ d ) lipid-lowering therapy .", "new_sentence": "METHODS@@AND@@RESULTS@@:@@In@@a@@double@@-@@blind@@,@@multicenter@@trial@@,@@we@@randomized@@615@@hyperlipidemic@@,@@postmenopausal@@women@@to@@intensive@@(@@atorvastatin@@80@@mg@@@@@d@@)@@and@@moderate@@(@@pravastatin@@40@@mg@@@@@d@@)@@lipid@@-@@lowering@@therapy@@.@@", "replace_sentence": "METHODS@@AND@@RESULTS@@:@@In@@a@@double@@-@@blind@@,@@multicenter@@trial@@,@@we@@randomized@@615@@drug1@@,@@postmenopausal@@women@@to@@intensive@@(@@atorvastatin@@80@@mg@@@@@d@@)@@and@@moderate@@(@@drug2@@40@@mg@@@@@d@@)@@lipid@@-@@lowering@@therapy@@.@@", "new_pair": "hyperlipidemic@@,@@postmenopausal@@women@@to@@intensive@@(@@atorvastatin@@80@@mg@@@@@d@@)@@and@@moderate@@(@@pravastatin", "replace_pair": "drug1@@,@@postmenopausal@@women@@to@@intensive@@(@@atorvastatin@@80@@mg@@@@@d@@)@@and@@moderate@@(@@drug2", "relation": "NA"}, {"head": {"id": "726", "type": "", "word": "heparin", "begin": "64", "end": "71", "new_begin": "72", "new_end": "79", "replace_begin": "72", "replace_end": "77"}, "tail": {"id": "727", "type": "", "word": "stroke", "begin": "89", "end": "95", "new_begin": "101", "new_end": "107", "replace_begin": "99", "replace_end": "104"}, "sentence": "CONCLUSIONS : Use of therapeutic anticoagulants or prophylactic heparin prevented VTE in stroke patients during inpatient rehabilitation .", "new_sentence": "CONCLUSIONS@@:@@Use@@of@@therapeutic@@anticoagulants@@or@@prophylactic@@heparin@@prevented@@VTE@@in@@stroke@@patients@@during@@inpatient@@rehabilitation@@.@@", "replace_sentence": "CONCLUSIONS@@:@@Use@@of@@therapeutic@@anticoagulants@@or@@prophylactic@@drug1@@prevented@@VTE@@in@@drug2@@patients@@during@@inpatient@@rehabilitation@@.@@", "new_pair": "heparin@@prevented@@VTE@@in@@stroke", "replace_pair": "drug1@@prevented@@VTE@@in@@drug2", "relation": "NA"}, {"head": {"id": "728", "type": "", "word": "palivizumab", "begin": "33", "end": "44", "new_begin": "38", "new_end": "49", "replace_begin": "38", "replace_end": "43"}, "tail": {"id": "729", "type": "", "word": "BPDU @ UCLD", "begin": "241", "end": "252", "new_begin": "281", "new_end": "292", "replace_begin": "275", "replace_end": "280"}, "sentence": "In conclusion , prophylaxis with palivizumab significantly reduces the incidence of RSV - related hospitalization relative to placebo and is generally well tolerated in high-risk infants aged < 2 years , including those with prematurity and BPDU @ UCLD or HSCHD , which are risk factors for early or serious RSV infection .", "new_sentence": "In@@conclusion@@,@@prophylaxis@@with@@palivizumab@@significantly@@reduces@@the@@incidence@@of@@RSV@@-@@related@@hospitalization@@relative@@to@@placebo@@and@@is@@generally@@well@@tolerated@@in@@high@@-@@risk@@infants@@aged@@<@@2@@years@@,@@including@@those@@with@@prematurity@@and@@BPDU @ UCLD@@or@@HSCHD@@,@@which@@are@@risk@@factors@@for@@early@@or@@serious@@RSV@@infection@@.@@", "replace_sentence": "In@@conclusion@@,@@prophylaxis@@with@@drug1@@significantly@@reduces@@the@@incidence@@of@@RSV@@-@@related@@hospitalization@@relative@@to@@placebo@@and@@is@@generally@@well@@tolerated@@in@@high@@-@@risk@@infants@@aged@@<@@2@@years@@,@@including@@those@@with@@prematurity@@and@@drug2@@or@@HSCHD@@,@@which@@are@@risk@@factors@@for@@early@@or@@serious@@RSV@@infection@@.@@", "new_pair": "palivizumab@@significantly@@reduces@@the@@incidence@@of@@RSV@@-@@related@@hospitalization@@relative@@to@@placebo@@and@@is@@generally@@well@@tolerated@@in@@high@@-@@risk@@infants@@aged@@<@@2@@years@@,@@including@@those@@with@@prematurity@@and@@BPDU @ UCLD", "replace_pair": "drug1@@significantly@@reduces@@the@@incidence@@of@@RSV@@-@@related@@hospitalization@@relative@@to@@placebo@@and@@is@@generally@@well@@tolerated@@in@@high@@-@@risk@@infants@@aged@@<@@2@@years@@,@@including@@those@@with@@prematurity@@and@@drug2", "relation": "NA"}, {"head": {"id": "730", "type": "", "word": "hepatitisUBUimmunoglobulin", "begin": "54", "end": "80", "new_begin": "63", "new_end": "89", "replace_begin": "63", "replace_end": "68"}, "tail": {"id": "731", "type": "", "word": "hepatitisUB", "begin": "170", "end": "181", "new_begin": "194", "new_end": "205", "replace_begin": "173", "replace_end": "178"}, "sentence": "OBJECTIVE : To explore the possible efficacy of using hepatitisUBUimmunoglobulin ( HBIG ) during the third trimester of pregnancy to prevent intrauterine transmission of hepatitisUB virus ( HBV ) .", "new_sentence": "OBJECTIVE@@:@@To@@explore@@the@@possible@@efficacy@@of@@using@@hepatitisUBUimmunoglobulin@@(@@HBIG@@)@@during@@the@@third@@trimester@@of@@pregnancy@@to@@prevent@@intrauterine@@transmission@@of@@hepatitisUB@@virus@@(@@HBV@@)@@.@@", "replace_sentence": "OBJECTIVE@@:@@To@@explore@@the@@possible@@efficacy@@of@@using@@drug1@@(@@HBIG@@)@@during@@the@@third@@trimester@@of@@pregnancy@@to@@prevent@@intrauterine@@transmission@@of@@drug2@@virus@@(@@HBV@@)@@.@@", "new_pair": "hepatitisUBUimmunoglobulin@@(@@HBIG@@)@@during@@the@@third@@trimester@@of@@pregnancy@@to@@prevent@@intrauterine@@transmission@@of@@hepatitisUB", "replace_pair": "drug1@@(@@HBIG@@)@@during@@the@@third@@trimester@@of@@pregnancy@@to@@prevent@@intrauterine@@transmission@@of@@drug2", "relation": "NA"}, {"head": {"id": "732", "type": "", "word": "asthma", "begin": "89", "end": "95", "new_begin": "107", "new_end": "113", "replace_begin": "107", "replace_end": "112"}, "tail": {"id": "733", "type": "", "word": "vitaminUA", "begin": "312", "end": "321", "new_begin": "373", "new_end": "382", "replace_begin": "372", "replace_end": "377"}, "sentence": "METHODS : Information on physician- diagnosed non-malignant lung diseases ( asbestosis , asthma , chronic bronchitis or emphysema ( CB @ E ) , pneumonia , and tuberculosis ) was obtained at baseline from 17 , 698 men and women involved in CARET , a randomized lung cancer prevention trial of beta - carotene and vitaminUA among heavy smokers and asbestos - exposed workers .", "new_sentence": "METHODS@@:@@Information@@on@@physician@@-@@diagnosed@@non@@-@@malignant@@lung@@diseases@@(@@asbestosis@@,@@asthma@@,@@chronic@@bronchitis@@or@@emphysema@@(@@CB@@@@@E@@)@@,@@pneumonia@@,@@and@@tuberculosis@@)@@was@@obtained@@at@@baseline@@from@@17@@,@@698@@men@@and@@women@@involved@@in@@CARET@@,@@a@@randomized@@lung@@cancer@@prevention@@trial@@of@@beta@@-@@carotene@@and@@vitaminUA@@among@@heavy@@smokers@@and@@asbestos@@-@@exposed@@workers@@.@@", "replace_sentence": "METHODS@@:@@Information@@on@@physician@@-@@diagnosed@@non@@-@@malignant@@lung@@diseases@@(@@asbestosis@@,@@drug1@@,@@chronic@@bronchitis@@or@@emphysema@@(@@CB@@@@@E@@)@@,@@pneumonia@@,@@and@@tuberculosis@@)@@was@@obtained@@at@@baseline@@from@@17@@,@@698@@men@@and@@women@@involved@@in@@CARET@@,@@a@@randomized@@lung@@cancer@@prevention@@trial@@of@@beta@@-@@carotene@@and@@drug2@@among@@heavy@@smokers@@and@@asbestos@@-@@exposed@@workers@@.@@", "new_pair": "asthma@@,@@chronic@@bronchitis@@or@@emphysema@@(@@CB@@@@@E@@)@@,@@pneumonia@@,@@and@@tuberculosis@@)@@was@@obtained@@at@@baseline@@from@@17@@,@@698@@men@@and@@women@@involved@@in@@CARET@@,@@a@@randomized@@lung@@cancer@@prevention@@trial@@of@@beta@@-@@carotene@@and@@vitaminUA", "replace_pair": "drug1@@,@@chronic@@bronchitis@@or@@emphysema@@(@@CB@@@@@E@@)@@,@@pneumonia@@,@@and@@tuberculosis@@)@@was@@obtained@@at@@baseline@@from@@17@@,@@698@@men@@and@@women@@involved@@in@@CARET@@,@@a@@randomized@@lung@@cancer@@prevention@@trial@@of@@beta@@-@@carotene@@and@@drug2", "relation": "NA"}, {"head": {"id": "734", "type": "", "word": "aspirin", "begin": "299", "end": "306", "new_begin": "364", "new_end": "371", "replace_begin": "364", "replace_end": "369"}, "tail": {"id": "735", "type": "", "word": "thromboembolism", "begin": "461", "end": "476", "new_begin": "553", "new_end": "568", "replace_begin": "551", "replace_end": "556"}, "sentence": "METHODS : We conducted a randomized trial in which 109 patients with antiphospholipid syndrome ( APS ) and previous thrombosis were given either high - intensity warfarin ( INR range 3 . 0-4 . 5 , 54 patients ) or standard antithrombotic therapy ( warfarin , INR range 2 . 0-3 . 0 in 52 patients or aspirin alone , 100 mg day ( - 1 ) in three patients ) to determine whether intensive anticoagulation is superior to standard treatment in preventing symptomatic thromboembolism without increasing the bleeding risk .", "new_sentence": "METHODS@@:@@We@@conducted@@a@@randomized@@trial@@in@@which@@109@@patients@@with@@antiphospholipid@@syndrome@@(@@APS@@)@@and@@previous@@thrombosis@@were@@given@@either@@high@@-@@intensity@@warfarin@@(@@INR@@range@@3@@.@@0@@-@@4@@.@@5@@,@@54@@patients@@)@@or@@standard@@antithrombotic@@therapy@@(@@warfarin@@,@@INR@@range@@2@@.@@0@@-@@3@@.@@0@@in@@52@@patients@@or@@aspirin@@alone@@,@@100@@mg@@day@@(@@-@@1@@)@@in@@three@@patients@@)@@to@@determine@@whether@@intensive@@anticoagulation@@is@@superior@@to@@standard@@treatment@@in@@preventing@@symptomatic@@thromboembolism@@without@@increasing@@the@@bleeding@@risk@@.@@", "replace_sentence": "METHODS@@:@@We@@conducted@@a@@randomized@@trial@@in@@which@@109@@patients@@with@@antiphospholipid@@syndrome@@(@@APS@@)@@and@@previous@@thrombosis@@were@@given@@either@@high@@-@@intensity@@warfarin@@(@@INR@@range@@3@@.@@0@@-@@4@@.@@5@@,@@54@@patients@@)@@or@@standard@@antithrombotic@@therapy@@(@@warfarin@@,@@INR@@range@@2@@.@@0@@-@@3@@.@@0@@in@@52@@patients@@or@@drug1@@alone@@,@@100@@mg@@day@@(@@-@@1@@)@@in@@three@@patients@@)@@to@@determine@@whether@@intensive@@anticoagulation@@is@@superior@@to@@standard@@treatment@@in@@preventing@@symptomatic@@drug2@@without@@increasing@@the@@bleeding@@risk@@.@@", "new_pair": "aspirin@@alone@@,@@100@@mg@@day@@(@@-@@1@@)@@in@@three@@patients@@)@@to@@determine@@whether@@intensive@@anticoagulation@@is@@superior@@to@@standard@@treatment@@in@@preventing@@symptomatic@@thromboembolism", "replace_pair": "drug1@@alone@@,@@100@@mg@@day@@(@@-@@1@@)@@in@@three@@patients@@)@@to@@determine@@whether@@intensive@@anticoagulation@@is@@superior@@to@@standard@@treatment@@in@@preventing@@symptomatic@@drug2", "relation": "NA"}, {"head": {"id": "736", "type": "", "word": "fungalUinfections", "begin": "147", "end": "164", "new_begin": "165", "new_end": "182", "replace_begin": "165", "replace_end": "170"}, "tail": {"id": "737", "type": "", "word": "itraconazole", "begin": "213", "end": "225", "new_begin": "239", "new_end": "251", "replace_begin": "227", "replace_end": "232"}, "sentence": "CONCLUSIONS : In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome , posaconazole prevented invasive fungalUinfections more effectively than did either fluconazole or itraconazole and improved overall survival .", "new_sentence": "CONCLUSIONS@@:@@In@@patients@@undergoing@@chemotherapy@@for@@acute@@myelogenous@@leukemia@@or@@the@@myelodysplastic@@syndrome@@,@@posaconazole@@prevented@@invasive@@fungalUinfections@@more@@effectively@@than@@did@@either@@fluconazole@@or@@itraconazole@@and@@improved@@overall@@survival@@.@@", "replace_sentence": "CONCLUSIONS@@:@@In@@patients@@undergoing@@chemotherapy@@for@@acute@@myelogenous@@leukemia@@or@@the@@myelodysplastic@@syndrome@@,@@posaconazole@@prevented@@invasive@@drug1@@more@@effectively@@than@@did@@either@@fluconazole@@or@@drug2@@and@@improved@@overall@@survival@@.@@", "new_pair": "fungalUinfections@@more@@effectively@@than@@did@@either@@fluconazole@@or@@itraconazole", "replace_pair": "drug1@@more@@effectively@@than@@did@@either@@fluconazole@@or@@drug2", "relation": "NA"}, {"head": {"id": "738", "type": "", "word": "aspirin", "begin": "66", "end": "73", "new_begin": "75", "new_end": "82", "replace_begin": "75", "replace_end": "80"}, "tail": {"id": "739", "type": "", "word": "cerebralUischemia", "begin": "150", "end": "167", "new_begin": "173", "new_end": "190", "replace_begin": "171", "replace_end": "176"}, "sentence": "Based on cardiovascular studies , clopidogrel in combination with aspirin has not been proven superior to aspirin alone for the primary prevention of cerebralUischemia .", "new_sentence": "Based@@on@@cardiovascular@@studies@@,@@clopidogrel@@in@@combination@@with@@aspirin@@has@@not@@been@@proven@@superior@@to@@aspirin@@alone@@for@@the@@primary@@prevention@@of@@cerebralUischemia@@.@@", "replace_sentence": "Based@@on@@cardiovascular@@studies@@,@@clopidogrel@@in@@combination@@with@@drug1@@has@@not@@been@@proven@@superior@@to@@aspirin@@alone@@for@@the@@primary@@prevention@@of@@drug2@@.@@", "new_pair": "aspirin@@has@@not@@been@@proven@@superior@@to@@aspirin@@alone@@for@@the@@primary@@prevention@@of@@cerebralUischemia", "replace_pair": "drug1@@has@@not@@been@@proven@@superior@@to@@aspirin@@alone@@for@@the@@primary@@prevention@@of@@drug2", "relation": "NA"}, {"head": {"id": "740", "type": "", "word": "pulmonaryUembolism", "begin": "3", "end": "21", "new_begin": "4", "new_end": "22", "replace_begin": "4", "replace_end": "9"}, "tail": {"id": "741", "type": "", "word": "fondaparinux", "begin": "28", "end": "40", "new_begin": "32", "new_end": "44", "replace_begin": "19", "replace_end": "24"}, "sentence": "In pulmonaryUembolism , the fondaparinux seems to be an alternative to NFH .", "new_sentence": "In@@pulmonaryUembolism@@,@@the@@fondaparinux@@seems@@to@@be@@an@@alternative@@to@@NFH@@.@@", "replace_sentence": "In@@drug1@@,@@the@@drug2@@seems@@to@@be@@an@@alternative@@to@@NFH@@.@@", "new_pair": "pulmonaryUembolism@@,@@the@@fondaparinux", "replace_pair": "drug1@@,@@the@@drug2", "relation": "NA"}, {"head": {"id": "742", "type": "", "word": "F", "begin": "29", "end": "30", "new_begin": "35", "new_end": "36", "replace_begin": "35", "replace_end": "40"}, "tail": {"id": "743", "type": "", "word": "caries", "begin": "151", "end": "157", "new_begin": "184", "new_end": "190", "replace_begin": "188", "replace_end": "193"}, "sentence": "To conclude , school - based F varnish treatment every 6 months in 13- to 16- year - olds is excellent to prevent approximal caries in medium and high caries risk areas .", "new_sentence": "To@@conclude@@,@@school@@-@@based@@F@@varnish@@treatment@@every@@6@@months@@in@@13@@-@@to@@16@@-@@year@@-@@olds@@is@@excellent@@to@@prevent@@approximal@@caries@@in@@medium@@and@@high@@caries@@risk@@areas@@.@@", "replace_sentence": "To@@conclude@@,@@school@@-@@based@@drug1@@varnish@@treatment@@every@@6@@months@@in@@13@@-@@to@@16@@-@@year@@-@@olds@@is@@excellent@@to@@prevent@@approximal@@caries@@in@@medium@@and@@high@@drug2@@risk@@areas@@.@@", "new_pair": "F@@varnish@@treatment@@every@@6@@months@@in@@13@@-@@to@@16@@-@@year@@-@@olds@@is@@excellent@@to@@prevent@@approximal@@caries@@in@@medium@@and@@high@@caries", "replace_pair": "drug1@@varnish@@treatment@@every@@6@@months@@in@@13@@-@@to@@16@@-@@year@@-@@olds@@is@@excellent@@to@@prevent@@approximal@@caries@@in@@medium@@and@@high@@drug2", "relation": "may_prevent"}, {"head": {"id": "744", "type": "", "word": "intravenousUimmunoglobulins", "begin": "30", "end": "57", "new_begin": "35", "new_end": "62", "replace_begin": "35", "replace_end": "40"}, "tail": {"id": "745", "type": "", "word": "graft-versus-hostUdisease", "begin": "105", "end": "130", "new_begin": "120", "new_end": "145", "replace_begin": "98", "replace_end": "103"}, "sentence": "To explore the suitability of intravenousUimmunoglobulins ( IVIg ) as prophylaxis of acute rejection and graft-versus-hostUdisease ( GVHD ) after allograft transplantation , the effects of IVIg and calcineurin inhibitors ( CNI ) on human blood - derived T-cells and DC were compared .", "new_sentence": "To@@explore@@the@@suitability@@of@@intravenousUimmunoglobulins@@(@@IVIg@@)@@as@@prophylaxis@@of@@acute@@rejection@@and@@graft-versus-hostUdisease@@(@@GVHD@@)@@after@@allograft@@transplantation@@,@@the@@effects@@of@@IVIg@@and@@calcineurin@@inhibitors@@(@@CNI@@)@@on@@human@@blood@@-@@derived@@T@@-@@cells@@and@@DC@@were@@compared@@.@@", "replace_sentence": "To@@explore@@the@@suitability@@of@@drug1@@(@@IVIg@@)@@as@@prophylaxis@@of@@acute@@rejection@@and@@drug2@@(@@GVHD@@)@@after@@allograft@@transplantation@@,@@the@@effects@@of@@IVIg@@and@@calcineurin@@inhibitors@@(@@CNI@@)@@on@@human@@blood@@-@@derived@@T@@-@@cells@@and@@DC@@were@@compared@@.@@", "new_pair": "intravenousUimmunoglobulins@@(@@IVIg@@)@@as@@prophylaxis@@of@@acute@@rejection@@and@@graft-versus-hostUdisease", "replace_pair": "drug1@@(@@IVIg@@)@@as@@prophylaxis@@of@@acute@@rejection@@and@@drug2", "relation": "NA"}, {"head": {"id": "746", "type": "", "word": "hepatitisUBUimmunoglobulin", "begin": "44", "end": "70", "new_begin": "54", "new_end": "80", "replace_begin": "54", "replace_end": "59"}, "tail": {"id": "747", "type": "", "word": "HBVUinfection", "begin": "210", "end": "223", "new_begin": "247", "new_end": "260", "replace_begin": "226", "replace_end": "231"}, "sentence": "BACKGROUND AND AIMS : High-dose intravenous hepatitisUBUimmunoglobulin ( HBIG ) may prevent recurrent hepatitis B virus ( HBV ) infection , but the cost has limited its widespread use in countries with endemic HBVUinfection .", "new_sentence": "BACKGROUND@@AND@@AIMS@@:@@High@@-@@dose@@intravenous@@hepatitisUBUimmunoglobulin@@(@@HBIG@@)@@may@@prevent@@recurrent@@hepatitis@@B@@virus@@(@@HBV@@)@@infection@@,@@but@@the@@cost@@has@@limited@@its@@widespread@@use@@in@@countries@@with@@endemic@@HBVUinfection@@.@@", "replace_sentence": "BACKGROUND@@AND@@AIMS@@:@@High@@-@@dose@@intravenous@@drug1@@(@@HBIG@@)@@may@@prevent@@recurrent@@hepatitis@@B@@virus@@(@@HBV@@)@@infection@@,@@but@@the@@cost@@has@@limited@@its@@widespread@@use@@in@@countries@@with@@endemic@@drug2@@.@@", "new_pair": "hepatitisUBUimmunoglobulin@@(@@HBIG@@)@@may@@prevent@@recurrent@@hepatitis@@B@@virus@@(@@HBV@@)@@infection@@,@@but@@the@@cost@@has@@limited@@its@@widespread@@use@@in@@countries@@with@@endemic@@HBVUinfection", "replace_pair": "drug1@@(@@HBIG@@)@@may@@prevent@@recurrent@@hepatitis@@B@@virus@@(@@HBV@@)@@infection@@,@@but@@the@@cost@@has@@limited@@its@@widespread@@use@@in@@countries@@with@@endemic@@drug2", "relation": "NA"}, {"head": {"id": "748", "type": "", "word": "Aspirin", "begin": "747", "end": "754", "new_begin": "893", "new_end": "900", "replace_begin": "893", "replace_end": "898"}, "tail": {"id": "749", "type": "", "word": "CerebralUInfarction", "begin": "758", "end": "777", "new_begin": "906", "new_end": "925", "replace_begin": "904", "replace_end": "909"}, "sentence": "The results of the following studies are reviewed and compared : the Swedish Aspirin Low-Dose Trial ( SALT ) , the United Kingdom Transient Ischaemic Attack ( UK-TIA ) Aspirin Trial , Dutch Transient Ischemic Attack ( Dutch TIA ) study ( aspirin ) , the Canadian American Ticlopidine Study ( CATS ) , the Ticlopidine Aspirin Stroke Study ( TASS ) , the African American Antiplatelet Stroke Prevention Study ( AAASPS ) ( ticlopidine ) , the Clopidogrel versus Aspirin in Patients at Risk of Recurrent Ischemic Events ( CAPRIE ) trial , the Management of Atherothrombosis With Clopidogrel in High-Risk Patients study ( MATCH ) ( clopidogrel ) , the second European Stroke Prevention Study ( ESPS2 ) ( aspirin plus ER-DP ) , and the Triflusal versus Aspirin in CerebralUInfarction Prevention ( TACIP ) study .", "new_sentence": "The@@results@@of@@the@@following@@studies@@are@@reviewed@@and@@compared@@:@@the@@Swedish@@Aspirin@@Low@@-@@Dose@@Trial@@(@@SALT@@)@@,@@the@@United@@Kingdom@@Transient@@Ischaemic@@Attack@@(@@UK@@-@@TIA@@)@@Aspirin@@Trial@@,@@Dutch@@Transient@@Ischemic@@Attack@@(@@Dutch@@TIA@@)@@study@@(@@aspirin@@)@@,@@the@@Canadian@@American@@Ticlopidine@@Study@@(@@CATS@@)@@,@@the@@Ticlopidine@@Aspirin@@Stroke@@Study@@(@@TASS@@)@@,@@the@@African@@American@@Antiplatelet@@Stroke@@Prevention@@Study@@(@@AAASPS@@)@@(@@ticlopidine@@)@@,@@the@@Clopidogrel@@versus@@Aspirin@@in@@Patients@@at@@Risk@@of@@Recurrent@@Ischemic@@Events@@(@@CAPRIE@@)@@trial@@,@@the@@Management@@of@@Atherothrombosis@@With@@Clopidogrel@@in@@High@@-@@Risk@@Patients@@study@@(@@MATCH@@)@@(@@clopidogrel@@)@@,@@the@@second@@European@@Stroke@@Prevention@@Study@@(@@ESPS2@@)@@(@@aspirin@@plus@@ER@@-@@DP@@)@@,@@and@@the@@Triflusal@@versus@@Aspirin@@in@@CerebralUInfarction@@Prevention@@(@@TACIP@@)@@study@@.@@", "replace_sentence": "The@@results@@of@@the@@following@@studies@@are@@reviewed@@and@@compared@@:@@the@@Swedish@@Aspirin@@Low@@-@@Dose@@Trial@@(@@SALT@@)@@,@@the@@United@@Kingdom@@Transient@@Ischaemic@@Attack@@(@@UK@@-@@TIA@@)@@Aspirin@@Trial@@,@@Dutch@@Transient@@Ischemic@@Attack@@(@@Dutch@@TIA@@)@@study@@(@@aspirin@@)@@,@@the@@Canadian@@American@@Ticlopidine@@Study@@(@@CATS@@)@@,@@the@@Ticlopidine@@Aspirin@@Stroke@@Study@@(@@TASS@@)@@,@@the@@African@@American@@Antiplatelet@@Stroke@@Prevention@@Study@@(@@AAASPS@@)@@(@@ticlopidine@@)@@,@@the@@Clopidogrel@@versus@@Aspirin@@in@@Patients@@at@@Risk@@of@@Recurrent@@Ischemic@@Events@@(@@CAPRIE@@)@@trial@@,@@the@@Management@@of@@Atherothrombosis@@With@@Clopidogrel@@in@@High@@-@@Risk@@Patients@@study@@(@@MATCH@@)@@(@@clopidogrel@@)@@,@@the@@second@@European@@Stroke@@Prevention@@Study@@(@@ESPS2@@)@@(@@aspirin@@plus@@ER@@-@@DP@@)@@,@@and@@the@@Triflusal@@versus@@drug1@@in@@drug2@@Prevention@@(@@TACIP@@)@@study@@.@@", "new_pair": "Aspirin@@in@@CerebralUInfarction", "replace_pair": "drug1@@in@@drug2", "relation": "NA"}, {"head": {"id": "750", "type": "", "word": "dapsone", "begin": "20", "end": "27", "new_begin": "23", "new_end": "30", "replace_begin": "23", "replace_end": "28"}, "tail": {"id": "751", "type": "", "word": "malaria", "begin": "140", "end": "147", "new_begin": "162", "new_end": "169", "replace_begin": "160", "replace_end": "165"}, "sentence": "CONCLUSIONS : While dapsone is traditionally used for the treatment of leprosy and dermatitis herpetiformis , its use for PCP prophylaxis , malaria , brown recluse spider bites , and acne is not uncommon .", "new_sentence": "CONCLUSIONS@@:@@While@@dapsone@@is@@traditionally@@used@@for@@the@@treatment@@of@@leprosy@@and@@dermatitis@@herpetiformis@@,@@its@@use@@for@@PCP@@prophylaxis@@,@@malaria@@,@@brown@@recluse@@spider@@bites@@,@@and@@acne@@is@@not@@uncommon@@.@@", "replace_sentence": "CONCLUSIONS@@:@@While@@drug1@@is@@traditionally@@used@@for@@the@@treatment@@of@@leprosy@@and@@dermatitis@@herpetiformis@@,@@its@@use@@for@@PCP@@prophylaxis@@,@@drug2@@,@@brown@@recluse@@spider@@bites@@,@@and@@acne@@is@@not@@uncommon@@.@@", "new_pair": "dapsone@@is@@traditionally@@used@@for@@the@@treatment@@of@@leprosy@@and@@dermatitis@@herpetiformis@@,@@its@@use@@for@@PCP@@prophylaxis@@,@@malaria", "replace_pair": "drug1@@is@@traditionally@@used@@for@@the@@treatment@@of@@leprosy@@and@@dermatitis@@herpetiformis@@,@@its@@use@@for@@PCP@@prophylaxis@@,@@drug2", "relation": "NA"}, {"head": {"id": "752", "type": "", "word": "fluoride", "begin": "40", "end": "48", "new_begin": "48", "new_end": "56", "replace_begin": "48", "replace_end": "53"}, "tail": {"id": "753", "type": "", "word": "caries", "begin": "72", "end": "78", "new_begin": "84", "new_end": "90", "replace_begin": "81", "replace_end": "86"}, "sentence": "It was concluded that the effect of the fluoride application service on caries prevalence in 3 - year - old children , although statistically significant , was of far lower clinical significance than sociodemographic characteristics .", "new_sentence": "It@@was@@concluded@@that@@the@@effect@@of@@the@@fluoride@@application@@service@@on@@caries@@prevalence@@in@@3@@-@@year@@-@@old@@children@@,@@although@@statistically@@significant@@,@@was@@of@@far@@lower@@clinical@@significance@@than@@sociodemographic@@characteristics@@.@@", "replace_sentence": "It@@was@@concluded@@that@@the@@effect@@of@@the@@drug1@@application@@service@@on@@drug2@@prevalence@@in@@3@@-@@year@@-@@old@@children@@,@@although@@statistically@@significant@@,@@was@@of@@far@@lower@@clinical@@significance@@than@@sociodemographic@@characteristics@@.@@", "new_pair": "fluoride@@application@@service@@on@@caries", "replace_pair": "drug1@@application@@service@@on@@drug2", "relation": "may_prevent"}, {"head": {"id": "754", "type": "", "word": "triamcinolone", "begin": "52", "end": "65", "new_begin": "59", "new_end": "72", "replace_begin": "59", "replace_end": "64"}, "tail": {"id": "755", "type": "", "word": "cystoidUmacularUedema", "begin": "100", "end": "121", "new_begin": "113", "new_end": "134", "replace_begin": "105", "replace_end": "110"}, "sentence": "CONCLUSION : Pars plana vitrectomy and intravitreal triamcinolone in eyes with chronic pseudophakic cystoidUmacularUedema resulted in a reduction of cystoid macular edema , and visual acuity improvement .", "new_sentence": "CONCLUSION@@:@@Pars@@plana@@vitrectomy@@and@@intravitreal@@triamcinolone@@in@@eyes@@with@@chronic@@pseudophakic@@cystoidUmacularUedema@@resulted@@in@@a@@reduction@@of@@cystoid@@macular@@edema@@,@@and@@visual@@acuity@@improvement@@.@@", "replace_sentence": "CONCLUSION@@:@@Pars@@plana@@vitrectomy@@and@@intravitreal@@drug1@@in@@eyes@@with@@chronic@@pseudophakic@@drug2@@resulted@@in@@a@@reduction@@of@@cystoid@@macular@@edema@@,@@and@@visual@@acuity@@improvement@@.@@", "new_pair": "triamcinolone@@in@@eyes@@with@@chronic@@pseudophakic@@cystoidUmacularUedema", "replace_pair": "drug1@@in@@eyes@@with@@chronic@@pseudophakic@@drug2", "relation": "NA"}, {"head": {"id": "756", "type": "", "word": "tacrolimus", "begin": "26", "end": "36", "new_begin": "30", "new_end": "40", "replace_begin": "30", "replace_end": "35"}, "tail": {"id": "757", "type": "", "word": "ischemia", "begin": "163", "end": "171", "new_begin": "187", "new_end": "195", "replace_begin": "182", "replace_end": "187"}, "sentence": "This protective effect of tacrolimus was further confirmed in vivo by a significantly improved survival following pretreatment with tacrolimus , 24 hours prior to ischemia .", "new_sentence": "This@@protective@@effect@@of@@tacrolimus@@was@@further@@confirmed@@in@@vivo@@by@@a@@significantly@@improved@@survival@@following@@pretreatment@@with@@tacrolimus@@,@@24@@hours@@prior@@to@@ischemia@@.@@", "replace_sentence": "This@@protective@@effect@@of@@drug1@@was@@further@@confirmed@@in@@vivo@@by@@a@@significantly@@improved@@survival@@following@@pretreatment@@with@@tacrolimus@@,@@24@@hours@@prior@@to@@drug2@@.@@", "new_pair": "tacrolimus@@was@@further@@confirmed@@in@@vivo@@by@@a@@significantly@@improved@@survival@@following@@pretreatment@@with@@tacrolimus@@,@@24@@hours@@prior@@to@@ischemia", "replace_pair": "drug1@@was@@further@@confirmed@@in@@vivo@@by@@a@@significantly@@improved@@survival@@following@@pretreatment@@with@@tacrolimus@@,@@24@@hours@@prior@@to@@drug2", "relation": "may_prevent"}, {"head": {"id": "758", "type": "", "word": "allopurinol", "begin": "196", "end": "207", "new_begin": "232", "new_end": "243", "replace_begin": "232", "replace_end": "237"}, "tail": {"id": "759", "type": "", "word": "TLS", "begin": "223", "end": "226", "new_begin": "263", "new_end": "266", "replace_begin": "257", "replace_end": "262"}, "sentence": "Nevertheless , a limit of rasburicase s use remains its cost , which obliges to a judicious choice to prevent TLS in high risk patients with cancer and in case of allergy or impossibility to take allopurinol orally both in TLS and in gout .", "new_sentence": "Nevertheless@@,@@a@@limit@@of@@rasburicase@@s@@use@@remains@@its@@cost@@,@@which@@obliges@@to@@a@@judicious@@choice@@to@@prevent@@TLS@@in@@high@@risk@@patients@@with@@cancer@@and@@in@@case@@of@@allergy@@or@@impossibility@@to@@take@@allopurinol@@orally@@both@@in@@TLS@@and@@in@@gout@@.@@", "replace_sentence": "Nevertheless@@,@@a@@limit@@of@@rasburicase@@s@@use@@remains@@its@@cost@@,@@which@@obliges@@to@@a@@judicious@@choice@@to@@prevent@@TLS@@in@@high@@risk@@patients@@with@@cancer@@and@@in@@case@@of@@allergy@@or@@impossibility@@to@@take@@drug1@@orally@@both@@in@@drug2@@and@@in@@gout@@.@@", "new_pair": "allopurinol@@orally@@both@@in@@TLS", "replace_pair": "drug1@@orally@@both@@in@@drug2", "relation": "may_prevent"}, {"head": {"id": "760", "type": "", "word": "ganciclovir", "begin": "82", "end": "93", "new_begin": "96", "new_end": "107", "replace_begin": "96", "replace_end": "101"}, "tail": {"id": "761", "type": "", "word": "CMVUdisease", "begin": "163", "end": "174", "new_begin": "194", "new_end": "205", "replace_begin": "188", "replace_end": "193"}, "sentence": "The aim of this study was to investigate the effect of combined prophylaxis using ganciclovir ( GAN ) and CMV hyperimmune globulin ( CMV - IG ) on CMV infection , CMVUdisease , survival and its role in preventing Bronchiolitis obliterans syndrome ( BOS ) .", "new_sentence": "The@@aim@@of@@this@@study@@was@@to@@investigate@@the@@effect@@of@@combined@@prophylaxis@@using@@ganciclovir@@(@@GAN@@)@@and@@CMV@@hyperimmune@@globulin@@(@@CMV@@-@@IG@@)@@on@@CMV@@infection@@,@@CMVUdisease@@,@@survival@@and@@its@@role@@in@@preventing@@Bronchiolitis@@obliterans@@syndrome@@(@@BOS@@)@@.@@", "replace_sentence": "The@@aim@@of@@this@@study@@was@@to@@investigate@@the@@effect@@of@@combined@@prophylaxis@@using@@drug1@@(@@GAN@@)@@and@@CMV@@hyperimmune@@globulin@@(@@CMV@@-@@IG@@)@@on@@CMV@@infection@@,@@drug2@@,@@survival@@and@@its@@role@@in@@preventing@@Bronchiolitis@@obliterans@@syndrome@@(@@BOS@@)@@.@@", "new_pair": "ganciclovir@@(@@GAN@@)@@and@@CMV@@hyperimmune@@globulin@@(@@CMV@@-@@IG@@)@@on@@CMV@@infection@@,@@CMVUdisease", "replace_pair": "drug1@@(@@GAN@@)@@and@@CMV@@hyperimmune@@globulin@@(@@CMV@@-@@IG@@)@@on@@CMV@@infection@@,@@drug2", "relation": "NA"}, {"head": {"id": "762", "type": "", "word": "chloroquine", "begin": "121", "end": "132", "new_begin": "145", "new_end": "156", "replace_begin": "145", "replace_end": "150"}, "tail": {"id": "763", "type": "", "word": "malaria", "begin": "260", "end": "267", "new_begin": "305", "new_end": "312", "replace_begin": "299", "replace_end": "304"}, "sentence": "In summary , the pharmacokinetic profile and metabolism of AQ-13 are very similar to that reported in the literature for chloroquine , suggesting that this new agent is a promising candidate for further development for the treatment of chloroquine - resistant malaria .", "new_sentence": "In@@summary@@,@@the@@pharmacokinetic@@profile@@and@@metabolism@@of@@AQ@@-@@13@@are@@very@@similar@@to@@that@@reported@@in@@the@@literature@@for@@chloroquine@@,@@suggesting@@that@@this@@new@@agent@@is@@a@@promising@@candidate@@for@@further@@development@@for@@the@@treatment@@of@@chloroquine@@-@@resistant@@malaria@@.@@", "replace_sentence": "In@@summary@@,@@the@@pharmacokinetic@@profile@@and@@metabolism@@of@@AQ@@-@@13@@are@@very@@similar@@to@@that@@reported@@in@@the@@literature@@for@@drug1@@,@@suggesting@@that@@this@@new@@agent@@is@@a@@promising@@candidate@@for@@further@@development@@for@@the@@treatment@@of@@chloroquine@@-@@resistant@@drug2@@.@@", "new_pair": "chloroquine@@,@@suggesting@@that@@this@@new@@agent@@is@@a@@promising@@candidate@@for@@further@@development@@for@@the@@treatment@@of@@chloroquine@@-@@resistant@@malaria", "replace_pair": "drug1@@,@@suggesting@@that@@this@@new@@agent@@is@@a@@promising@@candidate@@for@@further@@development@@for@@the@@treatment@@of@@chloroquine@@-@@resistant@@drug2", "relation": "NA"}, {"head": {"id": "764", "type": "", "word": "caries", "begin": "111", "end": "117", "new_begin": "132", "new_end": "138", "replace_begin": "132", "replace_end": "137"}, "tail": {"id": "765", "type": "", "word": "fluoride", "begin": "240", "end": "248", "new_begin": "285", "new_end": "293", "replace_begin": "284", "replace_end": "289"}, "sentence": "A 24- month clinical study was carried out to evaluate and compare the retention rate , marginal integrity and caries preventing effects of a polyacid- modified resin composite based fissure sealant , Dyract Seal , to that of a resin based fluoride fissure sealant , Delton FS + .", "new_sentence": "A@@24@@-@@month@@clinical@@study@@was@@carried@@out@@to@@evaluate@@and@@compare@@the@@retention@@rate@@,@@marginal@@integrity@@and@@caries@@preventing@@effects@@of@@a@@polyacid@@-@@modified@@resin@@composite@@based@@fissure@@sealant@@,@@Dyract@@Seal@@,@@to@@that@@of@@a@@resin@@based@@fluoride@@fissure@@sealant@@,@@Delton@@FS@@+@@.@@", "replace_sentence": "A@@24@@-@@month@@clinical@@study@@was@@carried@@out@@to@@evaluate@@and@@compare@@the@@retention@@rate@@,@@marginal@@integrity@@and@@drug1@@preventing@@effects@@of@@a@@polyacid@@-@@modified@@resin@@composite@@based@@fissure@@sealant@@,@@Dyract@@Seal@@,@@to@@that@@of@@a@@resin@@based@@drug2@@fissure@@sealant@@,@@Delton@@FS@@+@@.@@", "new_pair": "caries@@preventing@@effects@@of@@a@@polyacid@@-@@modified@@resin@@composite@@based@@fissure@@sealant@@,@@Dyract@@Seal@@,@@to@@that@@of@@a@@resin@@based@@fluoride", "replace_pair": "drug1@@preventing@@effects@@of@@a@@polyacid@@-@@modified@@resin@@composite@@based@@fissure@@sealant@@,@@Dyract@@Seal@@,@@to@@that@@of@@a@@resin@@based@@drug2", "relation": "NA"}, {"head": {"id": "766", "type": "", "word": "stroke", "begin": "103", "end": "109", "new_begin": "119", "new_end": "125", "replace_begin": "119", "replace_end": "124"}, "tail": {"id": "767", "type": "", "word": "aspirin", "begin": "136", "end": "143", "new_begin": "158", "new_end": "165", "replace_begin": "157", "replace_end": "162"}, "sentence": "For example , the antiplatelet agent clopidogrel has reduced end points in the secondary prevention of stroke , as have combinations of aspirin with traditional therapies , including dipyramidole .", "new_sentence": "For@@example@@,@@the@@antiplatelet@@agent@@clopidogrel@@has@@reduced@@end@@points@@in@@the@@secondary@@prevention@@of@@stroke@@,@@as@@have@@combinations@@of@@aspirin@@with@@traditional@@therapies@@,@@including@@dipyramidole@@.@@", "replace_sentence": "For@@example@@,@@the@@antiplatelet@@agent@@clopidogrel@@has@@reduced@@end@@points@@in@@the@@secondary@@prevention@@of@@drug1@@,@@as@@have@@combinations@@of@@drug2@@with@@traditional@@therapies@@,@@including@@dipyramidole@@.@@", "new_pair": "stroke@@,@@as@@have@@combinations@@of@@aspirin", "replace_pair": "drug1@@,@@as@@have@@combinations@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "768", "type": "", "word": "stroke", "begin": "76", "end": "82", "new_begin": "89", "new_end": "95", "replace_begin": "89", "replace_end": "94"}, "tail": {"id": "769", "type": "", "word": "simvastatin", "begin": "129", "end": "140", "new_begin": "148", "new_end": "159", "replace_begin": "147", "replace_end": "152"}, "sentence": "The present study was undertaken to evaluate whether in a neonatal model of stroke a prophylactic neuroprotective treatment with simvastatin modulates hypoxia - ischemia - induced inflammatory and apoptotic signaling .", "new_sentence": "The@@present@@study@@was@@undertaken@@to@@evaluate@@whether@@in@@a@@neonatal@@model@@of@@stroke@@a@@prophylactic@@neuroprotective@@treatment@@with@@simvastatin@@modulates@@hypoxia@@-@@ischemia@@-@@induced@@inflammatory@@and@@apoptotic@@signaling@@.@@", "replace_sentence": "The@@present@@study@@was@@undertaken@@to@@evaluate@@whether@@in@@a@@neonatal@@model@@of@@drug1@@a@@prophylactic@@neuroprotective@@treatment@@with@@drug2@@modulates@@hypoxia@@-@@ischemia@@-@@induced@@inflammatory@@and@@apoptotic@@signaling@@.@@", "new_pair": "stroke@@a@@prophylactic@@neuroprotective@@treatment@@with@@simvastatin", "replace_pair": "drug1@@a@@prophylactic@@neuroprotective@@treatment@@with@@drug2", "relation": "NA"}, {"head": {"id": "770", "type": "", "word": "malaria", "begin": "29", "end": "36", "new_begin": "34", "new_end": "41", "replace_begin": "34", "replace_end": "39"}, "tail": {"id": "771", "type": "", "word": "chloroquine", "begin": "100", "end": "111", "new_begin": "115", "new_end": "126", "replace_begin": "113", "replace_end": "118"}, "sentence": "The most pressing problem in malaria is parasite resistance to classical antimalarial drugs such as chloroquine , particularly as no alternative antimalarial agents are currently available that combine the low cost , safety and efficacy that once characterized chloroquine .", "new_sentence": "The@@most@@pressing@@problem@@in@@malaria@@is@@parasite@@resistance@@to@@classical@@antimalarial@@drugs@@such@@as@@chloroquine@@,@@particularly@@as@@no@@alternative@@antimalarial@@agents@@are@@currently@@available@@that@@combine@@the@@low@@cost@@,@@safety@@and@@efficacy@@that@@once@@characterized@@chloroquine@@.@@", "replace_sentence": "The@@most@@pressing@@problem@@in@@drug1@@is@@parasite@@resistance@@to@@classical@@antimalarial@@drugs@@such@@as@@drug2@@,@@particularly@@as@@no@@alternative@@antimalarial@@agents@@are@@currently@@available@@that@@combine@@the@@low@@cost@@,@@safety@@and@@efficacy@@that@@once@@characterized@@chloroquine@@.@@", "new_pair": "malaria@@is@@parasite@@resistance@@to@@classical@@antimalarial@@drugs@@such@@as@@chloroquine", "replace_pair": "drug1@@is@@parasite@@resistance@@to@@classical@@antimalarial@@drugs@@such@@as@@drug2", "relation": "may_prevent"}, {"head": {"id": "772", "type": "", "word": "aspirin", "begin": "46", "end": "53", "new_begin": "52", "new_end": "59", "replace_begin": "52", "replace_end": "57"}, "tail": {"id": "773", "type": "", "word": "MI", "begin": "114", "end": "116", "new_begin": "132", "new_end": "134", "replace_begin": "130", "replace_end": "135"}, "sentence": "Five randomized clinical trials have compared aspirin with placebo or no therapy for the prevention of stroke and MI .", "new_sentence": "Five@@randomized@@clinical@@trials@@have@@compared@@aspirin@@with@@placebo@@or@@no@@therapy@@for@@the@@prevention@@of@@stroke@@and@@MI@@.@@", "replace_sentence": "Five@@randomized@@clinical@@trials@@have@@compared@@drug1@@with@@placebo@@or@@no@@therapy@@for@@the@@prevention@@of@@stroke@@and@@drug2@@.@@", "new_pair": "aspirin@@with@@placebo@@or@@no@@therapy@@for@@the@@prevention@@of@@stroke@@and@@MI", "replace_pair": "drug1@@with@@placebo@@or@@no@@therapy@@for@@the@@prevention@@of@@stroke@@and@@drug2", "relation": "NA"}, {"head": {"id": "774", "type": "", "word": "CytomegalovirusU ( UCMVU ) Udisease", "begin": "13", "end": "48", "new_begin": "15", "new_end": "50", "replace_begin": "15", "replace_end": "20"}, "tail": {"id": "775", "type": "", "word": "ganciclovir", "begin": "128", "end": "139", "new_begin": "143", "new_end": "154", "replace_begin": "113", "replace_end": "118"}, "sentence": "BACKGROUND : CytomegalovirusU ( UCMVU ) Udisease is a major cause of morbidity and mortality after lung transplantation despite ganciclovir prophylaxis .", "new_sentence": "BACKGROUND@@:@@CytomegalovirusU ( UCMVU ) Udisease@@is@@a@@major@@cause@@of@@morbidity@@and@@mortality@@after@@lung@@transplantation@@despite@@ganciclovir@@prophylaxis@@.@@", "replace_sentence": "BACKGROUND@@:@@drug1@@is@@a@@major@@cause@@of@@morbidity@@and@@mortality@@after@@lung@@transplantation@@despite@@drug2@@prophylaxis@@.@@", "new_pair": "CytomegalovirusU ( UCMVU ) Udisease@@is@@a@@major@@cause@@of@@morbidity@@and@@mortality@@after@@lung@@transplantation@@despite@@ganciclovir", "replace_pair": "drug1@@is@@a@@major@@cause@@of@@morbidity@@and@@mortality@@after@@lung@@transplantation@@despite@@drug2", "relation": "may_prevent"}, {"head": {"id": "776", "type": "", "word": "vitaminUD", "begin": "19", "end": "28", "new_begin": "22", "new_end": "31", "replace_begin": "22", "replace_end": "27"}, "tail": {"id": "777", "type": "", "word": "osteoporosis", "begin": "75", "end": "87", "new_begin": "87", "new_end": "99", "replace_begin": "83", "replace_end": "88"}, "sentence": "INTRODUCTION : Low vitaminUD level may predict rickets , osteomalacia , or osteoporosis .", "new_sentence": "INTRODUCTION@@:@@Low@@vitaminUD@@level@@may@@predict@@rickets@@,@@osteomalacia@@,@@or@@osteoporosis@@.@@", "replace_sentence": "INTRODUCTION@@:@@Low@@drug1@@level@@may@@predict@@rickets@@,@@osteomalacia@@,@@or@@drug2@@.@@", "new_pair": "vitaminUD@@level@@may@@predict@@rickets@@,@@osteomalacia@@,@@or@@osteoporosis", "replace_pair": "drug1@@level@@may@@predict@@rickets@@,@@osteomalacia@@,@@or@@drug2", "relation": "NA"}, {"head": {"id": "778", "type": "", "word": "0U . U4U % UstannousUfluoride-gel", "begin": "129", "end": "162", "new_begin": "155", "new_end": "188", "replace_begin": "155", "replace_end": "160"}, "tail": {"id": "779", "type": "", "word": "caries", "begin": "306", "end": "312", "new_begin": "359", "new_end": "365", "replace_begin": "331", "replace_end": "336"}, "sentence": "Anderson Cancer Center , with radiation-induced xerostomia , were entered into a pilot study to contrast the daily home use of a 0U . U4U % UstannousUfluoride-gel - containing tray ( control group ) to IFRS ( study group ) with respect to tolerability and adherence , and to obtain information on relative caries preventive efficacy .", "new_sentence": "Anderson@@Cancer@@Center@@,@@with@@radiation@@-@@induced@@xerostomia@@,@@were@@entered@@into@@a@@pilot@@study@@to@@contrast@@the@@daily@@home@@use@@of@@a@@0U . U4U % UstannousUfluoride-gel@@-@@containing@@tray@@(@@control@@group@@)@@to@@IFRS@@(@@study@@group@@)@@with@@respect@@to@@tolerability@@and@@adherence@@,@@and@@to@@obtain@@information@@on@@relative@@caries@@preventive@@efficacy@@.@@", "replace_sentence": "Anderson@@Cancer@@Center@@,@@with@@radiation@@-@@induced@@xerostomia@@,@@were@@entered@@into@@a@@pilot@@study@@to@@contrast@@the@@daily@@home@@use@@of@@a@@drug1@@-@@containing@@tray@@(@@control@@group@@)@@to@@IFRS@@(@@study@@group@@)@@with@@respect@@to@@tolerability@@and@@adherence@@,@@and@@to@@obtain@@information@@on@@relative@@drug2@@preventive@@efficacy@@.@@", "new_pair": "0U . U4U % UstannousUfluoride-gel@@-@@containing@@tray@@(@@control@@group@@)@@to@@IFRS@@(@@study@@group@@)@@with@@respect@@to@@tolerability@@and@@adherence@@,@@and@@to@@obtain@@information@@on@@relative@@caries", "replace_pair": "drug1@@-@@containing@@tray@@(@@control@@group@@)@@to@@IFRS@@(@@study@@group@@)@@with@@respect@@to@@tolerability@@and@@adherence@@,@@and@@to@@obtain@@information@@on@@relative@@drug2", "relation": "NA"}, {"head": {"id": "780", "type": "", "word": "coronaryUstentUthrombosis", "begin": "8", "end": "33", "new_begin": "10", "new_end": "35", "replace_begin": "10", "replace_end": "15"}, "tail": {"id": "781", "type": "", "word": "aspirin", "begin": "54", "end": "61", "new_begin": "60", "new_end": "67", "replace_begin": "40", "replace_end": "45"}, "sentence": "( Fatal coronaryUstentUthrombosis after withdrawal of aspirin treatment before performing a colonoscopy ) .", "new_sentence": "(@@Fatal@@coronaryUstentUthrombosis@@after@@withdrawal@@of@@aspirin@@treatment@@before@@performing@@a@@colonoscopy@@)@@.@@", "replace_sentence": "(@@Fatal@@drug1@@after@@withdrawal@@of@@drug2@@treatment@@before@@performing@@a@@colonoscopy@@)@@.@@", "new_pair": "coronaryUstentUthrombosis@@after@@withdrawal@@of@@aspirin", "replace_pair": "drug1@@after@@withdrawal@@of@@drug2", "relation": "may_prevent"}, {"head": {"id": "782", "type": "", "word": "AspirinUplusUextended-releaseUdipyridamole", "begin": "13", "end": "55", "new_begin": "15", "new_end": "57", "replace_begin": "15", "replace_end": "20"}, "tail": {"id": "783", "type": "", "word": "stroke", "begin": "107", "end": "113", "new_begin": "118", "new_end": "124", "replace_begin": "81", "replace_end": "86"}, "sentence": "CONCLUSION : AspirinUplusUextended-releaseUdipyridamole is more effective than aspirin alone at preventing stroke , and the difference in efficacy increases in higher-risk patients .", "new_sentence": "CONCLUSION@@:@@AspirinUplusUextended-releaseUdipyridamole@@is@@more@@effective@@than@@aspirin@@alone@@at@@preventing@@stroke@@,@@and@@the@@difference@@in@@efficacy@@increases@@in@@higher@@-@@risk@@patients@@.@@", "replace_sentence": "CONCLUSION@@:@@drug1@@is@@more@@effective@@than@@aspirin@@alone@@at@@preventing@@drug2@@,@@and@@the@@difference@@in@@efficacy@@increases@@in@@higher@@-@@risk@@patients@@.@@", "new_pair": "AspirinUplusUextended-releaseUdipyridamole@@is@@more@@effective@@than@@aspirin@@alone@@at@@preventing@@stroke", "replace_pair": "drug1@@is@@more@@effective@@than@@aspirin@@alone@@at@@preventing@@drug2", "relation": "may_prevent"}, {"head": {"id": "784", "type": "", "word": "aspirin", "begin": "186", "end": "193", "new_begin": "217", "new_end": "224", "replace_begin": "217", "replace_end": "222"}, "tail": {"id": "785", "type": "", "word": "myocardialUinfarction", "begin": "351", "end": "372", "new_begin": "408", "new_end": "429", "replace_begin": "406", "replace_end": "411"}, "sentence": "BACKGROUND : The Percutaneous Coronary Intervention - Clopidogrel in Unstable Angina to Prevent Recurrent Events ( PCI- CURE ) study , which examined the effect of adding clopidogrel to aspirin versus aspirin alone in patients with unstable coronary artery disease ( CAD ) undergoing PCI , found a relative risk reduction in cardiovascular deaths and myocardialUinfarction among those treated with clopidogrel .", "new_sentence": "BACKGROUND@@:@@The@@Percutaneous@@Coronary@@Intervention@@-@@Clopidogrel@@in@@Unstable@@Angina@@to@@Prevent@@Recurrent@@Events@@(@@PCI@@-@@CURE@@)@@study@@,@@which@@examined@@the@@effect@@of@@adding@@clopidogrel@@to@@aspirin@@versus@@aspirin@@alone@@in@@patients@@with@@unstable@@coronary@@artery@@disease@@(@@CAD@@)@@undergoing@@PCI@@,@@found@@a@@relative@@risk@@reduction@@in@@cardiovascular@@deaths@@and@@myocardialUinfarction@@among@@those@@treated@@with@@clopidogrel@@.@@", "replace_sentence": "BACKGROUND@@:@@The@@Percutaneous@@Coronary@@Intervention@@-@@Clopidogrel@@in@@Unstable@@Angina@@to@@Prevent@@Recurrent@@Events@@(@@PCI@@-@@CURE@@)@@study@@,@@which@@examined@@the@@effect@@of@@adding@@clopidogrel@@to@@drug1@@versus@@aspirin@@alone@@in@@patients@@with@@unstable@@coronary@@artery@@disease@@(@@CAD@@)@@undergoing@@PCI@@,@@found@@a@@relative@@risk@@reduction@@in@@cardiovascular@@deaths@@and@@drug2@@among@@those@@treated@@with@@clopidogrel@@.@@", "new_pair": "aspirin@@versus@@aspirin@@alone@@in@@patients@@with@@unstable@@coronary@@artery@@disease@@(@@CAD@@)@@undergoing@@PCI@@,@@found@@a@@relative@@risk@@reduction@@in@@cardiovascular@@deaths@@and@@myocardialUinfarction", "replace_pair": "drug1@@versus@@aspirin@@alone@@in@@patients@@with@@unstable@@coronary@@artery@@disease@@(@@CAD@@)@@undergoing@@PCI@@,@@found@@a@@relative@@risk@@reduction@@in@@cardiovascular@@deaths@@and@@drug2", "relation": "may_prevent"}, {"head": {"id": "786", "type": "", "word": "fluoride", "begin": "170", "end": "178", "new_begin": "198", "new_end": "206", "replace_begin": "198", "replace_end": "203"}, "tail": {"id": "787", "type": "", "word": "caries", "begin": "402", "end": "408", "new_begin": "470", "new_end": "476", "replace_begin": "467", "replace_end": "472"}, "sentence": "CONCLUSIONS : There are no gold standards for setting up a universal optimal level of fluoride in drinking water and each country needs to determine the concentration of fluoride in their drinking water in accordance with its socio- economic and climatic conditions , dietary and oral hygiene habits of its population , and local research to determine how much fluoride is beneficial in the control of caries .", "new_sentence": "CONCLUSIONS@@:@@There@@are@@no@@gold@@standards@@for@@setting@@up@@a@@universal@@optimal@@level@@of@@fluoride@@in@@drinking@@water@@and@@each@@country@@needs@@to@@determine@@the@@concentration@@of@@fluoride@@in@@their@@drinking@@water@@in@@accordance@@with@@its@@socio@@-@@economic@@and@@climatic@@conditions@@,@@dietary@@and@@oral@@hygiene@@habits@@of@@its@@population@@,@@and@@local@@research@@to@@determine@@how@@much@@fluoride@@is@@beneficial@@in@@the@@control@@of@@caries@@.@@", "replace_sentence": "CONCLUSIONS@@:@@There@@are@@no@@gold@@standards@@for@@setting@@up@@a@@universal@@optimal@@level@@of@@fluoride@@in@@drinking@@water@@and@@each@@country@@needs@@to@@determine@@the@@concentration@@of@@drug1@@in@@their@@drinking@@water@@in@@accordance@@with@@its@@socio@@-@@economic@@and@@climatic@@conditions@@,@@dietary@@and@@oral@@hygiene@@habits@@of@@its@@population@@,@@and@@local@@research@@to@@determine@@how@@much@@fluoride@@is@@beneficial@@in@@the@@control@@of@@drug2@@.@@", "new_pair": "fluoride@@in@@their@@drinking@@water@@in@@accordance@@with@@its@@socio@@-@@economic@@and@@climatic@@conditions@@,@@dietary@@and@@oral@@hygiene@@habits@@of@@its@@population@@,@@and@@local@@research@@to@@determine@@how@@much@@fluoride@@is@@beneficial@@in@@the@@control@@of@@caries", "replace_pair": "drug1@@in@@their@@drinking@@water@@in@@accordance@@with@@its@@socio@@-@@economic@@and@@climatic@@conditions@@,@@dietary@@and@@oral@@hygiene@@habits@@of@@its@@population@@,@@and@@local@@research@@to@@determine@@how@@much@@fluoride@@is@@beneficial@@in@@the@@control@@of@@drug2", "relation": "NA"}, {"head": {"id": "788", "type": "", "word": "fungalUinfection", "begin": "87", "end": "103", "new_begin": "100", "new_end": "116", "replace_begin": "100", "replace_end": "105"}, "tail": {"id": "789", "type": "", "word": "fluconazole", "begin": "226", "end": "237", "new_begin": "270", "new_end": "281", "replace_begin": "259", "replace_end": "264"}, "sentence": "As demonstrated in two pivotal Phase III trials , posaconazole prophylaxis of invasive fungalUinfection in patients severely immunocompromised by graft-versus-host disease ( n = 600 ) or neutropenia ( n = 602 ) is superior to fluconazole and @ or itraconazole prophylaxis .", "new_sentence": "As@@demonstrated@@in@@two@@pivotal@@Phase@@III@@trials@@,@@posaconazole@@prophylaxis@@of@@invasive@@fungalUinfection@@in@@patients@@severely@@immunocompromised@@by@@graft@@-@@versus@@-@@host@@disease@@(@@n@@=@@600@@)@@or@@neutropenia@@(@@n@@=@@602@@)@@is@@superior@@to@@fluconazole@@and@@@@@or@@itraconazole@@prophylaxis@@.@@", "replace_sentence": "As@@demonstrated@@in@@two@@pivotal@@Phase@@III@@trials@@,@@posaconazole@@prophylaxis@@of@@invasive@@drug1@@in@@patients@@severely@@immunocompromised@@by@@graft@@-@@versus@@-@@host@@disease@@(@@n@@=@@600@@)@@or@@neutropenia@@(@@n@@=@@602@@)@@is@@superior@@to@@drug2@@and@@@@@or@@itraconazole@@prophylaxis@@.@@", "new_pair": "fungalUinfection@@in@@patients@@severely@@immunocompromised@@by@@graft@@-@@versus@@-@@host@@disease@@(@@n@@=@@600@@)@@or@@neutropenia@@(@@n@@=@@602@@)@@is@@superior@@to@@fluconazole", "replace_pair": "drug1@@in@@patients@@severely@@immunocompromised@@by@@graft@@-@@versus@@-@@host@@disease@@(@@n@@=@@600@@)@@or@@neutropenia@@(@@n@@=@@602@@)@@is@@superior@@to@@drug2", "relation": "NA"}, {"head": {"id": "790", "type": "", "word": "RisedronateUsodium", "begin": "0", "end": "18", "new_begin": "0", "new_end": "18", "replace_begin": "0", "replace_end": "5"}, "tail": {"id": "791", "type": "", "word": "stroke", "begin": "89", "end": "95", "new_begin": "103", "new_end": "109", "replace_begin": "90", "replace_end": "95"}, "sentence": "RisedronateUsodium therapy for prevention of hip fracture in men 65 years or older after stroke .", "new_sentence": "RisedronateUsodium@@therapy@@for@@prevention@@of@@hip@@fracture@@in@@men@@65@@years@@or@@older@@after@@stroke@@.@@", "replace_sentence": "drug1@@therapy@@for@@prevention@@of@@hip@@fracture@@in@@men@@65@@years@@or@@older@@after@@drug2@@.@@", "new_pair": "RisedronateUsodium@@therapy@@for@@prevention@@of@@hip@@fracture@@in@@men@@65@@years@@or@@older@@after@@stroke", "replace_pair": "drug1@@therapy@@for@@prevention@@of@@hip@@fracture@@in@@men@@65@@years@@or@@older@@after@@drug2", "relation": "NA"}, {"head": {"id": "792", "type": "", "word": "myocardialUinfarction", "begin": "90", "end": "111", "new_begin": "104", "new_end": "125", "replace_begin": "104", "replace_end": "109"}, "tail": {"id": "793", "type": "", "word": "clopidogrelUplusUaspirin", "begin": "180", "end": "204", "new_begin": "206", "new_end": "230", "replace_begin": "190", "replace_end": "195"}, "sentence": "Clinical trial results have demonstrated a reduction in the composite endpoint of death , myocardialUinfarction , or stroke for patients with acute coronary syndromes who received clopidogrelUplusUaspirin compared with aspirin alone .", "new_sentence": "Clinical@@trial@@results@@have@@demonstrated@@a@@reduction@@in@@the@@composite@@endpoint@@of@@death@@,@@myocardialUinfarction@@,@@or@@stroke@@for@@patients@@with@@acute@@coronary@@syndromes@@who@@received@@clopidogrelUplusUaspirin@@compared@@with@@aspirin@@alone@@.@@", "replace_sentence": "Clinical@@trial@@results@@have@@demonstrated@@a@@reduction@@in@@the@@composite@@endpoint@@of@@death@@,@@drug1@@,@@or@@stroke@@for@@patients@@with@@acute@@coronary@@syndromes@@who@@received@@drug2@@compared@@with@@aspirin@@alone@@.@@", "new_pair": "myocardialUinfarction@@,@@or@@stroke@@for@@patients@@with@@acute@@coronary@@syndromes@@who@@received@@clopidogrelUplusUaspirin", "replace_pair": "drug1@@,@@or@@stroke@@for@@patients@@with@@acute@@coronary@@syndromes@@who@@received@@drug2", "relation": "may_prevent"}, {"head": {"id": "794", "type": "", "word": "myocardialUinfarction", "begin": "33", "end": "54", "new_begin": "39", "new_end": "60", "replace_begin": "39", "replace_end": "44"}, "tail": {"id": "795", "type": "", "word": "perindopril", "begin": "92", "end": "103", "new_begin": "106", "new_end": "117", "replace_begin": "90", "replace_end": "95"}, "sentence": "( Hypertension , heart failure , myocardialUinfarction , secondary prevention : the role of perindopril ) .", "new_sentence": "(@@Hypertension@@,@@heart@@failure@@,@@myocardialUinfarction@@,@@secondary@@prevention@@:@@the@@role@@of@@perindopril@@)@@.@@", "replace_sentence": "(@@Hypertension@@,@@heart@@failure@@,@@drug1@@,@@secondary@@prevention@@:@@the@@role@@of@@drug2@@)@@.@@", "new_pair": "myocardialUinfarction@@,@@secondary@@prevention@@:@@the@@role@@of@@perindopril", "replace_pair": "drug1@@,@@secondary@@prevention@@:@@the@@role@@of@@drug2", "relation": "NA"}, {"head": {"id": "796", "type": "", "word": "myocardialUinfarction", "begin": "157", "end": "178", "new_begin": "183", "new_end": "204", "replace_begin": "183", "replace_end": "188"}, "tail": {"id": "797", "type": "", "word": "aspirin", "begin": "241", "end": "248", "new_begin": "279", "new_end": "286", "replace_begin": "263", "replace_end": "268"}, "sentence": "As such , triflusal has a role in the primary prevention of cerebrovascular events in atrial fibrillation , and for the secondary prevention of cerebral and myocardialUinfarction , primarily as an alternative to aspirin in patients for whom aspirin is unsuitable .", "new_sentence": "As@@such@@,@@triflusal@@has@@a@@role@@in@@the@@primary@@prevention@@of@@cerebrovascular@@events@@in@@atrial@@fibrillation@@,@@and@@for@@the@@secondary@@prevention@@of@@cerebral@@and@@myocardialUinfarction@@,@@primarily@@as@@an@@alternative@@to@@aspirin@@in@@patients@@for@@whom@@aspirin@@is@@unsuitable@@.@@", "replace_sentence": "As@@such@@,@@triflusal@@has@@a@@role@@in@@the@@primary@@prevention@@of@@cerebrovascular@@events@@in@@atrial@@fibrillation@@,@@and@@for@@the@@secondary@@prevention@@of@@cerebral@@and@@drug1@@,@@primarily@@as@@an@@alternative@@to@@aspirin@@in@@patients@@for@@whom@@drug2@@is@@unsuitable@@.@@", "new_pair": "myocardialUinfarction@@,@@primarily@@as@@an@@alternative@@to@@aspirin@@in@@patients@@for@@whom@@aspirin", "replace_pair": "drug1@@,@@primarily@@as@@an@@alternative@@to@@aspirin@@in@@patients@@for@@whom@@drug2", "relation": "NA"}, {"head": {"id": "798", "type": "", "word": "vitaminUA", "begin": "108", "end": "117", "new_begin": "121", "new_end": "130", "replace_begin": "121", "replace_end": "126"}, "tail": {"id": "799", "type": "", "word": "measlesUblindness", "begin": "175", "end": "192", "new_begin": "198", "new_end": "215", "replace_begin": "194", "replace_end": "199"}, "sentence": "Higher measles immunization coverage to interrupt measles transmission and interventions aimed at improving vitaminUA nutriture of children are the main strategies to prevent measlesUblindness .", "new_sentence": "Higher@@measles@@immunization@@coverage@@to@@interrupt@@measles@@transmission@@and@@interventions@@aimed@@at@@improving@@vitaminUA@@nutriture@@of@@children@@are@@the@@main@@strategies@@to@@prevent@@measlesUblindness@@.@@", "replace_sentence": "Higher@@measles@@immunization@@coverage@@to@@interrupt@@measles@@transmission@@and@@interventions@@aimed@@at@@improving@@drug1@@nutriture@@of@@children@@are@@the@@main@@strategies@@to@@prevent@@drug2@@.@@", "new_pair": "vitaminUA@@nutriture@@of@@children@@are@@the@@main@@strategies@@to@@prevent@@measlesUblindness", "replace_pair": "drug1@@nutriture@@of@@children@@are@@the@@main@@strategies@@to@@prevent@@drug2", "relation": "may_prevent"}]
|